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SATURDAY, MAY 3
PLENARY SESSION
Neural Development and Neurodevelopmental 
Disorders
Saturday, May 3, 2008 8:30 AM - 10:30 AM
Location: Regency Ballroom
Chair: Raquel Gur
697. Experience and Brain Development
Holly Cline
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
Hollis Cline is the Robertson Professor of Neuroscience at Cold Spring Harbor 
Laboratory. She is a recent NIH Director’s Pioneer Awardee, is on the Board 
of Scientific Counselors for the NINDS and a previous Counselor of the 
Society for Neuroscience. Dr. Cline’s research investigates mechanisms of 
brain development using in vivo imaging, electrophysiological recordings and 
molecular manipulations. She is particularly interested in the role of experience 
in shaping or modifying brain circuitry.
698. Tuning up Circuits: Brain Waves and Immune 
Genes
Carla J. Shatz
Stanford University, Stanford, CA
Carla Shatz is Professor of Biological Sciences and Neurobiology and the Director 
of Stanford University’s Bio-X program. She studies how our early experiences 
change brain circuits during critical periods of learning and development. She 
received her Ph.D. in Neurobiology from Harvard Medical School and has held 
faculty appointments at Stanford, UC Berkeley and Harvard Medical School, 
where she was Chairwoman of the Department of Neurobiology until 2007. Her 
neuroscience research has advanced understanding of how connections between 
eye and brain are tuned up by use. She was the first to observe how, during fetal 
development, the eye tests its connections to the brain’s visual processing regions 
by sending and resending waves of electrical activity through nerve cells across 
the retina. She has served as the President of the 38,000 member Society for 
Neuroscience, and has received many honors and awards, including being elected 
a member of the American Academy of Arts and Sciences, the National Academy 
of Sciences and the Institute of Medicine.
699. Critical Period Brain Development and Disorders 
Takao Hensch
Harvard University, Cambridge, MA
Takao K. Hensch is joint Professor of Neurology (Children’s Hospital Boston) 
at Harvard Medical School and Professor of Molecular and Cellular Biology 
(Center for Brain Science) at Harvard University. After his undergraduate studies 
on sleep mechanisms with Dr. J Allan Hobson at Harvard, he was a student 
of Dr. Masao Ito at the Univ Tokyo (MPH) and Fulbright Fellow with Dr. 
Wolf Singer at the Max-Planck Institute for Brain Research, prior to receiving a 
PhD in Neuroscience from the University of California San Francisco in 1996 
working with Dr. Michael Stryker. He then helped to launch the RIKEN Brain 
Science Institute as Lab Head for Neuronal Circuit Development then served 
as Group Director since 2000. Hensch’s research focuses on critical periods in 
brain development. By applying cellular and molecular biology techniques to 
neural systems, he identified inhibitory circuits that orchestrate the structural 
and functional rewiring of connections in response to early sensory experience. 
His work impacts not only basic understanding of brain development, but 
also the potential treatment for devastating cognitive disorders in adulthood. 
Hensch has received several honors, including the Tsukahara Prize (Japan Brain 
Science Foundation); Japanese Minister of Education, Culture, Sports, Science 
and Technology (MEXT) Prize; NIH Director’s Pioneer Award and the first 
US Society for NeuroscienceYoung Investigator Award to a foreign scientist. 
He serves among others on the editorial board of J Neurosci (reviewing editor), 
Brain Structure & Function, NeuroSignals, Neural Development, HFSP Journal 
and Neuron.
700. Translating Between Genes, Brain, and 
Behavior: “Top-Down” and “Bottom-Up” Searches 
for Mechanisms in Schizophrenia and Williams 
Syndrome
Karen Berman
Section on Integrative Neuroimaging, National Institute of Mental 
Health, Bethesda, MD
Dr. Berman is the Chief of the Section on Integrative Neuroimaging in the 
Clinical Brain Disorders Branch and the Genes, Cognition, and Psychosis 
Program at the National Institutes of Health, NIMH Intramural Research 
Program. After receiving her M.D. degree at St. Louis University, she 
undertook a medical internship at Washington University in St. Louis and had 
residency training in psychiatry at the University of California at San Diego. 
Dr. Berman also completed residency training in nuclear medicine at the NIH 
Warren G. Magnusen Clinical Center and is board certified in both psychiatry 
and nuclear medicine. Among other awards, she has received the A.E. Bennett 
Award for Neuropsychiatric Research of the Society of Biological Psychiatry. 
Dr. Berman’s research group conducts translational investigations, using 
multimodal neuroimaging to bridge the gap between neurogenetic, molecular, 
cellular, and system-level mechanisms of brain dysfunction and the cognitive 
and behavioral manifestations of neurosychiatric disorders neurodevelopmental 
and genetic sources such as schizophrenia and Williams syndrome, as well of 
other conditions impacting cognition such as normal aging. They also study 
the effects of gonadal steroid hormones on brain function. This body of work 
has been published in Nature Neuroscience, Neuron, the Journal of Clinical 
Investigation, the Proceedings of the National Academy of Sciences, and the 
Journal of Neuroscience.
PRESIDENTIAL INVITED LECTURE
Saturday, May 3, 2008 11:00 AM - 12:00 PM
Location: Regency Ballroom
Chair: Raquel Gur 




Thomas R. Insel, M.D., is Director of the National Institute of Mental Health 
(NIMH), which leads the nation’s research effort to understand, treat, and prevent 
mental disorders. Appointed as Director in 2002, Dr. Insel’s association with 
NIMH actually spans over two decades, as he began his research career at the 
Institute in 1979, leaving it in 1994 to become Professor of Psychiatry at Emory 
University in Atlanta, Georgia. While at Emory he founded and led the Center for 
Behavioral Neuroscience, and continued his groundbreaking line of research, begun 
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at NIMH, on the molecular basis of social behaviors. Among Dr. Insel’s many 
scientific achievements, he is perhaps best known for his research on oxytocin and 
affiliative behaviors. Dr. Insel identified the important role of neuropeptides such 
as oxytocin or vasopressin for social attachment in comparative neurobiological 
studies of monogamous mammals. This discovery led to greater understanding of 
the molecular and cellular basis of parental behavior, pair bonding, and aggression. 
A prolific author, Dr. Insel has published over 200 scientific articles and four 
books. He is a member of the Institute of Medicine, a Fellow of the American 
College of Neuropsychopharmacology, and the recipient of several awards. Dr. 
Insel graduated from the combined B.A.-M.D. program at Boston University.
WORKSHOP
Use of Epigenetic, Genetic, and Molecular 
Approaches in Suicide Research
Saturday, May 3, 2008 12:30 PM - 2:00 PM
Location: Yorktown
Chair: Yogesh Dwivedi*
Moderator: Ghanshyam N. Pandey**
*Supported by RO1MH068777
**Supported by RO1MH56528
702. Use of Epigenetic, Genetic, and Molecular 
Approaches in Suicide Research
Gustavo Turecki1, Karoly Mirnics2, Dan Rujescu3,
Yogesh Dwivedi4
1McGill Universuty, Canada, Montreal, QC, Canada, 2Vanderbilt 
University and VU Kennedy Center, Nashville, TN, 3Ludwig-
Maximilians-University, Munich, Germany, 4University of Illinois at 
Chicago, Chicago, IL
Novel mechanistic concepts of the neurobiology of suicide are rapidly evolving 
based on studies conducted in postmortem brain or in peripheral tissues 
of patients with suicidal ideation or of suicide attempters. One such recent 
breakthrough in understanding the neurobiology of suicide is associated 
with the recently observed abnormalities in the regulation of gene expression. 
Studies using cDNA microarray, epigenetic, and other molecular approaches, 
by revealing novel genes that may be undergoing regulation in suicide, have 
added new dimensions to the exploration of the neurobiology of suicide. 
Moreover, consistent evidence suggests that the predisposition to suicidal 
behavior has a genetic component and that genetic transmission of suicide risk 
is independent of the presence of mental disorders. The proposed workshop will 
detail recent crucial findings of suicide research utilizing epigenetic, genetic, 
and molecular approaches. Gustavo Turecki, MD, Ph.D., will present recent 
data of the epigenetic changes associated with suicide, particularly focusing on 
the polyamine system. Karoly Mirnics, MD, will compare the frontal cortical 
gene expression profile of patients with schizophrenia who committed suicide 
with the expression profile of subjects with schizophrenia who died from non-
suicidal events and of the matched controls. Dan Rujescu, MD, will discuss 
case control genetic association studies of aggression-related genes in suicidal 
behavior. Lastly, Yogesh Dwivedi, PhD., will discuss recent molecular studies 
implicating apoptotic-regulatory genes in the pathophysiology of suicide. This 
workshop will demonstrate a combination of novel approaches that may be 
useful in identifying the pathogenic mechanisms associated with suicide and 
development of novel site-specific therapeutic interventions. 
Supported by R01 MH079299 (KM), RO1MH068777
WORKSHOP
Re-Formulation and Novel Tests of the Dopamine 
Hypothesis of Schizophrenia
Saturday, May 3, 2008 12:30 PM - 2:00 PM
Location: Ticonderoga
Chair: Vishwajit L. Nimgaonkar*
Moderator: Robin M. Murray**
*Supported by R01MH56232
**Supported by MRC
703. Re-Formulation and Novel Tests of the 
Dopamine Hypothesis of Schizophrenia
Robin M. Murray1, Vishwajit L. Nimgaonkar2, David 
A. Collier3, Andreas Meyer-Lindenberg4
1Institute of Psychiatry, 2University of Pittsburgh, Pittsburgh, PA, 
3Institute of Psychiatry, London, United Kingdom, 4Central Institute of 
Mental Health, Mannheim, Germany
Much schizophrenia research has been driven by the heuristic ‘Dopamine (DA) 
hypothesis’, but the original simplistic formulation of DA hyperfunction has 
never been satisfactory. There is growing evidence for regional differences and 
intricate homeostatic mechanisms, prompting more sophisticated formulations 
in recent years. Genetic association studies offer the opportunity to validate 
the DA hypothesis from an etiological perspective, but early association 
studies tested one or only a handful of polymorphisms, in small samples at 
conventional DA loci. The current availability of large samples and high 
throughput analytic methods offer the opportunity to re-evaluate the DA 
hypothesis from several perspectives. Though the focus of our symposium 
will be on genetic epidemiologic studies, we aim to weave in perspectives 
from complementary arenas in order to enable a lively debate, re-synthesis 
and reformulation of the DA hypothesis. The panel will include evaluations 
of the DA hypothesis from a genome-wide vantage, including genome-wide 
analyses, focused candidate gene studies, studies of environmental factors 
in conjunction with genetic risk and quantitative trait variation in relation 
to the DA hypothesis (phenomenological, cognitive and imaging variables). 
Chair/ Co-moderator: Vishwajit Nimgaonkar Moderator: Robin M Murray 
Titles and presenters: 1. The Dopamine hypothesis from the perspective of 
environmental factors and gene-environment interactions: Robin M Murray, 
Institute of Psychiatry, London, UK. 2. Focus on candidate gene studies: 
Vishwajit L Nimgaonkar, University of Pittsburgh, Pittsburgh USA. 3. 
Dopamine hypothesis from a genome-wide vantage: David Collier, Institute 
of Psychiatry, London, UK 4. Genetic variation impacting on dopamine and 
neural mechanisms of schizophrenia: Andreas Meyer-Lindenberg, Central 
Institute of Mental Health, Mannheim, Germany 
Supported by NIMH\IRP, R01MH56232, mrc
www.sobp.org/journal
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WORKSHOP
Distinguishing Bipolar and Unipolar Depression: 
A Lifespan Perspective
Saturday, May 3, 2008 12:30 PM - 2:00 PM
Location: Regency A
Chair: Mary L. Phillips*
Moderator: Alan C. Swann
*Supported by 1R01 MH076971-01; NARSAD Independent Investigator Award
**Supported by Pat R. Rutherford, Jr. Chair in Psychiatry
704. Distinguishing Bipolar and Unipolar 
Depression: A Lifespan Perspective
Nick Craddock1, Madhukar H. Trivedi2, Mary L. 
Phillips3, Cecile D. Ladouceur4
1Cardiff University, Cardiff, United Kingdom, 2University of Texas 
Southwestern Medical Center, Dallas, TX, 3University of Pittsburgh, 
Pittsburgh, PA, 4University of Pittsburgh, Pittsburgh, PA
Individuals with bipolar disorder are often misdiagnosed with unipolar 
depression, leading to inadequate treatment and poor outcome. Identifying 
specific characteristics that distinguish bipolar and unipolar depression is 
critical to refining assessment and treatment strategies. As such, the goal of this 
workshop is to assemble a group of researchers that will contrast the genetic, 
clinical, and neurobiological aspects of bipolar and unipolar depression in 
patients and individuals at risk for these disorders. Dr. Craddock will present 
genotyping data on 2700 patients with bipolar spectrum illness and 3000 
population controls, which he will discuss in view of elucidating the biological 
mechanisms underlying mood disorders and their psychiatric nosology. 
Dr.Trivedi will contrast data on the phenomenology, clinical course, and 
treatment outcomes for adult patients with bipolar and unipolar depression. 
Dr. Phillips will present fMRI and neurocognitive data in adult patients with 
bipolar and unipolar depression compared to healthy controls and discuss 
how distinguishable patterns of abnormal neural and behavioral responses to 
emotional stimuli may reflect specific endophenotypes of bipolar and unipolar 
depression. Finally, Dr. Ladouceur will compare neural responses to emotional 
stimuli in offspring at risk for bipolar disorder, offspring at risk for depression, 
and healthy controls. Results will be discussed focusing on the specificity of 
neurodevelopmental risk markers of bipolar and unipolar depression and how 
such findings can inform early intervention strategies. Dr. Swann will lead 
the discussion centered on the importance of combining genetic, clinical, and 
neuroimaging measures in ways that will improve diagnostic accuracy and 
treatment of bipolar and unipolar depression.
Supported by Wellcome Trust, NIMH, 1R01 MH076971-01; NARSAD 
Independent investigator Award, NARSAD
MINI SYMPOSIA
Regulation of Adult Neurogenesis in the Monkey
Saturday, May 3, 2008 12:30 PM - 2:00 PM
Location: Capitol A
Chair: Cynthia Shannon Weickert*
Co-Chair: Andrew J. Dwork
*Supported by Schizophrenia Research Institute, Sydney, Australia
**Supported by K08 MH070954 (Perera), NARSAD
705. Stress and Aging Decrease Adult 
Neurogenesis in the Marmoset
Elizabeth Gould
Princeton, New Jersey, NJ
Background: Adult neurogenesis in the hippocampus has been extensively 
studied in the rodent. Whether the findings from rodent studies are relevant to 
the primate brain is a matter of debate. The possibility that structural change is 
reduced in more complex animals, as opposed to rodents, has been raised. We 
examined whether the same conditions which regulate adult neurogenesis in 
the rodent do so in the nonhuman primate by investigating known modulators 
of this process, stress and age.
Methods: Adult marmoset monkeys were used for these studies. The effects 
of subordination stress were examined in animals subsequently injected with 
BrdU and perfused after a short time interval. Additional marmosets were 
examined for the rate of adult neurogenesis at different ages.
Results: Subordination stress decreased the number of BrdU labeled cells in the 
dentate gyrus of marmosets. This effect was similar in magnitude and timing 
to that observed for effects of stress on adult neurogenesis in rats. The rate of 
adult neurogenesis was also negatively correlated with age in adult marmosets. 
Older marmosets generated significantly fewer neurons than did young adults 
- the decline in adult neurogenesis occurred long before the animals reached 
senescence. This decline was similar in timing and magnitude to what has been 
observed for rats.
Conclusions: These findings indicate that adult neurogenesis in the 
hippocampus is a robust phenomenon in nonhuman primates. Stress and aging 
downregulate new neuron production in primates. Taken together, the results 
suggest conservation of plasticity mechanisms across mammalian species.
Supported by NARSAD and NIH
706. The Number, Type and Function of New 
Neurons in the Primate Frontal Cortex
Richard Saunders
NIMH
Background: Questions have been raised regarding the biological and 
functional relevance of newly generated cortical neurons in postnatal primate 
brain. While large numbers of new cells are dividing during postnatal life, 
only a small proportion of adult-born macaque pre-frontal cortex cells express 
NeuN, a marker of mature neurons. Some newly generated cortical cells 
are also co-labeled with GAD67 and calretinin, demonstrating that new 
neurons can differentiate into cortical interneurons. Newly generated cells in 
neurogenic zones become progressively restricted throughout life with aging 
brains showing only 10% of the dividing cells found in infant brains.
Methods: Determine if restricted amount of adult postnatal cortical 
neurogenesis could be enhanced by molecular or environmental factors and 
whether newly generated neurons increase in monkeys engaging prefrontal 
cortex during working memory relative to control and baseline.
www.sobp.org/journal
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Results: Proliferating cells doubled in the subventricular zone after peripheral 
injection of basic Fibroblast Growth Factor. These did not translate into a 
change in the number of new prefrontal cortex neurons at longer survival times 
(4 weeks), suggesting other factors may recruit or retain new cortical cells. 
There were no differences in total number of BrdU/NeuN+ cells in frontal 
cortex during working memory. There was a significant increase in newly 
generated neurons co-labeled for immediate early genes in monkeys engaging 
working memory.
Conclusions: These findings suggest that newly generated neurons are more 
likely to be activated in adult primate prefrontal cortex during working memory 
and that neurogenesis is a developmentally dynamic, modifiable phenomenon 
having functional significance in adult primates.
707. Characterizing Immature Neurons in the 
Primate Amygdala: A Developmental Approach
Julie Fudge
University of Rochester, Rochester, NY
Background: The amygdala, a brain structure involved emotional processing, 
is dysregulated in mood and anxiety disorders based on human studies. These 
disorders often appear in late childhood and adolescence. However, animal 
models of depression have focused primarily on hippocampal changes. Rodent 
models show that chronic stress results in deleterious effects on hippocampal 
size, and cell morphology and proliferation, and antidepressants prevent these 
changes.
Methods: To bridge the ‘disconnect’ between human (amygdala) and rodent 
(hippocampus) models, we used immunocytochemical studies to show that the 
primate amygdala is enriched with immature neurons, which persist through 
adulthood. Moreover, immature neurons are expressed in amygdala subregions 
associated with hippocampal inputs, based on additional tract tracing studies. 
We are now using markers of neuronal immaturity (polysialated neural cell 
adhesion and doublecortin immunoreactivity) to quantify the relative numbers 
of immature neurons in the primate amygdala at discrete developmental 
timepoints.
Results: High levels of immature neurons are regionally distributed in the adult 
primate amygdala. The distribution of these cells indicates that they are positioned 
for modulation by the hippocampus. The relative numbers of immature neurons 
in infant, juvenile, adult, and senescent brain will be presented.
Conclusions: In higher primates, immature neurons in the amygdala suggest 
a substrate for emotional processing; this system is influenced by hippocampal 
memory circuits. Stress may negatively impact the growth and function of 
these cells, based on studies in rodent hippocampus. Identification of the 
density curve for immature neurons across the lifespan will help pinpoint 
critical periods of growth and vulnerability.
708. Role of Adult Neurogenesis in Antidepressant 
Action Modeled in Non-human Primates
Tarique Dhyan Perera
Psychiatry, Columbia University and New York State Psychiatric 
Institute, New York, NY
Background: Antidepressants stimulate neurogenesis in the rodent 
hippocampus and blocking neurogenesis abolishes therapeutic effects of 
antidepressants in certain mouse strains. These results generated the hypothesis 
that stimulation of neurogenesis is necessary for antidepressant action. This 
study is the first test of this hypothesis in monkeys.
Methods: Socially housed, female, adult, bonnet macaque monkeys were 
randomized to CONTROLS conditions (n=6); repeated separation and 
reunion STRESS (n=6); temporal lobe irradiation-XRT (n=6) prior to stress. 
The antidepressant fluoxetine was administered to half the animals in the 
CONTROL and STRESS groups, and all animals XRT group. The remaining 
3 subjects in the CONTROL and STRESS groups received saline-placebo. 
Stress and drug were administered for 15-weeks followed by sacrifice.
Results: Weekly home-cage behavior ratings showed a progressive increase 
in scores for ‘Anhedonia’ (lack of activity and social withdrawal) in placebo-
treated animals compared to fluoxetine-treated animals in the STRESS 
group and all subjects in the CONTROL group. Postmortem hippocampal 
cell proliferation rates were decreased in the placebo-treated animals of the 
STRESS group while neurogenesis rates were increased in fluoxetine-treated 
animals. The XRT group showed increases in stress-induced ‘Anhedonia’ and 
decreases in neurogenesis rates despite fluoxetine treatment.
Conclusions: The results suggest that irradiation abolished antidepressant-
mediated therapeutic effects by blocking the induction of neurogenesis. This 
is the first demonstration of the necessity of neurogenesis for antidepressant 
action in monkeys. Given the bio-behavioral similarities between across 




Substance P (Neurokinin-1) Receptor:
Neurobiology, Imaging, and Potential 
Therapeutic Target




709. Substance P: A Pioneer amongst 
Neuropeptides
Tomas Hokfelt
Karolinska Institutet, Stockholm, Sweden
Background: Substance P was discovered 1931 by von Euler and Gaddum. 
In 1971 Susan Leeman and collaborators showed that substance P is an 
undecapeptide. Other members of the tachykinin family are neurokinin B and 
neurokinin A, the latter with some N-terminally extended forms. Recently 
hemokinin-1 and endokinins have been identified. The tachykinins act via 
three G-protein coupled receptors, NK1-3.
Methods: Radioimmunoassay, immunohistochemistry and electrophysiology 
have been used to explore the distribution, levels and role of substance P.
Results: In the rat brain substance P has a wide distribution with high 
levels in the brain stem, including substantia nigra, striatum, hypothalamus, 
nucleus accumbens, basal forebrain, amygdala, the periaqueductal grey and 
the superficial spinal trigeminal nucleus. However, cortex and hippocampus 
only contain comparatively low numbers of cell bodies. Neurokinin B has a 
partly overlapping, partly complementary distribution. Also the NK1 and -3 
receptors are widely distributed. The distribution of substance P in the human 
lower brainstem is similar to that in rodents. In the monkey cortex substance 
P and substance K are present in two populations of cell bodies one being 
GABAergic cells. In the human cortex bipolar and some multipolar cells 
have been described. The hippocampus in man harbours three major classes 
of substance P interneurons. The NK1 receptor seems to be the predominant 
neurokinin receptor in the primate brain.
Conclusions: These findings suggest that tachykinin systems may be more 
widely expressed and possibly involved to a larger extent in higher brain 
functions in the primate as compared to rodent brain.
www.sobp.org/journal
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710. Patients with Panic Disorder Show Widespread 
Loss of NK1 Receptor Binding in Brain Measured 
with Positron Emission Tomography
Robert Innis
NIMH, Bethesda, MD
Background: Studies in animals have shown that pain and stress cause the 
release of substance P, which binds to and leads to the internalization of NK1 
receptors. For example, NK1 receptor internalization occurs in rat dorsal horn 
of the spinal cord after exposure to pain and in several forebrain regions after 
forced swim test. We sought to determine if similar internalization occurs in 
patients with panic disorder after induction of a panic attack.
Methods: One or two PET scans with [18F]SPA-RQ were performed in a total 
of 14 patients with panic disorder and 14 healthy subjects. Of these two groups, 
7 patients and 10 healthy subjects were scanned twice, at baseline and after 
injection of doxapram (to induce a panic attack).
Results: Doxapram effectively produced panic attacks in 6 of 7 patients with 
panic disorder but only 2 of 10 healthy subjects. Doxapram caused no significant 
change of [18F]SPA-RQ binding in either patients or healthy subjects. However, 
the binding at baseline in patients (n=14) compared to healthy subjects (n=14) 
showed widespread and statistically significant decreases. For example, most 
neocortical regions had 15~20% decrease (P<0.007).
Conclusions: Induction of a panic attack had no significant effect on NK1 
receptor binding in brain, suggesting that any released substance P neither 
displaced the radioligand nor that caused internalization of the receptor. 
Although the acute stress of a panic attack had no effect, the chronic presence 
in panic disorder caused the patients to have widespread decrease of NK1 
receptor binding in brain.
Supported by NIMH
711. PET Neuroimaging Studies of Substance P NK1 
Receptors in Major Depression
Jarmo Hietala
University of Turku, Finland, Turku, Finland
Background: Experimental studies have implicated substance P NK1 receptors 
in the regulation of mood and anxiety but clinical trials do not support a role of 
NK1 receptor antagonism as an antidepressant mechanism (aprepitant studies, 
Keller et al Biol Psychiatry 2006). However, direct measurements of NK1
receptors in vivo in patients with major depression have not been reported.
Methods: This is a cross-sectional case-control study in an outpatient setting 
in Finland. Nine antidepressant-naïve patients with major depression and nine 
age- and gender-matched screened healthy controls were included. Brain NK1
receptor availability (BPND) was measured in vivo using positron emission 
tomography and fluorine-18 labeled substance P NK1 receptor antagonist SPA-
RQ. Symptom severity was measured with the 17-item Hamilton depression 
rating scale (HAM-D).
Results: Patients with major depression had increased hippocampal NK1
receptor BPND. In addition, total HAM-D total scores correlated positively 
with NK1 BPND in widespread cortical and subcortical brain areas.
Conclusions: These preliminary PET neuroimaging studies suggest that 
hippocampal substance P NK1 receptors are altered in medication-naïve 
patients with major depression. The link between NK1 receptor availability 
and depresive symptoms as measured with the HAM-D supports a modulatory 
action of substance P NK1 receptors in the biology of major depression.
Supported by Merck Research Laboratories, USA,
712. Therapeutic Trials of NK1 Antagonists in 
Neuropsychiatric Disorders
Mary F. Morrison
Psychiatry, University of Pennsylvania, Philadelphia, PA
Background: Substance P is located in brain regions that coordinate stress 
responses and receive monoaminergic innervation. This observation suggested 
that substance P antagonists might have psychotherapeutic properties, 
particularly in depression and anxiety.
Methods: Review of scientific literature through PubMed, OVID and other search 
services for published data relating to use of NK-1 antagonists in neuropsychiatric 
disorders, particularly depression and anxiety. Contacted pharmaceutical companies 
who have or had NK-1 antagonists in development, for clinical data in neuropsychiatry 
not yet in the public domain that the companies were agreeable to release.
Results: When small efficacy trials of two NK-1 antagonists suggested 
antidepressant effects, there was significant excitement by psychiatrists eager 
for a novel antidepressant with a different side effect profile. Larger studies 
of MK-869 (aprepitant) did not confirm antidepressant efficacy, while active 
comparator paroxetine confirmed successful trials (p <or= .05). Imaging studies 
in patients with anxiety disorders (simple phobia, PTSD) suggest involvement 
of the substance P-NK-1 system in anxiety disorders. The only therapeutic 
trial performed with NK-1 antagonists and anxiety was a Phase II study in 
social anxiety disorder, but no results have been released yet. NK-1 antagonists 
for pain disorders, specifically studies in dental pain and painful diabetic 
neuropathy, were negative. An exploratory study of MK-869 in acute psychosis 
did not suggest efficacy of NK-1 antagonists in schizophrenia
Conclusions: Currently, there is no clear role for NK-1 antagonists in the 
treatment of neuropsychiatric disorders. Future directions for NK-1 antagonists 
in neuropsychiatry will be discussed.
SLIDE
Schizophrenia III: Endophenotypes
Saturday, May 3, 2008 12:30 PM - 2:00 PM
Location: Congressional A
Chair: Judith M. Ford 
713. Tones and “Voices” Compete for Auditory 
Cortical Resources: Multi-Site Fmri Study of 
Schizophrenia
Judith M. Ford1, Brian J. Roach1, Jessica Turner2,
Gregory Brown3, Gregory McCarthy4, Cynthia Wible5,
Keator David2, Steven Potkin2, Douglas Greve5,
Aysenil Belger6, Daniel O’Leary7, John Lauriello8,
Bryon Mueller9, Kelvin O. Lim9, Gary Glover10, Vince 
Calhoun11, Daniel H. Mathalon1
1Psychiatry, UCSF, San Francisco, CA,2Psychiatry, UCI, Irvine, 
CA,3Psychiatry, UCSD, San Diego, CA,4Psychology, Yale, New Haven, 
CT,5Psychiatry, Harvard, Cambridge, MA,6Psychiatry, University 
of North Carolina, Chapel Hill, NC,7Psychiatry, University of Iowa, 
Iowa City, IA,8Psychiatry, University of New Mexico, Albuquerque, 
NM,9Psychiatry, University of Minnesota, Minneapolis, MN,10Psychiatry, 
Stanford University, Stanford, CA,11Engineering, University of New 
Mexico, Albuquerque, NM
Background: Auditory hallucinations are experienced as one or more voices 
speaking in sentences or fragments, sometimes to the patient, sometimes to 
each other, in the absence external stimulation. Activation of primary auditory 
www.sobp.org/journal
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cortex may account for why these voices are “heard” as coming from outside the 
head, rather than as inner speech or thoughts. Hubl et al (2007) showed the N1 
component of the event-related brain potential to auditory probes was reduced 
during periods of hallucinations, suggesting competition for primary auditory 
cortex resources during hallucinations. Although N1 generation involves primary 
auditory cortex, it also involves other nearby structures. The current study uses 
the superior spatial resolution of functional magnetic resonance imaging (fMRI) 
to examine primary auditory cortex activation to frequently occurring tones as a 
function of hallucination presence, severity, and specific type (i.e., Schneiderian 
First Rank Symptoms of Voices Commenting or Voices Conversing).
Methods: fMRI data were collected from 65 frequently hallucinating patients 
with schizophrenia (DSM-IV), at 9 different national MR sites, as they 
performed an auditory oddball task. The strength of the neural response to 
2320 frequently occurring 1000 Hz tones was regressed against ratings of 
auditory hallucinations from the SAPS.
Results: Recent presence of auditory hallucinations, as well severity of 
hallucinations, were associated with less auditory cortex activation to tones 
(p<.01, uncorrected). This effect was most pronounced in patients who 
experienced voices conversing (p<.05, corrected).
Conclusions: This may reflect direct competition between voices and tones for 
auditory processing resources, particularly when the hallucinations involved 
interacting voices.
Supported by Biomedical Informatics Research Network U24RR021992.
714. In Vivo Assessment of Thalamocortical 
Connectivity in Schizophrenia Using DTI and 
Integrative Evidence from fMRI
Antonina A. Savostyanova1, Jason L. Stein1, Hao Y. 
Tan1, Aaron L. Goldman1, Joseph H. Callicott1, Jose 
A. Apud1, Andreas Meyer-Lindenberg2, Daniel R. 
Weinberger1, Stefano Marenco1
1Clinical Brain Disorders Branch, National Institute of Mental Health, 
Bethesda, MD,2Department of Psychiatry and Psychotherapy, Central 
Institute of Mental Health, Mannheim, Germany
Background: Despite evidence of altered dorsolateral prefrontal cortex 
(dlPFC) function in schizophrenia, the literature has been mixed regarding 
structural deficits in the thalamic medio-dorsal nucleus, which projects to the 
prefrontal cortex. We investigated in vivo whether the region of the thalamus 
preferentially projecting to the dlPFC is reduced in size in patients with 
schizophrenia and explored its functional significance.
Methods: We acquired diffusion-weighted images on 15 patients with 
schizophrenia and age- and gender- matched healthy volunteers. The thalamus 
was parcellated using probabilistic tractography (Behrens et al., 2003), allowing 
for overlapping connectivity defined regions (CDRs) by using a threshold of 
25% of connections reaching a particular cortical region of interest (ROI). A 
subset of our sample also underwent functional magnetic resonance imaging 
(fMRI) while engaging in the n-back working memory task.
Results: A significant interaction of cortical target ROI by diagnosis was found 
for the size of thalamic CDRs (Repeated-measures ANOVA: p=0.03). Post-hoc 
analyses revealed that only the size of the thalamic CDR connecting to the dlPFC 
differed between groups, with patients < controls (p=0.02). The size of this CDR 
correlated with blood-oxygenation-level-dependent (BOLD) activation in the 
dlPFC during n-back performance in healthy controls (BA9/46: r=-.843, p<.001) 
but not patients, who had less efficient activation despite matched performance.
Conclusions: These results suggest that connectivity between the thalamus 
and the dlPFC may be altered in patients with schizophrenia. The association 
of greater probabilistic thalamus-dlPFC connectivity with BOLD activation 
efficiency during a working memory task corroborates the biological 
significance of our tractography-derived measure.
Supported by NIMH-IRP
715. An fMRI Investigation of D-Cycloserine and 
Symptom Provocation in Spider Phobia
Robin L. Aupperle1, Lisa R. Hale2, Rebecca J. 
Chambers1, Sharon E. Cain3, Frank X. Barth3, Susan C. 
Sharp3, Douglas R. Denney4, Cary R. Savage3
1Hoglund Brain Imaging Center, University of Kansas Medical Center, 
Kansas City, KS,2Department of Neurology, University of Kansas 
Medical Center, Kansas City, KS,3Department of Psychiatry and 
Behavioral Sciences, University of Kansas Medical Center, Kansas City, 
KS,4Department of Psychology, University of Kansas, Lawrence, KS
Background: Research has shown acute D-cycloserine administration to 
enhance effects of exposure-based therapy. This fMRI study aims to elucidate 
mechanisms of DCS by examining brain activity associated with symptom 
provocation in spider phobia.
Methods: This study is in progress and results are preliminary. Data have 
been collected for 22 phobic and 20 non-phobic participants; 2 remain to be 
tested. We randomized all participants to receive 100mg DCS or placebo. At 
two hours (Session 1) and one week (Session 2) post-medication, two BOLD 
scans were acquired and included blocks of spider, butterfly, and Gaussian-
blurred pictures. We broke the blind and analyzed data for 8 phobic (3-DCS, 
5-Placebo) and 11 non-phobic (6-DCS, 5-Placebo) participants. Multiple 
regression analyses were conducted comparing Session 1 and 2 activations. 
Regions considered significant met p≤.01 (corrected) and cluster size>10.
Results: The DCS-phobic group showed greater activation to phobic 
stimuli during Session 1 v. 2 in bilateral amygdala (x,y,z=15,-4,-14), bilateral 
hippocampus (x,y,z=-30,-10,-17), left cingulate (x,y,z=-3,8,46), right fusiform 
gyrus (x,y,a=27,-1,-35), left orbitofrontal cortex (x,y,z=-30,32,1), left premotor 
cortex (x,y,z=-57,-3,40), and left prefrontal cortex (PFC;BA9,x,y,z=-30,44,38; 
BA10,x,y,z=-16,65,19; BA46,x,y,z=-54,35,11). The same contrast in the placebo 
group revealed activations in only the left primary motor cortex (x,y,z=-51,2,31) 
and left PFC (BA44;x,y,z=-51,-1,22). The control groups showed no differential 
activations between sessions.
Conclusions: Results indicate that, compared to placebo, DCS produces greater 
differential activations between sessions involving symptom provocation. This 
suggests that DCS modulates activity in regions important for emotional 
learning - primarily amygdala, hippocampus, and PFC. This study will be 
completed and results updated for presentation.
Supported by KUMC Research Institute; HBIC Pilot Funds; APA Dissertation 
Research Award; APF Research Scholarship
716. Striatal Dopaminergic Dysfunction Underlies 
‘Prodromal’ Psychotic Symptoms and Predates 
the Onset of Schizophrenia: Results from an [18F]-
DOPA PET Study
Oliver D. Howes1, Andrew Montgomery2, Isabel Valli1,
Marie-Claude Asselin3, Robin M. Murray1, Philip K. 
McGuire1, Paul M. Grasby4
1Psychological Medicine, Institute of Psychiatry, London, 
United Kingdom,2Hammersmith Hospital, PET centre, Clinical 
Sciences Centre, LONDON, United Kingdom,3Wolfson Molecular 
Imaging Centre, University of Manchester, Manchester, United 
Kingdom,4Hammersmith Hospital, PET Centre, Clinical Sciences 
Centre, London, United Kingdom
Background: It is not known when dopaminergic overactivity first occurs in 
schizophrenia. We investigated this in people with ‘prodromal’ schizophrenic 
symptoms, who have an ‘at risk mental state’ (ARMS) and are at ultra high risk 
of developing schizophrenia in the next year.
www.sobp.org/journal
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Methods: The following age-matched groups have received an [18F]-DOPA 
PET scan: A) individuals with ARMS (n= 24); B) patients in the first episode 
of schizophrenia (n=7); C) healthy controls (n=12). To date six ARMS and 
five control subjects have been re-scanned after over one year. Subjects were 
antipsychotic naïve/ free. [18F]-DOPA influx constants (Ki values) were calculated 
from region-of-interest (ROI) derived time-activity curves (Patlak et al, 1985).
Results: Figure 1 shows the results of the ROI analysis for the whole striatum. 
Dopamine synthesis capacity was significantly greater in the ARMS group 
(t=2.2, df=34 , p=0.038), and psychosis group (t=2.5,df=17, p=0.02) than the 
healthy controls. Within the ARMS group, there was a positive correlation 
between the whole striatal Ki values and the total prodromal symptoms (r=0.48, 
p=0.019) and PANSS score (r=0.49, p=0.014), but not other symptoms.
Conclusions: Striatal dopaminergic overactivity predates the onset of psychosis 
in people at risk of schizophrenia, and is related to psychotic psychopathology. 
Further follow-up scans are required to determine if ARMS convertors and non 
- convertors (to psychosis) show differential striatal FDOPA uptake over time.
Supported by Medical Research Council UK
717. [11C]PHNO and [11C]racloride PET Imaging of 
Dopamine Receptors in Drug-Naive Parkinson’s 
Disease
Isabelle Boileau1, Mark Guttman1, Sylvain Houle2,
Pablo Rusjan2, Alan A. Wilson2, Shitij Kapur2, Stephen 
J. Kish1
1Human Neurochemical Pathology Laboratory, Centre for Addiction and 
Mental Health, Toronto, ON, Canada,2Vivian M. Rakoff PET Imaging 
Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada
Background: Long-term treatment of Parkinson’s disease (PD) with 
dopaminergic drugs often leads to abnormal movements as well as disabling 
psychological disturbances. Animal models suggest that changes in the 
expression of dopamine receptors (DAr) might contribute to these complications. 
It has been proposed that a disproportionate stimulation of D3DAr could be 
responsible for complications secondary to levodopa. To date, there are no data 
on the status of the D3DAr system in PD. Recently it has been shown that the 
new DAr ligand [11C]PHNO is a D3-preferring agonist and therefore allows 
better measurement of the D3DAr system in humans. The objective of this 
study was to investigate the expression of D2DAr ([11C] raclopride binding) 
and D3DAr ([11C]PHNO binding) in PD.
Methods: 8 never-treated PD patients and 9 healthy-controls participated in 
(2) scans: following [11C]PHNO and [11C] raclopride.
Results: Preliminary results indicate that relative to controls, PD patients 
have decreased [11C]PHNO binding in D3-rich regions including the ventral 
striatum (-13%; p=0.03) and globus pallidus (-35%; p=0.02). In contrast, [11C]
PHNO as well as [11C]raclopride binding in the predominantly D2-dense 
putamen is increased (26%; p=0.002; 26%; p=0.001).
Conclusions: These preliminary findings suggesting a downregulation of 
D3DAr and upregulation of D2DAr in never-treated PD patients are in line 
with previous PET [11C]raclopride studies and with animal models of 
dopaminergic denervation. A better understanding of the role of the D3DAr
in the mechanism of sensitization to DA replacement therapy could provide
insight into identifying new drug targets for PD.
718. Comorbid Major Depression Accounts for 
Lower Early Morning Plasma Cortisol Levels 
and Alterations in Plasma Dehydroeandosterone 
Sulphate (DHEA- S) in Posttraumatic Stress 
Disorder
Jessica M. Gill1, Dave Luckenbaugh2, Carlos Collin3,
Katherine Plumb2, Kathleen West2, Omer Bonne4,
Dennis Charney5, Meena Vythilingam2
1National Institute of Nursing Research, National Institutes of Health, 
Bethesda, MD,2National Institute of Mental Health, National Institutes 
of Health, Bethesda, MD,3Behavioral Health, Community Behavioral 
Health, Rockville, MD,4Department of Psychiatry, Hadassah Medical 
Center, Jerusalem, Israel,5Psychiatry, Neuroscience, Mount Sinai 
School of Medicine, New York, NY
Background: Alterations in function of the hypothalamic-pituitary-adrenal 
(HPA) axis have been reported in posttraumatic stress disorder (PTSD) 
patients; however the influence of co-morbid major depressive disorder (MDD) 
has not been well studied.
Methods: Overnight (7pm- 7am) plasma cortisol, adrenocorticotropic hormone 
(ACTH), dehydroeandosterone sulphate (DHEA- S) levels were measured in 
15 patients with PTSD without MDD, 6 with PTSD and MDD and 16 non-
traumatized healthy controls. Linear mixed models with BMI and age as covariates 
and Bonferroni corrected post hoc tests were used to examine group differences.
Results: When plasma cortisol levels in patients with PTSD with and without 
MDD were compared to healthy controls, there was a significant group by time 
interaction (F=1.50, df=48,500, p=.02). Patients with PTSD and MDD had 
significantly lower plasma cortisol levels at 1:30 am and between 2:30 and 4:30 
am compared to healthy controls (p’s<.02), whereas those with PTSD without 
MDD did not differ from the control group at any time point (p’s>.07). Plasma 
DHEA-S levels were also significantly different between the three groups. 
While plasma DHEA-S levels in healthy controls returned to baseline (7 pm) 
levels by 6:00 am, the PTSD patient groups returned to baseline slower. ACTH 
levels did not differ by group.
Conclusions: Co-morbid MDD may contribute to lower plasma cortisol levels 
and abnormalities in plasma DHEA-S levels seen in PTSD patients.
Supported by NIMH-03-M-0292
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719. One Year Stability of Cognitive and 
Neurophysiological Endophenotypes of 
Schizophrenia
Gregory A. Light1, Neal R. Swerdlow1, Kristin S. 
Cadenhead1, Joyce Sprock1, Allen Radant2, David L. Braff1
1Psychiatry, University of California, San Diego, La Jolla, CA,2Psychiatry 
and Behavioral Sciences, University of Washington, Seattle, WA
Background: Endophenotypes are quantitative, laboratory-based measures 
that are thought to represent intermediate links in the pathways between 
genetic variation and the clinical expression of the disorder. The aim of the 
present study was to examine the one-year stability of several neurocognitive 
and neurophysiological endophenotypes in schizophrenia patients and 
nonpsychiatric community comparison subjects (NCS).
Methods: Schizophrenia patients (N=120) and NCS (N=40) were assessed on 
a battery of neurocognitive and neurophysiological measures at intake (N=200) 
and after 12 months.
Results: Neurocognitive endophenotypes, mismatch negativity, P3a, 
prepulse inhibition, and oculomotor antisaccade measures were highly 
stable (ICCs=0.80 to 0.95) in both schizophrenia patients and NCS. Startle 
habituation was reliable in NCS (ICC=0.86) but not in the schizophrenia 
patients (ICC=0.42). While P50 suppression ratios were not stable in either 
NCS or patients (ICCs=0.10, 0.22 respectively), the stability of individual 
S1 (ICCs>0.80) and S2 amplitudes (ICCs>0.65) and S1-S2 difference scores 
were significant (ICCs>0.50) for both groups. No significant differences in 
the baseline characteristics were observed across several clinical, cognitive, 
functional, or endophenotype variables for the patients who returned vs. failed 
to return for follow-up testing.
Conclusions: The results of the present study indicate that the majority of 
putative endophenotypes in schizophrenia research are highly reliable over a 
1 year interval. These measures did not demonstrate practice or maturation 
effects, suggesting that they are suitable as repeated measures for clinical 
outcome studies (e.g., drug effects). Attrition in the schizophrenia sample was 
not associated with baseline clinical, cognitive, or functional variables.
Supported by NARSAD, VISN-22 MIRECC, MH042228, MH079777, and 
MH065571
720. Epigenetic Regulation of the Reelin and GAD1 
Promoters in Schizophrenia
Dennis R. Grayson
Psychiatry, University of Illinois at Chicago, Chicago, IL
Background: Evidence is accumulating that in schizophrenia, cognitive 
deficits appear to relate to a GABAergic neuronal pathology. The reelin and 
GAD1 down-regulation in post mortem schizophrenia brains is well established 
and likely part of a larger GABAergic core deficit associated with the disease. 
Dnmt1 is highly expressed in post-mitotic neurons and is increased in those 
same neurons in which the reelin and GAD1 mRNAs are decreased. This 
suggests that Dnmt1, possibly acting together with other Dnmts and methyl 
binding proteins, functions in establishing DNA methylation patterns in post-
mitotic neurons.
Methods: We have used a combination of methylation and HDAC inhibitors 
to activate reelin and GAD1 expression in human neural progenitor cells. 
Using Western blots, competitive PCR and ChIP assays, we are able to examine 
changes in local chromatin remodeling.
Results: Inhibitors of Dnmt and HDAC activity induce reelin and GAD1 
mRNAs with identical EC50 values and a comparable time frame. These 
treatments are accompanied by reduced amounts of Dnmt activity, Dnmt1 
mRNA and protein. ChIP assays show that expression of the human reelin 
gene correlates with the dissociation of Dnmt1, Dnmt3a, Dnmt3b and MeCP2 
from the promoter.
Conclusions: Our data are consistent with the concept that reelin and GAD 
1 are epigenetically regulated through changes in methylation. Moreover, the 
data suggest that both Dnmt and HDAC inhibitors act through a common 
mechanism by disrupting a large repressor complex that blocks expression. It 
seems likely that Dnmts and HDACS may represent new targets for developing 
drugs that may be useful in treating patients with schizophrenia.
Supported by R01MH062682
721. Neurophysiological Distinction between 
Schizophrenia and Schizoaffective Disorder
Daniel H. Mathalon, Ralph Hoffman, Brian Roach, 
Todd D. Watson, Judith M. Ford
Psychiatry, Yale University School of Medicine, West Haven, CT
Background: Schizoaffective disorder (SAD) is distinguished from 
schizophrenia (SZ) based on the presence of prominent mood symptoms over 
the illness course. Despite this clinical distinction, SAD and SZ patients are 
often combined in research studies, in part because data supporting a distinct 
pathophysiological boundary between the disorders are lacking. Indeed, few 
studies have addressed whether neurobiological abnormalities associated with 
SZ, such as the widely replicated reduction and delay of the P300 event-related 
potential (ERP), are also present in SAD.
Methods: Scalp EEG was acquired from patients with DSM-IV SAD (n=15) or SZ 
(n=22), as well as healthy controls (HC; n=22), to assess the P300 elicited by infrequent 
target (10%) and novel (10%) stimuli in separate auditory and visual “oddball” tasks.
Results: P300 amplitude was reduced and delayed in SZ, relative to HC, 
consistent with prior studies. These SZ abnormalities did not significantly 
interact with stimulus type (target vs. novel) or modality (auditory vs. visual). 
Across sensory modality and stimulus type, SAD patients exhibited normal 
P300 amplitudes (significantly larger than SZ patients and indistinguishable 
from HC). However, P300 latency and reaction time were both equivalently 
delayed in SZ and SAD patients, relative to HC. P300 differences between 
SAD and SZ patients could not be accounted for by variation in symptom 
severity, socio-economic status, education, age, or antipsychotic medication.
Conclusions: Although both groups show similar deficits in processing speed, SAD 
patients do not exhibit the P300 amplitude deficits evident in SZ, providing validating 
evidence for an underlying pathophysiological boundary between these disorders.
www.sobp.org/journal
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722. 18F-Fluorodeoxyglucose PET-Gided Versus 
Left Standard 10 Hz Repetitive Transcranial 
Magnetic Stimulation in Patients with Medication-
Resistant Depression: A Randomized Sham-
Controlled Add-On Study
Marie-Laure Paillère Martinot1, André Galinowski2,
Damien Ringuenet3, Frank Bellivier4, Jean-Pascal 
Lefaucheur5, Christine Picq6, Thierry Gallarda2,
Pascale Bruguière6, Jean-François Mangin7, Denis 
Rivière8, Bruno Falissard9, Jean-Claude Willer10, Marion 
Leboyer11, Jean-Pierre Olié12, Eric Artiges13, Jean-Luc 
Martinot13
1Adolescent Medicine, APHP, Hôpital Cochin, Paris, France,2Service 
Hospitalo-Universitaire, Hôpital Sainte-Anne, Paris, France,3Psychiatry, 
APHP, Hôpital Paul Brousse, Villejuif, France,4Psychiatry, APHP, 
Hopital Henri Mondor-Albert Chenevier, Créteil, France,5Physiology, 
APHP, Hôpital Henri Mondor-Albert Chenevier, Créteil, 
France,6Physical Medicine and Rehabilitation, APHP, Hôpital 
Pitié-Salpêtrière, Paris, France,7NMR Lab, Inserm-CEA-U797, 
I2BM, CEA Neurospin, IFR49, Gif-sur-Yvette, France,8NMR 
Lab, Inserm-CEA U797, I2BM, CEA Neurospin, IFR49, Gif-sur-
Yvette, France,9Biostatistics, APHP, Hôpital Paul Brousse, Villejuif, 
France,10Physiology, APHP, Hôpital Pitié-Salpêtrière, Paris, 
France,11Psychiatry, APHP, Hôpital Henri Mondor-Albert Chenevier, 
Créteil, France,12Service hospitalo-universitaire, Hôpital Sainte-Anne, 
Paris, France,13Service Hospitalier Frédéric Joliot, Inserm-CEA U797, 
I2BM, IFR49, Orsay, France
Background: Whether the antidepressant effects of repetitive Transcranial 
Magnetic Stimulation (rTMS) relate to targeting metabolic prefrontal changes 
or specific anatomical areas remains unclear. We investigated the effects of 
high-frequency rTMS over the most hypometabolic prefrontal area in patients 
with medication-resistant depression, in a multisite, double-blind, randomized 
placebo-controlled add-on study.
Methods: 48 patients with major depression underwent Magnetic Resonance 
imaging (MRI) and 18-Fluorodeoxyglucose Positron Emission tomography 
(PET) to determine a target for rTMS. They were randomized to PET-guided 
(N=16), standard (N=18) or sham rTMS (N=14) conditions to receive 10 
sessions of 10-Hz rTMS, 1600 pulses/session, at 90% motor threshold. Primary 
outcome was the Montgomery and Asberg Depression Rating Scale (MADRS) 
symptom score change from baseline. Anatomical stimulated Brodmann areas 
(BA) were a posteriori determined from MRIs. Right and left PET-guided 
rTMS effects and effects of stimulation over dorsolateral prefrontal cortex 
(BA9-46) were assessed in exploratory analyses.
Results: Neither PET-guided nor standard rTMS was superior to sham rTMS 
on the MADRS at 2-week end-point. However, left PET-guided patients 
(N=9) showed a significant improvement over sham-treated, and a larger 
improvement over standard-treated patients. Right PET-guided was similar 
to sham stimulation. Eight patients in the PET-guided and 7 patients in the 
standard group were stimulated over BA9-46. BA9-46 stimulation was more 
effective than stimulation over other areas.
Conclusions: High-frequency rTMS is more effective over left hypometabolic 
prefrontal areas and over the left dorsolateral prefrontal cortex (BA9-46). Left 
prefrontal metabolic status and anatomical area underneath the coil might 
both interact to account for the antidepressant effects of rTMS.
Supported by PHRC/AOM-98099, Inserm-Progres A99013LS, & APHP/
Inserm interface grant
723. A Novel Electrophysiological Model of 
Chemotherapy-Induced Cognitive Impairment in 
Mice
Michael J. Gandal1, Rich S. Ehrlichman2, Noam D. 
Rudnick2, Steven J. Siegel2
1Medical Scientist Training Program, University of Pennsylvania, 
Philadelphia, PA,2Department of Psychiatry, University of Pennsylvania, 
Philadelphia, PA
Background: Chemotherapeutic agents have been shown to produce moderate, 
persistent cognitive deficits in cancer patients. However, little progress has been 
made in developing an animal model to explore underlying mechanisms and 
potential therapeutic interventions. Here, we have created an electrophysiological 
model of chemotherapy-induced cognitive deficits using a sensory gating 
paradigm, to correspond with performance in two behavioral tasks.
Methods: Adult mice (n=24) were divided into three groups and received four 
weekly injections of Methotrexate and 5-Fluorouracil at high dose (37.5mg/kg 
MTX + 75mg/kg 5-FU), low dose (1:2 dilution), or control. Whole-brain ERPs 
were recorded at weeks 1,3, and 5 with unipolar electrodes using a paired-
click paradigm. Mice underwent contextual fear conditioning and novel-object 
recognition testing. Data was analyzed using repeated-measures ANOVA.
Results: A significant interaction (p=0.00306) was found between gating ratios 
and week, with higher ratios (suppressed auditory gating) in low (p=0.022) 
and high-dose (p=0.036) groups compared to control at week 5. There was no 
effect of drug on the amplitude of P20-N40 or latency of P20. The drug treated 
animals showed significantly increased freezing during fear conditioning 
(p=0.044) but no impairment during novel object recognition.
Conclusions: Treatment with chronic chemotherapy causes decreased ability 
to gate incoming auditory stimuli, which may underlie its associated cognitive 
deficits. These gating deficits were associated with a hyperactive response to 
fear, suggesting an additional component of emotional dysregulation. However, 
amplitudes and latencies of ERP components were unaffected, as was NOR 
performance, indicative of the subtle nature of these deficits.
Supported by Abramson Cancer Center, University of Pennsylvania
724. Abbreviated Cognitive Assessment in 
Schizophrenia: Prediction of Functional and 
Cognitive Outcomes
Philip D. Harvey1, Christopher R. Bowie2, Robert K. 
Heaton3, Thomas L. Patterson4
1Psychiatry and Behavioral Sciences, Emory University School of 
Medicine, Atlanta, GA,2Psychiatry, Mt. Sinai School of Medicine, 
New York, NY,3Psychiatry, UCSD School of medicine, LaJolla, 
CA,4Psychiatry, UCSD School of Medicine, LaJolla, CA
Background: The aim of this study was to identify the best subset of 
neuropsychological tests for prediction of different aspects of functioning 
in a large (n=236) sample of older people with schizophrenia. Efficient 
neuropsychological assessment may increase availability of neuropsychological 
assessment and improvements in research methods. 
Methods: Scores on ten different NP tests were used to predict global NP 
performance (indexed with averaged or general deficit scores), performance-
based indices of everyday living skills and social competence, and ratings of 
real-world functioning. Stepwise regression analyses were used to identify the 
best predictors for each of the outcomes measures. Then, a set of three NP tests 
previously shown to predict overall NP performance was applied to each of the 
outcomes measures.
www.sobp.org/journal
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Results: Substantial amounts (over 70%) of the variance in NP performance 
were accounted for by a limited number of NP tests. Considerable variance in 
measures of functional capacity were accounted for by a limited number of 
tests. Processing speed was the best predictor of all outcomes, although the 
other predictors included working and episodic memory. When the a priori set 
of three tests was applied to each outcome variable, the level of predictability 
was minimally affected.
Conclusions: A substantial proportion of the variance in several different NP 
and functional outcomes can be accounted for by a small number of NP tests 
that can be completed in a few minutes. Future studies should determine if 
responses to treatments can be captured with brief assessments as well.
Supported by NIMH R01MH63116
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725. Predictors of Neonatal Hypothalamic-Pituitary-
Adrenal Axis Activity at Delivery in Women with 
Psychiatric Illness
Alicia K. Smith1, Elyse R. Katz2, D. Jeffrey Newport3,
Patricia A. Brennan4, James C. Ritchie5, Morgan P. 
Ashe3, Charles B. Nemeroff3, Joseph F. Cubells1,
Zachary N. Stowe3
1Human Genetics, Emory University, Atlanta, GA,2Neuroscience, 
Emory University, Atlanta, GA,3Psychiatry and Behavioral Sciences, 
Emory University, Atlanta, GA,4Pyschology, Emory University, Atlanta, 
GA,5Pathology & Laboratory Medicine, Emory University, Atlanta, GA
Background: Evidence suggests that maternal psychiatric illness during 
pregnancy influences both the maternal and neonatal hypothalamic-pituitary-
adrenal (HPA) axis, potentially predisposing the neonate to significant, long-
term consequences.
Methods: Measures of HPA axis components [adrenocorticotrophic hormone 
(ACTH), total cortisol, free cortisol, and cortisol-binding globulin (CBG)] were 
analyzed in 216 paired maternal and umbilical cord blood samples collected at 
delivery from women with a history of psychiatric illness. ANOVA was used to 
test the association of maternal race, age, body-mass index (BMI) at delivery, 
current psychiatric diagnosis, method of delivery and neonatal estimated 
gestational age at delivery with neonatal HPA axis measures, followed by 
logistic regression to determine if indices of the maternal HPA axis predicted 
corresponding neonatal measures.
Results: Method of delivery was associated with neonatal ACTH concentrations 
(p= 0.025) as well as total and free cortisol concentrations (p<0.0001-0.027). 
Estimated gestational age (weeks) was associated with neonatal free cortisol 
(p=0.031). After controlling for method of delivery and estimated gestational 
age where appropriate, we found that maternal ACTH predicted 25.0% of the 
variance in neonatal ACTH (p<0.0001), and maternal free and total cortisol 
predicted of 42.3% and 23.5% of the variance in neonatal free and total 
cortisol, respectively (p<0.0001).
Conclusions: Indices of maternal and neonatal HPA axis activity at parturition 
are remarkably similar. We hypothesize that the neonate is not insulated from 
neuroendocrine sequelae of maternal stress. Future investigations are required 
to determine if there is a persistent effect on later child development.
Supported by K02 DA15766; P50 MH-58922 (Conte Center); P50 MH-77928 
(TRCBS)
726. High Dose Magnetic Seizure Therapy (HD-MST) 
Increases Mossy Fiber Sprouting but not Cellular 
Proliferation in the Primate Dentate Gyrus
Sarah H. Lisanby1, Jason Scalia1, Elisabeth 
Bernhardt1, Timothy Spellman1, Mark D. Underwood2,
Andrew J. Dwork2, Victoria Arango2
1Brain Stimulation and Therapeutic Modulation Division, Columbia 
University, New York, NY,2Molecular Imaging and Neuropathology 
Division, Columbia University, New York, NY
Background: Dentate gyrus mossy fiber sprouting (MFS) and cellular 
proliferation are elicited by electroconvulsive therapy (ECT), however their 
role in clinical efficacy and cognitive side effects is not understood. Magnetic 
seizure therapy (MST) is under development to improve the safety of ECT 
through enhanced control over stimulation and seizure initiation. We 
previously reported that MST does not induce cellular proliferation or MFS 
in monkey dentate gyrus, while electroconvulsive shock (ECS) induced both. 
Possible explanations include inadequate MST dosing and the use of ketamine 
as a pre-anesthetic. We sought to determine whether high dose MST (HD-
MST) shares the neuroplastic effects of ECS, using a ketamine-free protocol.
Methods: 18 rhesus monkeys were randomly assigned to receive 5 weeks 
of daily HD- MST (6x seizure threshold), ECS (2.5x seizure threshold), or 
anesthesia-alone SHAM. Bromodeoxyuridine (100 mg/kg qD x 6 days) was 
injected 5 weeks prior to sacrifice. Masked raters counted BrdU positive nuclei 
and scored the degree of MFS (Timm stain).
Results: HD-MST and ECS increased MFS relative to sham (p’s<0.01). ECS 
and HD-MST did not differ in the degree of MFS. ECS increased BrdU labeled 
cells relative to MST (p<0.05), while MST did not differ from SHAM.
Conclusions: Both ECS and HD-MST increase MFS, while only ECS increases 
cellular proliferation. This suggests that inducing a seizure is insufficient to 
enhance hippocampal proliferation and that the distribution of the induced 
electrical field and/or the seizure propagation may be critical. Differences in 
the neuroanatomical effects of HD-MST and ECS may be informative about 
their differential cognitive effects.
Supported by R01 MH60884
727. 5-HTTLPR Polymorphisms (SLC6A4 & rs25531) 
do not Affect 5-HT Transporter Expression in the 
Living Human Brain
Naga Venkatesha Murthy1, Philip J. Cowen2, Sudhakar 
Selvaraj2, Wim J. Riedel3, Polly Peers4, James Kennedy5,
Marc Laruelle6, Eugenii Rabiner6, Paul M. Grasby7
1Psychiatry CPDM, GSK Clinical Imaging Centre, Imperial College 
London, London, United Kingdom,2Department of Psychiatry, 
University of Oxford, Oxford, United Kingdom,3Department of Neruo 
& Psychopharmacology, Maastricht University, Maastricht, The 
Netherlands,4MRC-CBU, University of Cambridge, Cambridge, 
United Kingdom,5CAMH, University of Toronto, Toronto, ON, 
Canada,6Molecular Imaging, GSK Clinical Imaging Centre, Imperial 
College London, London, United Kingdom,7PET Psychiatry, MRC CSC, 
Imperial College London, London, United Kingdom
Background: Studies in vitro suggest the expression of the serotonin transporter 
(5-HTT) is regulated by polymorphic variation in the promoter region of the 
5-HTT gene (5-HTTLPR; Lesch, 1996, Science, 274:1527-1531; Hu, 2006, 
Am J Hum Genet, 78(5):815-826). However, evidence for this effect in vivo 
is inconsistent in human studies e.g. Praschak-Rieder, 2007, Biol Psychiatry, 
62:327-331; Parsey, 2006, Am J Psychiatry, 163:48-51. The reasons for this 
inconsistency may be smaller subject numbers or use of sub-optimal radiotracer.
Methods: We used positron emission tomography in conjunction with 
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the selective 5-HTT ligand [11C] DASB to examine the availability of 
the 5-HTT in seven brain regions in 63 healthy volunteers who were 
genotyped for short (S) and long (L) variants (SLC6A4 & rs25531) of the 
5-HTTLPR.
Results: [11C] DASB binding potential was not influenced by allelic status of 
participants whether classified on a biallelic or triallelic basis in any of the 
seven regions tested (see figure).
Conclusions: Our PET findings, in a large cohort with a near optimal 
radiotracer, suggest 5-HTTLPR polymorphic variations do not affect the 
expression of the 5-HTT in adult human brain. The reported impact of 
5-HTTLPR polymorphic variations on emotional processing and vulnerability 
to depression are more likely therefore to be expressed through effects during 
neurodevelopment.
Supported by Funded in part by GlaxoSmithKline & Medical Research Council
728. Cognitive Effects of DBS in the Ventral 
Striatum in Patients with Severe Major Depression 
and Obsessive Compulsive Disorder
Cynthia S. Kubu1, Benjamin Greenberg2, Don Malone1,
Steve Rasumssen2, Gerhard Friehs3, Andre Machado1,
Ali Rezai1
1Center for Neurological Restoration, Cleveland Clinic, Cleveland, 
OH,2Department of Psychiatry, Butler Hospital and Brown University, 
Providence, RI,3Neurosurgery, Brown University, Providence, RI
Background: Deep brain stimulation (DBS) for the treatment of severe 
Major Depression (MDD) and Obsessive Compulsive (OCD) appears to be 
a promising treatment. Thus far, little is known regarding neuropsychological 
outcome following DBS for the treatment of severe psychiatric disorders. We 
present neuropsychological data from our series of OCD (n=10) and MDD 
(n=10) patients who underwent DBS in the anterior limb of the internal 
capsule/ventral striatum (AC/VS).
Methods: The data reported in this study were obtained with approval by 
the relevant IRBs and the FDA. All patients completed a neuropsychological 
battery prior to and following surgery. Patients who had been undergoing 
maintenance ECT prior to surgery were not included in the study. Standardized 
change scores taking into account test-retest reliability and practice effects 
were computed. The OCD and MDD groups were compared to each other 
on the neuropsychological variables and the relationships between changes 
in neuropsychological status were analyzed with respect to improvements in 
psychiatric status.
Results: There were no significant group differences in neuropsychological 
outcome. DBS in the ventral striatum resulted in significant improvements 
in immediate (t(19)=2.7,p=0.014) and delayed (t(19)=2.8,p=0.012) recall of 
short stories. The cognitive improvements were not significantly related to 
improvements in psychiatric status (all r values <0.126, p>0.5).
Conclusions: These initial data suggest that DBS in the AC/VS for the 
treatment of severe OCD and MDD is safe from a cognitive perspective. These 
data also suggest that DBS in this region may result in improvements in memory 
independent of the concomitant improvements in psychiatric disability.
Supported by Medtronic; NARSAD
729. New Onset Depression in Parkinson 
Disease is Associated with Increased Memory 
Decline Following Deep Brain Stimulation in the 
Subthalamic Nucleus
Cynthia S. Kubu, Hooman Azmi, Darlene Floden, 
Andre Machado, Ali Rezai
Center for Neurological Restoration, Cleveland Clinic, Cleveland, OH
Background: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) 
for the treatment of Parkinson disease (PD) is well accepted. Unfortunately, 
few studies have identified clear risk factors for cognitive decline following 
STN DBS. We examined the role of depression and neuroimaging variables in 
neuropsychological outcome following STN DBS in patients with PD.
Methods: 38 patients with PD who underwent placement of bilateral DBS electrodes 
in the STN completed pre- and post-operative neuropsychological assessments 
as part of routine clinical care. Patients were divided into two groups (Depressed, 
n=11; Nondepressed, n=27) based on pre-operative Beck Depression Inventory 
score. Repeated measures ANOVAs were completed to evaluate differences in 
neuropsychological outcome between the two depressed groups. The two groups were 
compared on several different neuroimaging variables (e.g., corrected hippocampal 
volumes, total brain volumes, ventricular ratio, white matter disease).
Results: The groups did not differ with respect to demographic, pre-operative 
neuropsychological, or any of the neuroimaging variables. Several significant 
interactions were evident indicating that the Depressed group sustained greater 
declines on measures of verbal learning following surgery despite improvements 
in self-reported symptoms of depression after surgery.
Conclusions: Depressed PD patients who undergo bilateral placement of DBS 
electrodes in the STN are at greater risk for memory decline compared to non-
depressed patients. This relationship does not appear to reflect differences in 
neuroimaging variables. We argue that new onset depression in PD may be a 
marker of increased disease burden and, hence, reflect increased vulnerability 
for cognitive decline following STN DBS in patients with PD.
Supported by National Parkinson’s Foundation
730. Amygdala Enlargement and Shape Distortion 
in Bipolar Disorder
David C. Glahn1, Mark Jenkinson2, E Serap Monkul1,
Jennifer L. Robinson1, Carrie E. Bearden3, Michael 
A. Escamilla4, Peter T. Fox5, Stephen Smith2, Brian 
Patenaude2
1Psychiatry & Research Imaging Center, UTHSCSA, San Antonio, 
TX,2Oxford University Centre for Functional MRI of the Brain (FMRIB), 
Oxford University, Oxford, United Kingdom,3Psychiatry & Biobehavioral 
Sciences & Psychology, UCLA, Los Angeles, CA,4Psychiatry, 
UTHSCSA, San Antonio, TX,5Research Imaging Center, UTHSCSA, 
San Antonio, TX
Background: Although the amygdala may be central to the pathophysiology 
of bipolar disorder (BP), MRI-based findings of aberrant amygdala volumes in 
BP are inconsistent. Here, we applied a novel computational method to test for 
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shape and volume changes in the amygdala of BP patients.
Methods: 31 BP and 36 control subjects matched for age, gender, education 
and race participated. 800 μm isotropic neuroanatomic images were acquired 
and analyzed with a novel neural-network method that segments an individual’s 
anatomy, parameterize regions into a surface mesh, and models each vertex in 
a mesh as a multivariate point distribution.
Results: Gender (p=0.01) and age (p=0.05) significantly contributed to 
amygdala volume. After controlling for these factors, left (1763±235 vs 
1614±257, t=2.70, p=0.01) and right (1801±257 vs 1665±208, t=2.74, p=0.01) 
amygdala volumes were larger in BP patients compared to healthy subjects. 
Neither valproate (n=10; p=0.8) nor lamotrigine (n=9; p=0.3) significantly 
affected amygdala volumes in the BP sample. Shape analysis indicated that the 
amygdala enlargement was not uniform, rather significant group differences 
were primarily within the basolateral region (see Figure).
Conclusions: These data represent the first in vivo demonstration of basolateral 
amygdala disturbances in BP and help to confirm the importance of this region 
in the pathophysiology of the illness.
Supported by NIMH, NARSAD
SYMPOSIUM
Mechanistic Convergence of D2 and mGlu2/3 
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731. Preliminary Clinical Evidence Supporting the 
Therapeutic Potential of mGluR2/3 Agonists for the 
Treatment of Schizophrenia
John Krystal
Yale University School of Medicine
Background: Schizophrenia is a disorder associated with reduced pyramidal 
neuronal neuropil in post-mortem studies and abnormal cortical connectivity 
in structural neuroimaging and diffusion tensor imaging studies. Thus, it might 
seem that the efficacy of of metabotropic glutamate receptor 2/3 (mGluR2/3) 
agonists, drugs that inhibit glutamate release, might seem paradoxical.
Methods: This presentation would briefly review two human studies.
Results: 1) a human laboratory study conducted in our laboratory that suggested 
that pretreatment with single doses of LY354740 reduced the cognitive effects 
of the NMDA receptor antagonist, ketamine, in healthy human subjects and 
2) a recently published treatment study conducted by Eli Lilly and Company 
that provided initial evidence that another drug from this class, LY2140023, 
was efficacious in treating symptoms of schizophrenia. To our knowledge, 
these two studies constitute the entire published human literature linking 
mGluR2/3 agonism to schizophrenia.
Conclusions: These two studies support the further exploration of mGluR2/3 
agonism as a treatment strategy for schizophrenia.
Supported by NARSAD, NIMH, VA
732. Antipsychotic Drugs and mGlu2/3 Agonists 
Normalize the Impact of NMDA Hypofunction on 
Cortical Neurons
Bita Moghaddam
University of Pittsburgh, Pittsburgh, PA
Background: Hypofuntion of NMDA receptors may lead to some symptoms 
of schizophrenia, especially cognitive deficits such as impairments in working 
memory and attention that are dependent on the functional integrity of the 
prefrontal cortex (PFC). Postmortem studies indicate that schizophrenia may 
be associated with reduced cortical GABA function. We hypothesized that 
NMDA receptor hypofunction results in functional deficits of cortical GABA 
interneurons and that antipsychotic drugs ameliorate this deficit.
Methods: Ensemble recording in behaving animals was used to assess the 
firing rate and pattern of pyramidal and putative GABA interneurons in the 
prefrontal cortex
Results: NMDA receptor hypofunction selectively inhibits the firing of 
cortical GABA interneurons thus reducing the inhibitory influence of these 
neurons on cortical pyramidal cells. This reduced inhibitory control leads to 
a tonic state of disinhibition at these neurons as demonstrated by a sustained 
increase in random firing of cortical pyramidal neurons. This effect may 
diminish the capacity of PFC neurons to fire appropriately to task relevant 
stimuli and provides a neuronal model for large-scale integration abnormalities 
in schizophrenia. We also find that in behaving animals, existing antipsychotic 
drugs (including clozapine and haloperidol) as well as an mGlu2/3 receptor 
agonist reduce the impact of NMDA hypofunction on firing of cortical 
pyramidal neurons.
Conclusions: These data indicate that inhibition of D2 receptors and activation 
of mGlu2/3 receptors normalizes the disruptive effects of NMDA receptor 
hypofunction on spike activity and bursting of PFC pyramidal neurons. This 
mechanism may provide a physiological basis for the clinical efficacy of these 
compounds.
Supported by R37MH48408
733. Altered Dopaminergic Modulation of GABA 
and Glutamate Cortical Transmission in a 
Developmental Animal Model of Schizophrenia
Patricio O’Donnell1, Kuei-Yuan Tseng2, Carlos 
Feleder3
1Departments of Anatomy & Neurobiology and Psychiatry, University of 
Maryland School of Medicine, Baltimore, MD,2Cellular and Molecular 
Pharmacology, Rosalind Franklin University of Medicine and Science, 
North Chicago, IL,3Basic and Pharmaceutical Sciences, Albany College 
of Pharmacy, Albany, NY
Background: Interneurons are critical for prefrontal cortical (PFC) function 
and are affected in schizophrenia. As the D2 modulation of PFC interneurons 
changes during adolescence, we sought to determine whether this late 
maturation was altered in adult animals with a neonatal ventral hippocampal 
lesion (NVHL) or a neonatal immune challenge.
Methods: PD6-8 rat pups were injected in the ventral hippocampus with either 
ibotenic acid (NVHL) or a bacterial endotoxin (LPS). Once NVHL, LPS or 
sham animals were adults (PD>60), sensorimotor gating deficits were tested 
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with PPI; a week later whole-cell recordings were conducted from PFC fast-
spiking interneurons.
Results: The D2 agonist quinpirole increased cell excitability of PFC 
interneurons in slices from sham and naïve animals, but only in slices from 
adult rats. In pre-adolescent rats, quinpirole did not affect interneuron 
excitability in any group. In NVHL and LPS treated adult rats, quinpirole 
decreased interneuron excitability in many cases.
Conclusions: In the developmental animal models tested, the D2 agonist 
decrease in interneuron excitability may render prefrontal cortical circuits in a 
hyperactive state in which salient stimuli cannot be highlighted by decreasing 
background pyramidal neuron activity yielding an inefficient PFC; a functional 
equivalent of hypofrontality due to reduced cortical capacity. D2 blockade by 
antipsychotics is likely to restore some balance in these circuits by alleviating 
the abnormal D2 inhibition of interneurons and restoring local inhibitory 
function to some extent. Any compound that can restore interneuron function 
could provide a similar outcome, and this could be a reasonable target for novel 
therapeutic approaches in schizophrenia.
Supported by R01MH57683
734. The Role of D-Serine in NMDA Receptor 
Hypofunction in Schizophrenia
Joseph T. Coyle
McLean Hospital, Harvard Medical School, Belmont, MA
Background: For glumamate to open the channel on the NMDA receptor(R), 
the glycine B receptor on the NR1 subunit must be occupied by either 
glycine or D-serine. D-serine appears to be the primary agonist in cortical-
limbic regions. Recent genetic studies strongly implicate G72, an activator of 
D-amino acid oxidase (DAAO), DAAO itself and serine racemase (SR) as risk 
genes for schizophrenia.
Methods: To inactivate the gene encoding SR, lox-P sites were introduced flanking 
exon 1, which encodes the pyridoxal 5’-phosphate cofactor site. The mutant mice 
were crossed with mice expressing cre-recombinase, resulting the excision of exon 
1.Studies were carried out on mice back-crossed for >6 generations.
Results: SR-/- mice had no detectable SR mRNA on qPCR, and D-serine levels 
in brain were decreased by >80% by HPLC and at background levels with 
immunocytochemical staining. Whole cell clamping of the hippocampal CA1 
pyramidal cells revealed reduced NMDAR currents and profoundly impaired 
long-term potentiation that could be restored by perfusion with exogenous 
D-serine. Male SR-/- mice exhibited mild persistent hyperactivity and anxiety 
traits. In the Morris water maze, SR-/- acquired the task similar to WT but 
showed significant impairments in the working memory component. qPCR 
revealed significant reductions in the expression of glutamate decarboxylase 
(GAD72) and parvalbumen in the hippocampus, the signature neurocheical 
pathology of schizophrenia.
Conclusions: Reduced D-serine impairs NMDAR function. Cortical 
GABAergic neurons appear to be particularly vulnerable, resulting in the 




Gray Matter Abnormalities in Schizophrenia - 
What Do They Mean?
Saturday, May 3, 2008 2:30 PM - 5:00 PM
Location: Ticonderoga
Chair: Nitin Gogtay*
*Supported by NIMH Intramural Program
735. Gray Matter Abnormalities in Childhood-Onset 
Schizophrenia and Their Full Siblings from Early 
Childhood to Young Adulthood
Nitin Gogtay
NIMH, Bethesda, MD
Background: Cortical gray matter(GM) abnormalities, which are most 
prominently seen in childhood-onset schizophrenia(COS), are now an 
established feature in schizophrenia
Methods: COS Patients and their full siblings are studied longitudinally and clinical, 
genetic, and structural brain MRI data are obtained every two years. Cortical GM 
and white matter(WM) development are mapped using novel algorithms.
Results: Dynamic maps revealed a pattern of ‘back to front wave’ of GM loss for 
COS during adolescence that merged into the adult pattern by age 25. This pattern 
was distinct from that seen in pediatric bipolar illness. Preliminary analysis (n=12, 
36 scans, ages 12 to18) showed delayed WM maturation for COS compared to 
matched healthy controls. Healthy COS siblings (n=52, 110 scans) shared GM 
abnormalities in the prefrontal and temporal cortices in early ages, which were 
normalized by age 20. Analysis of 59 COS probands(160 scans), their 39 healthy 
siblings(80 scans) and 183 healthy controls (221 scans) showed that both COS 
probands and siblings with risk allele for glutamate decarboxylase(GAD1) risk 
allele had steeper slopes of prefrontal cortical GM loss. Slopes of GM thickness 
in healthy siblings correlated with overall functional outcome in healthy siblings 
and with remission status at discharge in COS probands.
Conclusions: Cortical GM loss in COS is profound, diagnostically specific, not due to 
WM encroachment, and neurobiologically continuous with AOS. GM development 
in schizophrenia could be considered an endophenotype that is influenced by 
individual risk gene status, overall functioning, and treatment outcome.
Supported by NIMH Intramural Program
736. Genetic Imaging in a High Risk Population for 
Schizophrenia
Stephen Lawrie
Edinburgh University Division of Psychiatry, Edinburgh, United Kingdom
Background: We have recently completed a ten year longitudinal study of brain 
structure and function in a group of individuals at high risk of schizophrenia 
for familial reasons, and have taken blood for genetic analyses.
Methods: 162 initially healthy people aged 15-25 at high genetic risk of 
schizophrenia, because they had at least one close relative with the disorder, 
were recruited and examined with structural MRI and functional MRI. The 
development of psychotic symptoms and/or schizophrenia itself was monitored 
at serial assessments, which most participants had at 18-24 month intervals 
over up to 10 years.
Results: 21 developed schizophrenia during the study and an additional 
66 subjects had psychotic symptoms at one or more assessments. Single 
nucleotide polymorphisms in the BNDF and DAO genes were associated with 
abnormalities of frontal and temporal function, but not structure, in the high 
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risk cohort as a whole. The Val(158)Met polymorphism in the Catechol-O-
MethylTransferase (COMT) gene predicted schizophrenia in this cohort in 
a dose-dependent manner. It was also associated with reduced gray matter 
density and BOLD signal in anterior cingulate cortex.
Conclusions: These patterns of altered brain structure and function have 
previously been associated with schizophrenia in this and other samples. DAO 
may have trait effects, while the NRG1 variant appears to be a risk factor for an 
extended or intermediate phenotype and the COMT Val allele is associated with 
an increased risk of schizophrenia. This genetic background provides a mechanistic 
framework in which to study the effects of environmental risk factors.
Supported by Medical research Council and the Sackler Foundation
737. High Resolution Neuroimaging in Schizophrenia
Hilleke E. Hulshoff Pol, Rene C. W. Mandl, Martijn P. 
Van den Heuvel, Rene S. Kahn
University Medical Center Utrecht, Utrecht, The Netherlands
Background: Progressive brain tissue loss in patients, particularly of gray matter 
(GM), suggest that a pathophysiological process is ongoing in schizophrenia. 
Finding the causes for this pathophysiological process is important. It could 
enable us to attenuate or halt the progressive brain changes. However, we do 
not know what process(es) underlie(s) the brain changes in schizophrenia. 
High field MRI may aid us in our search.
Methods: In 40 patients with schizophrenia and 40 healthy comparison subjects 
at 1.5 Tesla and in 18 patients with schizophrenia and 18 healthy comparisons at 3 
Tesla, a T1w and T2w MRI, DTI and MTR of the whole head were acquired. In 
addition, a resting-state fMRI acquisition was done at 3 Tesla in 26 healthy subjects.
Results: Altered levels of myelination in the uncinate fasciculus, connecting the 
decreased GM density areas of medial inferior frontal and anterior temporal lobes, 
were found in patients as compared to controls (t=2.64, p=0.01). Seven resting state 
networks with underlying anatomical connections were found in healthy subjects 
and are currently assessed in patients.Included was the default mode network with 
medial frontal GM and precuneus, both decreased in GM density in schizophrenia.
Conclusions: GM areas with decreased density in schizophrenia show 
structural and functional connectivity in health and aberrant connectivity 
in schizophrenia. Methods to detect subtle variations in cortical GM tissue 
composition at ultra high field MRI (7 Tesla) are under way. With these new 
possibilities we can be carefully optimistic about future progress in finding 
pathophysiological processes in schizophrenia.
Supported by a grant from the Dutch Science Organization for Medical 
Research NWO ZON-MW VIDI Program (917.46.370) (HEH) and by a grant 
from the High Potential (HiPo) Program of the Utrecht University (HEH)
738. Cellular Substrates and Molecular Mechanisms 
Underlying Cortical Gray Matter Abnormalities in 
Schizophrenia
David A. Lewis, Guillermo Gonzalez-Burgos
University of Pittsburgh, Pittsburgh, PA
Background: The core features of schizophrenia include deficits in cognitive 
processes mediated by the circuitry of the dorsolateral prefrontal cortex 
(DLPFC). These deficits are associated with a range of molecular and 
morphological alterations in the DLFPC, including smaller somal volumes and 
a lower density of dendritic spines on pyramidal cells.
Methods: This presentation will review postmortem studies that address four 
questions: 1) Is the decrease in spine density specific to a certain subpopulation 
of DLPFC pyramidal neurons? 2) Is the decrease in spine density associated 
with a deficit in a specific source of excitatory inputs? 3) What molecular 
mechanisms mediate the lower spine density in schizophrenia? 4) How might 
developmental plasticity in excitatory synapses contribute to dendritic spine 
alterations in schizophrenia?
Results: Findings from recent postmortem human studies suggest that a convergence 
of both pre-synaptic (alterations in specific sources of inputs) and post-synaptic 
(expression changes in certain molecular cascades that regulate the actin cytoskeleton) 
are required for the reduction in spine density. Consistent with this interpretation, 
recent anatomical and electrophysiological findings in monkey DLPFC indicate 
that the pruning of axospinous synapses during adolescence is not determined by the 
functional maturity of the synapse but by the source of the input.
Conclusions: Together, these findings suggest possible cellular and molecular 
substrates for a smaller cortical gray matter volume in schizophrenia and may aid 
in the identification of novel targets for therapeutic or preventative interventions.
Supported by MH45156
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739. Update on the Project among African 
Americans to Explore Risks for Schizophrenia 
(PAARTNERS)
Rodney C. P. Go
Epidemiology and International Health, University of Alabama at 
Birmingham, School of Public Health, Birmingham, AL
Background: A genetic etiology is now widely accepted for schizophrenia (SZ). 
Recent reviews have identified several suggestive linkages, , e.g., 1q22, 6q25, 
8p21-22, and 11q21, primarily in Caucasian populations.
The Project among African-Americans to Explore Risks for Schizophrenia 
(PAARTNERS) is a multi-site study that seeks to identify genes that confer 
susceptibility to schizophrenia and neurocogntive endophenotypes by linkage 
mapping and targeted association analyses.
Methods: PAARTNERS utilizes for diagnostic assessment, the Diagnostic 
Interview for Genetic Studies (DIGS) and the Penn Computerized 
Neurocognitive Battery (CNB) to assess cognitive abilities. Medical chart 
information is incorporated into the DIGS. The Family Interview for 
Genetic Studies (FIGS), conducted with family member informants, provides 
additional diagnostic. A Best Estimate Final Diagnosis (BEFD) is reached by 
the clinicians on each participant based on this information. Genome wide 
linkage analyses using the Center for Inherited Disease Research (CIDR) 
Linkage IV SNP Panel genotypes, are performed using MERLIN and SIBPAL 
on clinical phenotypes, while MERLIN -regress and SOLAR are used for the 
normalized cognitive domains.
Results: Preliminary linkage results on heritable cognitive domains are 
reported on 217 (n=1.078) linkage informative families in Table 1
Conclusions: Our preliminary results indicate that several of the cognitive 
domains exhibit significant heritabilities, and that several significant linkage 
peaks are in common among clinical and endophenotypic phenotypes, 
indicating there maybe genes with pleiotropic effects on several of these 
phenotypes.
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Table 1. Heritability Estimates (AIREML) and Representative Linkages for 
Cognitive Traits (MERLIN)
Study Type ATT VME FME SME LAN
PAARTNERS AccuracyHeritability 0.18 0.45 0.39 0.27 0.32
Chromosome 13 6 1 17 1
LOD 2.8 3.8 4.7 3.1 2.5
Location
(cM) 110 88 82 128 230
Attention (ATT); Working 
Memory (WME); Verbal 
Memory (VME); Face 
Memory (FME); Spatial 
Memory (SME); Language 
(LAN);
Supported by R01MH66181,R01MH6606, R01MH66278, R01MH66049, 
R01MH66121, R01MH66005, R01MH66050, R01MH66263, R01MH66004
740. Update on the Multiplex Multigenerational 
Investigation of Schizophrenia (MGI)
Raquel E. Gur1, Laura Almasy2, Vishwajit Nimgaonkar3,
Karin Haack2, Shelley A. Cole4, Monica E. Calkins1,
Konsale Prasad3, Michael F. Pogue-Geile5, Ruben C. Gur1
1Psychiatry, University of Pennsylvania School of Medicine, 
Philadelphia, PA,2Genetics, Southwest Foundation for Biomedical 
Research, San Antonio, TX,3Psychiatry, University of Pittsburgh, 
Pittsburgh, PA,4Southwest Foundation for Biomedical Research, 
University of Pennsylvania School of Medicine, San Antonio, 
TX,5Psychology, University of Pittsburgh, Pittsburgh, PA
Background: Marked cognitive deficits are evident in schizophrenia. They 
may provide complementary7 measures to the diagnostic phenotype in the 
efforts to elucidate the neurobioloby of liability to schizophrenia.
Methods: The MGI Consortium ascertained European-Americans from 
multiplex multigenerational families, with two first-degree affected members, 
as well as community controls. Participants underwent clinical assessments, 
neurocognitive measurements and provided blood samples. The computerized 
neurocognitive battery (CNB) was administered to provide quantitiative traits 
that complement clinical diagnosis. The CNB measures accuracy and speed on 
abstraction and mental f lexibility, attention, verbal, face, and spatial memory, 
emotion processing, and sensorimotor processing. A genome-wide linkage 
screen was performed using standard variance component methods.
Results: Performance on the neurocognitive phenotypes was most impaired 
in schizophrenia, with unaffected relatives’ performance intermediate between 
probands and community controls. Significant heritability estimates were 
obtained in several neurocognitive domains. There was significant evidence 
of linkage for the diagnostic phenotype of schizophrenia on chromosome 
19q (LOD=3.44). This finding is novel. For the neurocognitive phenotypes, 
significant linkage was observed for abstraction and mental f lexibility on 
chromosome 5q (LOD=3.43). Other neurocognitive traits also showed nominal 
evidence of linkage in the 5q region. Chromosome 5 has been implicated in 
previous linkage studies of the schizophrenia phenotype.
Conclusions: Complementary phenotypes in the study of complex brain 
disorders may guide functional hypotheses on the cascade of neurobiological 
pathways linking genotypes to clinical manifestations of the disease.
Supported by MH042191, MH61622, MH063480
741. Update on the Consortium on the Genetics of 
Schizophrenia (COGS)
David L. Braff
Department of Psychiatry, University of California San Diego, School of 
Medicine, La Jolla, CA
Background: Converging model organism, candidate gene and genome-wide 
association (GWA) studies offer much promise in explicating the
neurobiological significance of genes implicated in schizophrenia.
Methods: The COGS has constructed a 1536 COGS SNP Chip to interrogate 
94 schizophrenia-related genes of interest in schizophrenia. CIDR linkage 
analyses are also forthcoming. COGS families include both parents, one 
proband and one or more unaffected siblings, and 12 heritable
endophenotypes are assessed.
Results: 129 (of 350) families have been examined using the COGS SNP 
Chip. Figure 1 illustrates the distribution of SNPs that are interrogated. Figure 
2 shows the striking results. Genes such as NEURG have significant “hits” 
on almost all of the 12 endophenotypes, suggesting pleiotropy, and possible 
common pathways that influence the expression of multiple endophenotypes. 
Other genes “light up” singular endophenotypes suggesting alternative, 
perhaps simpler pathways, leading to schizophrenia.
Conclusions: The initial analysis of the COGS SNP Chip SNPs provide a 
wealth of data on (1) the heritabilities of neurophysiological and
neurocognitive endophenotypes, (2) the strong inference based SNPs reveal 
many (N=194) significant associations between heritable endophenotypes and 
the 94 genes in the SNP Chip. These results will be discussed.
Supported by NIMH R01MH065571, NARSAD Distinguished Investigator 
Award
742. Advances in Statistical Genetics: Applications 
to Schizophrenia and Related Neuropsychiatric 
Disorders
Nicholas J. Schork
Scripps Health and The Scripps Research Institute, La Jolla, CA
Background: The identification and characterization of genetic factors 
contributing to common, complex neuropsychiatric diseases such as 
schizophrenia has been advanced by major breakthroughs in high-throughput, 
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whole-genome genotyping assays and related genetic technologies. 
Unfortunately, the massive amounts of data these technologies generate require 
sophisticated data analysis methods for their reliable and compelling use.
Methods: Genome Wide Association Studies (GWAS) are typically based 
on more 500,000 genotype assays performed on each of many thousands of 
subjects. Such studies require data analysis tools that can accommodate genetic 
background heterogeneity among the subjects, linkage disequilibrium between 
genetic variations, missing data, and the fact that many loci -- both within and 
across different genic regions -- may contribute to phenotypic expression.
Results: We describe, in a non-mathematical way, the use of novel data analysis 
methods for pursuing genetic background assessments on the subjects in a 
large-scale genetic study as well as haplotype-based studies that accommodate 
allelic complexities in GWAS contexts. These methods are showcased on actual 
data and a brief discussion of their merits, as well as room for improvements, 
is provided.
Conclusions: Advances in statistical analysis methods, when coupled with 
commensurate advances in genetic/genomic technologies and phenotyping 
technologies, will lead to insights into inherited predisposition to schizophrenia 
and related neuropsychiatric disorders.
Supported by NIMH R01MH065571
SYMPOSIUM
Progressive Brain Changes in Schizophrenia
Saturday, May 3, 2008 2:30 PM - 5:00 PM
Location: Capitol A
Chair: Robert W. McCarley*
*Supported by P50MH080272, R01MH40799
743. Cross-Sectional and Longitudinal Ventricular 
Volume Changes in Chronic Schizophrenia, First-
Episode Psychosis, and Ultra-High Risk Individuals
Christos Pantelis1, Gregor E. Berger2, Sephen J. 
Wood1, Anthony Ang1, Warrick J. Brewer3, Lisa J. 
Phillips4, Alison R. Yung3, Tina M. Proffitt3, Dennis 
Velakoulis1, Patrick D. McGorry3
1Melbourne Neuropsychiatry Centre, Department of Psychiatry, University 
of Melbourne & Melbourne Health, Melbourne, Australia,2Department 
of Psychiatry, University Hospital Basel, Basel, Switzerland,3ORYGEN 
Research Centre, Department of Psychiatry, University of Melbourne 
& Melbourne Health, Melbourne, Australia,4Department of Psychology, 
University of Melbourne, Melbourne, Australia
Background: Ventricular enlargement (VE) has been robustly replicated in 
schizophrenia. However, studies are limited by small samples, illness chronicity 
and medication effects. Studies of first-episode psychosis (FEP) suggest VE 
occurs early, with evidence of progression, although it is unclear if these 
changes occur premorbidly. We recently identified structural grey matter brain 
changes in individuals at ultra-high risk of psychosis (Pantelis et al, Lancet, 
2003), with further progressive cortical changes following illness onset. We 
report cross-sectional and longitudinal ventricular changes in this ultra-high 
risk group compared with FEP, chronic schizophrenia and controls.
Methods: MRI scans were acquired on 473 subjects: chronic schizophrenia 
(CHR, 89), FEP (162), ultra-high risk for psychosis (UHR, 135, with 39 
â€~convertersâ€™ to psychosis), and controls (CTLS, 87). Follow-up scans 
conducted on 13 CHR, 25 FEP, 29 UHR and 24 CTLS.
Results: Significant group effect (F3,473=7.165; P<.001); compared with CTLS, VE 
was 43.9% greater in CHR, 11.9% larger in FEP and 3.3% larger in UHR (regardless 
of subsequent psychosis status). VE enlargement in CHR correlated with illness 
duration (r=0.388; p<0.01). Longitudinal ventricular expansion found in patients 
with schizophreniform FEP (18% increase, p=0.023, Cohenâ€™s d=1.47).
Conclusions: The cross-sectional findings indicate that VE is a feature of 
chronic schizophrenia, mildly enlarged in FEP, with no VE pre-illness onset. 
Longitudinal results suggest progressive changes occur soon after onset of 
schizophreniform psychosis. These results indicate that VE is progressive early 
in schizophrenia and does not represent an endophenotype of schizophrenia.
Supported by National Health & Medical Research Council (Australia)
744. Effects of Genes and Illness on Brain Changes 
in Schizophrenia and Bipolar Disorder
Rene S. Kahn
Dept. Psychiatry, Rudolf Magnus Institute of Neuroscience, UMC 
Utrecht, Utrecht, The Netherlands
Background: Brain abnormalities have been demonstrated in both schizophrenia 
and bipolar disorder although the data on bipolar disorder are less consistent. It 
is unclear whether the brain changes in bipolar disorder and schizophrenia are 
related to the illness or to the genetic risk of developing this disorder. Moreover it 
is unclear what if any genes may be related to these abnormalities.
Methods: Two separate twin MRI studies, one in schizophrenia and one in 
bipolar disorder, were conducted including in total over 350 subjects. A separate 
cohort of around 100 patients (non-twins) and a similar number of healthy 
subjects were scanned using MRI and genotyping was done in these subjects.
Results: In both bipolar disorder and schizophrenia, reductions in white matter 
volume were related to the genetic risk to develop these disorders. Grey matter 
reductions were related to the effects of illness in both disorders, although the 
effect was less pronounced in bipolar disorder. This smaller effect could almost 
completely be accounted for by the effect of lithium. Some of the fibroblast 
growth factor (FGF) genes were found to be significantly related to the white 
matter volumes in controls and patients.
Conclusions: White matter abnormalities may be related to a shared (genetic) 
vulnerability to develop schizophrenia and bipolar disorder and may be related to 
abnormalities in the FGF gene family. This gene is essential for normal neuronal 
growth, especially in the dopaminergic system. The FGF gene family may be 
interesting candidates for risk genes in schizophrenia as well as bipolar disorder.
745. Progression of MRI and Electrophysiological 
Abnormalities in First Episode Patients with 
Schizophrenia & Affective (Bipolar) Psychosis
Robert W. McCarley1, Motoaki Nakamura2, Martha E. 
Shenton3, Dean F. Salisbury4
1Psychiatry, Harvard Medical School/VA Med Ctr-Brockton, Brockton, 
MA,2Psychiatry, Yokohama City University Medical School, Yokohama, 
Japan,3Psychiatry, Harvard Medical School/Brigham & Women’s 
Hospital, Boston, MA,4Psychiatry, Harvard Medical School/McLean 
Hospital, Belmont, MA
Background: The nature of post-onset progression of structural and functional 
changes in schizophrenia is important for understanding its pathophysiology 
and rational treatment.
Methods: Using 1.5T MRI and evoked potentials, we examined schizophrenia 
and affective psychosis (bipolar) patients at first hospitalization (first episode, 
FE) and 1.5 years later, together with their healthy controls. Patients with 
chronic schizophrenia (mean 16yr illness) were studied longitudinally over 3 
years.
Results: In FE schizophrenia, MRI showed progressive neocortical gray matter 
(NCGM) volume loss, whose degree varied: overall NCGM -1.7%, temporal 
and frontal NCGM -2.5% (parieto-occipital not significant); right superior 
temporal gyrus (STG), -2.9%; left STG, Heschl’s Gyrus, and Planum Temporale 
-8 to -9%. Progression rate was maximal near initial hospitalization. Volume 
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increases occurred in subcortical CSF (7.2%) and lateral ventricles (10.4%). 
NCGM loss/CSF increases were associated with a worse longitudinal course 
of clinical symptoms. The Mismatch Negativity evoked potential, initially 
normal, became abnormal at 1.5 yr retest, with a degree of progression highly 
correlated with the degree of volume loss in left Heschl’s gyrus. FE affective 
psychosis showed a longitudinal increase in overall NCGM (3.6%), associated 
with lithium and valproate medication, but not with clinical symptoms. In 
contrast, chronic patients showed no statistical evidence of progressive volume 
loss in STG and hippocampus/amygdala or MMN progression.
Conclusions: These data suggest most of the post-onset structural and 
functional brain alterations in schizophrenia occur near the onset (first 
hospitalization), implying that this epoch is critical for therapeutic intervention. 
In contrast to schizophrenia, FE affective psychosis showed a lithium/valproate 
medication-related NCGM volume increase.
Supported by P50MH080272, R01MH40799
746. Mapping Progressive Brain Changes in an 
Antipsychotic Trial
Paul M. Thompson
Laboratory of NeuroImaging and Brain Research Institute, UCLA 
School of Medicine, Los Angeles, CA
Background: With recent innovations in brain mapping, structural 
brain changes in schizophrenia patients can now be charted as they spread 
dynamically in the living brain. Using time-lapse maps, we visualized the 
dynamics of schizophrenia progression, showing that cortical changes spread 
in a pattern that depends on the type of antipsychotic treatment.
Methods: Dynamic, four-dimensional models of disease progression were created 
from 4 repeated MRI scans of 36 subjects experiencing their first episode of non-
affective psychosis (30 men/6 women; mean age: 24.2+/-5.1SD years); 15 and 21 
were randomized to haloperidol or olanzapine treatment, respectively. All subjects 
underwent high-resolution brain MRI, at baseline, 3, 6, and 12 months (144 scans). 
Surface-based cortical models and point-by-point measures of gray matter volume 
were combined to create a time-lapse map for each treatment.
Results: Disease trajectories differed for atypical versus typical neuroleptic 
drugs. A rapidly advancing parietal-to-frontal deficit trajectory was tracked in 
haloperidol-treated patients, mirroring normal cortical maturation but greatly 
intensified. Areas with fastest tissue loss shifted anteriorly in the first year of 
psychosis. This trajectory was not seen with olanzapine, which may be less 
neurotoxic or neuroprotective. Time-lapse maps may be viewed here:
http://www.loni.ucla.edu/~thompson/MOVIES/HGDH/sz.html
Conclusions: These maps reveal a disease trajectory that advances even after 
symptom normalization and engulfs the frontal cortex within 12 months 
with typical drug treatment. These maps revise current models schizophrenia 
progression, reconciling several discrepant findings from cross-sectional studies 
by mapping time-varying disease effects.
Supported by NIH grants EB01651, RR019771, AG016570, LM05639, 
HD050735 and P41 RR13642.
SYMPOSIUM
Effects of Altered 5-HTT function on Cognition
 and Learning – Evidence from Genetic Studies in 
Mice, Monkey & Man
Saturday, May 3, 2008 2:30 PM - 5:00 PM
Location: Capitol B
Chair: Ahmad R. Hariri*
*Supported by K01MH072837




Background: There is growing evidence that the 5-HT is an important modulator 
of executive functions including cognitive flexibility. How variation in 5-HT genes 
such as the 5-HTT, might impact cognitive flexibility is stll not well understood.
Methods: I will provide evidence ofaltered reversal learning in 5-HTT knockout mice.
Results: Using a touchscreen-based operant assay of cognitive flexibility I will 
compare the executive function of 5-HTT knockout mice with the effects of 
pharmacological and genetic depletion of central serotonin.
Conclusions: Our studies may provide further insight into the influence of 
5-HTT gene variation on executive functions.
Supported by NIH IRP
748. Genetic Modulation of Cognitive Flexibility and 
Socioemotional Behavior in Rhesus Monkeys
Elisabeth (Betsy) A. Murray
Laboratory of Neuropsychology, NIMH, Bethesda, MD
Background: In human and nonhuman primates, structural variants of the 
gene encoding the serotonin transporter (5-HTT) affect the transcription and 
functional efficacy of 5-HTT. Prior work has shown that structural variants 
differentially affect the function of the amygdala, as well as the orbital and 
medial sectors of prefrontal cortex, regions important for the regulation and 
expression of emotion. However, relatively little is known about the impact of 
5-HTT allelic variants on cognition.
Methods: Rhesus monkeys carrying orthologous structural variants of 5-HTT 
were tested on a battery of tasks that assess cognitive flexibility, reward 
processing, and emotion.
Results: Relative to monkeys carrying one or two copies of the long allele (SL 
and LL), monkeys carrying two copies of the short allele (SS) of the rhesus 
5-HTT gene-linked polymorphic region (rh5-HTTLPR) show significantly 
reduced cognitive flexibility as measured by two tasks in the battery: object 
discrimination reversal learning and instrumental extinction. Socioemotional 
behavior also differed by genotype. Genotype variation was not related to 
visual perceptual abilities, valuation of food rewards, or the ability to express a 
wide range of defensive responses.
Conclusions: Although emotional alterations associated with 5-HTT variation 
have been described as the primary phenotype, the rh5-HTTLPR variation 
appears to influence cognitive functions outside the affective domain. Because 
behaviors modulated by the 5-HTTLPR are a subset of those dependent on 
the orbital and medial sectors of prefrontal cortex, analysis of structural and 
functional correlates of gene variation in this region may inform the nature of 
the genetic modulation of cognition.
Supported by NIMH Intramural Research Program
www.sobp.org/journal
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749. 5-HTTLPR Variants in Rhesus Monkeys 
Modulate Anterior Cingulate Dependent Cognition 
without Impact on Transporter Levels
Charles W. Bradberry
Psychiatry, University of Pittsburgh, Pittsburgh, PA
Background: Rhesus monkeys carry 5-HTTLPR variants orthologous to those 
in humans shown to alter risk for affective disorders and cognitive performance. 
The basis for these effects are unknown. Monkey studies permit a comparison 
of environmental manipulations such as peer- vs mother rearing with genotype 
effects on cognitive function and 5-HT transporter binding in-vivo.
Methods: Rhesus monkeys carry 5-HTTLPR variants orthologous to those in 
humans shown to alter risk for affective disorders and cognitive performance. 
The basis for these effects are unknown. Monkey studies permit a comparison 
of environmental manipulations such as peer- vs mother rearing with genotype 
effects on cognitive function and 5-HT transporter binding in-vivo.
Results: Analyzed by genotype, striking group differences in cognitive 
performance were seen that were consistent with altered cingulate cortex 
function. In addition to the genotype effects, a rearing effect was seen on the 
stop signal response time, a measure of instrumental impulsivity. Imaging the 
5-HT transporter revealed a very close match with the regional distribution 
seen in humans, however no significant differences were seen either by 
genotype or rearing condition.
Conclusions: A clear impact of 5-HTTLPR genotype on cognitive performance 
was seen in the monkey. The type of functionality impacted is consistent with 
anterior cingulate cortex as a locus for differences. Consistent with the bulk of 
in-vivo and ex-vivo studies, there are not differences in 5-HT transporter by 
genotype, suggesting other mechanisms are mediating the effects observed.
Supported by R01AA014646
750. The Effect of Serotonin Transporter 
Polymorphism on Cognitive Function in Healthy 
Volunteers
Jonathan P. Roiser
Institute of Cognitive Neuroscience, University College London, 
London, United Kingdom
Background: Genetic variation at the serotonin transporter linked polymorphic 
region (5-HTTLPR) has been associated with psychopathology, brain structure 
and function. However, few studies have reported an association between 
5-HTTLPR polymorphism and behavioral measures.
Methods: Data from three studies investigating the effect of 5-HTTLPR 
polymorphism on cognitive function in healthy volunteers will be presented. 
The first study was an investigation of the effect of 5-HTTLPR polymorphism 
on cognitive function in ecstasy users and controls. The second study 
examined how 5-HTTLPR genotype modulated response to acute tryptophan 
depletion (ATD), utilizing measures of motivation, memory and attention. 
The third study examined the neural correlates of economic decision-making 
in volunteers of different 5-HTTLPR genotypes.
Results: 5-HTTLPR genotype had significant effects on emotional processing 
in all three studies. In the first study, carriers of the ss genotype exhibited 
more irrational decision-making; in the ecstasy users, the ss group reported 
the highest levels of current depressive symptomatology. In the second 
study, the ss group outperformed the ll group on measures of verbal recall 
memory and attention, and were also most vulnerable to serotonin depletion, 
demonstrating motivational and mnemonic deficits following ATD. Data from 
a neuroimaging study of economic decision-making in volunteers of different 
5-HTTLPR genotypes will also be presented.
Conclusions: Polymorphism at the 5-HTTLPR appears to affect cognitive 
performance, particularly on tests making use of emotionally-valenced 
material, and ss individuals appear to be more susceptible to serotonin 
depletion. Studying the effects of the 5-HTTLPR polymorphism using 
functional neuroimaging may aid our understanding of the pathophysiology 
of mood and anxiety disorders.
Supported by Wellcome Trust
SYMPOSIUM
Functional Studies of DAOA
Saturday, May 3, 2008 2:30 PM - 5:00 PM
Location: Congressional A
Chair: Elliot S. Gershon*
Co-Chair: Chunyu Liu**
*Supported by 5R01 MH61613
**Supported by NIH 1R01MH080425-01
751. G72/G30 Transgenic Mice: A Model for 
Schizophrenia?
Andras Bilkei-Gorzo
Institute of Molecular Psychiatry, University of Bonn, Bonn, Germany
Background: The G72/G30 gene locus is a strong candidate susceptibility 
region for schizophrenia and bipolar disorder, whose function remains to be 
elucidated. LG72 is an evolutionary novel, primate-specific gene encoding 
for a protein with no recognizable motifs and controversial functions. One 
hypothesis suggests that LG72 is an activator of the D-amino acid oxidase 
(DAO), an enzyme known to oxidize D-amino acids such as D-serine, an 
agonist of N-methyl-D-aspartic acid (NMDA) receptors.
Methods: To further analyze the function of G72 in vivo we generated BAC 
transgenic mice. The presence and intensity of gene expression was tested using 
in-situ hybridization method. Animals were tested in a series of models covering 
the most prominent symptoms of schizophrenia: cognitive deficits, emotional 
and information processing disturbances, positive and negative symptoms.
Results: The G72 transgenic mice expressed G72 transcripts in the brain with 
high levels in different brain areas and showed a complex alternative splicing 
pattern. Biochemical and histological analysis of the brain of the transgenic 
animals did not support the existence of interaction between G72 and DAO. 
Behavioral analysis of the transgenic strain revealed a phenotype of the 
transgenic strain in models relevant to schizophrenia.
Conclusions: The phenotypic analysis of this strain showed that G72 
transgenic mice might represent an interesting disease model.
Supported by NGFN2 01GS0474
752. Gene Expression, Biochemistry, and Behavior 
Study in a G72 Transgenic Mouse Model
Lijun Cheng
University of Chicago, Chicago, IL
Background: The G72/G30 gene has multiple reports of association with both 
bipolar disorder and schizophrenia. A G72-D aminoacid oxidase (DAAO)-
NMDA receptor hypothesis and a G72- mitochondria hypothesis have been 
proposed as possible G72 roles.
Methods: The human 110kb BAC clone “RP11-166E2” encompassing the 
G72/G30 gene complex was microinjected into C57BL/6J mouse eggs to 
generate a G72/G30 transgenic mouse line. RT-PCR and real-time PCR 
were used to examine G72 expression in human and transgenic mouse brain. 
The genome expression profile of transgenic mouse cortex was studied with 
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the Illumina Mouse-6 beadChip. DAAO enzyme activity was examined in 
transgenic mouse to test the G72-DAAO-NMDA hypothesis. Behavioral tests 
(open-field, sucrose preference, water maze et al) were performed to evaluate 
possible behavioral phenotypes.
Results: We have established G72 hemi- and homozygous transgenic mice 
lines. G72 expresses at very low level in human brain and testis. G72 expresses 
at a relatively high level in transgenic mouse brain cortex, followed by striatum, 
hippocampus and (almost undetectably) cerebellum. No significant changes 
in G72 expression level were observed during brain postnatal development. 
Thirteen novel G72 splicing forms were identified from human and transgenic 
mouse. Preliminary results indicated significantly different expression of 
several genes between transgenic and wild type mouse in beadchip study. DAO 
enzyme activity of transgenic mouse cerebellum is higher than that of wild 
type mouse. Transgenic mice did not show abnormal locomotor activity in 
open field test.
Conclusions: The G72 transgenic mice may serve as a useful in vivo model to 
study G72 function and its role in disease etiology.
Supported by RO1MH61613-05A1; RO1MH65560-02
753. Evidence Implicating the Candidate 
Schizophrenia/Bipolar Disorder Susceptibility Gene 
G72 in Mitochondrial Function
Mirna Kvajo
Psychiatric Instutute, Columbia University, New York, NY
Background: G72 is a strong candidate susceptibility gene for schizophrenia 
and bipolar disorder, whose function remains enigmatic. One hypothesis 
regarding its role is based on in vitro observations suggesting that one splice 
variant of G72 (LG72) binds to and activates D-amino acid oxidase (DAO), 
an enzyme known to oxidize D-amino acids such as D-serine, an agonist of 
NMDA receptors. These in vitro results suggested a role for the G72 gene in 
the regulation of NMDA-type glutamate receptors signaling.
Methods: We investigated the subcellular localization of exogenous LG72 in 
several cell lines using immunocytochemistry and Western blotting. We further 
established the localization of the endogenous LG72 protein, and determined 
its role in the modulation of mitochondrial morphology. Furthermore, primary 
neuronal cultures were used to assess its function in dendritic arborization. 
Immunocytochemistry, immunoprecipitation and activity assays were 
performed to analyze its interaction with DAO.
Results: We show that LG72 encodes for a mitochondrial protein and provide 
convergent lines of evidence showing that increase of LG72 levels promotes 
robust mitochondrial fission in cell lines and primary neurons, which proceeds 
in a manner that does not depend on induction of apoptosis or alteration in 
mitochondrial transmembrane potential. Finally we show that increase in LG72 
levels in immature primary neurons is accompanied by a marked increase in 
dendritic arborization. By contrast, we fail to confirm the originally proposed 
functional interaction between LG72 and DAO in mammalian cell lines.
Conclusions: Our results suggest an alternative role for at least some G72 
isoforms in modulating mitochondrial function and dendritic development.
Supported by NIMH; New York Academy of Science
754. DAOA and Intermediate Phenotypes
Terry E. Goldberg
Zucker Hillside Hospital/Feinstein Institute, Glen Oaks, NY
Background: DAOA (formerly called G72) has been found to be associated with 
schizophrenia and has impacted several important intermediate phenotypes. 
Meta-analyses have also been positive. The gene may have an indirect effect on 
NMDA neurotransmission; it may also have a role in modulating mitochondrial 
function.
Methods: We examined DAOA’s impact on intermediate phenotypes using 
cognitive measures and fMRI.
Results: In an NIMH sample diagnosis x genotype interaction effects for 
DAOA alleles at the 3’ end of the gene were significant for cognitive variables 
assessing working memory, attention, and episodic memory, such that in the 
schizophrenia group an exaggerated allele load effect in the predicted direction 
was observed (i.e., epistasis was perhaps present). In a ZHH sample a counter 
intuitive finding was observed: A previously identified risk haplotype from the 
5’ region of the gene was associated with better semantic fluency.
Patients with schizophrenia who were carriers of the advantageous DAOA allele 
demonstrated more improvement in executive function and episodic memory 
than those with the disadvantageous allele when administered antipsychotic 
medication.
In healthy controls a strong effect of DAOA genotype was observed on fMRI 
BOLD activation in the MTL during an episodic memory paradigm that 
involved encoding visual scenes.
Conclusions: We have provided evidence that variations in the DAOA gene 
region may modulate some aspects of cognition in schizophrenia and influence 
BOLD signal in regions critical for memory processing. More broadly, the 
studies raise important questions about what constitutes a replication, multiple 
comparisons, and the possibility of balanced selection.
SYMPOSIUM
Mapping the Development of Cortical Circuits 
Through Adolescence in Healthy Subjects and 
Neurodevelopmental Disorders
Saturday, May 3, 2008 2:30 PM - 5:00 PM
Location: Congressional B
Chair: Aysenil Belger*
Co-Chair: Larry J. Seidman**
*Supported by NIMH 5P50 MH064065-06; NIMH 2R01 MH58251-06-A2; 
Foundation of Hope; NARSAD Independnet Investigator Award
**Supported by MH 43518 63951 65562 P41RR14075 NARSAD Stanley 
Medical Research Institute MIND Institute
755. Immaturities of Cognitive Control and Reward 
Processing in Adolescence
Beatriz Luna
University of Pittsburgh School of Medicine, Pittsburgh, PA
Background: Adolescence is a time of vulnerability for mortality due to risk 
taking behavior and the emergence of major psychopathology. The neural 
basis of the development of cognitive control and reward processing through 
adolescence is not well-understood.
Methods: We use oculomotor tasks that assess fundamental aspects of the 
maturation of cognitive/executive control as well as fMRI to assess changes 
in brain function and DTI neuroimaging to characterize maturation of white 
matter integrity reflecting protracted myelination.
Results: Behavioral results indicate a continued maturation of cognitive control 
into adolescence and enhanced modulation of reward processing. fMRI results 
indicate immaturities in adolescence in the neural circuitry supporting the ability 
to inhibit responses and importantly to retain an inhibitory response ‘state’. 
Reward studies indicate under-activity of reward assessment in ventral striatum 
and orbitofrontal cortex and over-activity of the motivational/anticipatory 
processing of rewards. DTI studies indicate immaturities in pathways connecting 
frontal regions with other cortical regions, as well as subcortical regions including 
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ventral striatum, regions that underlie cognitive control and reward processing.
Conclusions: Collectively, our work indicates that adolescence is a critical 
stage of developmental transition when collaborative function between widely-
distributed brain systems reaches adult-like levels of maturities. Importantly, 
however, adolescence may also be a stage of development particularly vulnerable 
to error and disruption, as risk-taking behavior and major psychopathology 
have been shown to emerge during this time. 
Supported by MH067924
756. Functional and Structural Indices of 
Adolescent Brain Development in the Risk for 
Schizophrenia
Larry J. Seidman
Department of Psychiatry, Beth Israel Deaconess Medical Center and 
Massachusetts General Hospital, Boston, MA
Background: In the Harvard Adolescent High Risk study, we sought to 
demonstrate that young, non-psychotic relatives of persons with schizophrenia 
(i.e., who are at genetic risk (GR) for the illness) have altered brain structure 
and function during adolescence prior to onset of psychosis, in order to define 
brain vulnerability indicators for schizophrenia.
Methods: We focused on working and declarative memory probes of medial 
temporal lobe (MTL) and prefrontal (PFC) activation, measures of the 
default network, volumetric measures of the hippocampus, and measures of 
cortical thickness. Participants were 35 non-psychotic, unmedicated first-
degree relatives of persons with a DSM-IV diagnosis of schizophrenia or 
schizoaffective disorder, depressed type and 55 unmedicated controls (ages 13-
28). Twenty-seven persons at GR for schizophrenia and 48 controls received 
structural MRI. Twenty-one persons at GR for schizophrenia and 26 controls 
were studied with functional MRI (fMRI).
Results: The GR subjects showed significant impairments on working and 
declarative memory tasks outside the scanner and significantly greater task-
elicited activation in the right prefrontal cortex (PFC) on the working memory 
task, and greater activation in the parahippocampal gyrus bilaterally on the 
verbal encoding task. Compared to controls they exhibited significantly 
reduced task-related suppression of activation in the default network including 
medial prefrontal cortex, lateral parietal cortex, and hippocampus. GR subjects 
had smaller hippocampi, significantly smaller in the left hemisphere, and 
reduced cortical thickness.
Conclusions: Data support physiological and structural brain differences in 
adolescents at genetic risk for schizophrenia, independent of psychosis. Further 
work is necessary to identify predictors of psychosis.
Supported by MH 43518 63951 65562 P41RR14075 NARSAD Stanley 
Medical Research Institute MIND Institute
757. Functional Cortical Alterations in Children and 
Adolescents at Genetic Risk for Schizophrenia
Aysenil Belger
Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background: Puberty is a critical period for the maturation of the fronto-
limbic and fronto-striate circuits critical for executive function and affective 
processing. Puberty also coincides with the emergence of the prodromal signs of 
schizophrenia, possibly indicating an association between these two processes.
Methods: We studied neural maturation of circuits supporting exective 
attention and affective processing in 22 healthy control (HC) subjects and 23 
individuals at genetic risk for schizophrenia (GHR) between the ages of 9 and 
18 using functional magnetic resonance imaging (MRI) on a 3T GE scanner. 
Subjects performed an emotional oddball task, where they identified rare visual 
targets while ignoring emotional and neutral distractor pictures.
Results: There were no significant group differences in age, gender, ethnicity, 
education (p<.08) and parental education (p<.06). GHR children had greater 
early prodromal symptoms of schizophrenia as assessed using the Scale of 
Prodromal Symptoms (p<.001). FMRI Random effects analyses revealed that 
prefrontal regions, in particular the insular and dorsal prefrontal regions and 
the anterior cingulate gyrus showed significantly greater activation amplitude 
and extent in GHR subjects during executive attention (p<.01). Similarly, 
limbic regions including the amygdala and the ventral prefrontal regions also 
showed significantly greater activation in GHR subjects.
Conclusions: Cortical information processing inefficiency in fronto-limbic 
and fronto-striate regions during puberty may be an early neurodevelopmental 
alteration in children at risk for schizophrenia, and may represent vulnerability 
markers for illness onset. Longitudinal assessments will further inform about 
their predictive value for illness onset in high-risk populations.
Supported by NIMH 5P50 MH064065-06; NIMH 2R01 MH58251-06-A2; 
Foundation of Hope; NARSAD Independnet Investigator Award
758. Neuroimaging and Treatment of Pediatric 
Bipolar Disorder
Jean A. Frazier
Child Psychiatry, Cambridge Health Alliance, Harvard Medical School, 
Cambridge, MA
Background: Neurodevelopmental models of bipolar disorder (BPD) posit 
subtle disease processes that affect brain circuits early in development that then 
manifest in illness around puberty. Puberty is pivotal in these models, yet to 
date no neuroimaging studies in early-onset BPD have assessed associations 
between pubertal development, brain abnormalities, and disease expression. 
This presentation will include cross-sectional neuroimaging data that evaluate 
developmental processes and expression of BPD.
Methods: Subjects received neurological and psychiatric assessment, semi-
structured interviews, and structural MRIs on a 1.5 Tesla scanner. After image 
segmentation, subcortical gray matter volumes were analyzed using three-way 
(diagnosis, sex, Tanner) univariate analysis of variance, controlling for cerebral 
volume and age.
Results: Fifty-four BPD I youths (19 with psychosis) and 29 healthy controls, 
similar in age, participated in this study. There were more males in both 
groups. Just over half of both diagnostic groups were prepubertal; however, 
most boys with BPD were prepubertal (80%), while most girls (67%) were 
pubertal. Youths with BPD had larger right nucleus accumbens (NA) volumes. 
Relative to controls, the hippocampus was smaller in the BPD pubertal female 
group. Amygdala volumes were similar between groups, though only BPD 
youth showed increasing amygdala volume with age.
Conclusions: Our data suggest that limbic structures in children with BPD are 
vulnerable to sexual dimorphism and peripubertal change. Future longitudinal 
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studies with larger samples may enhance our knowledge about critical developmental 
periods during which interventions might be most helpful to prevent illness onset 
and progression for these youths, perhaps in a sex-specific way.
Supported by K08MH01573
SYMPOSIUM
New Human Genetic and Neurobiological Data 
Implicate Bcl-2 in the Pathophysiology and 
Treatment of Severe Mood Disorders
Saturday, May 3, 2008 2:30 PM - 5:00 PM
Location: Concord/Lexington
Chair: Husseini K. Manji*
Co-Chair: Jing Du**
*Supported by NIMH Intramural Research Program
**Supported by NIMH intramural
759. Efficacy and Neurochemical Effects of 
Adjunctive Cytidine Supplementation in Treating 
Bipolar Depression: 12-week Results from a 
Randomized, Double-Blind, Placebo-Controlled Trial
Sujung J. Yoon1, In Kyoon Lyoo2,3, Bruce M. Cohen3,
Perry F. Renshaw3
1Department of Psychiatry, Catholic University Medical College, Seoul, 
Republic of Korea,2Department of Psychiatry, Seoul National University 
Hospital, Seoul, Republic of Korea,3Department of Psychiatry, Harvard 
Medical School, Belmont, MA
Background: Recent magnetic resonance spectroscopy (MRS) studies 
suggest that mitochondrial dysfunction is a central component of bipolar 
pathophysiology. For instance, increases in lactate, glutamate and glutamine 
(Glx) levels, measured in bipolar patients with proton MRS, indicate 
disturbances in energy metabolism. Impaired oxidative phosphorylation leads 
to glycolytic energy production and a decrease in phospholipid metabolism. 
Hypometabolism decreases de novo synthesis of pyrimidine in mitochondria, 
which requires high-energy phosphates. Consequently, exogenous pyrimidine 
administration should reduce the energy requirements of the mitochondria and 
ameliorate the energy imbalance in bipolar patients.
Recent animal studies found that pyrimidine nucleosides, cytidine and uridine, 
have antidepressant-like effects. Exogenous pyrimidine administration has 
been shown to have beneficial effects on 1) catecholamine levels, including 
norepinephrine and dopamine, 2) phospholipid metabolism, and 3) 
mitochondrial function.
In the current study we investigated whether cytidine, given in conjunction 
with valproate, improved depressive symptoms in bipolar patients.
Methods: Sixty-five adult, bipolar depressed subjects were randomly assigned 
to receive valproate with either placebo or oral cytidine. Clinical assessments 
were conducted at baseline and weekly intervals during the 12-week trial. 35 
patients underwent MRI scans at baseline, week 2, week 4, and week 12 to 
investigate the association between cytidine administration and the brain 
levels of Glx, as measured by 1H-MRS.
Results: As compared with placebo, cytidine supplementation significantly 
improved the depressive symptoms of bipolar patients in early treatment and 
reduced Glx levels.
Conclusions: Due to its efficacy and its rapid onset, cytidine supplementation 
should be considered as a viable treatment for depressive bipolar disorder.
Supported by the Stanley Medical Research Institute
760. Dynamic Regulation of Mitochondrial 
Functions by Glucocorticoids and Stress
Jing Du1, Yun Wang1, Richard Hunter2, Rodrigo 
Machado-Vieira1, Yanling Wei1, Cynthia Falke1, Bruce 
MvEwen2, Husseini Manji1
1NIMH/NIH, Bethesda, MD,2The Rockefeller University, Laboratory of 
Neuroendocrinology, New York, NY
Background: Corticosterone plays an important role in modulating 
neuroplasticity and in morphological reorganization, especially during chronic 
stress. The mechanisms underlying corticosterone’s ability to modulate 
neuronal functions, especially mitochondrial functions, remain unclear.
Methods: Mitochondrial GR and Bcl-2 levels, mitochondrial calcium holding 
capacity, mitochondrial oxidation, and membrane potential were determined 
after corticosterone treatment in cultured cortical neurons. Formation of Bcl-2 
and GR complex also were tested by immunoprecipitation. In addition, the 
mitochondrial GR and Bcl-2 levels in prefrontal cortex of chronically stressed 
or corticosterone-treated animals were analyzed by Western blot analysis.
Results: We found that glucocorticoid receptors (GRs) formed a complex 
with Bcl-2 in response to corticosterone treatment, and translocated with 
Bcl-2 into mitochondria after acute treatment with low and high doses of 
corticosterone in primary cortical neurons. However, after three days of 
treatment, high corticosterone resulted in a decrease in GR and Bcl-2 levels 
in the mitochondria. In addition, three independent mitochondrial functional 
measurements, mitochondrial calcium holding capacity, mitochondrial 
oxidation, and membrane potential were also regulated by low and high doses 
of corticosterone after long-term treatment in a bell-shaped manner. Similarly, 
after chronic stress and long-term treatment with corticosterone, GR and Bcl-2 
levels in the mitochondria were significantly decreased in prefrontal cortex.
Conclusions: These findings suggest that, in response to corticosterone, GR 
recruits Bcl-2 into mitochondria and regulate mitochondrial functions. These 
findings have the potential to contribute to a more complete understanding 
of the mechanisms by which chronic stress and hormones regulate cellular 
plasticity and resilience, and to inform the future development of improved 
therapeutics.
Supported by NIMH intramural




Background: Synapses are contact sites between neurons that transmit 
neuronal activity and undergo structural and functional modifications 
(synaptic plasticity) in development, cognition and diseases. NMDA receptor-
dependent long-term modifications of synapses (such as long-term potentiation 
(LTP) and long-term depression (LTD)) are important cellular mechanisms 
of synaptic plasticity. Mitochondria are vital organelles in all eukaryotic cells 
that function in aerobic respiration, buffering of intracellular Ca2+ and in the 
mechanisms of apoptosis. The association of mitochondrial dysfunctions with 
many neurological diseases suggest that mitochondria are important for neural 
functions.
www.sobp.org/journal
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Methods: We took time-lapse confocal images of mitochondria in primary 
culture of hippocampal neurons to monitor the motility and subcellular 
distribution of mitochondria and their response to neuronal activity. We 
induced LTP and LTD in hippocampal slices and tested the effect of caspase 
inhibitors on LTP/LTD. Using an antibody feeding assay, we examined the 
endocytosis of AMPA receptors following a chemical LTD stimulation.
Results: Our studies reveal that mitochondria dynamically redistribute into 
dendritic protrusions in response to synaptic excitation and correlated with 
synaptogenesis and spine formation. The dendritic distribution of mitochondria 
is essential for synapse development. Mitochondria play an important role in 
synaptic plasticity as well. After LTD stimulation, caspases are activated by the 
mitochondria pathway. Inhibition of caspases block LTD and AMPA receptor 
endocytosis.
Conclusions: Our results suggest that mitochondria are critical for synapse 
development and plasticity. Mitochondria support synapse formation during 
development. In synapstic plasticity, the mitochondrial pathway is activated 
by LTD stimulation, which leads to activation of caspases and subsequent 
endocytosis of AMPA receptors.
Supported by F2NS046126
762. Bcl-2: A Key Regulator of Affective Resilience 
in the Pathophysiology and Treatment of Severe 
Mood Disorders
Husseini K. Manji
Mood and Anxiety Disorders Program, National Institute of Mental 
Health, National Institutes of Health, Bethesda, MD
Background: Recent studies have suggested that the neurotrophic protein 
Bcl-2 not only regulates cell survival and death, but also plays a critical role in 
‘here and now’ synaptic plasticity. As such, it represents a potentially critical 
molecule in the pathophysiology and treatment of severe mood disorders.
Methods: An integrated series of human genetic, molecular neurobiologic, and 
rodent behavioral studies were undertaken to determine the precise role of Bcl-2 
in mood disorders.
Results: Human genetic studies demonstrated that a SNP in the Bcl-2 gene was 
significantly associated with bipolar disorder in two large, independent samples. 
Furthermore, a Bcl-2 SNP was also associated with the likelihood of going into 
full remission with chronic citalopram treatment in the STAR*D study. The Bcl-2 
SNP associated with bipolar disorder resulted in significantly lower Bcl-2 mRNA, 
~ 50% lower Bcl-2 protein levels, and greater cellular sensitivity to stress-induced 
apoptosis. Bcl-2 +/- mice displayed higher rates of helplessness, and lower rates of 
recovery from helplessness in the learned helplessness paradigm. The Bcl-2 +/- mice 
also displayed blunted responsiveness to citalopram treatment in the forced swim test, 
tail suspension test, and helplessness paradigm. Infusion of a Bcl-2 inhibitor into the 
third ventricle of the brain resulted in a similar behavioral profile in wild-type mice.
Conclusions: The human genetic and neurobiologic data suggest that Bcl-2 regulates 
affective-like behavioral resilience in animals and that targeting Bcl-2- mediated 
plasticity cascades may result in improved therapeutics for mood disorders.
Supported by NIMH Intramural Program-NIH
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763. Cortical Thinning in Comorbid ADHD and 
Bipolar Disorder
Joseph Biederman1, Nikos Makris2, Eve M. Valera1,3,
Michael Monuteaux1, Steven Hodge4, Jonathan Kaiser4,
Ariel B. Brown1,5, Megan Aleardi1, Verne Caviness6,
Stephen Faraone7, Larry Seidman1,8
1Clinical and Research Programs in Pediatric Psychopharmacology and 
Adult ADHD, Massachusetts General Hospital, Boston, MA,2Departments 
of Neurology and Radiology, Massachusetts General Hospital, Boston, 
MA,3Department of Psychiatry, Harvard Medical School, Boston, MA,4Center 
for Morphometric Analysis, Martinos Center For Biomedical Imaging, 
Charlestown, MA,5Ph.D. Program in Behavioral Neuroscience, Boston 
University School of Medicine, Boston, MA,6Department of Neurology, 
Massachusetts General Hospital, Boston, MA,7Department of Psychiatry 
and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, 
NY,8Massachusetts Mental Health Center Public Psychiatry Division, Beth 
Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background: Although attention deficit-hyperactivity disorder (ADHD) 
and bipolar disorder (BPD) frequently co-occur and represent a particularly 
morbid clinical form of both disorders, neuroimaging research addressing this 
comorbidity is scarce. In a previous study, we found significant cortical thinning 
in ADHD in a distinct cortical network supporting attention especially in 
the right hemisphere involving the inferior parietal lobule, the dorsolateral 
prefrontal, and the anterior cingulate cortices. Our current study investigates 
cortical thinning in a sample of adults with comorbid ADHD+BPD, and we 
hypothesize that additional cortical areas, specifically involved in emotional 
circuitry, will be affected in this sample.
Methods: We carried out a structural magnetic resonance imaging study of 
cortical thickness in a sample of adults with ADHD+BPD (N=31) and controls 
(N=23), hypothesizing that emotional as well as attentional and executive 
circuitry would be affected. Participants were group matched on age, sex, 
handedness and whole brain volume.
Results: Compared to controls, individuals with ADHD+BPD showed cortical 
thinning in lateral prefrontal and paracingulate cortex as well as anterior insula, 
medial frontal cortex, orbitofrontal cortex and the frontal pole.
Conclusions: As compared to a previous study that showed cortical thinning 
in attentional and executive circuitry in individuals with ADHD alone, this 
sample with comorbid bipolar disorder showed additional areas of significant 
thinning, particularly in areas associated with emotional processing and self-
monitoring such as insula, orbitofrontal cortex, and frontal pole. Dysfunction 
in these regions, critically important for emotional regulation, may predispose 
individuals with comorbid ADHD +BPD to particularly significant behavioral 
and mood problems.
Supported by MH 62152; NARSAD; March of Dimes Foundation
www.sobp.org/journal
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764. Effect of Dopamine Transporter Gene (DAT1) on 
Dorsal Anterior Cingulate Activation in ADHD
Ariel B. Brown1,2, Joseph Biederman2, Eve M. Valera3,
George Bush3, Thomas Spencer2, Nikos Makris4,
Stephen Faraone5, Alysa Doyle2, Eric Mick2, Michael 
Monuteaux2, Larry Seidman2,6
1Ph.D. Program in Behavioral Neurosciences, Boston University School 
of Medicine, Boston, MA,2Clinical and Research Programs in Pediatric 
Psychopharmacology and Adult ADHD, Massachusetts General 
Hospital, Boston, MA,3Department of Psychiatry, Massachusetts 
General Hospital, Charlestown, MA,4Departments of Neurology 
and Radiology, Massachusetts General Hospital, Charlestown, 
MA,5Departments of Psychiatry and of Neuroscience and Physiology, 
SUNY Upstate Medical University, Syracuse, NY,6Massachusetts 
Mental Health Center Public Psychiatry Division, Beth Israel 
Deaconess Medical Center, Harvard Medical School, Boston, MA
Background: Although ADHD is associated both with brain alterations in 
attentional and executive circuitry as well as with genetic variations within 
the dopamine system, (including the dopamine transporter gene [DAT1] 10R 
allele), few studies have directly investigated how genetic variations are linked 
to brain alterations. We sought to investigate how a polymorphism in the 3’ 
untranslated region (UTR) of DAT1 is associated with functional activation in 
the Dorsal Anterior Cingulate (dACC), an area involved in complex cognitive 
tasks, rich in dopamine, and altered in ADHD.
Methods: We collected fMRI scans on 43 individuals with ADHD, all of 
European descent and over the age of 17, while they performed the Multi-
Source Interference Task (MSIT), shown to robustly activate dACC. DAT1 
genes for these individuals were sequenced, and brain activations were 
compared for groups based on genotype.
Results: ADHD individuals homozygous for the 10R allele showed significant 
hypoactivation in the dACC compared to others. Further breakdown of 
genotype groups showed similar dACC activation in individuals with zero 10R 
alleles and with one 10R allele. Exploratory analysis showed hypoactivation 
in the 10R homozygotes in left cerebellar vermis and right prefrontal cortex; 
however, statistical significance did not withstand correction for multiple 
comparisons.
Conclusions: Activations in ADHD may be influenced by DAT1 genotype. 
Activation in other areas of attentional and executive networks found previously 
to be affected in ADHD, including cerebellar vermis and prefrontal cortex, are 
also likely influenced by DAT genotype. This genotype may add variation to 
brain alterations found within ADHD samples.
Supported by MH 57934; MH 62152; MH 071535; MH065040; MH16259
765. A 12-month Outcome Study of Insight and 
Symptom Change in First-Episode Psychosis
Lisa Buchy1,2, Michael Bodnar1,2,3, Ashok Malla3,4,
Ridha Joober3,4, Martin Lepage1,2,3,4
1Neurology & Neurosurgery, McGill University, Montreal, QC, 
Canada,2Brain Imaging Group, Douglas Mental Health University 
Institute, Verdun, QC, Canada,3Prevention and Early Intervention 
Program for Psychoses (PEPP-Montreal), Douglas Mental Health 
University Institute, Verdun, QC, Canada,4Psychiatry, Allan Memorial 
Institute, McGill University, Montreal, QC, Canada
Background: Previous work has revealed that course of insight in psychosis 
is variable and associated with several psychopathological features. Changes 
in insight may be specifically and temporally associated with changes in 
psychopathology, and severity of psychopathology over time may distinguish 
between subgroups of patients with different course of insight.
Methods: One-hundred and fourty-six patients were administered an extensive 
clinical evaluation and insight was rated on the Positive and Negative Syndrome 
Scale item G12 at admission and after 1, 2, 3, 6, 9, and 12 months.
Results: Repeated measures ANOVAs revealed that patients showed 
improvement in insight, positive, negative, depression and anxiety between 
admission and 1 month, with an additional improvement in insight and 
positive symptoms at 2 months. Repeated measures ANOVAs revealed that 
patients with persistently poor insight, patients whose insight worsened over 
time, and patients who showed fluctuating insight levels displayed greater 
negative symptoms over the 12 months, relative to patients with persistently 
good insight or patients whose insight improved. In contrast, those with 
persistently poor insight or those whose insight diminished showed greatest 
positive symptoms between 6-12 months, relative to the other groups. 
Delusions and suspiciousness/persecution contributed the greatest variance. 
No group differences emerged for depression and anxiety.
Conclusions: Changes in insight were detectable immediately following 
initiation of treatment, and psychopathology appears to mediate the course 
of insight.
Supported by CIHR; FRSQ; Sackler Foundation; Canada Research Chairs 
program
766. Frequency of Schizoaffective Disorder 
Diagnosis in Patients with Psychotic Disorders 
using the Mini-International Neuropsychiatric 
Interview
Carla M. Canuso1, Colette Kosik-Gonzalez1, Bryan 
L. Dirks1, Amir H. Kalali2, Robert Lasser3, Georges M. 
Gharabawi4
1?????????? ?????????????????????????????????????????????2Medical and 
???????????????????????????????????????????????????3Statistical Analyses, 
Neuliance Consulting, Newtown, PA,4Medical Affairs, Hoffman-
LaRoche, Nutley, NJ
Background: Reports suggest schizoaffective disorder incidence rates ranging 
from 10%-30% among patients seeking psychiatric care. This international 
study determined the frequency of schizoaffective disorder among subjects 
with psychotic symptoms using the clinician-administered MINI-structured 
diagnostic interview and, in those with a MINI diagnosis of schizoaffective 
disorder, evaluated their existing chart diagnosis.
Methods: Subjects 18-65 years-of-age with symptoms consistent with acute 
or chronic psychosis presenting at a clinical pyschiatry setting were evaluated 
by MINI and charts of those with a diagnosis of schizoaffective disorder were 
reviewed.
Results: 208 subjects from the US (n=59), India (n=40), Eastern Europe 
(n=60), and Asia Pacific regions (n=49) were evaluated by MINI. 31% 
(65/208) were diagnosed with schizoaffective disorder. Across the 4 regions, 
the incidence of schizoaffective disorder by MINI ranged from 23.3% (14/60, 
Eastern Europe) to 40.8% (20/49, Asia Pacific). Among the 65 subjects with 
MINI diagnosis of schizoaffective disorder, 43.1% (28/65) also had a current 
psychosis chart diagnosis of schizoaffective disorder. Schizophrenia was the 
second most frequent chart diagnosis (38.5% [25/65]). Polypharmacy (i.e., 1 
antipsychotic agent or antipsychotic agent(s) with antidepressant and/or mood 
stabilizer therapy) was common in all regions.
Conclusions: In this global sampling of adults presenting with symptoms 
consistent with acute or chronic psychosis, schizoaffective disorder incidence 
diagnosed by MINI varied from 23% to 41% and was also often accompanied 
by a schizoaffective disorder chart diagnosis. Across the regions, polypharmacy 
regimens involving one or more classes of agents were common.
Supported by Janssen Scientific Affairs, LLC
www.sobp.org/journal
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767. Adults with Autism integrate Auditory and 
Visual Information over a Wider Temporal Window 
than Controls
Carissa Cascio1, Rachel E. Sassoon2, Abigail Carroll-
Sharpe3, Gregory K. Essick2, Grace T. Baranek4
1Department of Psychiatry, Vanderbilt University, Nashville, TN,2Center 
for Neurosensory Disorders, University of North Carolina School of 
Dentistry, Chapel Hill, NC,3Department of Biomedical Engineering, 
University of North Carolina, Chapel Hill, NC,4Department of Allied 
Health Sciences, University of North Carolina, Chapel Hill, NC
Background: Although anecdotal reports suggest aberrant cross-modal sensory 
integration in autism, few studies have tested this empirically. Audiovisual 
integration is of particular importance in human social and communicative 
abilities, and thus may be affected in autism.
Methods: Low-level audiovisual integration was tested in a group of eight high-
functioning adults with autism and eight controls (groups matched overall for 
age and IQ) using an illusory paradigm (Shams et al., 2002) in which multiple 
beeps presented concurrently with a single flash evoke the illusory percept of 
multiple flashes. The temporal window of this integration was explored by 
incrementally increasing the temporal separation of the stimuli.
Results: The autism group reported perceiving the illusory flashes similarly to 
controls at short (< 80 msec) temporal windows. At longer temporal windows 
(> 80 msec), the control group did not show the illusory effect but the effect 
persisted in the autism group, resulting in significant group differences that 
extended to 153 msec (t= 2.68; p=0.03).
Conclusions: Simple audiovisual integration appears to be intact in autism, 
but audiovisual information is integrated over a wider temporal window than 
normal. This extended window may interfere with the integration of more 
complex audiovisual stimuli.
Supported by Autism Speaks
768. The Incidence of Personality Disorder in 
Adults with ADHD, and the Effects on Response to 
Treatment with OROS Methylphenidate (OROS MPH)
Phillip Gale, Frederick W. Reimherr, Barrie K. 
Marchant, Reid Robison, Erika D. Williams, Robert E. 
Strong, Corinne Halls, Poonam Soni
Psychiatry, University of Utah, Salt Lake City, UT
Background: This study explored the association between personality disorder 
and treatment response in a clinical trial of OROS MPH in adults with ADHD.
Methods: 47 patients entered a clinical trial of OROS MPH using the Wender-
Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) and the 
ADHD Rating Scale as outcome measures. Personality was assessed at baseline 
using the Wisconsin Personality Inventory (WISPI-IV) and the SCID-II. 
Following the study, a staff consensus produced a final personality diagnosis 
using all available information. Patients were separated into three post hoc 
categories: PDnegative (no personality disorder), PDpositive (subjects meeting 
criteria for one personality disorder or personality disorder NOS), and PDplus 
(subjects meeting criteria for ≥2 disorders). Improvement in ADHD symptoms 
was assessed using a mixed models design with treatment and personality 
categories as fixed variables.
Results: At baseline, 62% (SCID-II) and 33% (WISPI-IV) of subjects 
were PDpositive or PDplus, compared with 45% at the psychiatrist’s final 
assessment; 30% had a Cluster C diagnosis, 17% Cluster B, and 11% Cluster 
A. A significant treatment response on the WRAADDS was experienced by 
PDnegative (40% on OROS MPH and 7% on placebo), and PDpositive (66% 
on OROS MPH and 9% on placebo) but not by PDplus (26% on OROS MPH 
and 23% on placebo) subjects.
Conclusions: These ADHD adults displayed great variability in the type and 
extent of personality disorder present. Subjects with ≥ 2 personality disorders 
exhibited poor treatment response in ADHD symptoms, while those with one 
or no personality disorders responded positively to OROS MPH.
Supported by Ortho-McNeil Janssen Scientific Affairs, LLC
769. The Physiological Response to Categorical 
Processing of Fear in Alexithymia
Alison M. Gilbert1, J. Richard Jennings2, Ellen Frank1,2,
Mary L. Phillips2, Spencer Sugarman1, Julie A. Fiez1
1Psychology, University of Pittsburgh, Pittsburgh, PA,2Psychiatry, 
University of Pittsburgh Medical Center, Pittsburgh, PA
Background: Alexithymia is a form of disordered emotional processing often 
associated with psychiatric illness and poor treatment outcomes in depression. 
Its clinical hallmarks are difficulty identifying, representing and evaluating 
emotional material. We determined the physiological response in alexithymia 
using explicit categorical processing tasks that manipulate emotion and 
cognition.
Methods: Sixty undergraduates completed the Toronto Alexithymia Scale 
(alexithymia ≥ 61, n=30; control ≤ 52, n=30). Participants labeled the emotion 
of a face that morphed from neutral to fear (emotion task) and the identity of 
a face that morphed from one person to another (identity task). We conducted 
ANOVA with morph (mostly faceA [0%-20%], ambiguous face [40%-60%], 
mostly faceB [80%-100%]) and group (alexithymia, control) as factors. 
Accuracy and heart rate were outcome measures. Planned t-tests assessed 
reactivity by comparing group HR responses to morphs at end-points of the 
emotion and identity continuums.
Results: ANOVA revealed main effects of morph, with subjects’ HR and 
accuracy decreasing when categorizing ambiguous versus unambiguous 
faces (F(2,59)≥12.236,p=.000). No significant group effects or interaction 
emerged. Planned t-tests found no group differences in HR for the identity 
task (t(58)=.723,p=.472). In the emotion task, controls exhibited greater HR 
reactivity compared to alexithymic subjects (t(58)=-1.753,p=.083).
Conclusions: The effects of ambiguity across both tasks suggest that HR 
decreases as attention increases. This physiological pattern seems intact in 
alexithymia. In contrast, only controls demonstrated predicted HR reactivity 
to affectively arousing faces. Findings suggest potentially distinguishable 
physiological correlates of cognitive and emotional processing in alexithymia 
and may have implications for the treatment of depression.
770. Gender Differences in the Developmental 
Trajectories of Borderline Personality
Marianne Goodman1,2, Uday Patil2, Joseph 
Triebwasser1,2, Elizabeth Diamond2, Antonia New1,2,
Larry Siever1,2
1Psychiatry, James J Peters VA Medical Center, Bronx, NY,2Psychiatry, 
Mount Sinai School of Medicine, New York, NY
Background: In order to identify precursors and trajectories of the development 
of borderline personality disorder (BPD), we solicited information from parents 
of adult and adolescent children diagnosed with BPD.
Methods: We developed a survey containing approximately 100 questions 
for parents to complete on their offspring with and without BPD. Questions 
cover the child’s life from pregnancy through young adulthood; family history; 
treatment history, and respondent demographics. BPD offspring will have met 
diagnostic criteria embedded within the survey and been given a diagnosis of 
BPD by a clinician.
Results: To date over 700 surveys have been completed, with 400 having usable 
www.sobp.org/journal
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data. We report on 170 offspring that met strict criteria for BPD and 120 non-
BPD siblings. Significant predictors of BPD, derived from separate multinomial 
logistic regressions by gender, included: 1) unusual difficulty with friends in 
elementary school aged girls (p< .004), 2) unusual temperament in elementary 
school boys (p<.008), 3) adolescent factors of moodiness (p<.004), problems with 
fighting (p<.004), and impulsivity (p<.000) for girls, and 4) adolescent substance 
abuse (p<.003) and suicidal thoughts (p<.002) in both genders.
Conclusions: BPD prodromal features can be identified as early as in elementary 
aged children. BPD may be viewed as a temperamental disturbance in affect 
that disturbs interpersonal relationships, coupled with adolescent impulsivity. 
These preliminary results will updated with a larger data set.
771. Cognitive and Sedative Effects of Guanfacine 
Extended Release in Children and Adolescents 
Aged 6 to 17 Years with Attention-Deficit/
Hyperactivity Disorder: Safety and Sleep Effects
Scott H. Kollins1, Timothy Wigal2, Bradley Vince3,
Andrew Lyne4, Kimberly Farrand5
1Department of Psychiatry, Duke University Medical Center, Durham, 
NC,2Child Development Center, University of California, Irvine, Irvine, 
CA,3N/A, Vince and Associates Clinical Research, Overland Park, 
KS,4N/A, Shire Pharmaceutical Development LTD, Basingstoke, United 
Kingdom,5N/A, Shire Development Inc, Wayne, PA
Background: Guanfacine extended release (GXR), a selective ?2A-adrenoceptor 
agonist, has demonstrated efficacy in attention-deficit/hyperactivity disorder 
(ADHD) in previous studies. This study assessed the effects of GXR on 
cognitive tasks in subjects aged 6 to 17 years with ADHD. A secondary 
objective was to evaluate potential sedative effects of GXR.
Methods: In this double-blind, dose-optimization noninferiority study, 121 
subjects were randomized to GXR and 57 subjects to placebo for 6.5 weeks. 
Cognitive assessments included the Choice Reaction Time (CRT) and Spatial 
Working Memory (SWM) tests (both from the Cambridge Neuropsychological 
Test Automated Battery), and Permanent Product Measure of Performance. The 
Pictorial Sleepiness Scale (PSS) measured daytime and evening sleepiness and the 
Pediatric Daytime Sleepiness Scale (PDSS) measured daytime sleepiness only.
Results: GXR did not impair reaction time as measured by the CRT: mean change 
from baseline to endpoint was 20.7±63.1 msec for GXR vs 21.9±64.0 msec for placebo, 
P=.84. Changes in other CRT parameters also showed no significant differences 
between GXR and placebo at endpoint (P=.30 for movement time, P=.72 for total time, 
and P=.98 for accuracy). GXR did not impair any aspect of SWM (P>.05 for all). PDSS 
showed that GXR slightly decreased daytime sleepiness (P=.02), while PSS subject and 
observer assessments showed no change in daytime sleepiness with GXR. Evaluations 
at 10 and 12 hours postdose showed greater evening sleepiness with GXR vs placebo.
Conclusions: GXR did not impair cognitive function or affect daytime sleepiness 
but did increase evening sleepiness in children and adolescents with ADHD.
Supported by funding from Shire Development Inc
772. Assessment of Personality Disorder in Adult 
ADHD Using Data from a Clinical Trial of OROS 
Methylphenidate (OROS MPH)
Barrie K. Marchant, Frederick W. Reimherr, Erika D. 
Williams, Robert E. Strong, Corinne Halls, Poonam Soni
Psychiatry, University of Utah, Salt Lake City, UT
Background: Studies have reported high comorbidity of personality disorder 
and adult ADHD. However, assessment of personality disorder is problematic 
and none have rigorously confirmed this observation with measures of 
concurrent validity.
Methods: 47 patients entered a double-blind trial of OROS MPH after administration 
of the Wisconsin Personality Inventory (WISPI-IV) and the SCID-II. At discharge, 
all information was reviewed to produce a final consensus personality diagnosis. 
Patients were separated into three post hoc categories: PDnegative (no personality 
disorder), PDpositive (subjects meeting diagnostic criteria for one disorder), and 
PDplus (subjects meeting diagnostic criteria for ≥2 disorders).
Results: 45% of subjects had a personality disorder on the final assessment 
versus 62% (SCID-II) and 33% (WISPI-IV): 11% cluster A, 17% cluster B and 
30% cluster C. Compared to the final assessment, the WISPI-IV identified 
PDnegative subjects with sensitivity = .92 and specificity = .67 and PDplus 
subjects with sensitivity = .40 and specificity = 1.00. The SCID-II identified 
PDnegative subjects with sensitivity = .64 and specificity = .90 and PDplus 
subjects with sensitivity = .90 and specificity = .84. There was a significant 
correlation between the number of SCID-II items endorsed by each subject and 
their WISPI-IV average z-score (r=.67, df=46, p<.001).
Conclusions: All three systems detected personality disorder in a large 
proportion of patients. The WISPI tended to under-estimate personality 
disorders while the SCID-II over-estimated them. The self-administered 
WISPI-IV would be more practical in a multicenter clinical trial to provide an 
estimate of personality disorder.
Supported by Ortho-McNeil Janssen Scientific Affairs, LLC
773. Does DRD4 Genotype Predict Brain Volumes in 
Adults with ADHD?
Michael C. Monuteaux
Psychiatry, Massachusetts General Hospital, Boston, MA
Background: An emerging literature has begun to demonstrate an association 
between the dopamine D4 receptor (DRD4) gene and MRI findings in key 
brain regions in samples of children with ADHD. The present study sought to 
extend these findings to adults.
Methods: We examined two groups of adults: 24 with ADHD, and 20 healthy 
controls. Within each group, we compared subjects with and without the 
DRD4 7-repeat allele on brain volumes (cm3) of a priori selected brain regions 
(superior frontal cortex, middle frontal cortex, anterior cingulate cortex and 
cerebellum cortex) using linear regression models.
Results: The omnibus interaction between diagnostic status and genotype 
across the four ROIs was significant in both left hemisphere structures and 
right hemisphere structures, providing statistically significant evidence that 
the association between DRD4 genotype and the brain volumes differ by 
diagnostic status. Among adults with ADHD, subjects with the 7-repeat allele 
had a significantly smaller mean volume in the left superior frontal cortex 
and left and right cerebellum cortex. Among the Controls, no statistically 
significant volumetric differences were detected between subjects with and 
without the 7-repeat allele.
Conclusions: Our findings suggest that volumetric abnormalities in the 
dorsolateral prefrontal cortex and cerebellum may be an intermediate 
phenotype between DRD4 risk genes and the clinical expression of ADHD in 
adults. These results contribute to our understanding of the pathophysiology 
of ADHD.
Supported by F32 MH065040-01A1
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774. Reduced Medial Prefrontal Cortex Response 
during an Inhibition Task in Recovered Anorexic 
Women: A Pilot Study
Tyson A. Oberndorfer, Walter H. Kaye, Alan Simmons, 
Martin P. Paulus, Scott C. Matthews
Psychiatry, UCSD, La Jolla, CA
Background: Anorexia Nervosa (AN) is characterized by restrictive eating 
and emaciation, obssionality, and perfectionism. Behavioral inhibition, 
overcontrol, and decreased impulsivity on reaction time (RT) tasks are 
commonly observed. Neuroimaging studies in healthy volunteers have defined 
a neural network that includes prefrontal cortex and anterior cingulate, where 
these control mechanisms are instantiated. However, little is known about the 
neural substrates of inhibitory processing in AN.
Methods: To date, we have studied 5 recovered restricting-type AN subjects 
(RAN) and 6 age-matched control women (CW). Functional magnetic 
resonance imaging measured neural activity while subjects performed a 
validated motor inhibition “Stop” task. Subjects were asked to respond as 
quickly as possible by pressing left and right buttons when they saw “X” and 
“O” stimuli, but to not press either button when they heard a tone. Mean 
RT measured prior to the scan was used to construct individualized “hard,” 
“medium,” and “easy” trials based on tone delivery relative to RT.
Results: Replicating prior studies of healthy controls, we observed increased 
inferior frontal gyrus activation in both CW and RAN for all Stop trials 
minus Non-Stop trials (p<0.05). A group-by-task interaction was observed 
in the medial prefrontal cortex (mPFC) where, for hard-minus-easy trial 
comparisons, CW showed greater but RAN lesser mPFC activity (p<0.05) 
reflecting demand-specific mPFC dysfunction in AN.
Conclusions: Preliminary data suggest that RAN show a relative inability to 
appropriately increase mPFC activity as inhibitory load is increased and thus 
may provide a neural basis for aberrant impulse control symptoms.
Supported by 5RO1MH046001-14
775. Evidence of Endogenous Opioid System 
Dysregulation in Borderline Personality Disorder
Alan R. Prossin, Kenneth R. Silk, Tiffany Love, Jon-Kar 
Zubieta
Psychiatry/MBNI, University of Michigan, Ann Arbor, MI
Background: Affective dysregulation is central to the morbidity and mortality of 
borderline personality disorder (BPD). The role of the endogenous opioid system in 
affective control regulation in BPD’s was proposed based on the known functions 
of this neurotransmitter system in Major Depressives and controls(Kennedy et al, 
2006) and various challenge studies in BPD’s(Silk et al, 2000). No neuroimaging 
studies have examined directly the role of this neurotransmitter system in the 
pathophysiology of BPD(Lis et al, 2007). We hypothesize the presence of 
differences in baseline μ-opioid receptor concentrations in BPD’s compared to 
healthy controls in emotion processing regions.
Methods: 18 female BPD’s and 14 controls matched by age, gender, and 
educational level. Utilizing PET with the μ-opioid receptor selective radiotracer 
[11C]carfentanil, measures of μ-opioid receptor availability (binding potential, BP≈ 
Bmax/Kd) were obtained during a sustained neutral state, as previously described in 
healthy subjects and Major Depressive Disorder(Kennedy et al, 2006). Subtraction 
analyses of voxel-by-voxel BP maps were then performed between groups, using 
SPM99 and correction for multiple comparisons at p<0.05.
Results: At baseline, the BPD group showed greater μ-opioid receptor BP than 
controls in the orbito-frontal cortex, amygdala, nucleus accumbens, and infero 
temporal cortex but lower μ-opioid receptor BP in the posterior thalamus.
Conclusions: These data demonstrate differences in μ-opioid receptor availability 
at baseline in brain regions involved in emotional regulation (posterior thalamus) 
and in decision making and motivated behavior (orbitofrontal cortex) between 
BPD and healthy subjects, implicating an important role of the endogenous 
opioid system in the pathophysiology of BPD.
Supported by Borderline Personality Disorders Research Foundation
776. Long-Term Safety and Efficacy of Guanfacine 
Extended Release in Children and Adolescents with 
Attention-Deficit/Hyperactivity Disorder
Floyd Sallee1, James J. McGough2, Timothy Wigal3,
Kimberly Farrand4, Andrew Lyne5, Joseph Biederman6
1Department of Psychiatry, University of Cincinnati, Cincinatti, OH,2N/A, 
UCLA Psychiatric and Biobehavioral Sciences, Los Angeles, CA,3Child 
Development Center, University of California, Irvine, Irvine, CA,4N/A, 
Shire Development Inc, Wayne, PA,5N/A, Shire Pharmaceutical 
Development LTD, Basingstoke, United Kingdom,6Clinical and 
Research Program in Pediatric Psychopharmacology, Massachusetts 
General Hospital, Harvard Medical School, Boston, MA
Background: Guanfacine extended release (GXR), a selective ?2A-adrenoceptor 
agonist, has demonstrated efficacy as monotherapy for attention-deficit/
hyperactivity disorder (ADHD) in previous studies. The objectives of this 
study were to assess long-term safety and efficacy of GXR in patients aged 6 to 
17 years with ADHD.
Methods: This study was an open-label extension of a placebo-controlled phase 
III trial and an open-label phase II safety study of GXR and psychostimulant 
coadministration. Patients from the phase II trial receiving coadministered 
psychostimulants had the option to continue their psychostimulant treatment. 
Of 259 patients who received GXR, 53 were coadministered psychostimulants. 
Optimal dose was achieved by upward titration to a maximum of 4 mg/d and 
maintained up to 24 months. Safety assessments included adverse events (AEs), 
laboratory tests, and electrocardiograms. The main efficacy measure was ADHD 
Rating Scale-IV (ADHD-RS-IV) total score change from baseline to endpoint.
Results: AEs were generally mild to moderate. The most common treatment-
emergent AEs (TEAEs) included somnolence (30.5%), headache (24.3%), and 
upper respiratory tract infection (17.8%). The incidence of TEAEs was 87.3% 
overall. Thirty-one patients (12%) discontinued due to TEAEs (13.6% in the 
monotherapy group and 5.7% in the coadministration group). Small changes 
in blood pressure and pulse were noted. No electrocardiogram abnormality was 
reported as a serious AE. At endpoint, mean changes in ADHD-RS-IV total score 
were significant overall and for all weight-adjusted dose groups (P<.001 for all).
Conclusions: In this long-term GXR treatment study, (up to 4 mg/d) was 
generally safe and effective in children and adolescents with ADHD.
Supported by funding from Shire Development Inc
777. Higher Cortisol and Cardiovascular Stress 
Responses Following Psychological Challenge in 
Women with Borderline-Personality-Disorder with High 
Dissociation Compared to a low Dissociation Group
Nicole C. Schommer, Nadine Meissner, Stefan Röpke, 
Isabella Heuser, Claas-Hinrich Lammers
Psychiatry and Psychotherapy, Charite- Campus Benjamin Franklin, 
Berlin, Germany
Background: Borderline-Personality-Disorder (BPD) is a severe psychiatric 
disorder, characterized by a pervasive pattern of instability in affect regulation, 
impulse control, behaviour of self-injury, and multiple suicide attempts. 
About 70% of BPD patients show comorbidity with post-traumatic stress 
disorder (PTSD). In contrast to PTSD, there is a paucity of data on HPA and 
cardiovascular stress reactivity in BPD patients.
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Methods: We investigated cortisol, heart rate, and blood pressure reactivity 
following a psychological challenge in 20 young women with BPD. We 
compared patients with high dissociation during the challenge with a group 
showing low dissociation during the stress exposure. The psychological 
challenge was a 15-minutes lasting interview concerning the last suicide 
attempt or self injury focusing on cognitive and emotional aspects. As control 
situations we conducted a first session without any challenge as well as a non-
challenging interview.
Results: In the total group the control session and the psychological challenge 
resulted in slight cortisol increases (Fs>10.3;p<0.001). However, separate 
ANOVAs revealed only in the high-dissociation group significant increases in 
cortisol stress reactivity (F= 4.9; p3.9; p 4.1; p < 0.05).
Conclusions: In all sessions very low endocrine and cardiovascular stress 
responses compared to usual observed levels in healthy controls after 
psychosocial stress tests are observed, however dissociation during stress 
exposure results in higher endocrine and cardiovascular responses.
778. Relationships between Early Visual Processing, 
White Matter Integrity, and Emotion Processing 
Deficits in Schizophrenia
Ilana Y. Abeles1, Matthew Hoptman2, Maria 
Jalbrzikowski1, Dean Catalano2, Ruben C. Gur3, Daniel 
C. Javitt4, Pamela D. Butler1
1Laboratory of Clinical Neuroscience, Nathan Kline Institute, 
Orangeburg, NY,2Department of Psychiatry, Nathan Kline Institute, 
Orangeburg, NY,3Department of Psychiatry, University of Pennsylvania, 
Philadelphia, PA,4Program in Cognitive Neuroscience and 
Schizophrenia, Nathan Kline Institute, Orangeburg, NY
Background: Schizophrenia patients (SCZ) have deficits in face emotion perception 
and show early visual processing deficits, evidenced by preferential magnocellular 
system dysfunction. SCZ also show decreased white matter integrity in emotion 
processing regions including optic radiations (OR), limbic areas, and inferior 
frontal cortex. We hypothesized that magnocellular deficits and decreased white 
matter integrity may be related to emotion perception deficits.
Methods: SCZ and controls participated. Emotion processing was examined 
using the PENN Emotion Recognition Task. Early-stage visual processing 
was assessed using contrast sensitivity (CS) measures. White matter integrity 
was assessed using diffusion tensor imaging. Two tracts were made using 
DTIStudio: the OR, which connects thalamus with primary visual cortex and 
the inferior fronto-occipital fasciculus (IFOF), which is thought to connect 
occipital and frontal regions.
Results: Emotion identification (p<0.001) and CS (p<0.001) performance 
were significantly impaired in SCZ vs controls. SCZ showed correlations 
between decreased CS in the magnocellular-biased (0.5 cycle/degree) condition 
and impaired emotion recognition (p=0.009). SCZ also showed reduced FA 
within left IFOF and OR (p<0.05). Correlations in SCZ were found between 
left IFOF FA and emotion identification (p=0.02).
Conclusions: We established for the first time direct associations of emotion 
identification, early visual processing and integrity of neural connectivity 
in SCZ. IFOF FA was decreased on the left side, which is in itself a novel 
observation, and this decrease was related to emotion recognition deficits, 
suggesting that impaired input to inferior frontal cortex from visual and other 
areas may contribute to emotion processing deficits.
Supported by NIMH
779. Social Cognition Mediates Illness Related 
and Cognitive Influences on Social Functioning in 
Schizophrenia-Spectrum Disorders
Jean Addington1,2,3, Todd A. Girard4, Bruce K. 
Christensen5, Donald Addington3
1Psychiatry, University of Toronto, Toronto, ON, Canada,2Schizophrenia 
Program, Centre for Addiction and Mental Health, Toronto, 
ON, Canada,3Psychiatry, University of Calgary, Calgary, AB, 
Canada,4Psychology, Ryerson University, Toronto, ON, Canada,5Psychiatry 
and Behavioral Sciences, McMaster University, Hamilton, ON, Canada
Background: The objective of the current study was to use structural equation 
modelling (SEM) to test the hypothesis that the relationship between cognitive 
performance and social functioning is mediated by patients’ social cognitive abilities.
Methods: The sample included 96 subjects who met criteria for a schizophrenia 
spectrum disorder with equal distribution amongst first and multi-episode 
subjects. The sample also included 55 non-psychiatric controls. Subjects were 
assessed on a range of measures within each of the domains of cognition, social 
cognition and social functioning.
Results: Using SEM, a model was derived that explained 79.7% of the variance 
in social functioning and demonstrated that the link between cognition and 
social functioning was fully mediated by social cognition.
Conclusions: This study provides some first steps in understanding the complex 
relationship between cognition and social functioning. Such a relationship has 
potential implications for the design of remediation strategies.
Supported by Canadian Institutes of Health Research
780. Sounding it Out: Auditory Processing Deficits 
and Reading Impairment in Schizophrenia
John Aspromonte, Erica Saccente, Rachel Ziwich, 
Daniel C. Javitt, Nadine Revheim
Program in Cognitive Neuroscience and Schizophrenia, Nathan Kline 
Institute for Psychiatric Research, Orangeburg, NY
Background: Impaired reading abilities, associated with visual processing 
deficits, have been found in schizophrenia. To date, relationships of reading 
deficits and auditory dysfunction have not been examined. Auditory processing 
deficits in schizophrenia have been demonstrated by poor performance 
on several behavioral measures, such as tone-matching (TMT), and voice 
discrimination and identification tasks (KNVD/KNVID).
Methods: This study examines the relationship between phonological 
processing, measured by standardized reading measures (CTOPP, GORT-4), 
and auditory processing (TMT, KNVD/KNVID) and their relationship to 
reading impairment in schizophrenia. Fifty-four individuals (33 patients, 
21 controls) participated in the study; 54.5% of patients (n=18) and 4.8% of 
controls (n=1) were diagnosed with reading impairment (p=.0001).
Results: Across groups, significant correlations were observed between both 
reading measures and auditory processing ability: CTOPP and KNVID, 
r=.53, p<.001,n=41; CTOPP and TMT, r=.43,p=.002,n=48; GORT-4 and 
KNVID, r=.42,p=.006,n=41; GORT-4 and TMT, r=.52,p<.001,n=48. Within 
group correlations differed by measure. For patients, GORT-4 and TMT 
were significant (r=.45,p=.009,n=33) and for controls, CTOPP and KNVID 
were significant (r=.55,p=.03,n=15). Using ANOVA, significant differences 
were found between groups for KNVID (impaired reading patients/controls, 
nonimpaired patients, nonimpaired controls: F=13.85,df=2,38;p<.001); post 
hoc analyses indicate differences are primarily between impaired patients/
controls and nonimpaired controls. Conversely, significant differences were 
found across all groups for TMT (F=9.74,df=2,45;p<.001), with post hoc tests 
demonstrating differences between impaired patients/controls vs. nonimpaired 
patients (p=.041) or nonimpaired controls (p<.001), respectively. Findings were 
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similar for repeated analyses that excluded the reading impaired control.
Conclusions: These results confirm prior reports of reading dysfunction in 
schizophrenia and suggest significant phonological contribution.
Supported by R37-MH49334
781. Amygdala Volume and Face Recognition 
Memory in Schizophrenia: A Magnetic Resonance 
Imaging Study
Audrey Benoit, Karine Sergerie, Yvonne Czechowska, 
Jorge L. Armony, Martin Lepage
Brain Imaging Group, Douglas Mental Health University Institute, 
Montreal, QC, Canada
Background: Several studies have shown that face recognition memory is 
significantly impaired in schizophrenia but little is known concerning the 
neural basis of such a problem. Structural and functional imaging studies 
suggest that deficits in emotional face processing are related to hypoactivity 
and smaller volume of the amygdala in schizophrenia. We investigated the 
association between face recognition memory and amygdala volume and how 
emotional expression may affect this association.
Methods: Nineteen healthy subjects and 19 people with schizophrenia underwent 
structural magnetic resonance imaging and a face recognition memory task using 
happy, neutral, and sad expressions. Amygdala volumes were obtained through manual 
segmentation and an estimate of memory accuracy was calculated for each expression.
Results: As expected, memory accuracy was lower in people with schizophrenia 
compared to the healthy controls in all emotional conditions; however, 
amygdala volumes were not different between the two groups. In schizophrenia, 
the right amygdala volume significantly related with memory performance for 
faces when averaged across all emotion conditions (r=0.57, p<0.05) whereas 
no significant association was found for controls. A subsidiary analysis in the 
schizophrenia group based on the emotional expressions revealed that sad, 
happy and neutral faces yield similar correlations (range 0.36-0.48) and their 
strength did not significantly differ (all p>0.60).
Conclusions: Despite lower memory performance, a specific association 
between right amygdala volume and face recognition accuracy was identified 
in schizophrenia. Moreover, this association seems independent of facial 
expressions. Hence, the right amygdala volume seems to represent one 
important region for face memory in this disorder.
Supported by CIHR: MOP 53280, MOP 57724
782. Non-Linear Response of the Anterior Cingulate 
and Prefrontal Cortex in Schizophrenia as a 
function of Variable Attentional Control
Giuseppe Blasi1, Paolo Taurisano1, Apostolos 
Papazacharias1, Grazia Caforio1, Raffaella Romano1,
Luciana Lobianco1, Leonardo Fazio1, Annabella Di 
Giorgio1, Valeria Latorre1, Fabio Sambataro2, Marcello 
Nardini1, Venkata Mattay2, Daniel Weinberger2,
Alessandro Bertolino1
1Department of Neurological and Psychiatric Sciences, University of 
Bari, Bari, Italy, Bari, Italy,2National Institute of Mental Health, National 
Institutes of Health, Bethesda, MD
Background: Previous studies have reported evidence of abnormal neuronal 
responses in prefrontal and cingulate cortex during attentional control 
processing in schizophrenia. However, it is not clear how variation in capacity 
limitations in schizophrenia may modulate activity within these brain regions 
during increasing levels of attentional control. Aim of this study is to investigate 
with fMRI in schizophrenia the impact of increasing levels of attentional 
control processing on prefrontal and cingulate activity.
Methods: BOLD responses of sixteen outpatients with schizophrenia on stable 
treatment with antipsychotic drugs were compared with those of twenty-one 
healthy subjects while performing a task eliciting increasing demands for 
attentional control processing during event-related fMRI at 3 Tesla.
Results: Patients had reduced behavioral performance at greater levels of 
attentional control. The fMRI results indicated that there was greater prefrontal 
activity at intermediate levels of attentional control in patients, while greater 
activity in prefrontal and cingulate in controls at high demands of attentional 
control processing. The BOLD activity profile of these regions in healthy 
subjects increased linearly with increasing cognitive loads, whereas in patients 
it had an inverted-U shaped profile. Correlation analysis consistently indicated 
differential region and load specific relationships between brain activity and 
behavior in these two groups of subjects.
Conclusions: These results indicate that varying attentional control load 
is associated in schizophrenia with non linear cortical responses, possibly 
suggesting earlier capacity saturation of attentional control.
Supported by NARSAD Young Investigator Award
783. Reduced Language Lateralization in 
Schizophrenia Patients with OCD: Are They 
Schizophrenia or OCD Like?
Maya Bleich-Cohen1,2, Michael Poyurovsky3, Ronit 
Weizman2, Sarit Faragian2, Talma Hendler1,2
1Functional Brain Imaging Unit, Wohl Institute for Advanced Imaging, 
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel,2Sackler Faculty 
of Medicine, Tel Aviv University, Tel Aviv, Israel,3Research Unit, Tirat 
Carmel Mental Health Center, Tirat Carmel, Israel., Haifa, Israel
Background: A substantial proportion of schizophrenia patients also meet DSM-
IV criteria for obsessive-compulsive disorder (OCD). Schizo-obsessive patients are 
characterized by a distinct course, poorer treatment response and prognosis.
As part of a project aiming to elucidate brain mechanisms underlying a schizo-
obsessive subgroup, in the present study we evaluated patterns of lateralization 
in the domain of language processing in schizo-obsessive patients compared to 
“pure” schizophrenia and OCD patients.
Methods: We used functional magnetic resonance imaging (fMRI) to 
investigate language lateralization during the language task of verb generation 
and passive music listening as a control condition. Regions-of-interest 
corresponded to Broca’s area in the inferior frontal gyrus (IFG), Wernicke’s 
area in the superior temporal sulcus (STS) and the auditory cortex. Eleven 
schizo-obsessive patients, 14 schizophrenia patients, 13 OCD patients and 14 
healthy controls were recruited.
Results: No between-group differences were found in the behavioral 
measurements of word generation. A reduced lateralization in the IFG and 
STS was noted in the two schizophrenia groups with and without OCD as 
compared to OCD patients and healthy controls. Reduced lateralization in the 
schizophrenia group was due to a significantly decreased left activation and 
increased right activation of the IFG and STS. No differences in lateralization 
were found between the OCD group and the normal controls.
Conclusions: The revealed similar pattern of reduced lateralization suggests 
that the OCD component does not substantially modify fMRI parameters in 
the language domain in the schizo-obsessive subgroup.
Supported by The Levi-Edersheim-Gitter institute for human brain mapping (MBC)
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784. Eyeblink Conditioning Deficits Indicate 
Temporal Processing Abnormalities in 
Schizophrenia
Amanda R. Bolbecker1, Crystal Mehta1, Chad R. 
Edwards1, Jennifer Boggs2, Anantha Shekhar3, Brian F. 
O’Donnell1, William P. Hetrick1
1Psychological and Brain Sciences, Indiana University, Bloomington, 
IN,2School of Social Work, University of Denver, Denver, 
CO,3Psychiatry, Indiana University Medical School, Indianapolis, IN
Background: Recent studies have documented both structural and functional 
abnormalities in the cerebellum of schizophrenia patients. Increasing evidence 
suggests that, in addition to motor coordination, the cerebellum plays a role 
in psychological processes. Theoretical and empirical evidence suggests that 
symptoms of schizophrenia may arise, at least in part, as a consequence of 
disturbed neural timing processes mediated by the cerebellum.
Methods: The present study employed eyeblink conditioning, a particularly 
appropriate test of the functional integrity of cerebellar timing processes, 
in a large sample of schizophrenic participants with the aim of clarifying 
conflicting results generated from previous reports. A single-cue tone delay 
eye-blink conditioning paradigm consisting of 10 blocks with 10 trials (9 
paired and 1 unpaired trials) was used to examine the functional integrity of 
cerebellar timing circuits in 63 medicated patients with schizophrenia and 63 
age-matched non-psychiatric controls. The conditioned stimulus was a 400 ms 
tone, which on paired trials co-terminated with a 50 ms air puff to the left eye, 
which served as the unconditioned stimulus.
Results: Schizophrenia patients were impaired on both the acquisition and 
timing of conditioned responses compared to non-psychiatric controls. The 
schizophrenic group produced significantly fewer conditioned responses and, 
when conditioned responses were produced, they were timed unusually early 
compared with air puff onset.
Conclusions: These results are consistent with models of schizophrenia in 
which timing deficits underlie information-processing abnormalities and 
clinical features of schizophrenia.
Supported by NARSAD; NIMH MH074983-01 awards to WPH
785. Neurodevelopment in Adolescence and Young 
Adulthood: Recruitment and Evaluation of Youths 
At-Risk for Psychosis
Karin E. Borgmann-Winter1,2, Christian Kohler1,
Raquel E. Gur1, Jan Richard1, Monica E. Calkins1
1Psychiatry, University of Pennsylvania, Philadelphia, PA,2Child 
and Adolescent Psychiatry, Children’s Hospital of Philadelphia, 
Philadelphia, PA
Background: Early intervention in schizophrenia is an emerging goal of 
investigations in the earliest phases of the illness. To develop strategies for early 
intervention, those at highest risk for the development of psychosis must be 
accurately identified. We present an approach to the longitudinal assessment of 
individuals at-risk for psychosis whose goal is to combine endophenotype and 
prodromal risk strategies to facilitate prediction of conversion to psychosis.
Methods: Participants are recruited from the University of Pennsylvania, 
Children’s Hospital of Philadelphia, local schools, and community mental 
health clinics. Participants in the following groups are enrolled and re-
assessed at 6-month intervals: Genetic Risk (GR: first-degree relative with 
schizophrenia), Clinical Risk (CR: current prodromal symptoms, no family 
history of schizophrenia), Psychotic (PSYG: current psychotic disorder), Low-
Risk (LR: no family history of psychosis, no prodromal symptoms). To assess 
familiality of measures, healthy siblings are recruited. The assessment protocol 
provides comprehensive psychopathology assessment using standardized 
instruments selected to maximize coverage of Axis I, Axis II and prodromal 
symptoms, and thus fully categorize baseline and outcome diagnoses. 
Behavioral, medical, developmental and psychosocial history is assessed using 
self-report scales, supplemented by collateral information obtained from parent 
or guardian. Participants are next invited to participate in a series of individual 
protocols assessing neurocognitive, emotion, olfactory, psychophysiology and 
neuroimaging performance.
Results: 24 subjects have been recruited and assessed to date: GR=9, CR=7, 
PSYG=3, LR=5.
Conclusions: The establishment the NAYA cohort lays the foundation 
for longitudinal characterization of the neurodevelopmental course of 
schizophrenia in the adolescent and young adult periods.
Supported by NARSAD (KBW), Unrestricted Funds from the Children’s 
Hospital of Philadelphia (KBW), K08MH079364 (MEC)
786. Specific Social Deficits in Schizophrenia 
are Differentially Predicted by Thought Disorder 
Subtypes
Christopher Bowie1, Philip D. Harvey2
1Psychiatry, Mount Sinai School of Medicine, New York, NY,2Psychiatry, 
Emory University, Atlanta, GA
Background: Thought disorder, a core symptom of schizophrenia, is often 
subtyped as positive thought disorder (PTD; e.g., tangential speech), or 
negative thought disorder (NTD; e.g., poverty of speech). Few studies have 
examined their functional consequences.
Methods: Over a 2.5 year follow-up, 317 patients with schizophrenia were 
twice assessed with standard cognitive, thought disorder, and social behavior 
instruments.
Pearson correlations examined associations of PTD and NTD with six types 
of social behaviors. Stepwise linear regressions were used to predict social 
behaviors and adaptive functions at follow-up with cognitive measures, PTD, 
and NTD entered as the independents.
Results: At baseline, PTD and NTD were moderately (r’s from .20 to .40) 
associated with impairments in communication skills, conversational skills, 
and instrumental social skills. PTD (r=.33), but not NTD (r=.08) was associated 
with socially inappropriate behavior, while NTD, but not PTD, was associated 
with disengagement (r=.40) and withdrawal (r=.37). Longitudinal analyses of 
social deficits showed a similar pattern of differential relationships with PTD 
versus NTD. Thought disorder accounted for more variance (R2 ranges .09 
to .15) in follow-up social behavior than cognition, with the exception of 
communication skills, where cognition entered first (R2=.13), and both PTD 
(R2?=.03) and NTD (R2?=.02) contributed to the prediction at a statistically 
significant level. In contrast to social behavior, follow-up adaptive behavior was 
largely accounted for by baseline cognition (R2=.18), though NTD (R2?=.03) 
and PTD (R2?=.02) contributed small, but significant variance.
Conclusions: Thought disorder contributes to persistent functional 
impairments in schizophrenia. Subtypes have differential relationships with 
specific functional domains.
Supported by NARSAD; NIMH MH 36692; NIMH R01 63116
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787. Neurodevelopment in Adolescence and Young 
Adulthood (NAYA): Neurocognitive Impairments in 
Youths At-Risk for Psychosis
Monica E. Calkins1, Karin E. Borgmann-Winter1,2,
Christian Kohler1, Jan Richard1, Noah Sasson1, Ruben 
C. Gur1, Raquel E. Gur1
1Neuropsychiatry Program, University of Pennsylvania School of 
Medicine, Philadelphia, PA,2Child and Adolescent Psychiatry, Children’s 
Hospital of Philadelphia, Philadelphia, PA
Background: Accumulating evidence suggests that neurodevelopmental 
abnormalities preceding clinical manifestation of illness are present in 
children at-risk for developing psychosis. Neurocognitive abilities, especially 
executive, attention and memory dysfunction, are extensively implicated 
as candidate endophenotypes in schizophrenia. Impaired endophenotype 
performance in adolescents deemed at-risk for schizophrenia bears directly 
on the endophenotype’s ability to serve as a marker for early identification 
and treatment. The primary purpose of the NAYA program is to combine 
endophenotype and prodromal risk strategies to facilitate early identification 
of individuals at-risk for psychosis.
Methods: Youths (ages 14-25) completed a comprehensive diagnostic assessment 
and the University of Pennsylvania Computerized Neurocognitive Battery 
(CNB) in the context of this and other ongoing studies. Groups included 
individuals deemed at-risk for psychosis [Genetic risk (GR; first-degree relative 
with schizophrenia), n=45; clinical risk (CR; prodromal symptoms but no family 
history), n=5; schizophrenia (SCZ), n=85; and healthy controls (CNT), n=86].
Results: Compared to CNT, youths with schizophrenia and those at-risk 
for psychosis showed significant (all p’s<0.05) impairments in accuracy of 
attention, memory (verbal, face, spatial), language and spatial ability. Young 
relatives exhibited impairments similar to adult relatives in prior studies. Pilot 
analyses revealed especially pronounced impairments in CR across domains.
Conclusions: Candidate neurocognitive endophenotypes are observable in 
youths at-risk for psychosis and may reflect pathophysiological abnormalities 
involved in development of schizophrenia. Thus, they may ultimately facilitate 
both prediction of schizophrenia and insight into its pathophysiology. As 
the NAYA longitudinal program grows, we will investigate heritability in at-
risk groups, developmental trajectory of endophenotypes, and prediction of 
conversion to psychosis.
Supported by K08MH079364 (MEC); NARSAD (KBW); Unrestricted funds 
from Children’s Hospital of Philadelphia (KBW); R01MH65578 (REG); 
R01MH66121 (REG); R01MH42191 (REG)
788. Functional Connectivity Abnormalities in 
Schizophrenia during Rest
Jazmin Camchong1, Christopher Bell1, Peter Fried1,
Bryon Mueller1, Angus MacDonald2
1Psychiatry, University of Minnesota, Minneapolis, MN,2Psychology, 
University of Minnesota, Minneapolis, MN
Background: Baseline brain activity has been observed in the normal brain at 
rest. Previous studies have found that this baseline brain activity is organized 
in functionally connected resting state networks. Schizophrenia participants 
have previously shown functional connectivity abnormalities in some of these 
resting state networks. The present study investigated the hypothesis that 
schizophrenia is associated with altered functional connectivity by performing 
independent components analysis (ICA) on resting state functional magnetic 
resonance imaging (rs-fMRI) data.
Methods: Twenty nine chronic schizophrenia patients (11 females, age: 
M=41.3, SD=9.28) and 29 healthy participants (11 females, age: M=41.1, 
SD=10.6) were recruited. Participants underwent a 6 min rs-fMRI scan 
(Siemens Trio 3T scanner) during which they were instructed to stay still with 
their eyes closed and remain awake. ICA (FSL - Melodic) was used to identify 
functionally connected networks.
Results: Functionally connected networks resulting from ICA were consistent 
with previous studies. Unpaired t-test results showed specific functional 
connectivity abnormalities associated with schizophrenia. The schizophrenia 
group showed lower functional connectivity in resting state networks that 
included prefrontal cortex, superior parietal lobule, precuneus, cuneus and 
cerebellum (p<0.05).
Conclusions: Results suggest that altered functional connectivity in 
schizophrenia is specific to networks associated with visual and attention (e.g. 
precuneus, cuneus) as well as cognitive (e.g. prefrontal cortex and superior 
parietal lobule) processing. The present study provides supporting evidence 
for the hypothesis of abnormal functional integration between brain regions 
in schizophrenia.
Supported by NIMH R01MH060662
789. GAD65 and GAD67 Protein Levels in the 
Dorsolateral Prefrontal Cortex of Subjects with 
Schizophrenia
Allison A. Curley1, Dominique Arion2, David A. Lewis3
1Department of Neuroscience, University of Pittsburgh, Pittsburgh, 
PA,2Department of Psychiatry, University of Pittsburgh, Pittsburgh, 
PA,3Departments of Neuroscience and Psychiatry, University of 
Pittsburgh, Pittsburgh, PA
Background: Impaired GABA neurotransmission in the dorsolateral prefrontal 
cortex (DLPFC) may contribute to the cognitive deficits of schizophrenia. 
Reduced levels of the mRNA encoding the 67-kDa, but not the 65-kDa, 
isoform of glutamic acid decarboxylase (GAD), the enzyme that synthesizes 
GABA, have been widely-replicated. However, protein levels of GAD isoforms 
have only been examined in one study.
Methods: We used antibodies specific for GAD65 and GAD67, and a pan-
GAD antibody that also detects a common degradation product, to assess by 
Western blots the effects of artificially created postmortem intervals (PMI) 
in monkey DLPFC. The same approach is being used to quantify GAD65, 
GAD67, and actin (used as a loading control) protein levels in DLPFC area 9 
from 20 matched pairs of schizophrenia and control subjects, each of whom has 
PMI < 20 hrs and RNA integrity number (RIN) > 7.
Results: In monkeys, GAD67 protein was well-preserved, and most GAD65 
protein was still detectable, with PMIs < 24 hrs. The band of degraded GAD 
increased in proportion to the decline in GAD65 levels. In pilot studies, actin-
corrected GAD65 levels did not differ between schizophrenia and control 
subjects, whereas GAD67 levels were reduced in the schizophrenia subjects 
across a range of PMIs. Blinded analyses of protein levels in the 20 pair cohort 
are ongoing.
Conclusions: A reduction in the levels of GAD67, but not GAD65, protein 
in subjects with schizophrenia would parallel the mRNA data and support the 
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790. The Hippocampus as a Neural Marker of 
Short-Term Clinical Outcome in First Episode 
Schizophrenia
Yvonne Czechowska, Michael Bodnar, Ashok Malla, 
Ridha Joober, Jens Pruessner, Martin Lepage
Psychiatry, Douglas Research Centre-McGill University, Montreal, QC, 
Canada
Background: In schizophrenia, poor outcome or response to treatment has 
been related to both cognitive (memory and executive dysfunctions) and 
neural (enlarged ventricles and reduced occipital-temporal lobes) markers. 
Although hippocampal volumes are reduced in both first episode and chronic 
schizophrenia, these deficits have only been related to long-term clinical 
measures of outcome.
Methods: To determine if volumetric hippocampal differences could identify 
a poor response to treatment in first episode of schizophrenia (FES) patients. 
Hippocampi were manually segmented into three parts: the body, head, and 
tail. Volumes were obtained in 40 FES patients (23 non-responders and 17 
responders - separated by six-month therapeutic response to treatment) and 26 
matched healthy controls.
Results: Non-responders showed a right tail hippocampal volume deficit 
compared to responders (NR= 573±134; R= 658±144; t=-1.91, p=0.03). 
Compared to healthy controls, non-responders displayed bi-lateral hippocampal 
body reductions (Left Body: NR=1227±176, HC=1333±222, t=-1.83, p=0.03; 
Left Body: NR=1134±206, HC=1242±192, t=-1.90, p=0.03) while responders 
showed no differences.
Conclusions: These findings suggest that a volume deficit in the right tail of the 
hippocampus may be a neural marker in FES patients who will not respond to 
treatment by six-months. The right hippocampus is suggested to help maintain 
short-term memory of object-location associations, so a volumetric deficit may 
affect this ability and ultimately treatment response. The early identification of 
treatment non-response may have therapeutic implications.
Supported by CIHR, Sackler Foundation
791. Visual and Verbal Tests of Social Cognition in 
Patients with Schizophrenia and their Unaffected 
First-Degree Relatives Delfina de Achával
Cognitive Neurology and Psychiatry Section, FLENI, Buenos Aires, 
Argentina
Background: Social cognition is affected in individuals with schizophrenia. It 
is unclear to what extent the deficits are shared by unaffected family members 
and the nature of the relationship between deficits in different social cognition 
subcomponents: emotional processing and theory of mind.
Methods: The performance in tests of emotional processing in faces (Baron 
Cohen, 1997) and eyes (Baron Cohen, 2001), in a test of social faux pas 
(Stone , 2002) and in theory-of-mind stories (Happé, 1999) were tested in 
16 individuals with chronic, stable schizophrenia attending the Cognitive 
Neurology and Psychiatry Section of FLENI, 19 first-degree relatives, and 
in 20 healthy persons. A one-way ANOVA was used to compare the groups, 
followed by a Tukey s´ test.
Results: Patients had a poorer overall verbal performance in recognition of 
faux pas stories (F=4.851, p=0.018) and Happe s´ theory-of-mind stories 
(F=3.411, p=0.032), but in our sample there were no significant differences in 
the visual emotional processing tested in eyes and faces. First-degree relatives 
of schizophrenic patients showed an impaired recognition of faux pas stories 
in comparison with healthy persons (p=0.044). We observed no significant 
differences in performance in social cognition tests between patients and 
their relatives. Performance in visual and verbal tests of social cognition were 
correlated in relatives (r=0.77, p<0.001) and patients with schizophrenia 
(r=0.493, p=0.052), but not in healthy individuals.
Conclusions: Our results suggest that individuals with schizophrenia and their 
first degree relatives display a similar pattern of social cognition information 
processing, although social cognition deficits seem less intense in the latter.
792. Pain Perception in Schizophrenia: An fMRI 
Longitudinal Study
Camilo De la Fuente-Sandoval1, Rafael Favila2,
Diana Gomez-Martin3, Francisco Pellicer4, Ariel Graff-
Guerrero5
1Laboratorio de Psiquiatria Experimental, Instituto Nacional de 
Neurologia y Neurocirugia, Mexico, Mexico,2Neurologia, GE 
Healthcare, Mexico, Mexico,3Inmunologia y Reumatologia, 
Instituto Nacional de la Nutricion, Mexico, Mexico,4Laboratorio de 
??????????????????????????????????????????????????????????????? ???????
Mexico,5Campus Juriquilla, Universidad Nacional Autonoma de Mexico, 
Queretaro, Mexico
Background: Several clinical reports suggest a higher threshold to pain 
sensitivity in schizophrenia; however, the mechanisms and implications of this 
remain unknown. Therefore, we examined the effect of antipsychotic treatment 
on blood oxygen level-dependent (BOLD) response to pain tolerance, as 
obtained by functional magnetic resonance imaging (fMRI) in patients with 
schizophrenia, before and after 6 weeks of antipsychotic treatment, versus 
healthy controls
Methods: We studied 12 patients with schizophrenia who were drug free and 
again after 6 weeks of clinically effective risperidone treatment. Patients were 
compared with 13 sex-and-age matched controls. fMRI was used to assess 
BOLD changes in response to a thermal tolerance pain stimulus vs. a non-
painful somatosensory stimulus.
Results: Drug-free group showed greater tolerance to higher temperatures 
than controls, and this tolerance decreased after 6 weeks of treatment with 
risperidone to levels closer to those observed in control subjects. Moreover, 
drug-free subjects showed a lack of activation of the posterior cingulate cortex 
(PCC), Insula (INS), and brainstem, and higher activation in the postcentral 
gyrus (S1) as compared with controls. Following treatment, patients recovered 
activity in the INS, but not in the PCC or brainstem. The S1 remained 
overactive after treatment
Conclusions: A higher pain tolerance is state dependent and it partially 
responds to effective antipsychotic treatment, though the underlying 
biological mechanisms may show differential response to treatment. Ongoing 
studies in subjects at high risk of schizophrenia will help to clarify whether 
underactivation of the PCC and brainstem and overactivation of S1 reflects a 
trait in schizophrenia
Supported by INNN, CONACyT and SNI Mexico
793. Evidence of Exacerbated Cognitive Deficits in 
Schizophrenia Patients with Diabetes
Dwight Dickinson1, James Gold2, Faith Dickerson3,
Deborah Medoff1, Lisa Dixon1
1Psychiatry, University of Maryland/MIRECC, Baltimore, 
MD,2Psychiatry, University of Maryland/MPRC, Baltimore, 
MD,3Psychiatry, University of Maryland/SEPH, Baltimore, MD
Background: The elevated rates of metabolic dysregulation and disease 
among individuals with schizophrenia are alarming, with 1.5 to 2 times the 
normal prevalence of diabetes and more than 40% of schizophrenia patients 
meeting criteria for the metabolic syndrome. Cognitive impairment in 
schizophrenia is well established as a critical determinant of disability and 
reduced role functioning. Less widely studied is the fact that cognition is 
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also impaired in diabetes. The cognitive impact of diabetes converges with 
known cognitive deficits in schizophrenia. Although schizophrenia deficits are 
broadly generalized, the most prominent impairment is in the processing speed 
domain. Literature suggests that diabetes may exert its largest cognitive effect 
in this same domain.
Methods: We compared cognitive performance, as measured by the Repeatable 
Battery for the Assessment of Neuropsychological Status, in three groups: 
patients with schizophrenia and diabetes (n=97), patients with diabetes only 
(n=95), and archival data on patients with schizophrenia only (n=575).
Results: Comparisons indicated that the schizophrenia/diabetes group was 
impaired cognitively relative to both other groups (t’s > 2.6, p’s < .01), especially 
in the domains of processing speed and visual/spatial ability (t’s > 3.6, p’s < 
.001). Additionally, key impairments were associated with diabetes severity 
markers in the schizophrenia/diabetes patients, including age of diabetes onset, 
duration of diabetes, and glycosylated hemoglobin.
Conclusions: Individuals with schizophrenia experience higher diabetes and 
pre-diabetes prevalence rates. Because either illness alone creates cognitive 
vulnerability, the two illnesses together are even more likely to result in an 
increased rate and magnitude of cognitive and functional decline.
Supported by VA RR&D Research Career Development (DD); RO1MH58717 (LD)
794. Disrupted Resting Functional Connectivity 
between a Dorsolateral Prefrontal Cortex (DLPFC) 
Region Showing Catechol-O-Methyltransferase 
(COMT) Genotype Effects and Inferior Parietal 
Lobule in Schizophrenia
Daniel P. Eisenberg1,2, Deepak Sarpal1,2, Philip D. 
Kohn1,2, Andreas Meyer-Lindenberg3, Dylan Wint1,2,
Bhaskar Kolachana2, Daniel R. Weinberger2, Karen F. 
Berman1,2
1Section on Integrative Neuroimaging, Intramural Research Program, 
National Institute of Mental Health, NIH, DHHS, Bethesda, MD,2Clinical 
Brain Disorders Branch, Genes, Cognition and Psychosis Program, 
Intramural Research Program, National Institute of Mental Health, NIH, 
DHHS, Bethesda, MD,3Unit for Systems Neuroscience in Psychiatry, 
Neuroimaging Core Facility, Intramural Research Program, National 
Institute of Mental Health, NIH, DHHS, Bethesda, MD
Background: Cognitive activation fMRI studies in schizophrenia have 
demonstrated both COMT genotype effects on prefrontal cortical efficiency 
and functional disconnectivities between prefrontal cortex and diverse 
brain regions. However, little is known about COMT effects on resting 
neurofunctional topography or illness-associated prefrontal functional 
connectivity in the resting state, particularly in medication-free patients.
Methods: Twenty-five participants with schizophrenia (28+6 years, 6 females), 
withdrawn from medication for four weeks, and 54 healthy participants (28+6 
years, 16 females) were genotyped for the COMT Val158Met polymorphism, 
and underwent two 10 mCi 15O-H2O PET scans during rest. Using random-
effects, general linear modeling, we identified regions where blood flow (rCBF) 
correlated with number of COMT met alleles. We used significant results 
(p<0.05, corrected) in the prefrontal cortex to functionally define seed-regions, 
with which we explored functional connectivity.
Results: Five met/met, 12 val/met, and 8 val/val patients and 13 met/met, 25 
val/met, and 16 val/val healthy individuals participated. In the schizophrenia 
group, COMT met (relative to val) carriers had greater right DLPFC, right 
superior temporal gyrus, and left precuneus rCBF, and less right amygdala 
rCBF. In healthy participants, met carriers showed less left precuneus rCBF. 
Between-group comparisons of functional connectivity revealed more robust 
correlation between right DLPFC and right inferior parietal lobule rCBF in 
healthy individuals than patients.
Conclusions: These data extend to the resting state previous findings in 
schizophrenia of both COMT genotype-related DLPFC neural activity 
changes and altered functional cooperativity of DLPFC with other nodes in 
key neural circuits, such as the working memory system.
Supported by IRP, NIMH, NIH, DHHS
795. Differential Visual Masking Performance in 
Individuals at Risk for Schizophrenia Suggests 
Specific rather than Generalized Information 
Processing Deficits
Ali Eslami, Kathy Shafer, Kristin Cadenhead
Psychiatry, UCSD, San Diego, CA
Background: Schizophrenia patients have information processing deficits 
that may be present prior to the onset of f lorid psychosis. Individuals in 
the prodromal stage of schizophrenia are a heterogeneous population who 
has either genetic risk for schizophrenia, with functional decline, and/or 
subsyndromal psychotic symptoms. One means to understand the pathogenic 
processes in this population is to use biological markers that are sensitive to 
these early changes. The Visual Backward Masking (VBM) paradigm has been 
used to detect deficits in schizophrenia patients, their first degree relatives and 
schizotypal personality disorder individuals.
Methods: Visual forward and backward masking performance of 39 First 
Episode Psychosis, 65 At Risk (AR) and 71 Normal Comparison (NC) 
subjects was assessed in a paradigm that included high and low energy masking 
conditions.
Results: Significant group-by-direction (forward versus backward) interactions 
were present across all masking conditions since AR subjects performed better 
than other groups in the forward direction but showed deficits in low-energy 
and reduced performance in the high-energy and location conditions relative 
to NCs. Interestingly, it was AR subjects who later converted to psychosis who 
had the most prominent VBM deficits across all conditions.
Conclusions: This is the first study to demonstrate VBM deficits in prodromal 
schizophrenia patients, consistent with those seen in other schizophrenia 
spectrum groups. The differential deficit in performance between the forward 
and backward conditions in AR subjects demonstrates that the deficit is not-
generalized. More longitudinal studies and larger samples are needed to better 
study the predictive value of VBM information processing in AR subjects.
Supported by RO1MH60720
796. Treatment Effect on Attentional Network 
Functions in Patients with Schizophrenia
Kai Wang1, Yi Dong2, Lilin Gao3, Panpan Hu1, Kevin G. 
Guise4, Laura Martin4, Philip D. Harvey5, Jin Fan4,6
1Department of Neurology, Anhui Medical University, Hefei, 
China,2Department of Psychiatry, Anhui Medical University, 
Hefei, China,3Neurology, Anhui Medical University, Hefei, 
China,4Department of Psychiatry, Mount Sinai School of Medicine, 
New York, NY,5Department of Psychiatry and Behavioral Sciences, 
Emory University School of Medicine, Atlanta, GA,6Department of 
Neuroscience, Mount Sinai School of Medicine, New York, NY
Background: Recent theories have conceptualized attention as comprising three 
separate functional components of alerting, orienting, and executive control. 
The alerting subsumes the capacity to increase vigilance to an impending 
stimulus, the orienting component involves the selection of task-specific 
information from among numerous sensory inputs, and the executive control 
involves more complex mental operations and has been implicated in conflict 
processing. Anatomically distinct neural networks and the norepinephrine, 
cholinergic, and dopamine systems mediate these functions. Many studies on 
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attention in patients schizophrenia have identified deficits in one or more of 
these functions and/or related networks. In a previous study, we have shown 
that hospitalized chronic schizophrenic patients exhibit a robust deficit in 
the executive network and a smaller but significant deficit in the orienting 
network as well as in overall RT and accuracy. Although the beneficial effects 
of treatment with atypical agents, such as clozapine, on cognition are apparent, 
it is not clear whether this is a global improvement of attention or it is related 
to improvement of specific attentional functions.
Methods: In this study we examined 21 first-break patients with schizophrenia 
before and after treatment with clozapine using the Attention Network Test 
(ANT) to determine whether a 4-week treatment regimen improves attentional 
functions.
Results: A marginal significant improvement in measures of all three 
attentional networks was observed, as well as overall improvement in speed 
and accuracy.
Conclusions: These results may help in better understanding treatment effects 
on fundamental cognitive functions.
Supported by NARSAD Young Investigator Award
797. Brain Networks Involved in Spatial Learning: 
An ICA Analysis of Individuals with Schizophrenia 
and Healthy Controls
Bradley S. Folley1,2, Kanchana Jagannathan1, Robert 
Astur1,3, Vince Calhoun1,4, Godfrey D. Pearlson1,3
1Institute of Living, Olin Neuropsychiatry Research Center, Hartford, 
CT,2Department of Psychiatry, Vanderbilt University, Nashville, 
TN,3School of Medicine, Yale University, New Haven, CT,4Engineering, 
The MIND Institute, Albuquerque, NM
Background: The Morris Water Maze test has been difficult to translate into 
human studies of allocentric spatial memory. With virtual reality (VR), it is now 
possible to examine performance in a computer generated water task. We examined 
the performance of individuals with schizophrenia (SZ) and healthy controls (HC) 
in a VR water task during fMRI scanning, analyzing the BOLD signal with ICA, 
to examine networks involved in allocentric processing in SZ and HC.
Methods: During 3T fMRI, participants (28 HC, 34 SZ) were placed in a 
virtual 3D pool with 4 balls f loating in the water and navigated by manipulating 
a joystick. During “hidden”, the 4 balls were identical, and the participants 
used distal cues to navigate to the 1 floating above a hidden platform. During 
“visible”, the platform changed locations, one unique ball f loated above the 
platform, and participants navigated to it by moving to the 1 unique ball 
among the 3 identical ones.
Results: SZ found the platform fewer times, made more errors, and spent more 
time and distance searching. ICA of fMRI data determined 5 relevant network 
components including: hippocampal/medial temporal lobe, basal ganglia, and 
superior temporal gyrus. Hippocampal component activation distinguished the 
2 groups, while VBM indicated an inverse correlation between hippocampal 
grey matter concentrations and fMRI data for SZ only.
Conclusions: These data suggest that SZ perform poorly on the VR water task. 
Instead of recruiting the hippocampus, they may recruit the dorsal striatum, 
leading to a procedural learning strategy rather than a navigationally-guided one.
798. In Vivo Measurement of Increased Extracellular 
GABA with Positron Emission Tomography in 
Healthy Control Subjects
W. Gordon Frankle1, Raj Narendran2, N. Scott Mason3,
Shivangi Vora4, Maralee Litschge4, Julie C. Price3,
Chester A. Mathis3, David A. Lewis5
1Psychiatry & Radiology, University of Pittsburgh, Pittsburgh, 
PA,2Radiology & Psychiatry, University of Pittsburgh, Pittsburgh, 
PA,3Radiology, University of Pittsburgh, Pittsburgh, PA,4Psychiatry, 
University of Pittsburgh, Pittsburgh, PA,5Neuroscience, University of 
Pittsburgh, Pittsburgh, PA
Background: This study represents the first step in validating a paradigm for 
measuring GABA transmission in human subjects.
Methods: Eight controls (29 ± 9.6 years, 4M/4F) underwent two [11C]
flumazenil PET scans: baseline and 30 minutes after 16 mg PO tiagabine 
(GABA transporter blocker). The outcome measure was difference in binding 
potential (BPND, unitless) between the scans. Regions of interest (ROIs) were 
applied to the MR co-registered PET data to generate regional time-activity 
curves. Three cortical ROIs were obtained: Association cortex (DLPFC, 
orbital frontal, medial prefrontal, anterior cingulate), sensory cortex (parietal, 
occipital), and limbic medial temporal lobe (MTL; amygdala, hippocampus, 
enterorrhinal ctx and parahippocampal gyrus). The pons was used as the 
region of reference.
Results: No difference was observed in VND (pons VT = 1.0 ± 0.2 mL/g under 
both conditions). Tiagabine resulted in a significant increase in BPND in all 
three cortical areas: Association 5.7 ± 1.3 vs. 6.5 ± 1.3 (p = 0.05); Sensory 5.8 
± 1.2 vs. 6.7 ± 1.3 (p = 0.03); MTL 4.3 ± 1.0 vs. 4.9 ± 1.1 (p = 0.03). BPND
increased post-tiagabine in all component ROIs as well. Results were similar 
for the arterial input derived BPND.
Conclusions: BPND increases in the larger cortical ROIs suggests an acute 
increase in GABA levels within the cortex may be detectable with this paradigm. 
This proof of concept study represents the first step towards validating a 
paradigm for detecting acute fluctuations in GABA in vivo that may explicate 
the role of GABA in schizophrenia.
799. Working Memory Dysfunction as Phenotypic 
Marker of Schizophrenic and Bipolar Affective 
Psychoses: Common and Differential Abnormalities 
in Brain Activation
Oliver Gruber1, Ilona Henseler1, Heike Tost2, Harald Scherk1,
Thomas Wobrock1, Marcella Rietschel3, Peter Falkai1
1Department of Psychiatry and Psychotherapy, Georg August 
University Goettingen, Goettingen, Germany,2Clinical Brain Disorders 
Branch, National Institute of Mental Health, Bethesda, MD,3Division of 
Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, 
Mannheim, Germany
Background: Working memory dysfunctions are considered to be promising 
intermediate phenotypes, i.e. biological markers, which may help to discover 
genetic and other neurobiological factors involved in the pathogenesis of 
schizophrenic and affective psychoses. However, little is known about the 
possible role of these brain dysfunctions for differential diagnosis, for instance 
between schizophrenia and bipolar affective disorder. In the present study 
we directly compared brain activation during verbal working memory task 
performance in matched groups of schizophrenic and bipolar patients as well 
as healthy controls.
Methods: 12 schizophrenic patients, 14 bipolar patients and 14 healthy 
controls underwent fMRI during a delayed matching to sample task 
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requiring the maintenance of verbal information in working memory. Data 
were preprocessed and statistically analyzed using standard procedures as 
implemented in SPM2.
Results: Both schizophrenic and bipolar patients exhibited significantly increased 
activation in bilateral dorsolateral prefrontal cortex and in right intraparietal cortex. 
Abnormal hyperactivations that were unique to either schizophrenia or bipolar disorder 
were found in bilateral caudate nucleus and the right amygdala, respectively.
Conclusions: Compatible with findings from genetic research into the 
pathogenesis of schizophrenia and bipolar disorder, the present data show both 
similarities and significant differences between these two diagnostic categories 
regarding the patterns of abnormal brain activation that may underlie verbal 
working memory deficits in these patients.
Supported by Fritz Thyssen Foundation
800. Effects of Risperidone on Procedural Learning 
in Antipsychotic-Naive First-Episode Schizophrenia
Margret S. H. Harris1, Courtney M. Nemeth1, James L. 
Reilly1, Tin T. Khine1, Matcheri S. Keshavan2, John A. 
Sweeney1
1Center for Cognitive Medicine, University of Illinois at Chicago, 
Chicago, IL,2Department of Psychiatry and Behavioral Neurosciences, 
Wayne State University, Detroit, MI
Background: Studies of procedural learning deficits of medicated schizophrenia 
patients using predictive saccade paradigms have consistently demonstrated 
hypometric predictive saccades. However, investigations with antipsychotic-
naïve schizophrenia patients have shown inconsistent results. Further, it is 
unknown whether there is an impact of atypical antipsychotic medications on 
frontostriatal systems supporting relevant cognitive and motor processes.
Methods: The accuracy and latency of predictive saccades were assessed in 25 
antipsychotic-naïve first-episode schizophrenia patients and 22 matched healthy 
individuals. Patients were tested before and after 6 weeks of treatment with 
risperidone. Healthy individuals were re-evaluated after a similar time period.
Results: The ability to learn to time response initiation in anticipation of 
target appearance (target prediction) was not impaired in patients before or 
after treatment. In contrast, although no deficits were evident before treatment 
initiation, after treatment patients showed a marked decrease in the accuracy 
of predictive but not visually guided responses.
Conclusions: The findings from pretreatment testing indicate that procedural 
learning is a relatively unaffected cognitive domain in treatment-naïve 
first-episode schizophrenia. The reduced accuracy of predictive saccades 
after antipsychotic treatment, even in the absence of treatment-emergent 
extrapyramidal symptoms, suggests that treatment-related D2 antagonism 
disrupted the balance of “go” and “no go” signaling in striatal systems to disrupt 
the generation of volitional behavior guided by internalized representations.
Supported by MH62134, MH01433, NIH/NCRR/GCRC Grant M01 
RR00056, and NARSAD
801. Auditory Sensory Gating Deficit to Voice in 
Schizophrenia: An MEG Study
Yoji Hirano, Toshiaki Onitsuka, Shogo Hirano, Toshihiko 
Maekawa, Choji Obayashi, Naoya Oribe, Shigenobu Kanba
Department of Neuropsychiatry, Graduate School of Medical 
Sciences,Kyushu University, Fukuoka, Japan
Background: It has been suggested that schizophrenia patients have 
dysfunctions to suppress incoming irrelevant sensory input, perhaps related to 
hallucination or delusion. The dysfunctions have been indexed by a particular 
neurophysiological phenomenon, P50 sensory gating (assessed via EEG in a 
paired-click paradigm). Magnetoencephalography (MEG) is complementary to 
EEG, and superior for localization and analysis of lateralized cortical auditory 
responses. Furthermore, dysfunctions in early stage of language processing 
have been demonstrated in schizophrenia. It may therefore be important to 
investigate auditory sensory gating to the voice using MEG in schizophrenia.
Methods: Auditory-evoked MEG responses using a paired-voice paradigm 
were obtained from 22 patients with schizophrenia and 28 (age-, gender-, 
handedness-, and parental socioeconomic status-matched) comparison 
subjects. P50m and N100m gating ratios were compared and MEG-symptom 
correlations were investigated with respect to scores on SAPS and SANS.
Results: In the left hemisphere, patients showed significantly larger P50m gating 
ratios (p=0.001) than did comparison subjects, but not in the right hemisphere. 
There were no significant group differences in N100m for both hemispheres. For 
MEG-symptom correlations, patients with larger left P50m gating ratios showed 
more severe auditory hallucinations (p=0.04). Patients with larger right P50m 
gating ratios showed more severe negative symptoms (P=0.01).
Conclusions: The present study suggested that schizophrenia patients showed 
sensory gating deficits to voice especially in the left hemisphere. For MEG-
symptom correlations, patients with severe left-hemispheric gating deficits 
showed more severe auditory hallucinations, while patients with larger right 
gating ratios showed more severe negative symptoms.
802. P300 Abnormalities in Schizotypal Personality 
Disorder and Siblings of Schizophrenia Patients 
revealed by LORETA
Hiroto Hokama1, Wang Jijun2, Tsuyoshi Kondo1
1Department of Neuropsychiatry, Ryukyu University, Okinawa, 
Japan,2Department of EEG Source Imaging, Shanghai Mental Health 
Center, Shanghai, China
Background: The reduction of P300 component of Event-Related Potentials in 
schizophrenia is one of the most robust biological findings of schizophrenia. It 
is also known to exist among subjects at high risk for schizophrenia, including 
Schizotypal Personality Disorder (SPD) subjects and the first-degree relatives of 
schizophrenia. However, whether the different groups of high risk subjects have the 
same or different neural origins of P300 abnormality has not yet been explored.
Methods: The present study examined P300 abnormalities in two high risk groups of 
schizophrenia with LORETA (low resolution brain electromagnetic tomography). The 
first group was consisted of nine SPD subjects recruited from university students using 
Schizotypal Personality Questionnaire (SPQ). The second group was consisted of ten 
siblings of schizophrenic patients. ERPs were recorded using oddball paradigm.
Results: In both high risk groups, P300 was reduced as compared to their sex/age 
matched normal controls. Reduction of P300 cortical current density was observed in 
temporal region with left dominancy in SPD subjects. The siblings of schizophrenia 
showed reduction of P300 cortical current density in the right frontal region.
Conclusions: These results suggest that P300 reduction in both 
symptomatological and genetic high risk groups of schizophrenia might have 
different origin of disturbance in the neural circuitry for P300 generation.
803. Diagnostic Specificity of Auditory ERPs as 
Endophenotypes for Schizophrenia: Are we Picking 
the Right Peaks?
Jason K. Johannesen1, Anantha Shekhar2, Brian 
O’Donnell3, William P. Hetrick3
1Psychiatry, Yale University, West Haven, CT,2Psychiatry, Indiana 
University, Indianapolis, IN,3Department of Psychological and Brain 
Sciences, Indiana University, Bloomington, IN
Background: Event-related potential paradigms are widely investigated as 
biological endophenotypes of schizophrenia. Abnormalities in P50 suppression, 
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P300 amplitude, and P300 latency are viable candidates given their reliable 
expression in schizophrenia, linkage to genes implicated in illness vulnerability, 
and aggregation among unaffected family members. However, evidence for 
similar abnormalities in bipolar disorder compromise specificity, and diagnostic 
utility, of these measures. The use of a multivariate endophenotype, derived 
from conventional P50 (paired-click) and P300 (standard, target) paradigms, 
was examined as a method to improve diagnostic efficiency.
Methods: Hierarchical logistic regression was used to classify schizophrenia 
(SZ; n = 52) against equal numbers of age-matched healthy normal (HN) and 
bipolar disorder (BP) participants. Predictors were entered as follows: Block 1 
- P50 suppression, P300 amplitude, P300 latency; Block 2 - N100 amplitudes; 
Block 3 - low-frequency (1-20 Hz) and gamma-band (20-50 Hz) spectral power 
density; Block 4 - P50 and P300 hemispheric asymmetry.
Results: Candidate endophenotypes (Block 1) yielded 71% overall classification 
accuracy distinguishing SZ from HN. N100 and spectral power measures contributed 
uniquely to the model and improved accuracy to 79%. The same model classified SZ 
against BP with 64% overall accuracy, but none of the candidate endophenotypes 
entered as significant predictors. A model based on N100 amplitudes and gamma 
spectral power optimally classified SZ and BP with 72% accuracy.
Conclusions: Although schizophrenia and bipolar disorder exhibit dissociable 
patterns of abnormality on standard ERP paradigms, results suggest that the 
measures most often assessed as endophenotypes are insensitive to their distinct 
pathophysiology.
804. Effect of Metabolic Syndrome on Cognition in 
Older Schizophrenic Patients
Isabella Kanellopoulou1, Christopher Bowie1, Hannah 
Anderson2, Brooke Halpern2, Phil D. Harvey3
1Psychiatry, James J. Peters VAMC/ Mount Sinai School of Medicine, 
Bronx, NY,2Psychiatry, Mount Sinai School of Medicine, New York, 
NY,3Psychiatry, Emory University School of Medicine, Atlanta, GA
Background: Studies have revealed mild cognitive impairment associated 
with early stage diabetes and hypertension in non-psychiatric populations, 
particularly in the areas of working memory, attention, and executive 
functioning. These conditions have been associated with the metabolic 
syndrome (MS), which is common in schizophrenia, yet their cognitive 
implications in schizophrenia are not understood.
Methods: Older schizophrenia outpatients on atypical antipsychotic 
medications with MS (n=58) were matched with those without MS (n=60) 
on age and education. Univariate analyses of variance were used to examine 
differences between groups on cognitive domains, with estimated premorbid 
functioning entered as a covariate.
Results: Effect sizes are presented with positive values representing higher 
scores for patients without MS. Groups were not significantly different (all 
p-values > .05) on verbal learning (ES=-.11), memory (ES=.01), attention 
(ES=.04), processing speed (ES=.32), working memory (ES=.13), or executive 
functioning (-.21).
Conclusions: In this cross-sectional analysis of older schizophrenia outpatients, 
there was no evidence for additional cognitive liability associated with symptoms 
of the metabolic syndrome. It is possible that the magnitude of cognitive 
impairment in schizophrenia is too large to detect the smaller impairments 
typically associated with symptoms of the MS. Longitudinal studies will be 
necessary before causal relationships can be discussed or ruled out.
Supported by NIMH R01 63116
805. White Matter Integrity and Prediction of Social 
and Role Functioning in Subjects at Ultra-High Risk 
for Psychosis
Katherine H. Karlsgodt1,2, Tara A. Niendam1,
Russell A. Poldrack1,3,4, Carrie E. Bearden4, Tyrone D. 
Cannon1,4,5
1Department of Psychology, UCLA, Los Angeles, CA,2Semel Institute, 
UCLA, Los Angeles, CA,3Brain Research Institute, UCLA, Los Angeles, 
CA,4Department of Psychiatry and Biobehavioral Science, UCLA, Los 
Angeles, CA,5Department of Human Genetics, UCLA, Los Angeles, CA
Background: Changes in white matter integrity have been observed in patients 
with schizophrenia, even in the first-episode. However, it is unknown whether 
these changes exist prior to the onset of schizophrenia or in individuals at 
clinical or genetic high-risk. Our study sought to determine whether baseline 
measures of white matter integrity as assessed by diffusion tensor imaging 
(DTI) were related to measures of global, social and role functioning at follow-
up in a sample of individuals at ultra-high-risk (UHR) for psychosis.
Methods: Twenty-four UHR participants completed DTI scans and 
comprehensive clinical and functional assessments at baseline, and clinical and 
functional assessments at follow-up, on average, 7.5 months later. DTI data was 
analyzed with a rigorous registration approach (Tract-Based Spatial Statistics 
(TBSS); FMRIB Software Library) in order to examine fractional anisotropy 
(FA). Region of interest analyses focused on the superior longitudinal fasciculus 
(SLF), which was previously shown to be disrupted in first episode patients.
Results: Robust regression demonstrated that lower FA in the right SLF, 
indicating reduced white matter integrity, was significantly associated with 
decline in global and social functioning, with a trend towards a decline in role 
functioning over the follow-up period. This finding was restricted to the anterior 
portion of the SLF, potentially representing a more frontally based deficit.
Conclusions: This finding is the first indication that indexes of white matter 
integrity as assessed by DTI may be predictive of changes in psychosocial 
functioning in patients at ultra-high risk for psychosis.
Supported by MH65079, MH066286, GM072978 and RR021992 to T.D.C 
and a gift to the UCLA Foundation by Garen and Shari Staglin
806. Brain Activation Patterns in Schizophrenia 
after Computerized Cognitive Skills Training
Saurabh Kaushik1,2, Jean-Pierre Lindenmayer1,2,3,
Craig Branch4, Susan R. McGurk5, Anzalee Khan1,2,
Deborah Wance6, Lisa Hoffman7, Barbara Simmon7,
Xiaobo Li4, Sashank Kaushik1
1Psychopharmacology Research Program, Manhattan Psychiatric 
Center, Wards Island, NY,2Psychopharmacology Research, Nathan S. 
Kline Institute for Psychiatric Research, Orangeburg, NY,3Psychiatry, 
New York University School of Medicine, New York, NY,4Medical 
Physics, Nathan S. Kline Institute for Psychiatric Research, Orangeburg, 
NY,5Psychiatry, Dartmouth College, Concord, NH,6Rehabiliation 
Services, Manhattan Psychiatric Center, Wards Island, NY,7Psychology, 
Manhattan Psychiatric Center, Wards Island, NY
Background: Cognitive abnormalities, particularly of working memory 
(WM), are important features of schizophrenia. WM functions appear to 
be mediated by neural networks involving the dorsolateral prefrontal cortex 
(DLPFC) and have shown hypoactivity in schizophrenia. The aim of this study 
is to determine brain activation changes in the DLPFC with stimulation with a 
neurocognitive task after cognitive remediation therapy (CRT).
Methods: Patients with DSM IV schizophrenia were randomized to a 12 week 
trial of CRT using COGPACK (Marker Software) or to a 12-week control 
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condition. Patients in the CRT group completed 36 one-hour sessions. Patients 
received fMRI with the N-back task, the MATRICS battery, functional and 
symptom assessments at baseline and endpoint.
Results: We present preliminary results of this ongoing study. Patients in CRT 
showed significantly more improvement in WM functions than patients in 
the control group. All patients in the CRT group who received an fMRI scan 
showed improvement in accuracy on the verbal letter 2-back task after CRT. 
The signal difference between 2-back and 0-back was not present or only 
present minimally at baseline (Pre-CRT); however, at endpoint (Post-CRT) 
there was signal difference in the pre-frontal areas. Patients demonstrated 
significantly increased activity in the right inferior frontal gyrus and anterior 
cingulate gyrus.
Conclusions: This study offers an opportunity to examine the underlying 
neurophysiological effects of neurocognitve treatments of WM deficits. Given 
the diversity and complexity of brain pathophysiology in schizophrenia, the 
changes in DLPFC after neurocognitive rehabilitation treatment may be 
valuable for customizing cognitive treatments for schizophrenia.
Supported by Center for Advanced Brain Imaging, NKI
807. Atlas-Based Segmentation of DTI in 
Schizophrenia
Usman Khan1, Marek Kubicki2,3, Carl-Fredrik Westin4,
Steven Pieper5, Robert McCarley3, Martha Shenton1,3,6
1Psychiatry, Brigham and Women’s Hospital, Boston, MA,2Psychiatry- 
Psychiatry and Neuroimaging Laboratory, Brigham and Women’s 
Hospital, Boston, MA,3Psychiatry, Veterans Affairs Boston Healthcare 
System, Brockton, MA,4Surgical Planning Lab- Laboratory for 
Mathematical Imaging, Brigham and Women’s Hospital, Boston, 
MA,5Surgical Planning Lab- Neuroimage Analysis Center, Brigham and 
Women’s Hospital, Boston, MA,6Surgical Planning Lab, Brigham and 
Women’s Hospital, Boston, MA
Background: Diffusion tensor imaging (DTI) allows for a more thorough 
analysis of anatomical connectivity in schizophrenia. Numerous studies report 
white matter (WM) abnormalities in schizophrenia, however these studies have 
either investigated single fiber tracts (region of interest analysis), or relied on 
error prone DTI normalization to the template space (voxel based morphometry 
analysis). In this investigation, we attempt to study regional WM alterations in 
schizophrenia using a WM atlas and individual subject DTI data.
Methods: Sixteen male patients with chronic schizophrenia and seventeen 
male controls were scanned using high resolution DTI. Fractional Anisotropy 
(FA) and Trace (Tr) were used to quantify water diffusion within several ROIs 
derived from an average of manual segmentations of eighty-one subjects selected 
from the 452 healthy subject MNI population (www.LONI.org). These ROIs 
were coregistered into subject DTI space using linear and non-linear intensity 
based algorithms, and FA and Tr within these ROIs averaged, and compared 
between groups.
Results: Findings revealed reduced FA within left striatum WM (ROI included 
inferior longitudinal and inferior occipito-frontal fasciculus) in schizophrenia 
(P=0.011). We also found increased Tr bilaterally in superior longitudinal 
fasciculus in schizophrenia (t33=2.420, P=0.022). Finally, FA within corpus 
callosum, showed a significant region by diagnosis interactions (P=0.036), 
with genu and splenium, but not body, having decreased FA in schizophrenia.
Conclusions: This investigation demonstrates the utility of white matter atlas 
based segmentation, and suggests regional WM abnormalities in schizophrenia 
existing in long association tracts interconnecting frontal and temporo-occipital 
regions, as well as in the corpus callosum.
Supported by R01-PA-07-070
808. Neuropsychological Performance at Industry 
Sponsored Trials and Academic Sites: Do the 
Results Differ?
Feea R. Leifker, Philip D. Harvey
Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA
Background: Cognitive impairment is a treatment target in schizophrenia. A 
consensus battery has been developed for clinical trials. Many clinical trials sites 
lack extensive experience performing neuropsychological (NP) assessments and 
it is unclear if results of these assessments are the same as would be obtained 
from assessments performed at academic sites.
Methods: Baseline neuropsychological performance from published papers 
on pharmaceutical industry sponsored clinical trials was collated. Results 
from specific tests of processing speed, executive functioning, working and 
episodic memory, attention, and verbal f luency was compared to performance 
in published studies conducted by academic sites. Data were examined from 
first episode patients, nongeriatric chronic patients, and geriatric patients.
Results: For first episode patients, both average performance and variance 
on all tests sampled was essentially identical across clinical and academic 
sites. In the analyses of chronic nongeriatric patients, performance in studies 
reporting industry clinical trials was significantly (p<.05) higher on processing 
speed and executive functioning and significantly lower (p<.05) on the CPT 
than academic studies. There were no significant differences in variance. For 
geriatric patients there was only one published clinical trial, but performance 
was significantly (p<.001) lower and variance was greater (p<.001) on all 
cognitive domains sampled than academic studies.
Conclusions: These results suggest that NP performance of patients with 
schizophrenia in industry clinical trials, other than first episode studies, is 
more variable than that obtained in academic sites, suggesting that increased 
quality assurance standards may be required to ensure that treatment effects 
are not obscured by poor assessment quality.
809. The Effects of Context on Schizophrenia Facial 
Affect Perception
David I. Leitman, Daniel Wolf, James Loughead, Kosha 
Ruparel, Jeffery N. Valdez, Christian G. Kohler, Mark A. 
Elliot, Raquel E. Gur, Ruben C. Gur
Brain Behavior Laboratory, University of Pennsylvania, Philadelphia, PA
Background: Facial affect recognition as a process is susceptible to bottom-up 
sensory and top-down contextual influences that are difficult to disentangle. 
Such dual influences complicate the interpretation of abnormalities seen in 
schizophrenia, where affective processing deficits may be attributable to limbic 
or executive dysfunction as well as sensory disturbance. Here, we examined 
the effects of context on facial affect processing by measuring the influence of 
task demand.
Methods: Seventeen controls and sixteen schizophrenia patients performed a 
facial affect detection task containing four blocks during 4-tesla BOLD fMRI 
scanning. For each block subjects respond to a particular affective target (e.g. 
anger) presented alongside foils of differing emotions (e.g. happy, sad, fear) in an 
“event-related” manner. We hypothesized that affiliative emotion target blocks 
such as happiness or sadness create one form of context, while threat blocks 
of emotions such as anger and fear create another. We then contrasted BOLD 
differences between threat and affiliative foils presented within affiliative or 
threat target blocks.
Results: Within controls, affiliative foils presented within threat-seeking blocks 
produced significantly higher bilateral activation in aspects of orbitofrontal 
(OFC) and ventrolateral prefrontal (VLPFC) cortex than the presentation 
of identical stimuli within non threat-seeking blocks. However, this contrast 
revealed no significant change in schizophrenia.
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Conclusions: Task demands reveal significant contextual effects during 
facial affective processing in affect evaluation brain regions. Such contextual 
modulation is reduced in patients, suggesting that affect detection in 
schizophrenia may be driven more by bottom-up (stimulus features) than by 
top-down contextual processing (task demands).
Supported by MH060722
810. Decreased Fractional Anisotropy in 
the Anterior Limb of the Internal Capsule in 
Schizophrenia: A Diffusion Tensor Imaging Study
James Levitt1,2, Jorge L. Alvarado2, Marek Kubicki2,
Paul G. Nestor1, Robert W. McCarley1, Martha E. 
Shenton1,2
1Psychiatry, VA Boston Health Care System, Harvard University, 
Brockton, MA,2Psychiatry, Brigham and Women’s Hospital, Psychiatry 
Neuroimaging Laboratory, Harvard Medical School, Boston, MA
Background: An integral part of higher order cognitive function lies in the 
cognitive and limbic feedback loops of the frontal-subcortical circuits. The 
white matter tracts in the anterior limb of the internal capsule (AL-IC) form the 
last segment of these loops. Using structural MR for volumetric measurements, 
and diffusion tensor imaging (DTI) for diffusion index analyses, we explored 
differences in the AL-IC between schizophrenics and normal controls.
Methods: Structural and DT MR images were acquired on a 1.5-T GE scanner 
for 20 male, chronic schizophrenics and 22 male, normal controls, group 
matched on age and parental socioeconomic status. The AL-IC was manually 
delineated on structural images - volume, normalized for head size, and 
residualized volume were obtained. DTI scans were upsampled to match the 
structural images’ resolution, and then coregistered with their corresponding 
segmented volumes. Fractional anisotropy (FA), mode, and mean diffusivity 
(MD) were measured within the AL-IC.
Results: Volumetric measurements revealed no differences between diagnostic 
groups. The diffusion analyses showed, for schizophrenics: significant bilateral 
FA decreases (p = 0.017 and p = 0.010 for left and right AL-IC, respectively), 
no significant left-sided mode difference, a trend right-sided mode decrease (p 
= 0.061), and trend MD increases (p = 0.068 and p = 0.063 for left and right 
AL-IC, respectively).
Conclusions: The FA decrease suggests AL-IC white matter pathology in 
schizophrenia, possibly associated with disordered fiber networks or decreased 
neuropil density. These findings provide evidence for structural abnormalities in 
frontal-subcortical circuitry that may underlie functional deficits characteristic 
of the disorder.
Supported by VA Merit Review (JJL); VA Merit Review (MES); VA Merit 
Review (RWM)
811. Predictors of Improvement for a Computerized 
Cognitive Remediation Program in Psychiatric 
Inpatients
Jean-Pierre Lindenmayer1, Susan McGurk2, Anzalee 
Khan3, Lisa Hoffman4, Frances Alcantara3
1Psychopharmacology Research Dept., New York University, 
New York, NY,2Psychiatry, Dartmouth University, Concord, 
NH,3Psychopharmacology Research Dept., Nathan Kline Institute 
for Psychiatric Research, New York, NY,4Psychology, Manhattan 
Psychiatric Center, New York, NY
Background: Cognitive impairments are core to schizophrenia and relate to 
poor functional outcomes. Cognitive Remediation Therapy (CRT) is designed 
to improve neurocognitive functioning. With CRT, patients practice cognitive 
functions using computer exercises and strategy coaching. CRT shows 
significant benefits on long-term outcomes with moderate effect sizes. Aims 
include 1) elucidating factors associated with good outcome in CRT and 2) 
examining baseline differences between ‘Improvers’ and ‘Non-Improvers.’
Methods: 74 schizophrenic/schizoaffective inpatients used COGPACK, 
computerized software, to practice a range of cognitive functions. 45 patients 
received 24 sessions and 29 patients received 36 sessions for 12-weeks, with 
weekly discussions to facilitate cognitive skills and adaptive functioning.
Results: Of 74 patients, 46 were ‘Improvers,’ 28 were ‘Non improvers’, based 
on ≥ 20% improvement in processing speed and executive functioning. Higher 
scores in measures of attention, WM and WRAT-III reading, more interaction 
with group leaders, lower PANSS - Positive and Total scores, WCST perseverative 
errors, and Personal and Social Performance (PSP) for Socially Useful Activities 
scores were retained at the endpoint, resulting in 81.2% classification accuracy. 
PANSS-Positive scores, PSP scores, WCST perseverative errors, and attention 
at baseline significantly predicted improvement with CRT. The overall fit of the 
8 predictors was fairly good and reliable in distinguishing between improvers 
and nonimprovers (p = .04).
Conclusions: Baseline characteristics are likely to predict positive response 
to CRT. These factors cover cognition and psychopathology and must be 
evaluated during screening to facilitate cognitive and functional improvement. 
Results support the feasibility of an emergent formula to predict treatment 
success.
812. Impairment of Associative Recognition with no 
Response Bias in Schizophrenia
David Luck
Psychiatry, McGill University, Verdun, QC, Canada
Background: Memory is one of the cognitive functions most affected in 
schizophrenia, but the severity of deficits varies from one task to another. In 
particular, greater impairments have been reported for associative recognition 
than item recognition. However, the exploration of decision biases and how 
it could affect memory dysfunction in schizophrenia has received scant 
attention.
Methods: In this study, 33 people with schizophrenia and 39 healthy controls 
were administrated an Association-Item recognition task. During encoding, 
participants studied pairs of visual objects, and had to memorise objects and 
their pairing. In a subsequent retrieval task, participants performed an item 
recognition test (old/ new items) and an associative recognition test (intact/ 
rearranged pairs).
Results: Results showed that both groups recognized better items than pairs, 
with overall lower performance in people with schizophrenia. Analyses of 
response biases revealed that people with schizophrenia had a familiarity 
response bias for items but not for pairs. A subsequent analysis revealed that 
relative to controls, patients with a significant familiarity response bias exhibited 
lower performance for both pairs and items. Individuals with schizophrenia 
with no response bias showed lower performance for pairs but not for items.
Conclusions: Together, these results confirm the associative recognition 
dysfunction largely observed in schizophrenia. Furthermore, the study provides 
evidence that this dysfunction may not result from a decisional bias but rather 
from cognitive processes impairments.
Supported by CIHR (grant #53280), a Young Investigator Award from 
NARSAD, and a salary award from FRSQ
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813. Attenuated Variation of Late Temporal ERPs to 
Facial Expressions in Schizophrenia
Spencer K. Lynn, Dean F. Salisbury
Cognitive Neuroscience, McLean Hospital, Harvard Medical School, 
Belmont, MA
Background: Emotional stimuli elicit amplitude variation in event related 
brain potentials (ERPs) at temporal sites after circa 500 ms. In psychiatrically-
well subjects this variation can distinguish between facial expressions. We 
sought to characterize this variation in schizophrenia and determine symptom 
and neurocognitive correlates.
Methods: ERPs were recorded to faces depicting angry, disgusted, fearful, 
happy, sad, and neutral expressions (the latter a button press target). Twenty-four 
schizophrenia subjects (nine female) and eight control subjects (three female) 
participated. EEG was recorded from 60 scalp channels and rerefereced to the 
average. Mean voltage between 600-800 ms was examined at occipitotemporal 
electrodes P9 (left) and P10 (right).
Results: Late ERP activity elicited by the neutral target was normal in 
schizophrenia (P>0.6). However, a marginal emotion x group interaction was 
observed among the remaining expressions (P=0.059). Among controls, at P10 
differences were found for sad vs. disgusted (P=0.003) and fearful (P=0.035), and 
happy vs. disgusted (P=0.032). P9 showed fewer differences. Patients exhibited 
no significant ERP variation among non-target faces; however, emotional 
modulation (indexed by disgusted-sad difference) was associated with better 
performance on the ERP task (r=0.4, P=0.047) and on immediate and delayed 
face recognition tests (r=0.4, P=0.04; r=0.6, P=0.005, respectively).
Conclusions: Modulation of the late temporal ERP has been associated with 
evaluation of a stimulus’ emotional significance within the larger behavioral 
context. Schizophrenia patients may fail to evaluate and integrate the 
motivational significance of different facial expressions relative to one another, 
leading to, e.g., reduced emotion-facilitated enhancement of performance in a 
face recall task.
Supported by R01MH58704;T32MH016259
814. Altered Visual Attentional System in 
Schizophrenia: Evidence from an ERP Study
Toshihiko Maekawa1, Yoji Hirano1, Shogo Hirano1,
Choji Obayashi1, Toshiaki Onitsuka1, Shozo Tobimatsu2,
Shigenobu Kanba1
1Neuropsychiatry, Kyushu University, Fukuoka, Japan,2Clinical 
Neurophysiology, Kyushu University, Fukuoka, Japan
Background: Cognitive dysfunction of schizophrenia (Scz) may result from 
abnormal attentional processing in the brain. Attentional processing consists 
of two streams: One is involuntary attention (automatic) processing and the 
other is voluntary attention processing. The former is assessed by mismatch 
negativity (MMN) while the latter is evaluated by P300. The aim of this study 
was to clarify abnormality of visual attention system in Scz.
Methods: Eighteen Scz were instructed to listen to a story and to also pay 
attention to a visual target. Black-white circular windmill patterns consisting 
of a standard, a deviant, and a target stimulus whose ratios were 8:1:1 were 
presented randomly. The difference in the three stimuli was the number of 
vanes. Visual MMN (V-MMN) was obtained by subtracting ERPs to the 
deviant stimulus from that to the standard. P300 was recorded by the response 
of the target stimulus.
Results: Sixteen Scz completed the experiment. P300 was evoked in all of them 
but their P300 was smaller than that of normal control (NC). V-MMN was 
evoked in 12 subjects. The mean amplitude of V-MMN was not significantly 
different from that of NC, but the latency of V-MMN was more prolonged 
than that of NC. The latencies of P300 and V-MMN were linearly related to 
age and dose of antipsychotics. The latency of P300 was related to negative 
symptoms.
Conclusions: Like the auditory system, visual MMN and P300 were declined 
in Scz. Our results suggest that there exists common mechanism of the 
abnormal sensory attentional processing in Scz.
815. Functional MRI of Choice Reaction Time in 
Schizophrenia
David P. McAllindon1,2, Alan H. Wilman1, Philip G. 
Tibbo2,3, Scot E. Purdon2,3
1Biomedical Engineering, University of Alberta, Edmonton, AB, 
Canada,2Bebensee Schizophrenia Research Unit, University of Alberta, 
Edmonton, AB, Canada,3Psychiatry, University of Alberta, Edmonton, 
AB, Canada
Background: Slower and more variable reaction time (RT) may represent 
a specific cognitive deficit in schizophrenia. Functional neuroimaging 
with electroencephalography (EEG) during an auditory choice RT task 
suggested a relative lack of activation in anterior cingulate cortex in people 
with schizophrenia compared to healthy volunteers (HV) [1]. We are using 
functional MRI to better locate the reported EEG results and examining 
asymptomatic first-degree relatives of people with schizophrenia.
Methods: A 2-choice visual RT task was used contrasting choice (respond) and 
watch-only conditions. Images were acquired using a GREPI sequence at 1.5T 
(TR 2s, TE 50ms) and covered the whole brain with 23 slices of thickness 4 
mm and 1 mm gap and 3.75x3.75mm inplane resolution. Data were analyzed 
using standard processing in SPM5.
Results: To date, 5 subjects in each group have been scanned. The behavioural 
performance is comparable among the groups. The first 8 regions of a fixed 
effects analysis of the HVs are shown in the table. Group comparisons are not 
statistically significant, but non-significant trends are evident. First-degree 
relatives have a trend to a larger activation than other groups in right and left 
cerebellum, left cingulate gyrus and right medial frontal gyrus.
Conclusions: At this stage, we see some trends toward differences between 
groups. Additional subjects will be examined.
[1] Mulert, C et al, 2001, Neuroimage 13, 589-600.
Most Significant Activations in HV Group
Anatomical Label Talairach Coordinates (Center of Gravity) Size (Voxels) t-Value
Right Cerebellum 33, -53, -20 1000 9.98
Left Inferior Parietal Lobule -50, -27, 46 189 8.79
Cingulate Gyrus 0, 5, 44 364 8.72
Left Middle Frontal Gyrus -33, -3, 61 56 8.39
Left Insula/Superior Temporal 
Gyrus -45, -3, 6 57 8.02
Right Precentral/Postcentral 
Gyrus 39, -41, 60 136 7.94
Right Insula/Superior 
Temporal Gyrus 48, 3, 3 94 7.05
Right Putamen 21, 12, 2 53 7.03
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816. Evidence for Anomalous Network Connectivity 
during Working Memory in Schizophrenia: An ICA 
Based Analysis
Shashwath Meda1, Bradley Folley1,2, Michael 
Stevens1,3, Vince Calhoun1,3,4, Godfrey Pearlson1,3,5
1Olin Neuropsychiatry Research Center, Hartford Hospital/IOL, 
Hartford, CT,2Kennedy Center and Department of Psychiatry, Vanderbilt 
University, Nashville, TN,3Department of Psychiatry, Yale University, 
New Haven, CT,4Department of ECE, The MIND Institute, Albuquerque, 
NM,5Department of Psychiatry, Johns Hopkins University, Baltimore, MD
Background: Numerous neuroimaging studies have reported abnormal brain 
activity during working memory (WM) performance in schizophrenia, but 
the majority of these studies have not examined brain network integration as 
determined through ‘functional connectivity’ analyses. We used independent 
component analysis (ICA) to identify and characterize dysfunctional 
spatiotemporal networks in schizophrenia engaged during a Sternberg WM 
fMRI paradigm.
Methods: 37 chronic schizophrenia and 54 healthy age/gender-matched 
participants performed a modified Sternberg fMRI task (Johnson et. al. 
2006). Timeseries images preprocessed with SPM2 were analyzed using ICA 
as implemented in the GIFT v1.3c toolbox.
Results: There were 4 functionally-integrated networks whose timeseries were 
correlated with either the encoding and recognition phases of the task and 
that differed between schizophrenic and control participants. In particular, 
schizophrenic patients showed relatively less engagement of several distinct 
‘normal’ encoding-related WM networks compared to controls:
Encoding:
E1. Left Superior Parietal-Left DLPFC-Cingulate (SZ vs HC: p=0.004)
E2. Bilateral Superior Parietal-Right DLPFC (SZ vs HC: p=0.02)
E3. Default Mode Network (SZ vs HC: p=0.009)
Recognition:
R1.PosteriorCingulate-Cuneus-Hippocampus/Parahippocampus (SZ vs HC: 
p=0.04)
Also, WM task accuracy differed between groups (p<0.0001) and was connected 
with degree of network engagement, further underscoring the relevance of 
these profiles of abnormal network integration to well-described schizophrenia 
WM impairment. During recognition, networks primarily related to motor 
functionality correlated significantly with task accuracy.
Conclusions: For the first time, we have shown the usefulness/sensitivity 
of ICA in delineating different WM networks and demonstrating specific 
network impairments in schizophrenia.
817. Neurocognitive Functioning in First-Episode 
Schizophrenia: A Meta-Analytic Review
Raquelle Mesholam-Gately1,2, Anthony J. Giuliano1,2,
Kirsten Plehn1, Stephen V. Faraone3, Larry J. Seidman1,2
1Department of Psychiatry, Beth Israel Deaconess Medical Center, 
Boston, MA,2Department of Psychiatry, Harvard Medical School, 
Boston, MA,3Department of Psychiatry, SUNY Upstate Medical 
University, Syracuse, NY
Background: Compromised neurocognition is a core feature of schizophrenia 
and related disorders. While individual studies have documented that cognitive 
deficits are present at the first episode (FE), the magnitude of deficits varies 
among cognitive domains and between studies. The aim of this study is to 
provide a meta-analysis of neurocognitive findings in FE schizophrenia.
Methods: A systematic literature search yielded 47 studies meeting inclusion 
criteria for meta-analysis. Inclusion criteria were publication in English, 
diagnoses of schizophrenia, schizoaffective or schizophreniform disorder, 
a healthy comparison group, and sufficient data for calculating effect sizes 
(ES). Meta-analytic procedures in STATA were used to model between-study 
variance across ten cognitive domains. Following Heinrichs & Zakzanis’ 
(1998) meta-analysis of older mixed schizophrenia samples, the 10 cognitive 
domains included general cognitive ability, verbal-language ability, global and 
selective verbal memory, nonverbal memory, attention, executive functioning, 
motor skills, visuospatial abilities, and social cognition.
Results: FE schizophrenia samples demonstrated medium-to-large impairments 
across the ten neurocognitive domains (ds = -0.44 to -1.79). Deficits were 
maximized in verbal memory and processing speed. However, heterogeneity of 
ES was considerable, with degree of variation in ES attributable to heterogeneity 
often exceeding 55% and up to 93%.
Conclusions: Findings support the notion that cognitive symptoms are well-
developed by the FE, approach the magnitude of deficit shown by individuals 
with well-established illness, and are maximized in verbal memory and 
processing speed. However, the magnitude of deficit varies considerably across 
studies, and important features of study samples and designs require careful 
consideration in reviews of this literature.
Supported by NARSAD
818. Direct Comparison of fMRI of Working Memory 
in Schizophrenia and Psychotic Bipolar Disorder
Snezana M. Milanovic1,2,3, Heidi W. Thermenos4,5, Jill 
M. Goldstein1,6,7, Susan W. Gabrieli3,8, Nikos Makris9,
Ariel Brown6,10, Peter LaViolette2, Jennifer K. Koch1,
Ming T. Tsuang1,2,11, Stephen L. Buka12, Larry J. 
Seidman1,2,3
1Department of Psychiatry, Harvard Medical School, Massachusetts 
Mental Health Center in the Division of Public Psychiatry, Boston, 
02115, MA,2Department of Psychiatry, Harvard Medical School, 
Massachusetts General Hospital,, Boston, 02114, MA,3Department 
of Psychiatry, Massachusetts General Hospital/ Martinos Center 
for Biomedical Imaging, Charlestown, 02129, MA,4Department of 
Psychiatry, Beth Israel Deaconess Medical Center, Harvard Medical 
School, Massachusetts Mental Health Center in the Division of 
Public Psychiatry, Boston, 02115, MA,5Department of Psychiaty, 
Massachusetts General Hospital/ Martinos Center for Biomedical 
Imaging, Charlestown, 02129, MA,6Department of Psychiatry, Harvard 
Medical School, Massachusetts General Hospital, Boston, 02114, 
MA,7Departments of Medicine, Brigham and Women’s Hospital, 
Harvard Medical School, Division of Women’s Health, Connor’s 
Center for Women’s Health & Gender Biology, & Department of 
Psychiatry, Boston, 02115, MA,8Department of Brain and Cognitive 
Sciences, Massachusetts Institute of Technology, Cambridge, 02139, 
MA,9Center for Morphometric Analysis, Massachusetts General 
Hospital, Charlestown, 02129, MA,10Department of Psychology, 
Boston University, Ph.D. Program in Behavioral Neuroscience, Boston, 
MA,11Department of Psychiatry, University of California, San Diego, 
Center for Behavioral Genomics, La Jolla, 92093, CA,12Department of 
Community Health, Brown University, Providence, 02912, RI
Background: We used a 2-back working memory (WM) task to directly 
examine the performance and brain activation differences in patients with SCH 
and BPp. We hypothesized that SCH and BPp will demonstrate reduced WM 
performance correlating with impaired control over switching from rest to the 
WM task mode. We predicted that the impairment will be observed through 
interactions of the medial prefrontal cortex (BA10) and anterior cingulate (AC) 
for BPp and BA10 and superior temporal gyrus (STG) for SCH.
Methods: Controls (CON), BPp or SCH were scanned using functional 
magnetic resonance imaging (fMRI) while performing X or 2-back memory 
tasks. All analysis were done on the 2-back>X contrasts using Statistical 
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Parametric Analysis-2.
Results: CON and BPp showed consistent suppression of BA10 and AC during 
the first and second runs of WM performance. In contrast, SCH demonstrated 
suppression in the first, followed by activation of the same regions in the second 
run. CON suppressed the STG during both runs, while BPp and SCH showed 
the first run suppression, followed by activation.
Conclusions: 1) Good memory performance in CON is associated with 
successful transition from rest to the WM mode as observed by BA10 and 
AC suppression, 2) SCH performance decline is associated with the failure 
of suppression in the BA10, AC, STG and possibly effort-related attenuated 
control over switching from rest to the WM mode, 3) BPp execute the switching 
process well but demonstrate STG suppression/activation patterns similar to 
SCH and possibly related to lower 2-back performance.
Supported by MH 50647, MH 56956, MH 63951, NARSAD, Stanley Medical 
Research Institute, MIND Institute
819. Meta-Analysis of 41 Functional Neuroimaging 
Studies of Executive Cognition Reveals Dysfunction 
in a General Purpose, Frontal Cortex-Dependent 
Cognitive Control System in Schizophrenia
Michael J. Minzenberg1, Angela R. Laird2, David C. 
Glahn2, Cameron S. Carter1
1Psychiatry, University of California Davis, Sacramento, CA,2Psychiatry, 
University of Texas Health Science Center, San Antonio, TX
Background: It remains unclear whether the prefrontal dysfunction observed 
in schizophrenia represents the coincidence of several PFC region- and task-
specific impairments, or rather the expression of a more unitary dysfunction in 
a distributed neocortical network mediating a superordinate cognitive control 
function. We used quantitative meta-analysis to test whether common nodes 
of this network would be identified with altered activity across a large set of 
functional neuroimaging studies of executive cognition in schizophrenia.
Methods: 41 reports were included. Tasks included Delayed Match to Sample, 
N-Back, AX-CPT, and Stroop. Activation Likelihood Estimation (ALE) 
modeled reported activation maxima as the center of a 3D Gaussian function, 
to integrate studies in the meta-analysis.
Results: Within-group analyses showed the Healthy Control group to activate 
a distributed cortical-subcortical network that prominently included the 
DLFPC, VLPFC, ACC and thalamus. The Schizophrenia group exhibited 
a similar network (varying modestly across task types), however with altered 
activation in various regions revealed in the between-group analysis as reduced 
activation in left DLPFC, rostral/dorsal ACC, left thalamus; and increased 
activation in left VLPFC, pre-supplemental motor area (SMA), left angular 
gyrus, SMA and orbitofrontal cortex (OFC).
Conclusions: Healthy adults and schizophrenia patients activate a qualitatively 
similar network during PFC-dependent executive task performance, consistent 
with a superordinate, general-purpose cognitive control network, with critical 
nodes in the DLPFC and ACC. In addition, schizophrenia patients show 
altered activity with deficits in DLPFC, ACC and thalamus, which could be 
associated in turn with compensatory increases in activity elsewhere in the 
network, such as VLPFC and OFC.
Supported by 2RO1MH059883-05A1
820. First-Break Schizophrenia Patients Exhibit 
Impaired Context-Related Gamma Oscillatory 
Activity Over Frontal Sites Measured by Scalp 
Electroencephalography During Cognitive Control 
Performance
Michael J. Minzenberg, Jong H. Yoon, Alana Firl, 
Celeste Reinking, Andrew Watrous, Cameron S. Carter
Psychiatry, University of California Davis School of Medicine, 
Sacramento, CA
Background: Schizophrenia patients exhibit impaired prefrontal cortex (PFC) 
activity during cognitive control processes. We hypothesized impaired frontal gamma 
oscillatory activity in patients during the delay period of a cognitive control task.
Methods: 30 first-year schizophrenia patients (SZ) and 30 healthy control 
subjects (HC) (mean age 20.0 vs. 21.3 years; 76% vs. 57% male) performed a task 
contrasting cued incongruent stimulus-response mapping with cued congruent 
S-R mapping. Scalp gamma was measured at 1000 Hz (Neuroscan 4.3) using 
132-channel, NSL layout Quik-Cap. Signals were resampled in EEGLab 
at 250Hz, average reference computed, baseline-subtracted and epoched. 
Noisy leads were excluded, and probability-based artifact rejection. ICA was 
performed to subtract blink components, then Morlet wavelet coefficients 
with baseline window 100 ms preceding cue onset. For each subject, mean 
gamma power difference was computed between high (incongruent) and low 
(congruent) control conditions, at each 10 Hz-subband within the 30-80Hz 
range in early (0-500 ms) and late (500-1000 ms) cue-probe delay periods, at 
each channel over the frontal scalp.
Results: SZ and HC groups were similar in the numbers of trials or channels 
retained for analysis. The SZ group exhibited significantly impaired power 
(compared to HC) across the full set of frontal channels, in all gamma subbands 
at both delay periods.
Conclusions: These results suggest that schizophrenia patients are deficient 
in mounting gamma-range cortical oscillatory activity to support context-
dependent cognitive control processes. This phenomenon may serve as a 
mechanistic basis for the PFC dysfunction observed in fMRI studies, and may 
reflect impaired local cortical network activity.
Supported by NIMH
821. ERP Evidence of Overactivated Semantic 
Networks in Chronic Schizophrenia
Margaret A. Niznikiewicz1, Moneeshidra Singh2, Paul 
Nestor3, Robert W. McCarley2
1Psychiatry, Harvard Medical School, Brockton, MA,2Psychiatry, 
harvard medical school, Brockton, MA,3Psychology, University of 
Massachusetts, Brockton, MA
Background: Abnormal language processing has been recognized as a hallmark 
of schizophrenia. Recent studies using event related potential (ERP) technique 
documented abnormalities in context and working memory utilization. 
However, there are few ERP studies of initial activation in semantic networks 
also proposed to be abnormal in schizophrenia (SZ) (Niznikiewicz et al., 
2002; Mathalon et al., 2002). If the hypothesis of overactivation in semantic 
networks is correct, the N400 ERP, indexing an ease of forming semantic 
links, is expected to be less negative in SZ when recorded in short stimulus 
asynchrony (SOA) paradigms.
Methods: We have conducted a short SOA word-pair priming study in 
21 chronic SZ and 23 normal control (NC) individuals matched on age, 
handedness and PSES, with English as first language, in a lexical decision task. 
EEG was recorded from 64 electrodes. Separate averages were made to related 
and not-related word targets.
Results: The N400, measured within 350-450 msec latency window was 
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found less negative in the unrelated word-pair condition in SZ relative to NC 
(p < 0.04). The N400 priming effect was found in NC (p < 0.01) but not in 
the SZ.
Conclusions: These results suggest over-activation in semantic networks in 
SZ that may be attributable to faulty inhibitory processes as suggested by 
significantly reduced N400 in unrelated but not related word condition. This is 
one of the first studies to provide evidence for overactivated semantic networks 
in SZ using word-pair stimuli.
Supported by RO1mh 63360
822. Abnormal N170 Modulation to Frequency 
Change in Male Patients with Chronic 
Schizophrenia
Choji Obayashi1, Taisuke Nakashima2, Toshihiko 
Maekawa1, Yoji Hirano1, Shogo Hirano1, Naoya Oribe1,
Shozo Tobimatsu2, Shigenobu Kanba1, Toshiaki Onitsuka1
1Neuropsychiatry, Graduate School of Medical 
Sciences,Kyushu,University, Fukuoka, Japan,2Clinical Neurophysiology, 
Graduate School of Medical Sciences,Kyushu,University, Fukuoka, Japan
Background: Impaired processing of faces in schizophrenic patients may 
underlie some aspects of their disturbance in social functions. The present 
study investigated whether or not schizophrenics modulate their N170 in 
response to different type of visual stimuli [faces vs. non-faces or high spatial 
frequency (HSF) vs. low spatial frequency (LSF) or positive vs. negative 
emotional faces]. This study also investigated whether or not schizophrenics 
show N170 reduction specific to faces in Japanese sample, and examined 
associations between face N170 reduction and reduced social function.
Methods: Sixteen male chronic schizophrenia patients and 24 age-, gender-, 
handedness-, and parental socioeconomic status-matched normal controls 
participated in this study. Event-related potentials were recorded to the filtered 
(HSF or LSF) and the unfiltered (broad spatial frequency: BSF) pictures of 
houses and, neutral, happy, anger and fearful faces.
Results: Normal controls exhibited the HSF>BSF>LSF N170 amplitude 
differences (p<0.001), while schizophrenics did not modulate their N170 
in response to different frequency stimuli (p=0.27). For N170 amplitude 
differences, there were significant group differences in neutral (p=0.003), 
happy (p=0.001), anger (p=0.001), and fearful (p=0.002) faces. However, there 
was no significant group difference in the house stimulus (p=0.51), indicating 
that schizophrenia patients showed bilateral face-specific N170 reduction. 
There were significant negative correlations between GAF scores and N170 to 
faces in schizophrenia.
Conclusions: These results suggest that abnormal N170 modulations to 
frequency change may underlie at least some of the deficits associated with 
visual perception in schizophrenia.
823. Abnormal Parietal Activation during 
Recognition of Old/New Items in Schizophrenia
Marc Pelletier, Alonso Montoya, Amélie Achim, 
Matthew Menear, Samarthji Lal, Martin Lepage
Psychiatry, McGill University, Verdun, QC, Canada
Background: Memory deficits affect schizophrenia subjects. Studies 
repeatedly report the prefrontal cortex (PFC) and the medial temporal lobes 
(MTL) as the neural correlates for these deficits but these correlates may simply 
be the consequence of schizophrenia subjects performing at a suboptimal 
level. In contrast, few studies have explored whether schizophrenia affects 
brain activation in the parietal cortex, a region that is reliably activated when 
contrasting old items recognition from new items in healthy subjects.
Methods: We used an event-related functional Magnetic Resonance Imaging 
(fMRI) to examine brain activation in fifteen chronic, medicated schizophrenia 
subjects and eighteen control subjects during the retrieval part of a recognition 
memory test that required subjects to make old/new judgments. We investigated 
both the neural correlates that were commonly activated while performing this 
task and the neural correlates that distinguished the two groups, with a random 
effects model and statistical significance set at p<0.001.
Results: At the behavioral level, both groups performed equally well. At the 
brain level, both groups commonly activated regions in the PFC, MTL, and 
the precuneus. Examining group differences for the old/new contrast revealed 
a deactivation in the schizophrenia group restricted in the left parietal lobule.
Conclusions: At equal performance for recognizing old and new items, 
schizophrenia subjects demonstrate apparently normal modulation of the PFC 
and MTL, but abnormal modulation of the left parietal lobule. The partially 
distinct network of activations underlies the role of the parietal cortex in the 
possible use of distinct cognitive strategies by schizophrenia subjects during 
memory recognition.
Supported by Canadian Institutes of Health Research and Fonds de la 
Recherche en Santé du Québec
824. Prefrontal Control of Item-Specific versus 
Relational Working Memory and Long-Term Memory 
Encoding in Schizophrenia
J. Daniel Ragland1, Robert S. Blumenfeld2, Jong H. 
Yoon1, Michael Minzenberg1, Stefan Ursu1, Marjorie 
Solomon1, Cameron S. Carter1, Charan Ranganath2
1Psychiatry and Behavioral Sciences, University of California at Davis, 
Sacramento, CA,2Psychology, University of California at Davis, Davis, CA
Background: Ventrolateral PFC (VLPFC) is critical for attending to relevant 
items (“item-specific” WM), whereas dorsolateral PFC (DLPFC) is critical for 
building relationships between items (“relational” WM). This fMRI study tests 
the prediction that DLPFC control of relational memory is disproportionately 
impaired in schizophrenia.
Methods: VLPFC and DLPFC function was examined while patients and 
controls performed item-specific versus relational WM tasks: on item-specific 
‘rehearse’ trials subjects maintained a set of 3 objects across a 12 second delay 
in anticipation of a memory probe for serial position of the items; on relational 
‘reorder’ trials participants rearranged a set of 3 items based on perceived weight 
and maintained this information in anticipation of a memory probe for serial 
order of items in the rearranged set. Following scanning, subjects were given a 
recognition test and fMRI responses during each trial type were averaged as a 
function of subsequent memory.
Results: There was a larger effect of schizophrenia on reorder versus rehearse 
performance. Both tasks engaged prefrontal, mesial temporal, and parietal 
regions. Region of interest analysis revealed predicted reductions in DLPFC 
versus VLPFC activation in patients. Functional connectivity analysis showed 
enhanced DLPFC connectivity with the PFC in patients and with posterior 
association cortices in controls.
Conclusions: Results support the conclusion that patients with schizophrenia 
have a specific deficit in DLPFC function that contributes to memory 
impairment, whereas the VLPFC is less disrupted and may play a compensatory 
role. Future remediation may build on preserved item-specific processing, 
whereas treatment development may target DLPFC dysfunction.
www.sobp.org/journal
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825. Reduced Attentional Engagement Contributes 
to Deficits in Prefrontal Inhibitory Control in 
Schizophrenia
James L. Reilly1, Margret S. H. Harris1, Tin T. Khine1,
Matcheri S. Keshavan2, John A. Sweeney1
1Center for Cognitive Medicine, University of Illinois at Chicago, 
Chicago, IL,2Department of Psychiatry and Behavioral Neurosciences, 
Wayne State University, Detroit, MI
Background: Problems with the voluntary control of behavior, such as 
those leading to increased antisaccade errors, are accepted as evidence of 
prefrontal dysfunction in schizophrenia. We previously reported that speeded 
prosaccade responses, i.e. shorter response latencies for automatic shifts of 
attention to visual targets, were associated with higher antisaccade error rates 
in schizophrenia. This suggests that dysregulation of automatic attentional 
processes may contribute to disturbances in prefrontally-mediated control of 
voluntary behavior.
Methods: Twenty-four antipsychotic-naïve schizophrenia patients and 30 
healthy individuals completed three tasks: a no-gap prosaccade task in which 
subjects shifted gaze toward a peripheral target that appeared coincident 
with the disappearance of a central fixation target, and separate prosaccade 
and antisaccade tasks in which a temporal gap or overlap of the central target 
offset and peripheral target onset occurred. Sixteen patients were retested after 
6-weeks of antipsychotic treatment. 
Results: Patients’ prosaccade latencies in the no-gap task were speeded compared 
to healthy individuals. While patients were not atypical in the degree to which 
response latencies were speeded or slowed by the gap and overlap manipulations, 
those patients with diminished attentional engagement on the prosaccade task 
(i.e., reduced overlap effect) had significantly elevated antisaccade error rates. 
This effect persisted in patients evaluated after antipsychotic treatment.
Conclusions: This study provides evidence that a reduced ability to engage 
attention may render patients more distracted by sensory inputs, thereby further 
compromising impaired executive control during antisaccade tasks. Thus, 
alterations in attentional and executive control functions can synergistically 
disrupt voluntary behavioral responses in schizophrenia.
Supported by MH62134, MH01433, NIH/NCRR/GCRC Grant M01 
RR00056, and NARSAD
826. Remembering Familiar and Novel Stimuli in 
Schizophrenia: Evidence for Lack of Automaticity 
using Functional MRI
Jennifer L. Robinson, Jennifer Barrett, Dawn I. 
Velligan, David C. Glahn
Psychiatry, University of Texas Health Science Center, San Antonio, TX
Background: Although working memory (WM) deficits are prevalent in 
schizophrenia, questions remain about the neural networks involved in 
familiar versus novel stimuli encoding/maintenance, and how these networks 
are compromised in schizophrenia. While the maintenance of familiar 
memoranda is typically associated with less mental effort and lower levels 
of activation throughout the WM network, we anticipate that patients with 
schizophrenia will not benefit from being exposed to stimuli, thus showing 
more activity when remembering familiar stimuli.
Methods: Seventeen schizophrenics (SZ) and twenty-five controls underwent 
fMRI while performing a delayed-non-match-to-sample task. This WM task 
involves two conditions, one using familiar stimuli (FAM), and one using 
novel stimuli (NOV). Activation patterns associated with task activity were 
examined for both conditions.
Results: SZ performed significantly worse than controls during FAM 
(F(1,41)=35.80,p<0.001) and NOV(F(1,41)=30.72,p<0.001). Controls show 
relatively more activity during NOV relative to the FAM, particularly within 
the bilateral inferior and left middle frontal gyri. In contrast, SZ did not show 
any differences between conditions. In comparison to controls, SZ had less 
activation in regions of the right inferior frontal, left middle frontal, bilateral 
precentral gyri, and right parietal lobule during FAM. Similar regions of 
hypoactivation were also noted in NOV.
Conclusions: Condition specific differentiation in the inferior frontal gyrus 
associated with the FAM may be indicative of a neural correlate for automaticity, in 
which schizophrenics have less activation. Furthermore, our findings suggest that 
disruption in other prefrontal and parietal cortices associated with both familiarity 
and novelty encoding may underlie memory difficulties observed in schizophrenia.
Supported by NARSAD
827. Frontal-Temporal Connectivity and Cognitive 
Dysfunction in Schizophrenia
Katherine V. Roe1,2, Eric A. King1,2, Deepak K. Sarpal1,2,
Aaron Bonner-Jackson1,2, Terry S. Goldberg2, Andreas 
Meyer-Lindenberg2, Daniel R. Weinberger2, Karen F. 
Berman1,2
1Section on Integrative Neuroimaging, Intramural Research Program, 
NIMH, NIH, DHHS, Bethesda, MD,2Clinical Brain Disorders Branch, 
Genes Cognition and Psychosis Program, Intramural Research 
Program, NIMH, NIH, DHHS, Bethesda, MD
Background: Cognitive and language dysfunction are core characteristics of 
schizophrenia. Numerous structural and functional findings suggest these 
symptoms are based in complex, network-level dysfunction that particularly 
impacts prefrontal as well medial and lateral temporal brain regions. To explore 
the role this neural system dysfunction has in cognitive and linguistic symptoms 
in schizophrenia, the current study assessed whether patients displayed atypical 
fronto-temporal connectivity during two paced fluency tasks believed to 
differentially tap language and executive functions (Baldo et al, 2006) and 
differentially rely on frontal-temporal interactions (Friston et al, 1995).
Methods: Regional cerebral blood flow (rCBF) was measured using oxygen-15 
water PET in 25 patients with schizophrenia (31.5±8.5 years, 5 females) and 25 
matched healthy controls (29.6±6 years, 10 females) performing paced Letter and 
Category Fluency tasks. To measure functional connectivity, scan by scan rCBF 
values were extracted from seeds in left hippocampus, Broca’s area, and Wernicke’s 
area and entered into a brain-wide cross-correlation analysis. Correlation maps 
for the two fluency conditions were compared across groups.
Results: Patients exhibited reduced positive intrahemispheric connectivity 
between left frontal and temporal regions during Letter fluency, and reduced 
negative interhemispheric fronto-temporal connectivity during Category 
fluency. Additionally, positive ipsilateral prefrontal-hippocampal connectivity 
and negative contralateral prefrontal-hippocampal connectivity was reduced in 
patients during both fluency tasks.
Conclusions: These data support previous evidence of altered fronto-temporal 
functional connectivity patients with schizophrenia, document inefficient 
cooperativity between these regions, and indicate that this system-level 
dysfunction plays a critical role in both the language and executive processing 
symptoms prevalent in this population.
Supported by DHHS, NIMH, NIH, IRP
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828. The Relationship between Visual Processing 
and Performance on the CPT-IP in Schizophrenia
Erica Saccente1, Pam Butler1,2, Rachel Ziwich1, Gail 
Silipo1, Daniel C. Javitt1,2
1Program in Cogntiive Neuroscience and Schizophrenia, Nathan Kline 
Institute, Orangeburg, NY,2Psychiatry, New York University School of 
Medicine, New York, NY
Background: The Continuous Performance Test - Identical Pairs Version 
(CPT-IP) has been used extensively to study attention in schizophrenia. 
Despite its apparent connection with visual components, performance on the 
task has not yet been compared to visual processing measures. Schizophrenia 
is associated with deficits in early visual performance, as reflected in reduced 
sensitivity to visual contrast. As opposed to CPT-IP, visual contrast tests do not 
require sustained attention or comparison between successive stimuli.
Methods: Performance on the CPT-IP was assessed in twenty-five patients 
with schizophrenia relative to matched controls. Participants were also given a 
behavioral measure of contrast sensitivity, which reflects early visual processing.
Results: Patient performance was significantly worse (p<0.05) on the CPT-
IP than the healthy controls. Further, patient performance on the CPT-IP, as 
measured by d’, significantly correlated (r=.6, p=.001) with contrast sensitivity, 
particularly at low spatial frequency (1 cycle/degree) and short stimulus duration 
(32 ms), suggesting involvement of magnocellular dysfunction. Correlations 
were also observed between CPT-IP and measures of working memory, speed 
of processing, problem solving and reasoning, verbal learning, visual learning, 
attention/vigilance, and social cognition, but no correlations were observed 
between CS and cognitive tests other than CPT-IP.
Conclusions: These results suggest that impaired performance on the CPT-IP 
in schizophrenia might be indicative of a visual processing deficit, particularly 
involving the magnocellular system. The CPT-IP, while conceptualized as a 
measure of attention, might also reflect early visual processing dysfunction. 
These findings suggest that the construct of attention, as currently measured, 
might also reflect early visual dysfunction.
Supported by R01MH066374; R37MH49334
829. Sensory Gating Deficit in Schizophrenia is not 
a Result of Lowered Response to S1
Monica P. Sangal, Ryan Mears, Nash Boutros
Psychiatry, Wayne State Universtiy School of Medicine, Detroit, MI
Background: Sensory gating deficit is becoming recognized as a major endophenotype 
for schizophrenia and schizophrenia spectrum disorders. Sensory gating is assessed 
via an evoked potential paradigm where two identical stimuli (S1-S2) are delivered in 
rapid succession (500 ms apart) with a longer inter-pair interval of 8-10 seconds. The 
lower the ratio of the response to S2 to the response to S1, the better is the inhibitory 
capacity of the brain (more intact sensory gating). The interrelationship between the 
responses to S1 and S2 have created questions about the value of the measurement, 
specifically whether a low amplitude response to S1 is the origin of the gating deficit in 
schizophrenia patients.
Methods: A comprehensive literature review was performed to examine the reported 
relationship between these variables. 35 datasets in 25 papers (because some papers had 
multiple schizophrenia groups) examining sensory gating in schizophrenia spectrum 
patients compared to healthy control subjects were identified and reviewed.
Results: 12 datasets found the responses to S1 to be lower (< 80%) in schizophrenia 
compared to controls, with ten finding a gating deficit (S2:S1 ratio >0.6). Among the 
other 23 datasets, 15 found a gating deficit. Fisher’s exact test examining the effect of 
the amplitude of the response to S1 on finding a gating deficit found no difference.
Conclusions: Sensory gating deficit in schizophrenia patients is found with similar 
prevalence whether S1 response is affected or not. This suggests the validity of the sensory 
gating measure as an independent physiological abnormality in schizophrenia patients.
830. Perceptual Closure Processes in Schizophrenia
Pejman Sehatpour, Elisa Dias, John J. Foxe, Daniel 
C. Javitt
Program in Cognitive Neuroscience and Schizophrenia, Nathan Kline 
Institute, Orangeburg, NY
Background: The term “perceptual closure” has been used to refer to the 
neural processes responsible for “filling-in” missing information in the visual 
image under adverse viewing conditions such as occlusion, poor lighting or 
novel orientations.
Methods: Here, we investigated the spatio-temporal dynamics of perceptual 
closure processes in schizophrenia using an integrative approach by co-
registering data from high-density scalp electrical recordings (ERPs) and 
functional magnetic resonance imaging (fMRI), while patients and controls 
participated in a perceptual closure task. Participants were presented with 
highly fragmented images and control scrambled images. Fragmented images 
were calibrated to be ‘just’ recognizable as objects (i.e., perceptual closure 
was necessary), whereas the scrambled images were unrecognizable. Previous 
electrophysiological studies of closure comparing the responses to these two 
stimulus classes have revealed the neural processes underlying perceptual 
closure. Preliminary results obtained by comparison of responses between the 
two populations are presented.
Results: These results revealed an object recognition system consisting of a 
network of areas including the LOC, the hippocampal formation and frontal 
regions mediating closure processes.
Conclusions: Preliminary results indicate significant task-dependant deficits 
in schizophrenia beginning as early as 100 ms post stimulus onset, accompanied 
by a secondary dysregulation of the neurocognitive network of brain regions 
engaged in closure processes.
Supported by R01 MH65350; MH49334
831. Correlation between Tests on the MATRICS 
Consensus Cognitive Battery (MCCB) and the 
IntegNeuro Computerized Battery in Schizophrenia 
and Healthy Controls
Steven M. Silverstein1, Judith Jaeger2, Anne-Marie 
Donovan Lepore3, Sandra Wilkniss4, Adam Savitz5,
Igor Malinovsky1, Danielle Hawthorne1, Shane Raines2,
Stephen Furlong2, Steven Zukin2, Gersham Dent2
1University Behavioral HealthCare, University of Medicine and Dentistry 
of New Jersey, Piscataway, NJ,2Discovery Medicine Neuroscience, 
AstraZeneca Pharmaceutical Company, Wilmington, DE,3Psychiatry, 
Zucker Hillside Hospital, Queens, NY,4Research, Thresholds, Inc., 
Chicago, IL,5Psychiatry, Weill Medical College of Cornell University, 
White Plains, NY
Background: The aim of this study was to measure the level of agreement 
between two alternative methods of assessing cognition in schizophrenia: 
the computerized IntegNeuro battery and the primarily paper and pencil 
MATRICS Consensus Cognitive Battery (MCCB).
Methods: Methods: In a 5-site study, 150 clinically stable patients with SCID-
confirmed schizophrenia and 75 healthy controls took both the MCCB and 
IntegNeuro batteries. Pearson correlation coefficients were computed between 
homologous measures on IntegNeuro and each of the 10 MCCB tests. These 
pairs were selected a-priori as the best match on the basis of similarity of test 
parameters/characteristics. As a second step, that IntegNeuro test which was 
most highly correlated with each MCCB test was identified.
Results: Correlation coefficients among predicted IntegNeuro measures for 
each of the 10 MCCB tests ranged from 0.40 (MSCEIT Social Cognition 
with Gur Facial Recognition Test) to 0.75 (each battery’s test of Letter 
www.sobp.org/journal
Saturday Abstracts BIOL PSYCHIATRY 2008;63:1S-301S 265S
Number Sequencing). All p values were <.0001. In 7 out of 10 cases, the 
highest IntegNeuro/ MCCB correlation pair was the same one predicted by 
a priori judgement. Interestingly, among all IntegNeuro measures, the highest 
correlation for the only computerized measure in the MCCB (the CPT-IP) is the 
IntegNeuro Letter Number Sequencing test (r=0.57). The highest correlation 
for the MSCEIT on the MCCB is with the IntegNeuro Mazes test gradient 
of errors over completion time (r=-0.48) suggesting that attributes other than 
social cognition are important for MSCEIT performance.
Conclusions: Results from these interim analyses suggest comparability 
between the IntegNeuro computerized test battery and the MCCB
Supported by AstraZeneca
832. Impaired Learning and Memory on the 
California Verbal Learning Test in Persons with 
Schizophrenia, but not their First-Degree Relatives: 
Findings from the Consortium on the Genetics of 
Schizophrenia (COGS)
William S. Stone1, Anthony J. Giuliano1, Stephen J. 
Glatt2, Stephen V. Faraone2, Ming T. Tsuang3, Larry J. 
Seidman1
1Psychiatry, Harvard Medical School / Beth Israel Deaconess Medical 
Center, Boston, MA,2Psychiatry, SUNY Upstate Medical University, 
Syracuse, NY,3Psychiatry, University of California, San Diego, La Jolla, CA
Background: Patients with schizophrenia are robustly impaired on measures of 
Verbal Declarative Memory (VDM), including the California Verbal Learning 
Test (CVLT). Reports of CVLT performance in first-degree relatives, however, 
are inconsistent.
Methods: The Consortium on the Genetics of Schizophrenia (COGS) aims 
to identify the genetic basis of common endophenotypes in schizophrenia, 
including VDM. This report presents data on the CVLT-II in probands 
with schizophrenia (n=253), their biological full siblings (n=353) and parents 
(n=202), and community comparison subjects (CCS; n=465) across seven 
geographically diverse sites. Stringent quality assurance protocols assured 
procedural uniformity.
Results: Probands learned significantly fewer words (Total Trials 1-5) than all 
other groups after controlling for significant effects of age, gender, and WRAT3 
Reading level, but the relative groups did not differ significantly from the CCS 
group. Follow-up analyses showed a significant group x site interaction, plus a 
significant difference between CCS and sibling relatives at one site and trends 
toward significance at two others. The significant difference resulted from a 
high-performing control group (0.95 SD above the CVLT-II standardization 
mean) rather than a low performing sibling group (z=0.17 above the mean of 
all the sites). Notably, significant site differences were limited to the CCS and 
sibling relative groups, with the larger differences occurring in the CCS group.
Conclusions: Based on the largest sample to date, the results show that relatives 
of probands with schizophrenia are not generally impaired on the CVLT-II. 
They also shed light on previous inconsistent findings by highlighting site 
differences, particularly in control subjects.
Supported by RO1-MH065562
833. Multisensory Mental Rotations are not 
Impaired in Schizophrenia
Cenk Tek, Pamela C. DeGeorge, Bruce E. Wexler
Psychiatry, Yale University School of Medicine, New Haven, CT
Background: Mental rotation of objects is an operation in which a mental 
image is rotated on a three dimensional axis. This mental operation has near-
perfect psychophysical properties: the time to make a judgment increases 
proportionally to the angle of rotation. Mental rotations can be reliably 
mapped to posterior parietal cortex, associated with dorsal visual pathway, and 
appear to be dependent on analog spatial representations. Furthermore, this 
function appears to be independent of sensory modality of the input. Patients 
with schizophrenia are generally impaired in various spatial tasks. We have 
utilized mental rotation paradigms to test the integrity of posterior parietal 
lobe function in schizophrenia.
Methods: 16 outpatients with schizophrenia and 10 healthy controls have 
been tested with a standard cognitive battery as well as four different mental 
rotation paradigms: 1) Visual three dimensional Shepard-Metzler figures, 2) 
Haptic Shepard-Metzler figures built from wooden blocks, 3) Visual letters 
and numbers, 4) Haptic letters and numbers.
Results: As expected, patients performed worse in the cognitive battery 
compared to healthy controls. On the rotation tasks patients were slightly 
slower and less accurate than controls, especially as the task became more 
difficult. However, their overall accuracy, and rotation angle-reaction time 
proportion was not significantly different than controls.
Conclusions: The results of this preliminary study do not point to a specific 
impairment in the parietal areas that are responsible for mental rotation 
operations in schizophrenia. The findings also did not support a presence 
of any earlier perceptual impairment that might affect later more complex 
operations negatively.
Supported by NARSAD Young Investigator Award
834. Associations between Childhood Trauma and 
Psychotic-Like Symptoms among Individuals at 
Clinical High Risk for Psychosis
Judy L. Thompson1, Meredith Kelly1, David Printz1,
David Kimhy1, Shamir Khan1, Julie Walsh1, Jill Harkavy-
Friedman1, Dolores Malaspina2, Cheryl Corcoran1
1Psychiatry, Columbia University, New York, NY,2Psychiatry, New York 
University, New York, NY
Background: Population-based and clinical-sample studies suggest that 
childhood trauma is associated with later psychosis, and it has been proposed 
that early trauma may play a causal role in the development of psychosis. The 
current study examined whether childhood trauma was associated with the 
severity of symptoms experienced by individuals considered to be at heightened 
clinical risk for psychotic illness.
Methods: Thirty participants, ages 13-25, who met prodromal research criteria 
were assessed with the Early Trauma Inventory (ETI). The ETI probes for 
experiences of varying degrees of severity within the domains of general trauma 
and physical, emotional, and sexual abuse.
Results: When including all events assessed by the ETI, 77% of the sample 
reported a history of physical punishment or abuse, 67% endorsed childhood 
emotional abuse, and 27% reported childhood sexual abuse; these rates are 
similar those obtained using the ETI with schizophrenia patients (Corcoran, 
unpublished data). Trauma scores were significantly associated with positive 
and disorganized symptoms. Specifically, physical punishment/abuse was 
associated with positive and disorganized symptoms and emotional abuse 
was related to disorganized symptoms (all rs>.43); further, sexual abuse 
(dichotomized) was related to positive symptoms (?2=5.87, p=.015). These 
associations were generally stronger for the ethnic minority (n=17) compared 
to Caucasian participants (n=13).
Conclusions: Results suggest that among individuals at heightened clinical 
risk for psychosis, childhood abuse is associated with severity of psychotic-like 
symptoms. Thus childhood abuse may contribute to more severe psychotic-like 
symptoms; conversely, childhood abuse may index psychosis risk but not play 
an etiological role in symptom development.
Supported by K23 MH 066279
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835. Self-Assessment of Negative Affect and 
Stress Sensitivity in Schizophrenia: Reliability and 
Predictive Validity
Ivy F. Tso1,2, Tyler B. Grove1, Ashley C. Chen3, Patricia 
J. Deldin1,2, Stephan F. Taylor1
1Psychiatry, University of Michigan, Ann Arbor, MI,2Psychology, 
University of Michigan, Ann Arbor, MI,3Neuroscience Program, 
University of Michigan, Ann Arbor, MI
Background: Anxiety, depression, and heightened stress sensitivity are 
predictive of onset and course of schizophrenia, but systematic assessments are 
not a part of routine clinical practice. This study sought to investigate the 
reliability and predictive validity of a battery of self-report scales assessing 
negative affect in schizophrenia.
Methods: Thirty-seven schizophrenic/schizoaffective patients (17 females), 27 
bipolar patients (13 females) and 30 healthy controls (13 females) matched for 
age, sex, reading level, and parental education participated. At baseline, subjects 
completed tests of neurocognition (BACS) and questionnaires measuring stress 
sensitivity (Perceived Stress Scale; Psychological Stress Index), anxiety (State/Trait 
Anxiety Inventory), depression (Beck Depression Inventory), hedonic capacity 
(Physical and Social Anhedonia Scales; Temporal Experience of Pleasure Scale), and 
social functioning (Social Adjustment Scale). Patients were also assessed for clinical 
symptomatology. Test-retest reliability for stress scales was obtained at 4 to 8 weeks. 
Thirty schizophrenic/schizoaffective patients were followed up at 12 months.
Results: Self-report measures of negative affect demonstrated satisfactory 
to good internal consistency, test-retest reliability, and convergence with 
clinician assessments. Schiz and bipolar groups performed more poorly 
on neurocognition, scored higher on stress sensitivity, anxiety, depression, 
anhedonia, and social maladjustment than controls. Schiz patients scored 
lower on anticipatory but not consumatory pleasure than bipolar and control 
groups. In schizophrenia, baseline anxiety (r=.48-.61), depression (r=.53-.73), 
stress sensitivity (r=.56-.66), and social anhedonia (r=.21-.51) were the strongest 
correlates of baseline and 12-month social functioning.
Conclusions: Heightened negative affect can be reliably assessed by self-
report in schizophrenia, and may have clinical utility as robust predictors of 
functional outcome.
Supported by Palencsar Family; NIMH
836. Remission in Schizophrenia Patients Treated 
with Long Acting Risperidone: 12-Month Results 
of Electronic Schizophrenia Treatment Adherence 
Registry
Ivan Tuma1, Jos Peuskens2, Jan Pecenak3, Lars 
Eriksson4, B. Bork5, Michael Povey6, Annette Lam7,
Zhongyun Zhao8
1Medical School and Teaching Hospital Hradec Kralove, Charles 
University in Prague, Hradec Kralove, Czech Republic,2KU Leuven 
campus UC St. Jozef Kortenberg, Universitair Psychiatrisch 
Centrum, Leuven, Belgium,3Psychiatry, FNSP Bratislava, 
Bratislava, Slovakia,4Psychiatry, SU/Östra RPV, Hisings-Backa, 
Sweden,5Psychiatry, DP Tønder, Tønder, Denmark,6Statistics, SGS 
Life Science Services,, Wavre, Belgium,7Health Economics, Johnson 
& Johnson Pharmaceutical Services, Toronto, ON, Canada,8Health 
Economics, Johnson & Johnson Pharmaceutical Services, Raritan, NJ
Background: To assess remission in patients with schizophrenia treated with 
risperidone long-acting injection (RLAI) and enrolled in the electronic-
Schizophrenia Treatment Adherence Registry (e-STAR) from Belgium, Czech 
Republic, Denmark, Slovakia, Sweden.
Methods: e-STAR is an international, long-term, prospective, observational 
study of patients with schizophrenia who commence RLAI. Remission was 
evaluated at baseline and every 3-months prospectively based on the following 
symptoms: delusions, conceptual disorganization, hallucinatory behavior, 
mannerisms and posturing, unusual thought content, blunted affect, passive/
apathetic social withdrawal, and lack of spontaneity and flow of conversation. 
Patients in whom all of these symptoms are absent/minimal/mild were 
considered to be in cross-sectional remission and if this persisted for at least 
6 months, they were considered to be in symptomatic remission. Results 
presented are based on data from patients who have completed their 12-month 
follow-up visit.
Results: To date, 2,157 patients have been enrolled from the 5 countries and 
1,092 patients have been followed for at least 12 months. Most were male (59.5%) 
with mean age of 38.9±12.7 years and mean time since diagnosis of 9.4±9.4 
years. At 12 months, 92.5% of patients are still on RLAI. Proportion of patients 
was in cross-sectional remission increased from 4.3% at baseline to 36.1% at 12 
months (p<0.001). Proportion of patients who achieved symptomatic remission 
was 2.1% at 6 months and 17.2% at 12 months (p<0.001).
Conclusions: This pooled interim data indicate that over one-third of 
patients met the criteria for cross-sectional remission and some even achieved 
symptomatic remission after 1-year treatment with RLAI.
Supported by Johnson & Johnson
837. The Neural Substrates of Emotional 
Processing in Schizophrenia: An Event-Related 
fMRI Study
Stefan Ursu1, Ann M. Kring2, Shauna Gordon-McKeon1,
Michael J. Minzenberg1, Jong H. Yoon1, J. Daniel 
Ragland1, Marjorie Solomon1, Cameron S. Carter1
1Psychiatry and Behavioral Sciences, UC Davis, Sacramento, 
CA,2Psychology, UC Berkely, Berkeley, CA
Background: Impairments in emotional processing in schizophrenia have long 
been described, but the precise mechanisms underlying these impairments, and 
especially their neural substrates, are still poorly understood. In an effort to 
further our understanding of these issues, we used event-related fMRI to study 
the neural circuitry involved in evaluating and responding to emotionally 
valenced stimuli.
Methods: Chronic schizophrenia patients and control subjects were scanned 
while viewing and rating their subjective reaction to images from the 
International Affective Picture System (IAPS).
Results: Data from 13 patients and 9 control subjects suggested that, across 
the two groups, a network of brain areas frequently implicated in processing 
of emotional information was robustly activated in response to positively and 
negatively valenced IAPS stimuli, relative to neutral ones. These areas included 
ventromedial prefrontal cortex, orbitofrontal cortex, ventral striatum, extended 
amygdala and insula.
Conclusions: This pattern of activation is consistent with the framework of Kring et 
al., which proposes that the ability of patients to directly experience affect is largely 
intact, and that abnormalities in the affective domain are, in fact, manifestations of 
altered representations of the anticipated effects of emotional stimuli. Results form 
a larger sample of subjects will be presented, including correlations of brain activity 
with measures of reactivity to emotional stimuli collected during scanning (i.e. 
subjective ratings and skin conductance response).
Supported by NARSAD
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838. Genetic Influences on Reinforcement Learning 
Performance in Schizophrenia
James A. Waltz1, Ikwunga Wonodi1, Amie Elliot1, Ping-I 
Lin1,2, L. Elliot Hong1, James M. Gold1, Gunvant Thaker1
1Dept. of Psychiatry, Univ. of Maryland School of Medicine, Baltimore, 
MD,2Dept. of Medicine, Univ. of Maryland School of Medicine, 
Baltimore, MD
Background: Recent findings of genetic influences on reinforcement learning 
performance suggest that measures of reinforcement learning could serve as 
markers for dopamine dysfunction in patients with schizophrenia (SZ).
Methods: We administered 95 SZ patients, 68 first-degree relatives of patients, 
and 82 controls a reinforcement learning task involving either a left or right 
button-press to 6 stimuli, each presented individually 33 times. For 2 stimuli 
(100% valid), one of the responses was always reinforced. For another 2 stimuli 
(80% valid), the “correct” response was reinforced 80% of the time. For a 
further 2 stimuli, left and right button-presses were reinforced equally. For 
the 4 stimuli involving a correct (more-frequently-reinforced) response, we 
computed subjects’ rates of choosing that response.
Results: Using ANOVAs, we observed main effects of both group (F=16.54; 
p<0.001) and reinforcement probability (F=65.48; p<0.001), as well as a trend 
toward a group x probability interaction (F=3.08; p<0.06). Post-hoc LSD tests 
revealed that patients’ combined performance on both 100% and 80% valid items 
(59+2%) was worse than that of their first-degree relatives (65+2%), which was in 
turn worse than that of controls (70+2%). When we assessed a subgroup of subjects 
for whom we had genetic data, we found that 16 patients with the Met-Met type 
of the COMT gene showed significantly better end performance (72+5%; t=2.50; 
p=0.013) than 63 patients with at least one valine allele (59+2%).
Conclusions: These results suggest that genes related to dopamine function 
contribute to learning impairments in SZ patients.
Supported by NIH Grants P30 MH068580-01, 1R24 MH72647-01A1, 2R01 
MH049826-09A2, and 1K12 RR023250-01
839. Functional Connectivity of Thalamo-Cortical 
Projections is Altered in Schizophrenia
Robert C. Welsh1, Ashley Chen2, Stephan F. Taylor3
1Radiology and Psychiatry, University of Michigan, Ann Arbor, 
MI,2Neuroscience, University of Michigan, Ann Arbor, MI,3Psychiatry, 
University of Michigan, Ann Arbor, MI
Background: Post-mortem data, structural neuromaging and functional 
neuroimaging have implicated the medial-dorsal nucleus (MDN) of the 
thalamus in schizophrenia. Reciprocal thalamo-cortical projections from the 
MDN to frontal cortex, including the anterior cingulate cortex, carry out higher 
level integration of cognition, emotion and motivation, functions disturbed in 
schizophrenia. As evidence has begun to accumulate that schizophrenia involves 
disturbances in connectivity, we used a resting state paradigm to analyze the 
functional connectivity of thalamo-cortical projections from the MDN.
Methods: Resting state fMRI data (6 min) was collected from 11 schizophrenia/
schizo-affective patients and 12 healthy, age-matched controls. High-
resolution structural T1 images were also obtained. fMRI time-series data were 
reconstructed off-line and corrected for physiological variance. Slice-timing and 
motion detection were done using FSL. Using anatomic atlases a seed region 
(2x2x2 3mm voxels) was identified in the MDN and correlation coefficients 
calculated for the extracted time-series with all other voxels of the brain.
Results: The functional connectivity analysis for the right and left MD 
thalamus revealed correlations with frontal cortical targets, including dorsal 
anterior cingulate cortex (ACC), rostral ACC, and dorsolateral PFC, whereas 
the schizophrenia group showed reduced connectivity throughout, significantly 
in rostral ACC. Gray matter signal from T1 images did not differ between 
groups for the seed region.
Conclusions: The results demonstrate the possibility of using resting state 
paradigms to analyze functional connectivity for thalamo-cortical projections. 
To our knowledge, this is the first demonstration of altered functional 
connectivity of the MDN in schizophrenia.
Supported by R01-MH64148
840. Impaired Forward Models in Schizophrenia as 
Assessed by the Size-Weight Illusion
Lisa E. Williams1, Vilayanur S. Ramachandran1, David 
Braff2, Gregory A. Light2
1Psychology, University of California, San Diego, La Jolla, 
CA,2Psychiatry, University of California, San Diego, La Jolla, CA
Background: The size-weight illusion (SWI) is a strking perceptual effect 
wherein an individual asked to compare the weight of two objects of identical 
physical weight but different sizes will feel the smaller object is substantially 
heavier. The forward model of motor control proposes that when a motor act 
is initiated an efference copy of the action is also generated. Comparisons 
between this copy and actual sensory feedback are used for online movement 
adjustments, cancelling sensory reafference, and movement prediction and 
planning. Previous research has suggested the source of the SWI may be a 
central mismatch between expected sensory feedback - efference copy - 
and actual proprioceptive feedback of the two stimuli. Disruptions in this 
mechanism have also been proposed to explain various positive symptoms of 
schizophrenia, including auditory hallucinations and delusions of control.
Methods: Schizophrenia patients (n=17) and nonpsychiatric comparison subjects 
(n=14) were asked to compare and report which of two grey disk stimuli was 
heavier. Disks were large (5 inches diameter) or small (2 inches diameter), and 
weighed 90, 120, 150, 180 or 210 grams. Testing included illusion trials (90 small 
vs. 120-210 large) and control trials (comparisons between same size weights).
Results: We found that on the two most difficult size-weight discriminations 
(90 small vs. 120 and 150 large), as a group, individuals with schizophrenia 
experience the size-weight illusion on fewer trials than control participants, 
despite demonstrating comparable weight discrimination.
Conclusions: This finding offers further support to the idea of a dysfunctional 
motor control comparator mechanism in schizophrenia.
Supported by NARSAD, VISN-22 MIRECC, NIMH MH079777, 
MH042228 and MH065571
841. Profile of Neuropsychological Functioning 
during the Prodrome to Psychosis
Kristen A. Woodberry1,2,3, Anthony J. Giuliano2,4, Mary 
Verdi3, Larry J. Seidman2,4
1Psychology, Harvard University, Cambridge, MA,2Department of 
Psychiatry and the Massachusetts Mental Health Center Division of 
Public Psychiatry, Beth Israel Deaconess Medical Center, Boston, 
MA,3Center for Psychiatric Research, Maine Medical Center, Portland, 
ME,4Psychiatry, Harvard Medical School, Boston, MA
Background: While previous studies have identified verbal memory and 
olfactory deficits in putatively prodromal subjects as potential predictors of 
later illness, there are limited data on whether the neuropsychological (NP) 
profiles of these individuals differ significantly from controls.
Methods: We compare NP data from a sample of 39 putatively prodromal 
youth (participants in the Portland Identification and Early Referral [PIER] 
program, NIMH RO1 MH065367, Robert Wood Johnson Foundation, 
William McFarlane, PI) to NP data from a demographically-matched healthy 
control sample (N = 33). Profile analysis is used to compare NP profiles 
based on eight cognitive domains: verbal and nonverbal IQ, verbal and visual 
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sustained attention and working memory, executive functions, learning and 
memory, motor functioning, and olfactory functioning.
Results: Preliminary analyses show that the NP profile of the prodromal sample 
is significantly different in magnitude from that of controls; prodromal subjects 
demonstrate overall deficits. While NP domain scores differ significantly 
from each other, we do not find evidence for a significant domain-by-group 
interaction. However, significant group effects for executive and olfactory 
functioning, verbal IQ and memory suggest that this may be primarily an issue 
of power. We plan to test this in ongoing analyses with a larger sample.
Conclusions: This prodromal sample demonstrates a moderate overall NP 
deficit, consistent with previous literature. Moderate effect sizes for executive, 
olfactory, and memory deficits suggest these domains may be particularly 
impaired relative to controls.
Supported by NIMH RO1 MH065367; Harvard Graduate Society 
Dissertation Completion Fellowship; Sackler Scholar Programme in 
Psychobiology; Commonwealth Research Center of the Massachusetts 
Department of Mental Health
842. Neuropsychological Functioning in 
Schizophrenia Patients with Average or Below 
Average Intellectual Abilities
Neil D. Woodward1, Herbert Y. Meltzer2, Karuna 
Jayathilake2
1Psychiatric Neuroimaging Program, Vanderbilt University Medical 
Center, Nashville, TN,2Dept. of Psychiatry, Vanderbilt University 
Medical Center, Nashville, TN
Background: Patients with schizophrenia demonstrate significant impairments 
in cognitive function. The deficits are often observed within the context of 
impaired general intellectual abilities. Consequently, it remains unclear if 
neuropsychological impairment in schizophrenia results from dysfunction in 
specific cognitive abilities and associated neural systems or deficient general 
intellectual ability and widespread alterations in cerebral function.
Methods: To better understand the profile of cognitive impairment in 
schizophrenia, 93 predominantly treatment resistant patients were classified 
on the basis of their estimated Wechsler Adult Intelligence Scale-Revised 
(WAIS-R) intelligence quotient (IQ) into average (IQ=85-115) and below 
average (IQ=70-85) groups and compared on a battery of neuropsychological 
tests to a sample of 20 control subjects matched for age, gender, and ethnicity.
Results: Compared to IQ matched controls and their own IQ, patients 
within the average IQ group demonstrated a moderate impairment in overall 
neuropsychological functioning (Z-score=-0.97) that was characterized 
by disproportionately worse verbal memory (Z-score=-1.57) and semantic 
verbal f luency (Z-score=-1.43). Patients within the below average IQ group 
demonstrated greater overall neuropsychological impairment (Z-score=-1.78) 
than both controls and average IQ patients, but did not demonstrate a deficit 
relative to their IQ.
Conclusions: Patients with an average IQ demonstrate neuropsychological 
impairment characterized by disproportionately worse performance on tests of 
verbal learning and semantic fluency. In contrast, patients with below average 
IQ do not perform disproportionately worse on neuropsychological testing, 
relative to their IQ, despite demonstrating greater impairment compared to a 
control sample. These findings indicate that neuropsychological functioning 
in schizophrenia varies as a function of overall intellectual ability.
Supported, in part, by grants from the Prentiss and Ritter Foundations.
843. Reduced Early Visual Processing in Drug-Naive 
First Episode Schizophrenia
Sherlyn Yeap1, Simon P. Kelly2, Jogin H. Thakore3, John 
J. Foxe2
1Psychiatry, Royal College of Surgeons Ireland, Dublin, 
Ireland,2Psychiatry, Nathan Kline Insitute for Psychiatric Research, New 
York, NY,3Psychiatry, St. Vincent’s Hospital Fairview, Dublin, Ireland
Background: Patients with schizophrenia show alterations in early visual 
information processing as indexed by the P1 visual evoked potential. Previous 
studies looking at chronic patients as well as first-degree relatives have shown 
marked reductions in P1 amplitude when compared to controls.
Methods: High-density electrical scalp recordings of drug-naive patients 
with DSM-IV diagnosed first episode schizophrenia (N=20) and healthy age-
matched controls (N=20) were recorded using simple isolated check stimuli.
Results: Preliminary results indicate a substantially reduced P1 amplitude in 
the patient group compared to controls.
Conclusions: In addition to well-documented deficits in chronic patients, first 
episode patients with schizophrenia also show deficits in early visual information 
processing suggesting that it may be longitudinally robust. We suggest that these 
deficits may further confirm that the P1 is a trait rather than a state marker.
Supported by Health Research Board, Ireland
844. Automated Diagnosis of Schizophrenia using 
Multivariate Pattern Analysis of fMRI Data
Jong H. Yoon, Diana Tamir, MIchael J. Minzenberg, J. 
Daniel Ragland, Stefan Ursu, Cameron S. Carter
Psychiatry, Univ Cal Davis, Sacramento, CA
Background: The development of objective, laboratory based diagnostic tools 
would significantly augment our ability to accurately identify individuals 
suffering from or at high risk of developing schizophrenia. Here we report 
on our efforts to use automated multivariate pattern analysis to differentiate 
activation patterns from individuals with schizophrenia from healthy subjects.
Methods: 25 patients with first episode schizophrenia and 24 demographically 
matched healthy control subjects underwent fMRI scanning while they completed 
the AXCPT. A non-linear neural network based pattern classifier analyzed DLPFC 
seeded functional connectivity maps of the contrast between B Cue (high cognitive 
control) and A Cue (low cognitive control) conditions. Training and testing was 
conducted using a jack-knife or n-1 procedure in which the subject data to be tested 
(classified) was excluded from the training set in an iterative manner.
Results: The pattern classifier achieved overall diagnostic accuracy of 75.5%, 
identifying 72% of patients and 79% of controls correctly.
Conclusions: Automated diagnosis based on fMRI activation pattern analysis 
achieved fairly high accuracy, suggesting that this procedure is a viable method 
to assist in the assessment and diagnosis of individuals with or thought to be 
at risk for schizophrenia.
845. Knowing What to do and doing What you 
Know: A Comparison of Daily Living Skills 
Measures in Schizophrenia
Rachel Ziwich, Maria Jalbrzikowski, Erica Saccente, 
Gina Forchelli, Daniel C. Javitt, Nadine Revheim
Cognitive Neuroscience, Nathan Kline Institute, Orangeburg, NY
Background: Individuals with schizophrenia have difficulties navigating 
the tasks of everyday living, which result in poor community adjustment 
and inability to live independently. While these problems are associated with 
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neurocognitive deficits, they can be measured independently as functional 
outcomes. Daily problem-solving skills have been measured using the semi-
structured interview format of the Independent Living Scales (ILS), with 33-
items comprising the problem-solving factor score, which evaluates abstract 
reasoning and judgment. The UCSD Performance-Based Skills Assessment 
(UPSA) has utilized a performance-based format to assess functional capacity 
using five domains of functioning. Recent reports for an UPSA-Brief measure 
have also suggested its validity for prediction of residential independence.
Methods: The purpose of this study was to examine individuals with persistent 
schizophrenia and compare the results of their ILS, UPSA and UPSA-Brief 
scores to each other and in relation to current community status. The 
instruments were administered to 45 inpatients and outpatients (35.5±11.3 y.o.; 
15.8±9.6 years illness duration.)
Results: ILS, UPSA and UPSA-Brief scores were found to be significantly 
correlated (ILS and UPSA, r=.70,p<.001,n=45; ILS and Brief-UPSA, 
r=.66,p<.001,n=45). Based on current residential placement, between group 
comparisons were made for patients requiring moderate-maximum supervision 
(n=40) with those requiring minimum-no supervision (n=5). Significant 
differences were found for ILS (t=-4.55,df=9.65,p=.001) and UPSA (t=-
2.49,df=43,p=.02), but not for UPSA-Brief (t=-1.68,df=43,p=.10). Mean scores 
are discussed in relation to “passing” scores for independent living. UPSA 
scores are also presented vis-a-vis 3 levels of supervision categorized by ILS.
Conclusions: Results suggest the interview-based ILS and performance-based 
UPSA are comparable functional outcome measures.
Supported by R37-MH49334
846. Motor-Behavior Abnormalities and 
Schizophrenia-Prodrome Symptoms in Adolescents 
and Young Adults with 22q11 Deletion Syndrome
Joseph F. Cubells1, Opal Y. Ousley2, Kimberly 
Rockers1, Amanda McMillan3, Evan Schoenberg1,
Thomas J. Sutton1, Sang-Hee Kim2, Karlene Coleman1,
Elaine F. Walker4
1Human Genetics, Emory Univ. Sch. Med., Atlanta, GA,2Psychiatry 
and Behavioral Sciences, Emory Univ. Sch. Med., Atlanta, GA,3School 
of Medicine, Mercer University, Macon, GA,4Psychology, Emory 
University, Atlanta, GA
Background: The 22q11 deletion syndrome (22q11DS) strongly associates with 
risk for schizophrenia. Abnormal motor movements (AMM) of the extremities, 
face, neck and oral region are common in schizophrenic patients, and associate 
with risk for development of schizophrenia in pre-morbid studies of children and 
adolescents. We tested the hypotheses that 22q11DS patients exhibit AMM, and 
that such movements associate with prodromal symptoms of schizophrenia.
Methods: 22q11DS patients (N = 26; 17-30 years old) were ascertained from a case 
registry at Children’s Healthcare of Atlanta. Consenting participants underwent 
evaluation using the Structured Interview for Prodromal Symptoms (SIPS), and 
videotapes of participants were rated using the Dyskinesia Identification System: 
Condensed User Scale (DISCUS). Data from 22q11DS patients were compared 
to those from previously-assessed non-22q11DS subjects with schizotypal 
personality disorder (SPD; N = 34), or no personality disorder (NPD; N = 46).
Results: Facial, oral, head/neck and upper-limb MMA scores were significantly 
higher in 22q11DS patients than in non-22q11DS subjects with NPD (all p 
<.001). Scores of oral, head/neck and upper-limb MMA were also significantly 
higher in 22q11DS patients than in SPD patients (all P .05). MMA scores in 
22q11DS patients significantly associated with severity of positive, negative and 
general-symptom SIPS scores (r = 0.39, 0.32 and 0.30, respectively, all p < 0.05).
Conclusions: 22q11DS patients exhibit elevated MMA, and severity of MMA 
in 22q11DS associates with severity of schizophrenia-prodrome symptoms.
Supported by The Predictive Health Institute and Robert W. Woodruff Fund, 
Emory University.
847. Effect of COMT Val158Met Genotype on 
Hippocampal Physiology in Schizophrenia
Annabella Di Giorgio1, Grazia Caforio1, Giuseppe 
Blasi1, Raffaella Romano1, Giuseppe De Simeis1,
Simona Aquilino1, Leonardo Fazio1, Paolo Taurisano1,
Barbara Gelao1, Marcello Nardini1, Teresa Popolizio2,
Alessandro Bertolino1
1Psychiatric Neuroscience Group, Department of Psychiatry and 
Neurology, University of Bari, Bari, Italy,2Section of Neuroradiology, IRCCS 
“Casa Sollievo della Sofferenza”, San Giovanni Rotondo (FG), Italy
Background: Catechol-O-Methyltransferase (COMT) Val158Met is thought to 
modulate dopamine regulated hippocampal activity during episodic memory, 
and to weakly increase risk for developing schizophrenia. Aim of the present 
study with fMRI was to evaluate the potential association between this COMT 
polymorphism and hippocampal physiology during recognition memory 
encoding in schizophrenia.
Methods: 28 schizophrenic patients (DSM-IV criteria, 25 males, mean age ±SD 
30.3 ± 9.3 yrs) and 33 healthy subjects matched for a series of socio-demographic 
variables were recruited. All participants were genotyped for COMT Val158Met 
genotype and underwent fMRI at 3T (gradient-echo EPI, TE 3000 ms, TR 20 
ms) during a recognition memory task, that has previously been associated with 
robust activation of the hippocampal memory system. SPM5 and random effects 
models were used for statistical analyses (all p<0.005).
Results: The two groups did not differ in COMT genotype distribution which 
was in Hardy Weinberg equilibrium. ANOVA of behavioral performance data 
demonstrated a main effect of diagnosis on encoding accuracy, with patients 
performing worse than healthy subjects (p<0.02). A Full Factorial ANOVA of 
the imaging data (including accuracy as a covariate) indicated a main effect of 
diagnosis, with healthy subjects showing greater hippocampal activity during 
memory encoding compared to patients; no main effect of genotype; and a 
significant genotype by diagnosis interaction, in that the effect of diagnosis on 
hippocampal engagement was evident only in Met/Met subjects.
Conclusions: These results suggest that modulation of dopamine signaling 
may be important in determining the phenotype of hippocampal physiology 
during recognition memory in schizophrenia.
848. Do Probands with First Episode Psychosis 
have Relatives with Specific or Non-Specific 
Psychopathology?
Kia Faridi1,2, Nicole Pawliuk2, Suzanne King1,2, Ridha 
Joober1,2, Ashok K. Malla1,2
1Department of Psychiatry, McGill University, Montreal, QC, 
Canada,2Douglas Research Centre, Douglas Mental Health University 
Institute, Montreal, QC, Canada
Background: It is well established that family members of individuals with 
schizophrenia suffer from elevated rates of schizophrenia-spectrum disorders 
(SSD) and other forms of psychopathology. However, few studies have 
examined familial psychopathology in first episode psychosis (FEP). In this 
study we systematically evaluated family history in patients experiencing an 
affective or non-affective FEP.
Methods: The Family Interview for Genetic Studies was used to obtain 
diagnostic information on all first- and second-degree relatives of probands 
admitted to a specialized FEP program. Probands were 93 previously untreated 
patients suffering from FEP, aged 14 to 30. Diagnoses ascertained included 
psychotic disorders, affective disorders, and substance use disorders (SUD).
Results: One in five probands (19.4%) had a history of psychosis among 
their first-degree relatives, while 34.5% had any family history of psychosis. 
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Fewer had a family history of SSD (7.5 % and 18.3% first-degree and any 
relatives, respectively). Over half of probands had a first-degree relative with 
Major Depressive Disorder, and 38.7% had a first-degree relative with a SUD. 
Overall, 69.9% of probands had a first-degree relative with a mental disorder. 
The proportion with a family history of any of these diagnoses did not vary by 
proband diagnosis.
Proportion of Probands with a Family History of Various Forms of 
Psychopathology
Diagnosis




Probands with Family 
History Amongst Any 
Relative (1st or 2nd 
Degree) n = 93
n % n %
Schizophrenia Spectrum 
Disorder 7 7.5% 17 18.3%
Any Psychosis 18 19.4% 32 34.5%
Major Depressive Disorder 49 52.7% 60 64.5%
Bipolar Disorder 7 7.5% 11 11.8%
Substance Use Disorder 36 38.7% 55 59.1%
Any Psychopathology 65 69.9% 78 83.9%
Conclusions: Diverse psychopathology is common in families of FEP patients. 
A family history of psychosis, depression, or SUD was common, while a family 
history of SSD was relatively less so.
Supported by Canadian Institute of Health Research
849. COMT Val/Met (158/108) Polymorphism and 
Schizophrenia: a Case-Control and Family Based 
Association Study
Ferid Fathalli1, Guy A. Rouleau2,3, Karim Tabbane4,
Alain Labelle5, Pierre Lalonde6, Chawki Benkelfat7,
Samarthji Lal7, Zoltan Danics8, Ridha Joober7,9
1Research Center (FBC), Douglas Hospital, Montreal, QC, 
Canada,2Research Center, Saint-Justine University Hospital, Montreal, 
QC, Canada,3Notre Dame Hospital, Notre Dame Hospital, Montreal, 
QC, Canada,4Department of Psychiatry, University of Tunis, Tunis, 
Tunisia,5Ottawa Royal Hospital, Ottawa Royal Hospital, Ottawa, ON, 
Canada,6Department of Psychiatry, University of Montreal, Montreal, 
QC, Canada,7Department of Psychiatry, McGill University, Montreal, 
QC, Canada,8National Institute of Psychiatry, National Institute of 
Psychiatry, Budapest, Hungary,9Research center (FBC), Douglas 
Hospital, Montreal, QC, Canada
Background: The COMT gene is of particular interest in schizophrenia 
since corticostriatal dopamine dysregulation is believed to be an important 
contributor to the pathogenesis of schizophrenia
Methods: A case-control study was performed with a sample of 292 
schizophrenic patients and 158 control subjects assessed for the COMT Val/
Met (158/108) variant. In addition, we carried out a family-based association 
study with 174 nuclear Caucasian families including 570 persons (133 European 
ancestry families with 417 individuals and 41 Tunisian -Arab Mediterranean- 
families including 153 individuals). For the case-control study, we compared 
allelic and genotype distribution between patients and controls. For the family 
based study, we used the transmission disequilibrium test as implemented in 
the Fbat program.
Results: No differences between patients and control subjects regarding 
genotype (?²=0.49; df = 2; p=0.78) and allelic frequencies (?² = 0.07; df = 1; p 
= 0.78) were observed. However, in patients with European ancestry, later age 
at onset (> 25 years) was associated with heterozygosity in males. No difference 
in genotype and allelic frequencies was found between patients separated 
according to the quality of their response to conventional neuroleptic. In 
the family study there was a preferential transmission of the Val allele (high 
activity) in Tunisian (additive model: Z= 2.2, p= 0.02; dominant model: 
Z=3.5, p=0.0003) but not in European families.
Conclusions: The COMT Val/Met (158/108) polymorphism may play a role 
in increasing the risk for schizophrenia in some populations. It also could play 
a role in modulating disease characteristics such as age at onset.
Supported by a grant from the Fond de Recherche de Santé du Québec and the 
Canadian Institutes of Health Research to RJ.
850. Reduced Acetylated Histone 3 (acetylH3) 
Levels and Impaired TSA-Induced Increases in 
Acetylation in Schizophrenia
David P. Gavin, Cherise Rosen, Saritha Kartan, Dennis 
R. Grayson, Rajiv P. Sharma
Psychiatry, University of Illinois at Chicago, Chicago, IL
Background: Histone deacetylases (HDAC) induce a restrictive chromatin 
state which has been implicated in schizophrenia. GAD1 is an epigenetically 
regulated schizophrenia candidate gene. HDAC inhibitors, such as trichostatin 
A (TSA), increase acetylated histone 3 (acetylH3) protein levels and GAD1 
mRNA expression in patients and in cultured lymphocytes.
Methods: Lymphocytes were isolated from 21 normal and 23 schizophrenia 
subjects. Diagnoses were confirmed using SCID and symptoms rated with 
PANSS. Cells were incubated with 100 nM TSA or vehicle (DMSO) for 24 
hours. GAD1 mRNA expression was measured using realtime RT-PCR, and 
acetylH3 by Western blot analysis.
Results: Schizophrenia subjects had significantly lower baseline acetylH3 levels 
compared with normal subjects (p<0.04) and showed significantly smaller 
increases in acetylH3 after TSA treatment than normal subjects (11% vs. 60%; 
p<0.01). There was a trend for smaller increases in GAD1 mRNA expression 
after TSA treatment in schizophrenia compared with normal subjects (-18% 
vs. 134%; p<0.08). GAD1 and acetylH3 were significantly correlated in TSA-
treated cells among normal subjects (r=0.692; p<0.01), but not among those 
with schizophrenia. There was a significant negative correlation between 
thought disorder symptoms and TSA-induced increases in GAD1 expression 
(r=-0.764; n=7; p<0.05).
Conclusions: Our results confirm previous findings that schizophrenia 
chromatin is generally more “rigid,” and that HDAC inhibitors are less 
effective at inducing chromatin remodeling. These results provide further 
evidence of the association between schizophrenia and chromatin remodeling 
abnormalities, and suggest these differences are more profound in a subset of 
schizophrenia patients.
851. Prepulse Inhibition and Baseline Startle are 
Heritable in Families of Schizophrenia Patients and 
Healthy Controls
Wendy Hasenkamp1, Michael Epstein2, Amanda Green1,
Lisette Wilcox1, William Boshoven1, Erica Duncan1,3
1Mental Health Service, Atlanta Veterans Affairs Medical Center, 
Atlanta, GA,2Department of Human Genetics, Emory University School 
of Medicine, Atlanta, GA,3Department of Psychiatry and Behavioral 
Sciences, Emory University School of Medicine, Atlanta, GA
Background: Prepulse inhibition of the acoustic startle reflex (PPI) is a 
measure of sensorimotor gating that has been proposed to be an endophenotype 
in schizophrenia. If this measure proves to have significant heritability, it may 
advance studies of the genetics of schizophrenia.
Methods: We evaluated baseline startle magnitude and PPI at 30, 60 and 
120-ms intervals between prepulse and startling stimuli in 181 subjects from 
75 families (38 families ascertained via a schizophrenic proband, 37 non-
psychiatric families ascertained at random). To assess whether PPI possessed 
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a significant genetic component, we conducted a heritability analysis using 
the popular variance-component approach, adjusting for the effects of age, 
gender and race. We conditioned these variance-component analyses on the 
outcome values of the 38 schizophrenic probands to remove any potential bias 
resulting from the non-random ascertainment of these families. Outcomes 
were transformed to normality to make the variance-component analyses 
robust to potential heavy tails in the outcome distribution. We based inference 
on likelihood-ratio statistics derived from the MENDEL software package.
Results: We estimated the heritability of baseline startle magnitude to be 
69% (p=0.0004), and the heritability of PPI at 60-ms to be 42% (p=0.015). 
Heritability estimates of PPI at 30 and 120-ms were moderately significant.
Conclusions: These data support the concept of PPI as a heritable 
endophenotype in schizophrenia, and agree with previous estimations of PPI 
and baseline startle heritability. Hopefully, future research will identify specific 
genes underlying PPI phenotypes, which will assist in the understanding of the 
genetic basis of schizophrenia.
Supported by Department of Veterans Affairs Merit Review Program
852. Protective and Risk Functional Diplotypes of 
PRODH Schizophrenia Risk Gene on 22q11, Impact 
on Brain Structure, Function and Clinical Risk
Lucas Kempf1, Kristin K. Nicodemus1, Bhaskar 
Kolochana1, Radhakrishna Vakkalanka1, Beth 
Verchinski1, Michael Egan2, Richard Straub1, Venkata 
Mattay1, Joseph Callicott1, Daniel Weinberger1, Andreas 
Meyer-Lindenberg3
1USNP/GCAP, NIMH, Bethesda, MD,2Clinical research, Merck and Co, 
West Point, PA,3Department of the Director, Central Institute of Mental 
Health, Mannheim, Germany
Background: Proline Dehydrogenase (PRODH) on 22q11.2 has been 
implicated in susceptibility to schizophrenia. Several functional changes in 
the enzyme have been characterized. Since interacting effects of common 
polymorphisms on enzyme activity are a likely pathophysiological mechanism, 
diplotypes are useful to separately characterize effects of interacting functional 
variants.
Methods: Clinical association for haplotypes in the GCAP sibling study was 
done with TDT. Imaging: We studied 144 healthy volunteers of European 
ancestry in a multimodal fashion using functional, connectivity and structural 
data. Diplotypes were constructed with Phase 2.1 and second level imaging 
analysis was conducted using a regression approach with probabilistic 
diplotypes in the design matrix.
Results: Clinical association was positive for the fast metabolizing haplotype 
and negatively for the slow metabolizing haplotype. Imaging results showed 
a significant effect of risk haplotype compared to the reference haplotype, on 
the structure of the striatum cluster maximum 21, 22, -6 T=3.36, FDR=0.038. 
The protective haplotype showed an increase in regional volume in the left 
superior prefrontal cortex (-20 60 1, Z=4.38, p<0.001) and right occipital lobe 
(FDR 0.033, 21 -86 17, Z=5.00, p<0.001). PRODH risk diplotype showed 
effects in activation of the inferior frontal and parietal lobes in the working 
memory network. Functional connectivity analysis with the striatum showed a 
diplotype dependant connectivity pattern.
Conclusions: Our data suggest that PRODH risk haplotype impacts on 
striatal function and structure, confirming previous results using single SNPs 
and suggesting a risk mechanism for schizophrenia involving neostriatum and 
the protective haplotype increases the left dorsal lateral prefrontal cortex.
Supported by NIH
853. Family History and Paternal Age-Related 
Gender Effects on Schizophrenia Reoccurrence in 
the Jerusalem Cohort.
M. C. Perrin1, S. Harlap2, K. Kleinhaus3, M. Opler4, P. 
Lichtenberg5, B.G. Draiman6, O. Manor6, D. Malaspina4
1Departments of Psychiatry and Environmental Medicine, New 
York University School of Medicine, New York, NY,2Departments 
of Psychiatry and Obstetrics and Gynecology, New York University 
School of Medicine, New York, NY,3Department of Psychiatry, 
Columbia University, New York, NY,4Department of Psychiatry, 
New York University School of Medicine, New York, NY,5Hadassah 
Medical School, Herzog Hospital and Hebrew University, Jerusalem, 
Israel,6School of Public Health, Hebrew University, Jerusalem, Israel
Background: Family history of schizophrenia is an established risk factor for 
schizophrenia. It has rarely been estimated using a prospective cohort and described 
in relation to sex of affected individuals, their relatives and paternal age.
Methods: We measured the incidence of schizophrenia associated with a history of 
a psychiatric hospitalization in first-degree relatives, using the Jerusalem Perinatal 
Study, a population-based cohort of 92,408 offspring. Families were traced in the 
Population Registry and linked by identity number to the Psychiatric Registry. 
Schizophrenia-related diagnosis (“schizophrenia”) was defined as a discharge 
diagnosis of [ICD-10] F20-F29. Cox proportional hazards models were used to 
estimate the relative risk (RR) of hospitalization for schizophrenia in offspring 
who had a first-degree relative hospitalized for schizophrenia.
Results: 806 offspring (0.94%) were hospitalized with schizophrenia. With 
both sexes combined, the RRs associated with an affected mother, father, 1+ 
brothers or 1+ sisters were; 4.7 (3.5-6.1); 3.3 (2.4-4.5); 3.7 (2.7-5.0) and 5.5 
( 4.0-7.6) respectively. Females with 1+ affected brothers were 2.7 (1.6-4.6) 
times as likely to be hospitalized with schizophrenia. Females with 1+ affected 
sisters showed a 10-fold increase in risk (6.5-15.6). Males with 1 + affected sister 
had an RR of 3.4 (2.1-5.4) and 4.4 (3.0-6.4) with 1+ affected brothers. In older 
fathers, the risk between sisters was three times the risk between brothers.
Conclusions: Our findings suggest an X-chromosome contribution to 
schizophrenia risk. The stronger association of schizophrenia between sisters 
than between brother and sister, imply involvement of a paternal rather than 
a maternal allele.
Supported by R01 MH59114-2
854. SAT-1 T589C Polymorphism and Susceptibility 
to Psychosis
Concepción Vaquero Lorenzo1, Carlos Riaza 
Bermudo-Soriano2, Enrique Baca Garcia3, Montserrat 
Diaz-Bernardez4, Jeronimo Saiz-Ruiz2, Jose Fernandez 
Piqueras4, Negueruela Monica3
1Department of Genetics, Universidad Autonoma De Madrid, Madrid, 
Spain,2Psychiatry, Hospital Ramon Y Cajal, Madrid, Spain,3Psychiatry, 
Fundación Jiménez Díaz, Madrid, Spain,4Department of Genetics, 
Universidad Autonoma de Madrid, Madrid, Spain
Background: Psychotic patients show several disturbances on polyamine 
metabolism. There is a significant positive correlation between blood polyamine 
concentration and the severity of illness. The aim of the present study was to 
examine the association between dbSNP 7891589 (T/C) polymorphism of the 
main gene regulating polyamine catabolism (SAT-1) and the risk of developing 
psychotic disorders.
Methods: A case-control design was used in order to compare the genotypes 
for that dbSNP between psychotic patients (n=180), other non-psychotic 
psychiatric patients (n=413), and healthy controls (n=251). DSM-IV diagnosis 
for psychiatric patients was provided using MINI 4.4. Genomic DNA was 
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extracted from peripheral blood samples collected from participants. PCR 
amplification of a 298-bp fragment from the promoter region of SAT-1 gene (X 
cromosome), containing the PRE and nearby dbSNPs: 7891589, was carried out 
using the following primers: forward: 5 -´GAAGGCCTTTTCCTCCTCTG-3´ 
and the reverse: 5 -´ GATAGGGCCTCACCATCTTG-3 ,´ and subsequently 
digested with Msp I and visualized in ethidium bromide agarose gels.
Results: No significant association in the distribution of the two genotypes of 
the T589C polymorphism between psychotic patients, non-psychotic controls, 
and healthy controls, was found in males (T/C) (Linear-by-Linear association 
?2=1,278; df=1; P=0,258), or in females (T/T, T/C, and C/C) (Linear-by-Linear 
association ?2=1,94; df=1; P=0,164).
Conclusions: This is the first study that analyses the role of polymorphic variants 
of genes involved in polyamine metabolism in psychosis. Though our study could 
not demonstrate a significant association between SAT-1-T589C polymorphism 
and the risk of suffering from psychosis, it opens a new field of research.
Supported by Spanish government (Fondo de Investigación Sanitaria (FIS) 
PI06/0497, FIS-RETIC RD06/0011/0016).
855. A PRODH Haplotype which Increases Risk for 
Schizophrenia, is Associated with Deficient PPI in 
Healthy Males
Panos Roussos, Stella G. Giakoumaki, Panos Bitsios
Psychiatry and Behavioral Sciences, University of Crete, Heraklion, 
Crete, Greece
Background: Prepulse inhibition (PPI) of the startle reflex has been proposed 
as an endophenotype for schizophrenia. There is evidence supporting a role 
for the PRODH locus in this disorder1 and knock out mice for PRODH have 
deficient PPI2. It is not known whether PRODH is a significant determinant 
of human PPI.
Methods: Three polymorphisms in the 3’ region of the gene (1945A>G, 
1766T>C and 1852G>A) were analyzed in 117 healthy males. PPI (75-dB and 
85-dB prepulses at 30-, 60-, 120-ms intervals) was examined. Hardy-Weinberg 
equilibrium for PRODH markers was checked using Haploview version 4.03.
Data for each separate allele were analyzed with repeated measures ANOVA 
with prepulse and interval as the within- and polymorphisms as the between-
subject factors. QTPHASE from the UNPHASED package was used for the 
association analysis of haplotype data4.
Results: The ANOVA and the QTPHASE analyses revealed significant main 
effects of the PRODH alleles and haplotypes, respectively. The 1945G, 1766C 
and 1852A alleles, and the GCA haplotype, consisted of these alleles, were 
associated with deficient PPI.
Conclusions: Healthy human subjects carrying the PRODH GCA haplotype 
have deficient PPI. This haplotype has been previously associated with an 
increased risk for schizophrenia. This risk may be attributed, at least in part, to 
deficient sensorimotor gating conferred by the PRODH GCA haplotype.
1Li T et al 2004. Am J Med Genet B Neuropsychiatr Genet. 129:13-5.
2Gogos JA et al 1999. Nat Genet. 21:434-9.
3Barrett JC et al 2005. Bioinformatics 21: 263-265.
4Dudbridge F 2003. Genet Epidemiol 25: 115-121.
856. Hyperactivity and Hyperconnectivity of the 
Default Network in Schizophrenia and in First 
Degree Relatives of Persons with Schizophrenia
Susan Whitfield-Gabrieli1, Heidi W. Thermenos2,3,
Snezana Milanovic2,4, Ming T. Tsuang5, Stephen V. 
Faraone6, Robert W. McCarley2,7, Martha E. Shenton7,8,
Alan I. Green9, Peter LaViolette4, Joanne Wojcik2, John D. 
E. Gabrieli1, Larry J. Seidman2,3,4
1Department of Brain and Cognitive Sciences, Massachusetts Institute 
of Technology, Boston, MA,2Department of Psychiatry, Harvard Medical 
School/ Beth Israel Deaconess Medical Center, Boston, MA,3Massachusetts 
Institute of Technology/ Harvard Medical School and Massachusetts 
General Hospital, Martinos Center for Biomedical Imaging, Charlestown, 
MA,4Department of Psychiatry, Harvard Medical School/ Massachusetts 
General Hospital, Boston, MA,5Department of Psychiatry, Institute of 
Behavior Genomics, University of California, San Diego, La Jolla, CA,6SUNY 
Genetics Research Program/ Department of Psychiatry, SUNY Upstate 
Medical University, Syracuse, NY,7Department of Psychiatry, Harvard 
Medical School/ Brockton/West Roxbury VA Medical Center, Brockton, 
MA,8Department of Psychiatry, Harvard Medical School/ Brigham and 
Womenâ€™s Hospital, Boston, MA,9Departments of Psychiatry and of 
Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH
Background: We examined the status of the neural network mediating the 
default mode of brain function, which typically exhibits greater activation 
during rest than during task, in patients in the early phase of schizophrenia 
and in young first-degree relatives of persons with schizophrenia.
Methods: During functional magnetic resonance imaging (fMRI), patients, relatives, 
and controls alternated between rest and performance of working memory tasks.
Results: As expected, controls exhibited task-related suppression of activation 
in the default network including medial prefrontal cortex (MPFC), posterior 
cingulate cortex (PCC)/Precuneus, lateral parietal cortex, and hippocampus. 
Patients and relatives exhibited reduced task-related suppression in all those 
regions, except in the PCC for the relatives. Increased task-related suppression 
in the MPFC was correlated with better working memory performance and less 
psychopathology in all three groups. Patients and relatives exhibited abnormally 
high functional connectivity between default network regions during rest, with 
the degree of connectivity correlating with psychopathology in the patients.
Conclusions: Hyperactivation (reduced task-related suppression) of default 
regions and hyperconnectivity of the default network may contribute to 
disturbances of thought in schizophrenia and the risk for the illness.
Supported by MIND Institute, NARSAD; R01MH43518, 65562, 63951
857. Effect of Sigma-1 Receptor Gene Polymorphism 
on Prefrontal Hemodynamic Response in 
Schizophrenia; a Multi-Channel NIRS Study
Ryu Takizawa1, Mamoru Tochigi1, Yuki Kawakubo1,
Kohei Marumo1, Tsukasa Sasaki2, Masato Fukuda3,
Kenji Hashimoto4, Kiyoto Kasai1
1Department of Neuropsychiatry, Graduate School of Medicine, 
The University of Tokyo, Tokyo, Japan,2Health Service Center, The 
University of Tokyo, Tokyo, Japan,3Department of Psychiatry and Human 
Behavior, Graduate School of Medicine, Gunma University, Maebashi, 
Japan,4Division of Clinical Neuroscience, Chiba University Center for 
Forensic Mental Health, Chiba, Japan
Background: Several lines of evidence suggest that the sigma-1 receptor (Sig-
1R) may contribute to the pathophysiology of schizophrenia and mechanisms 
of drug efficacy. A functional polymorphism (Gln2Pro) of Sig-1R that is 
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involved in endoplasmic reticulum retention signal is thought to be a candidate 
that affects brain function in schizophrenia. Spatiotemporal characteristics of 
prefrontal hemodynamic response and the association with Sig-1R genotype 
were investigated using a non-invasive neuroimaging technique, multi-channel 
near-infrared spectroscopy (NIRS).
Methods: Subjects included 40 right-handed patients with schizophrenia and 
60 healthy controls, who gave written informed consent in accordance with 
the ethics committee of the University of Tokyo Hospital. The NIRS signals, 
monitored over the prefrontal cortex (PFC) from 52-channel NIRS (HITACHI 
ETG-4000) during verbal f luency task, were compared between two Sig1-R 
genotype subgroups (Gln/Gln individuals and Pro carriers) matched for age, 
gender, premorbid IQ and task-performance.
Results: Even after controlling for medication effect, schizophrenia patients 
with Gln/Gln genotype had greater task-associated increase in [oxy-Hb] in the 
PFC than those with Pro carriers after false discovery rate (FDR) correction 
for multiple comparisons (p < FDR .05), although clinical symptoms were not 
significantly different between the two Sig-1R genotypes. These differences 
were not found to be significant in healthy controls.
Conclusions: Our finding is the first functional imaging-genetics study that 
implicated the effect of Sig-1R genotype on prefrontal cortical function in 
schizophrenia. Prefrontal hemodynamic response assessed by non-invasive 
NIRS might be a useful intermediate phenotype for schizophrenia.
858. AKT1 Influences Human Prefrontal Cortical 
Structure and Dopaminergic Function
Hao-Yang Tan1, Kristin K. Nicodemus1, Qiang Chen1,
Zhen Li1, Jennifer K. Brooke1, Robyn Honea1, Bhaskar 
S. Kolachana1, Richard E. Straub1, Yoshitasu Sei1,
Andreas Meyer-Lindenberg1,2, Venkata S. Mattay1,
Joseph H. Callicott1, Daniel R. Weinberger1
1Clinical Brain Disorders Branch, National Institute of Mental Health, 
Bethesda, MD,2Psychiatry and Psychotherapy, Central Institute of 
Mental Health, Mannheim, Germany
Background: AKT1-dependent molecular pathways control diverse aspects 
of cellular development and adaptation, including novel interactions with 
neuronal dopaminergic signaling implicated in working memory and 
neuropsychiatric disease.
Methods: We examined AKT1 effects on cognition, lymphoblast protein 
expression, fMRI of working memory, MRI grey matter volume and risk 
for schizophrenia. Further, the hypothesized AKT1 coupling with cortical 
dopamine was examined in the context of a functional polymorphism 
(Val158Met) in COMT.
Results: A coding genetic variation in AKT1 rs1130233 (Glu242Glu; formerly 
rs2498799) influenced frontostriatal cognitive performance in healthy 
individuals (n=319, p<0.005), prefrontal physiology assayed in fMRI in two 
independent samples (n=46 and n=68; combined p=9x10-7), frontostriatal gray 
matter volume (n=171, p<0.05 corrected), and AKT1 protein levels in human B 
lymphoblasts (n=32, p<0.05). Moreover, on prefrontal fMRI and MRI measures 
showing a main effect of AKT1 genotype, there was an epistatic interaction 
with COMT (fMRI: combined p=0.0008; MRI p=0.002). In a case-control 
dataset (n=358 probands and 370 controls), we found additional evidence for a 
genetic association of AKT1 rs1130233 with risk for schizophrenia (p=0.024).
Conclusions: These convergent data implicate AKT1 in modulating human 
prefrontal structure and function, and risk for psychosis, suggesting that 
the mechanism of this genetic effect involves, at least in part, dopaminergic 
signaling.
Supported by NIMH Intramural Research Program
859. Genetic Findings in Hispanic Schizophrenics 
James Wilcox
Psychiatry - VAMC, University of Arizona, Tucson, AZ
Background: Many candidate genes have been described for schizophrenia.
Although several ethnic groups have been examined in some detail, the 
Hispanic population is often ignored. There is presently a lack of information 
on this group. This poster is an attempt to include Hispanic populations into 
the genetic database.
Methods: Sets of triples were gathered from families of 56 Hispanic patients 
with schizophrenia. Similar sets of triples were gathered from Hsipanic families 
with no history of mental illness. Standardized laboratory methods were used 
to search for known genes of risk.
Results: No significance was found for the presence of Presenilin-1 or 2, 
Neuregulin-2 or D-4 loci in our study. Hispanic families of schizophrenics were 
more likely to carry positive COMT and Neuregulin-1 loci than controls.
Conclusions: We feel that it is possible that a grouping of genes related to the
expression of COMT and Neuregulin-1 is important in the expression of 
psychosis in Hispanic individuals.
860. Effect of Dopamine Transporter VNTR 
Polymorphism on Prepulse Inhibition in 
Schizophrenia
Ikwunga Wonodi1, L. Elliot Hong1, O. Colin Stine2, Jada 
Lewis1, Ping-I Lin1, Gunvant K. Thaker1
1Maryland Psychiatric Research Center, University of Maryland School 
of Medicine, Baltimore, MD,2General Clinical Research Center (GCRC) 
Genomics Core Facility, University of Maryland School of Medicine, 
Baltimore, MD
Background: Prepulse inhibition (PPI) is a schizophrenia endophenotype 
commonly used in animal models of psychosis. Extensive pharmacological 
profiling suggests a complex role of dopamine in modulating PPI. The 
dopamine transporter gene (DAT1) VNTR polymorphism affects extracellular 
dopamine availability and associated neurocognitive functions. Since PPI has 
high cross-species homology, and DAT1 knockout mice display PPI deficits, 
we hypothesized that DAT1 variation might affect PPI in humans.
Methods: We examined the effect of DAT1 10/10 genotype, which results 
in increased synaptic dopamine, on PPI. Genotyping was performed in 457 
individuals, including 240 schizophrenia patients and 217 healthy controls. 
PPI was tested in a subgroup of 275 subjects of which 93 cases and 71 controls 
were responders to startling stimulus.
Results: DAT1 10/10 genotype was not associated with schizophrenia (all 
p=0.40). Schizophrenia subjects had significantly reduced PPI compared to 
controls (p=0.046). There was no DAT1 genotype by diagnosis interaction on 
PPI (p=0.30). Analyses by ethnicity demonstrated a trend DAT1 by diagnosis 
interaction on PPI in Caucasian subjects (p=0.08), but not in African-American 
(AA) subjects (p=0.33). Separate analyses in cases and controls showed 
significant effect of DAT1 genotype on PPI in Caucasian controls (p=0.02), 
but not patients (p=0.80). In AA subjects, there was no effect in controls (p= 
0.65) or cases (p=0.29).
Conclusions: Data supports a dopaminergic effect on PPI in controls, but 
not in schizophrenia patients. This DAT1 variant may interact with race and 
perhaps medication status and other etiological factors in a complex way to 
affect the PPI endophenotype in schizophrenia.
Supported by NIMH 1K12RR023250-01, 5R03 MH075101-02, NARSAD, 
R01 MH49826-09
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861. The Gamma-Aminobutyric Acid Type A 
Receptor Gamma2 Subunit Gene is Associated 
with Schizophrenia
Clement C. Zai, Arun Tiwari, Vincenzo De Luca, Greg 
W. H. Wong, James L. Kennedy
Neurogenetics, Centre for Addiciton and Mental Health, Toronto, ON, 
Canada
Background: gamma-aminobutyric acid (GABA) is produced in areas of the 
brain implicated in schizophrenia, and several genes coding for GABAA subunits, 
including GABRG2 encoding the ?2 subunit, are clustered at 5q31-q35, a 
chromosomal region associated with schizophrenia in genome scan studies.
Methods: We tested five polymorphisms spanning GABRG2 for association with 
schizophrenia and also suicidal behaviour. The sample consisted of 109 small 
nuclear families and 229 schizophrenia cases paired with 229 healthy controls.
Results: rs183294 in the 5’ region of GABRG2 was found associated with 
schizophrenia in both samples with C over-represented in schizophrenia cases 
and over-transmitted in schizophrenia families (combined p=310-3).
Conclusions: Taken together, the results of the present study suggest GABRG2 
may be involved in schizophrenia susceptibility, but further studies are required. 
We are currently genotyping additional polymorphisms spanning GABRG2.
Supported by MOP79525
862. Reduced Phase Locking to Auditory 
Stimulation in Schizophrenia; Influence of Reduced 
NMDA Receptor Signaling
Stephan Bickel, Peter Lakatos, Elisa Dias, Charles E. 
Schroeder, Daniel C. Javitt
Cognitive Neuroscience and Schizophrenia Program, Nathan Kline 
Institute of Psychiatric Research, Orangeburg, NY
Background: Patients with schizophrenia show alterations in early auditory 
information processing. For example, they show reduced amplitudes of the 
auditory evoked potentials P1 and N1 in the EEG. Patients also show alterations 
in electrophysiological measures of neural synchrony. We investigated if 
patients show changes in phase resetting of ongoing oscillatory activity by tones 
presented with different inter-stimulus intervals. Furthermore, we investigated 
the involvement of the NMDA receptor in this mechanism by means of intra-
cortical recordings in the monkey.
Methods: The EEG of patients (N=33) and controls (N=18) was recorded 
while tones were delivered with different inter-stimulus intervals to investigate 
possible entrainment. We used the same paradigm to analyze the laminar 
response in the auditory cortex of the awake macaque monkey, prior and 
following systemic administration of the NMDA receptor antagonist 
phencyclidine (PCP).
Results: The controls showed significant inter-trial phase locking (IPL) between 
2 to 14Hz in the P1-N1 window. IPL was significantly reduced in the patients. 
Similar alterations were observed in the monkey recordings following PCP 
administration. Furthermore, PCP induced remarkable increases of baseline 
activity in the gamma frequency range (>30Hz) in supra-granular layers.
Conclusions: In addition to well-documented deficits in early auditory evoked 
potentials, patients with schizophrenia also show deficits in phase resetting of 
ongoing oscillatory activity. Though, it is still unclear how these alterations are 
related. We suggest that reduced signaling through the NMDA receptor could 
underlie both deficits.
Supported by MH49334 and MH55620 to DCJ, Swiss National Science 
Foundation
863. The Difference of Superior Temporal Gyrus 
Volume between Drug Naïve Schizophrenia and 
Healthy Volunteers
Wei-Tseng Chen1, Po See Chen1, Kao-Ching Chen1,
Yen Kuang Yang1, Ru Band Lu1,2
1Psychiatry, National Cheng Kung University Hospital, Tainan, 
Taiwan,2Institute of Behavioral Medicine, Hospital and College of 
Medicine, National Cheng Kung University, Tainan, Taiwan
Background: The most consistent brain image studies of structural changes 
in schizophrenia were volume decreasing of superior temporal gyrus. However, 
it was hard to exclude the drug effects in those studies. The current study was 
designed to compare the volume of superior temporal gyrus between the drug 
naïve schizophrenia patients and healthy volunteers. Results may help to clarify 
the factors attributing to the volume change of superior temporal gyrus.
Methods: Magnetic resonance scans was obtained from drug-naïve subjects 
with schizophrenia (n = 12) or control subjects (n = 12). Magnetic resonance 
images provided quantitative measures of temporal lobe regions of interest. The 
volume of right and left superior temporal gyrus was measured respectively. 
Statistics analysis was performed by using the SPSS software.
Results: There were no significant differences in either total superior temporal 
volume or each hemisphere between schizophrenic group and control group 
after control the variance of sex and age.
Conclusions: Our study showed inconsistent results with previous studies. 
Results from the drug-naïve patients suggested that the volume changes of 
superior temporal gyrus may not be the consequence of the disease only. The 
current study was limited by the small sample sizes. Moreover, further study 
need take the illness duration into consideration.
864. Alternative Strategies for Testing Epistasis in 
Pharmacogenetic Studies: Analysis of Serotonin 
System and Antipsychotic Response
Vincenzo De Luca1, R. de Souza1, Jan Volavka2, J. 
Lieberman3, Herbert Meltzer4, James L. Kennedy1
1Psychiatry, University of Toronto, Toronto, ON, Canada,2Psychiatry, 
Nathan Kline Institute, Orangeburg, NY,3Psychiatry, Columbia University, 
New York, NY,4Psychiatry, Vanderbilt University, Nashville, TN
Background: Serotonin receptors blockade is the major basis for the 
antipsychotic action of atypical antipsychotic drugs. Genetic factors affecting 
the density and/or function of serotonergic receptors, transporters and enzymes 
may therefore affect antipsychotic response. This exploratory study investigates 
the effect of ten polymorphisms from HTR1A, HTR1D, HTR2A, HTR3A, 
HTR3B, HTR4, HTR6, SLC6A4, TPH1, TPH2 genes on antipsychotic 
response in a sample of 289 patients with DSM-diagnosis of schizophrenia.
Methods: Clinical Response was assessed using Brief Psychiatric Rating 
Scale (BPRS). Response was determined as 20% reduction improvement of 
BPRS compared to baseline. Selection of the biological relevant interactions, 
regardless the phenotype was performed using different statistics strategies 
regardless the phenotype to investigate epistasis within the serotonin system.
Results: The test for relevant interaction selection showed that 5HT4 and 
5HT6 can be in epistatic relationship. The single locus analysis of these 
two receptor polymorphisms showed no significant results and the logistic 
regression model incorporating both genes, the clinical and demographic 
variables was not significant.
Conclusions: Even though this result is not significant, this strategy aimed to 
investigate the epistatic effect among genes could be useful for finding relevant 
biological interaction among genetic variants.
www.sobp.org/journal
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865. Unbiased Stereologic Quantification of Layer 
3 of the Primary Auditory Cortex in Subjects with 
Schizophrenia: Pyramidal Cell Number and Mean 
Volume Determination
Kristen M. Delevich1, Michael J. Marcsisin1, Karl-Anton 
Dorph-Petersen2, Hans Jorgen G. Gundersen3, Allan R. 
Sampson4, David A. Lewis1, Robert A. Sweet1
1Department of Psychiatry, University of Pittsburgh, Pittsburgh, 
PA,2Centre for Psychiatric Research, Aarhus University Hospital, 
Risskov, Denmark,3Stereological and Electron Microsopic Research 
Laboratory, Institute of Experimental Clinical Research, University of 
Aarhus, Denmark,4Department of Statistics, University of Pittsburgh, 
Pittsburgh, PA
Background: Subjects with schizophrenia demonstrate functional deficits 
in early auditory sensory processing localized to the primary auditory cortex. 
Studies have reported gray matter reductions mapped to the auditory cortex 
of the STG in schizophrenics. Our group previously reported significant 
reductions (10.4%) in mean somal volume of pyramidal cells in deep layer 3 of 
primary auditory cortex of subjects with schizophrenia, which may contribute 
regional gray matter volume reductions and to auditory processing deficits.
Methods: The current study utilized a novel stereologic method that provides 
unbiased estimation of cell volume and number within individual cortical 
layers and sublayers to assess the primary auditory cortex of 12 subjects with 
schizophrenia or schizoaffective disorder, each matched to a comparison 
subject for age, gender, and post-mortem interval.
Results: Data collection has been completed for all 24 subjects, yielding somal 
volume estimation for 11,882 layer 3 pyramidal cells. Diagnostic groups will be 
compared for mean pyramidal cell somal volumes and pyramidal cell numbers 
in deep layer 3 and contrasted with findings from superficial layer 3.
Conclusions: Whether reduced mean pyramidal cell somal volume in patients 
with schizophrenia results from a generalized decrease in pyramidal cell somal 
volume or an alteration in the number or distribution of cells by size is unknown. 
Interpretation of results within the context of prior findings of reductions 
in pyramidal cell somal volume, axon terminal density, and dendritic spine 
density in this region will help determine the source of mean pyramidal cell 
somal volume reductions and explain regional gray matter reductions.
Supported by USPHS grants MH 045156 and MH 071533 and by the VISN 
4 Mental Illness Research, Education and Clinical Center (MIRECC), VA 
Pittsburgh Healthcare System
866. Patients with Early-and Late-Onset 
Schizophrenia Show Grey Matter Volume 
Reductions of Different Brain Regions
Kazuteru Egashira1, Koji Matsuo1, Toshinari Mihara2,
Shuichi Yamauchi3, Naofumi Matsunaga3, Yoshifumi 
Watanabe1
1Psychiatry, Yamaguchi University, Ube, Japan,2Psychiatry, Wakamatsu 
Hospital, Okinawa, Japan,3Radiology, Yamaguchi University, Ube, Japan
Background: Manfred Bleular (1943) described late-onset schizophrenia 
(LOS) where illness onset is after age 40y. The different clinical characteristics 
between early-onset schizophrenia (EOS) and LOS are well documented. 
However, there are few neuroimaging studies concerning the affected brain 
mechanism between the two types of patients. We hypothesized that LOS and 
EOS patients would show volume reductions of different brain regions.
Methods: Twenty-five LOS and 30 EOS patients and 40 age- and sex- matched 
healthy subjects were studied. The mean±sd PANSS and SANS scores were 
19.6±2.9 and 7.2±7.8 for LOS patients and 20.7±3.5 and 14.5±16.9 for EOS patients, 
respectively. Images were processed using a voxel based morphometry protocol. We 
compared the grey (GM) and white matter volumes among the three groups.
Results: The LOS patients showed smaller posterior cingulate GM volumes, 
and the EOS patients showed smaller superior lateral frontal gyrus, thalamus 
and parahippocampus GM volumes compared to the healthy subjects.
Conclusions: The results suggest that LOS and EOS may have a different 
brain pathophysiology.
867. Progressive Decrease of Right Prefrontal 
Cortex Gray Matter Volume in First-Episode 
Schizophrenia: A Longitudinal Magnetic Resonance 
Imaging Study
Toshiro Kawashima1,2, Margaret Niznikiewicz1, Motoaki 
Nakamura1,2, Charlie Davidson2, Dean F. Salisbury1,3,
Martha E. Shenton1,2, Robert W. McCarley1
1Clinical Neuroscience Division, Laboratory of Neuroscience, 
Department of Psychiatry, Boston Veterans Affairs Healthcare System, 
Brockton Division, Harvard Medical School, Brockton, MA,2Psychiatry 
Neuroimaging Laboratory, Department of Psychiatry, Brigham and 
Women’s Hospital, Harvard Medical School, Boston, MA,3Cognitive 
Neuroscience Laboratory, Department of Psychiatry, McLean Hospital, 
Harvard Medical School, Belmont, MA
Background: The frontal lobes, and more specifically the prefrontal regions, 
have long been suspected to play an important role in the pathogenesis of 
schizophrenia. However, the findings of progressive prefrontal MRI grey 
matter volume reduction in first-episode schizophrenia have been inconsistent, 
possibly due to lack of gyral parcellation and a consequent inability to specify 
particular subcomponent regions that changed or did not change.
Methods: 1.5T MRIs were acquired from 17 first-episode (=first hospitalization) 
patients with schizophrenia (FESZ), 17 first-episode affective psychosis patients 
(FEAFF; bipolar disorder N=14, major depressive disorder N=3), and 17 healthy 
control subjects (HC) matched for age, gender, handedness, education, and 
socioeconomic status. Scans were repeated 1.5y later. Volumetric measurements 
of the grey matter in prefrontal regions were performed using 1.5mm thick 
coronal series of contiguous SPGR images. Anatomical criteria reliably (Intraclass 
correlation coefficients >0.94) guided parcellation of the prefrontal regions into 
four subcomponents (frontal pole, superior, middle, and inferior frontal gyrus).
Results: FESZ showed significant decreases in grey matter volume over time in 
the right frontal pole (p < 0.030) (5.70%) and, at trend level (p < 0.057), in the 
right superior frontal gyrus (3.39%). In contrast, no time-related changes were 
observed in FEAFF and HC. At initial scan, no significant group differences in 
grey matter volume in the four prefrontal subcomponents were found.
Conclusions: These findings suggest a right-biased progressive volume 
reduction in the frontal pole and superior frontal gyrus grey matter in FESZ in 
contrast to FEAFF and HC.
Supported by R01MH40799
868. Neurodevelopment in Adolescence and Young 
Adulthood (NAYA): Emotion Processing Impairment 
in Youths At-Risk for Psychosis
Christian G. Kohler, Monica E. Calkins, Karin E. 
Borgmann-Winter, Jan Richard, Noah Sasson, Colleen 
Brensinger, Ruben C. Gur, Raquel E. Gur
Neuropsychiatry, Univ. of PA, PHL, PA
Background: Neurodevelopmental abnormalities affecting behavior are 
present in children at-risk of developing psychosis long before the onset of 
illness. Cognitive abilities, including neurocognition and social cognition, 
www.sobp.org/journal
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are extensively implicated in schizophrenia and may represent â€¨candidate 
endophenotypes. Impaired endophenotype performance in adolescents deemed 
at-risk for schizophrenia is a characteristic reflecting the endophenotypeâ€™s 
ability to serve as a marker for early identification and treatment. The primary 
purpose of the NAYA program is to combine endophenotype and prodromal 
risk strategies to further facilitate early identification of individuals at-risk for 
psychosis.
Methods: Youths (ages 14-25) completed a comprehensive diagnostic 
assessment and the University of Pennsylvania Computerized Neurocognitive 
Battery, which includes tests of emotion identification (ER40) and emotion 
differentiation (EmoDiff), and other studies. Groups included individuals 
deemed at-risk for psychosis [Genetic risk (GR): family history of schizophrenia, 
n=40; Clinical Risk (CR): prodromal symptoms but no family history, n=5]; 
schizophrenia (SZP): n=82; and healthy controls (CNT), n=89.
Results: On ER40, youths with SZP and those at-risk compared to CNT 
showed impairments in overall (SZP:p<001, at risk:p<.010), happy (SZP:p=020), 
sad (SZP:p=021), anger (SZP:p=005, at risk:p=.008) and fear (SZP:p=016, at 
risk:p=.05) identification. On EmoDiff, youths with SZP compared to CNT 
showed impairments in happy (p<.001)and sad (p=.037) differentiation, while 
performance of at-risk youth was intermediate.
Conclusions: Tests of emotion processing revealed that at-risk youth 
showed decreased performance similar to young persons with schizophrenia. 
Processing of facial affect may represent an endophenotypic marker and 
reflect pathophysiological abnormalities involved in the development of 
schizophrenia.
Supported by MH-50787
869. “What” Versus “Where” in Patients with 
Schizophrenia: An Electrophysiological 
Investigation of Explicit Tasks of Dorsal and Ventral 
Pathway Auditory Processing
Victoria M. Leavitt1,2, Sophie Molholm2, John Foxe1,2,3
1Neuropsychology, CUNY-Queens College, Flushing, NY,2Cognitive 
Neurophysiology Laboratory, Nathan Kline Institute, Orangeburg, 
NY,3Psychiatry, St. Vincent’s Psychiatric Hospital, Dublin, Ireland
Background: There is now an abundance of evidence for functionally and 
anatomically distinct auditory pathways governing sound localization and 
sound object recognition- the dorsal and ventral pathways. A recent study 
from our group implicated the existence of distinct dorsal and ventral auditory 
processing networks underlying the “what” and “where” functions in healthy 
controls. We conducted the present investigation to determine whether they 
can likewise be identified in patients with schizophrenia.
Methods: 168-channel electrophysiological recordings were collected from 
12 controls and 6 patients as they completed tasks that distinguished dorsal 
(where) from ventral (what) auditory path functions. The ‘where’ task was 
to identify the location (1 of 7 speakers arranged on a 180-degree arc) from 
which an animal call was delivered. The ‘what’ task was to identify a target 
animal from seven randomly delivered animal calls. Participants were required 
to make a response immediately after each stimulus. Group averaged event-
related potentials (ERPs) were analyzed for each condition.
Results: In controls, the data suggest that there are distinct dorsal and ventral 
auditory processing networks underlying “what” and “where” functions. When 
ERPs across speakers were collapsed and averaged, substantial differences 
between conditions are seen as early as the onset of the N1. Patients show 
statistically significant, though less striking, differences emerging at the N1. 
Conclusions: Functional integrity of the dorsal and ventral auditory pathways 
in patients with schizophrenia may be compromised.
Supported by NRSA
870. Glucose Uptake and Anisotropy in the Anterior 
Cingulate in Schizophrenics and Normal Controls
Douglas S. Lehrer1, Meicheng Chiang1, Cemil Kirbas2,
Bin Wang2, Holly Short3, Mehdi Adineh2, Monte S. 
Buchsbaum4
1Psychiatry, Wright State University Boonshoft School of Medicine, 
Dayton, OH,2Imaging Lab, Wallace-Kettering Neuroscience Institute, 
Kettering, OH,3Neuroscience, Cell Biology, & Physiology, Wright State 
University Boonshoft School of Medicine, Dayton, OH,4Psychiatry, Mt. 
Sinai School of Medicine, New York, NY
Background: Anterior cingulate abnormalities are implicated in schizophrenia. 
We report 18F-fluorodeoxyglucose (FDG) distribution and anisotropy in gray/
white matter in anterior cingulate Brodmann areas (BA) 23, 24, and 25.
Methods: We acquired FDG PET images in 27 psychotic individuals (24 
schizophrenic, 3 schizoaffective; 24 never-medicated, 3 previously treated and 
not exposed to medications for at least 30 days) and in 17 matched controls. 
MRI diffusion tensor images (DTI) were also acquired in 24 of 27 ill subjects, 
and in 15 of 17 controls. Images were coregistered to MRI; gray/white matter 
pixels in BA 23, 24, 25 were identified using FSL segmentation and the Perry 
Atlas. We conducted ANOVA using diagnosis by hemisphere by BA by tissue 
(gray-white).
Results: Metabolism: There was a significant hemisphere-by-BA-by-tissue-by-
diagnosis interaction (Huynh-Feldt adjusted p = 0.039), particularly resulting 
from lower glucose uptake by schizophrenics in BA 24. Anisotropy: Contrary 
to expectations, schizophrenic subjects showed higher anisotropy in the 
anterior cingulate (p = 0.019). We observed a significant negative correlation 
between FDG and anisotropy in BA 23 & 24 gray and white matter in the left 
hemisphere in normal subjects. This was observed in the left hemisphere of ill 
subjects, but only reached significance in gray matter.
Conclusions: We replicated previous reports of anterior cingulate 
hypometabolism within a cohort of predominantly treatment naïve subjects. 
The finding of increased anisotropy along with negative anisotropy-metabolism 
correlations may indicate failure in proper fanning of white matter cingulum 
fibers, a state that may be associated with reduced metabolism. 
871. The Continuum of Psychotic Symptoms in a 
Population Based Study in Brazil
Alexandre A. Loch, Laura H. Andrade, Luis F. F. Tofoli, 
Bruno M. Coelho, Yuan-Pang Wang
Epidemiology Department, Psychiatry Institute - University of Sao 
Paulo, São Paulo, Brazil
Background: Psychotic symptoms are frequent in community samples. 
The perspective of considering psychotic symptoms as a continuum favors 
a framework towards etiologic search of complex mechanism underlying 
psychosis. This study aims to investigate the continuum of psychotic 
phenomena in a community sample in Brazil.
Methods: Data are from the Sao Paulo Catchment Area Study, a cross-sectional 
household survey with 1,464 subjects. Psychopathology was assessed through 
CIDI-1.1 interview. Seventeen psychotic-like symptoms were evaluated and 
classified as clinically relevant (CR), non-clinically relevant (NCR), secondary 
symptoms (SS) and symptoms with plausible explanation (PS).
Results: Although 1.9% of the total sample had an ICD-10 lifetime non-
affective psychosis, the presence of any lifetime psychotic symptom was 
observed in 38.1%, with 7.3% classified as CR. The prevalence of psychotic 
symptoms increased to 50.9% in the subsample with any lifetime psychiatric 
diagnosis other than non-affective psychosis, being 14.1% CR. Those without 
any lifetime diagnosis, 31.7% presented at least one psychotic symptom, being 
3.9% CR. Individuals with any psychiatric diagnosis were nine times more 
www.sobp.org/journal
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likely to present CR delusion (OR: 9.3; 95% CI: 4.9-17.5), and around 4 time 
to report CR hallucination (OR: 3.8; 95% CI: 2.3-6.4), compared to those 
without any lifetime psychiatric diagnosis.
Conclusions: This data clearly points us that psychotic symptoms are widely 
present in the general population and also spread among all other psychiatric 
diagnoses other than psychotic diagnosis. The existence of a symptomatic 
continuum between subjects from the general population and subjects with 
clinical psychosis support the dimensional model of psychosis.
872. Cognitive Functioning in Childhood and Early 
Onset Psychotic and Depressive Symptoms in the 
1970 British Birth Cohort
Valentin Matei1, Abraham Reichenberg2, Anthony S. David2
1Psychiatry, Lotus Medica, Bucharest, Romania,2Psychological 
Medicine, Institute of Psychiatry, King’s College London, London, 
United Kingdom
Background: It is well established that as a group, individuals destined to 
develop schizophrenia have persistent cognitive impairments which are already 
evident in childhood. Because there is a paucity of information about the 
relationship between childhood cognitive functioning and later psychotic 
and depressive symptoms, we examined the relationship between early 
childhood cognitive functioning and late adolescence psychotic and depressive 
symptomatology.
Methods: A prospective cohort study (based on the 1970 British Cohort 
Study) which includes data about childhood (age 5) cognitive functioning and 
about presence of psychotic and depressive symptoms at age 16. 5,832 cohort 
members were included in the analysis. 23 cohort members reported psychotic 
symptoms that were confirmed by informants and independent sources, and 
136 had confirmed depressive symptoms.
Results: Male adolescents with psychotic or depressive symptoms had lower 
age 5 IQ, and visual-constructional abilities compared to controls (all p values 
<0.05). Females did not show significant cognitive impairments at age 5.
Conclusions: Developmental abnormalities are common across depressive and 
psychotic symptoms. The gender specificity suggests differences in etiological 
processes between males and females.
Supported by Maudsley Forum Fellowship to Dr. Matei
873. Longer Duration of Illness Predicts Lower 
Grey Matter Availability in the Left Dorsomedial 
Prefrontal Cortex in Schizophrenia
Preethi Premkumar1, Dominic Fannon2, Elizabeth 
Kuipers1, Michael A. Cooke1, Andrew Simmons3,4,
Veena Kumari1
1Psychology, Institute of Psychiatry, King’s College London, London, 
United Kingdom,2Psychological Medicine, Institute of Psychiatry, King’s 
College London, London, United Kingdom,3Centre for Neuroimaging 
Sciences, Institute of Psychiatry, King’s College London, London, United 
Kingdom,4South London and Maudsley Foundation NHS Trust, NIHR 
Biomedical Research Centre for Mental Health, London, United Kingdom
Background: The prefrontal cortex has an extended maturation period and may 
have a larger window of vulnerability to the long-term effects of schizophrenia. 
We tested this hypothesis by studying the relation between duration of illness 
and grey matter availability across the whole brain.
Methods: Sixty-four patients with schizophrenia and 33 healthy controls 
underwent structural MRI scanning. Participants also took part in a 
comprehensive neuropsychological and clinical assessment. Regression analyses 
were used to examine the relationship between duration of illness and grey 
matter availability across the whole brain. Correlational analyses examined the 
associations between duration of illness and neuropsychological performance 
and clinical symptoms.
Results: Longer duration of illness most strongly predicted lower grey matter 
availability in the left dorsomedial prefrontal cortex. Longer duration of 
illness also predicted lower grey matter availability in the right middle frontal 
gyrus, left fusiform gyrus and left cerebellum and was associated with poorer 
performance on both motor dexterity and sustained attention but not with 
symptoms.
Conclusions: Grey matter availability in the prefrontal cortex and cerebellum 
is associated with, and may be vulnerable to the persistence of schizophrenia 
illness.
Supported by Wellcome Trust, UK (067427/z/02/z)
874. Cortical White Matter Diffusion Tensor 
Anisotropy in Schizophrenia
Jason S. Schneiderman1, Joseph Friedman1,
Chelain R. Goodman1, Randall E. Newmark1, Yuliua 
Torosjan1, Emily L. Camfield1, Jonathan Enits1, Karen 
Estefane1, Vivian Mitropoulou1, Cheuk Tang2, Arash 
Hajianpour2, Kenneth L. Davis1, Jack Gorman1, Monte 
S. Buchsbaum1
1Psychiatry, Mt Sinai School of Medicine, New York, NY,2Radiology, Mt 
Sinai School of Medicine, New York, NY
Background: In Diffusion Tensor Imaging (DTI) healthy organized 
myelinated axon bundles have high anisotropy. Bundles where the fibers are 
crossing, oriented in different directions, or in which the myelin or axons are 
unhealthy have low anisotropy. This study investigates the changes in white 
matter anisotropy by Brodmann Area in schizophrenia.
Methods: 90 adults with schizophrenia and 103 normal adults were scanned 
on a 3T MRI system. Each subject received a structural (MP-RAGE) sequence 
and a diffusion tensor sequence. Average Fractional Anisotropy (FA) values 
determined for white matter in each Brodmann Area in each hemisphere and 
T-tests were performed between groups.
Results: Regions with low anisotropy in patients included Brodmann Areas 
21, 22, 28 and 88 in the right temporal, and 21, 22, 27, 28, 41 and 42 in the 
left temporal. Regions with high anisotropy in patients included 4 in the right 
parietal, 32 in the right frontal, 37 in the right and left temporal, and 19 in the 
left occipital.
Conclusions: In schizophrenia deficits in language, memory, auditory 
hallucinations, social behavior, decision making, emotional processing and 
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875. Premorbid Adjustment in First-Episode 
Schizophrenia Patients with and without Cannabis 
use Disorders
Serge Sevy1, Delbert G. Robinson1, Margaret G. 
Woerner1, Barbara Napolitano1, Raman C. Patel2,
Handan Gunduz-Bruce3, Jose M. Soto-Perello2, Alan 
Mendelowitz1, Ali Khadivi2, Rachel Miller1, Joanne 
McCormack1, Beth S. Lorell2, Martin L. Lesser4, Nina R. 
Schooler5, John M. Kane1
1Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, 
NY,2Psychiatry, Bronx-Lebanon Hospital Center, Bronx, NY,3Psychiatry, 
Yale University School of Medicine, New Haven, CT,4Biostatistics, 
Feinstein Institute for Medical Research, Manhasset, NY,5Psychiatry, 
Georgetown University School of Medicine, Washington, DC
Background: Cannabis use disorders are common in first-episode schizophrenia 
patients and may be related to premorbid social, sexual, and scholastic 
adjustment factors. The purpose of this study is to assess these premorbid 
adjustment factors in first-episode patients with cannabis use disorders. 
Based on previous findings in multi-episode patients with schizophrenia 
and substance abuse, we hypothesized better premorbid social and sexual 
adjustments, but worse scholastic adjustment in first-episode patients with a 
lifetime history of cannabis use disorders compared to patients with no history 
of substance use disorders.
Methods: Forty-nine patients with first-episode schizophrenia and DSM-
IV criteria for cannabis abuse or dependence were compared to 51 patients 
with first-episode schizophrenia and no substance use disorders for scores on 
the items of the Premorbid Adjustment Scale (Cannon-Spoor et al, 1982). 
Statistical significance was defined as p<0.05.
Results: Compared to patients without substance use disorders, patients with 
cannabis use disorders had better premorbid social adjustment in childhood and 
early adolescence, and better premorbid sexual adjustment in adolescence. In 
contrast, they had worse scholastic performance in early and late adolescence.
Conclusions: Compared to first-episode patients without substance use, first-
episode patients with a lifetime history of cannabis use disorders had better 
premorbid social/sexual adjustments before the onset of cannabis use and 
psychotic symptoms. They had worse scholastic performance in adolescence, 
which may have been related to the onset of substance use during the same 
period. Multivariate analyses assessing the relationship between premorbid 
adjustment and cannabis use disorders will be explored.
Supported by NIMH60004; NIDA015541; NIMH41960; NCRR018535
876. Glutamate in the Medial Prefrontal Cortex of 
Chronic, Medicated Patients with Schizophrenia 
and Healthy Comparison Subjects Assessed with 
Proton MR Spectroscopy at 3 Tesla
Alexa J. Stern1, Yan Zhang2, Giacomo Salvadore2,
Antonina S. Savostyanova1, Jose A. Apud1, Jun Shen2,
Daniel R. Weinberger1, Stefano Marenco1
1Clinical Brain DisordersBranch, GCAP, National Institute of Mental 
Health, Bethesda, MD,2Mood and Anxiety Disorders Program, National 
Institute of Mental Health, Bethesda, MD
Background: Emerging evidence suggests that glutamatergic dysfunction 
is implicated in the pathogenesis of schizophrenia. However, findings from 
magnetic resonance spectroscopic (1H-MRS) studies are inconsistent and the 
majority of reports lack adequate spectral resolution to separate the glutamate 
(Glu) C4 proton signal from the overlapping glutamine, N-acetyl aspartate, 
glutathione and macromolecule signals. The present study was designed to 
measure Glu in the cortical gray matter and white matter of patients with 
schizophrenia and healthy adults. We hypothesized that, relative to healthy 
volunteers, patients would exhibit altered glutamate levels.
Methods: Single-voxel TE-averaged 1H-MRS was performed on 15 medicated 
patients with schizophrenia and 27 age- and gender-matched healthy control 
subjects on a 3 Telsa General Electric scanner. Glu spectra were obtained in the 
medial prefrontal cortex (mPFC) and the right frontal (fWM) and/or parietal 
white matter (pWM) regions. Cre values were assessed independently with a 
separate PRESS sequence (TE=35 ms) in a subset of subjects.
Results: Glu/Cre was significantly reduced in the mPFC of patients with 
schizophrenia compared to healthy controls when including age as a covariate 
(ANCOVA, p=0.027). This difference was only marginally significant when 
both age and Cre were used as covariates in the model (p=0.075). No differences 
in Glu/Cre were observed in the fWM or pWM regions.
Conclusions: These preliminary findings are consistent with some literature 
reporting decreases in Glu in the cortical gray matter of chronic, medicated patients 
with schizophrenia, although larger sample sizes and possibly absolute quantification 
of metabolites will be necessary to interpret these data with confidence.
Supported by NIMH-IRP
877. Cortical Gray Matter Mapping during the 
Psychosis Prodrome
Daqiang Sun1, Theo van Erp1, Melita Daley2, Carrie 
Bearden1,2, Arsen Mkrtchyan1, Molly Hardt1, Alexandria 
Marino1, Arthur Toga3, Paul Thompson3, Tyrone 
Cannon1,2
1Department of Psychology, UCLA, Los Angeles, CA,2Department 
of Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, 
CA,3Laboratory of Neuro Imaging and Department of Neurology, UCLA, 
Los Angeles, CA
Background: Deficits in brain structure volumes may predate the onset of 
schizophrenia and other psychotic disorders. Structural MRI studies have 
shown that patients who later converted to psychosis had smaller gray matter 
volumes during the prodromal phase of illness compared with those who did 
not develop psychosis, but a detailed mapping of cortical gray matter in these 
pre-onset individuals is still lacking.
Methods: High-resolution 3D brain MRI scans were acquired from 34 
participants who were at ultra-high risk for psychosis, of whom 7 (5 males 
and 2 females, aged 18.5±4.7 years) later converted to psychosis, while the 
other 27 (19 males and 8 females, aged 17.2±3.0) did not, after 12 months of 
follow-up. We compared gray matter density (GMD) across the cerebral cortex, 
at baseline, in converters versus non-converters. A cortical pattern matching 
method was applied to the brain images, aligning brain surfaces based on 
manually traced major sulcal landmarks. Group averaged maps of cortical gray 
matter distribution were visualized on 3D cortical surface models.
Results: Compared to non-converters, converters showed significantly reduced 
gray matter in widespread cortical areas, including bilateral dorsal frontal and 
superior temporal regions. A weighted multi-voxel summation of GMD for the 
voxels that showed significant group differences was able to differentiate the 
majority of the converters from the non-converters.
Conclusions: Cortical gray matter deficits in brain regions critical for integrated 
cognitive activity therefore predates the onset of psychosis, suggesting that 
detailed cortical gray matter mapping may be useful in predicting the future 
onset of psychosis.
Supported by NIH: MH65079, MH066286, GM072978 and RR021992 to 
T.D.C; NIMH K23MH074644-01; NARSAD; gift to the UCLA Foundation 
by Garen and Shari Staglin
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878. Psychotic Hyperactivity of the Prefrontal 
Cortex with Deficits in GABAergic Inhibition
Shoji Tanaka
Dept of Information and Communication Sciences, Sophia University, 
Tokyo, Japan
Background: Psychotic states are associated with hyperactivity of the prefrontal 
cortex (PFC) with hyperdopaminergic neurotransmission. GABAergic 
inhibition in the PFC has been reported to be reduced in schizophrenia.
Methods: A circuit model of the PFC is constructed, which describes 
dopaminergic modulation of neuronal activity in addition to glutamate 
and GABA neurotransmission. The GABAergic inhibition in the PFC has 
two different types in this model, which are chandelier cell-type inhibition 
with high activation threshold and general inhibition by other GABAergic 
interneurons.
Results: The PFC circuit has a bistable hyperactive mode (termed the ‘H mode’). 
This hyperactivity is characterized by hyperdopaminergic neurotransmission. 
Transition to the H mode from a normal state occurs when GABAergic 
inhibition is reduced. The results of the computer simulation with the above 
model show that the roles of the two different types of GABAergic inhibition on 
PFC circuit dynamics are markedly different: The inhibition by the GABAergic 
interneurons other than chandelier cells effectively regulates the PFC activity 
with rather low or modest levels of dopaminergic transmission, which has 
an inverted-U shaped profile of dopaminergic modulation and is associated 
with normal cognitive functions. In contrast, chandelier cell-type inhibition 
regulates only the PFC activity with hyperdopaminergic neurotransmission.
Conclusions: Deficits in effective inhibition by chandelier cells in the 
PFC would produce the H mode, a “psychotic” hyperactive state with 
hyperdopaminergic neurotransmission. Weakening of other GABAergic 
interneurons would make the transition to the H mode more readily occur, 
thereby increasing the vulnerability to psychosis.
Supported by Sophia University Open Research Center
879. Gamma Band Abnormalities in Schizophrenia 
and Bipolar Disorder during an Auditory Oddball Task
Grantley Taylor1, Dean Salisbury2, Robert McCarley3
1Psychiatry, McLean Hospital; Harvard Med. School, Belmont, 
MA,2Cognitive Neuroscience Laboratory, McLean Hospital; Harvard 
Med. School, Belmont, MA,3Psychiatry, VA Boston Healthcare System, 
Brockton, MA
Background: EEG synchronization in the gamma frequency range may 
index local and distributed neural network activity and associated cognitive 
activity. Cognitive dysfunction in schizophrenia likely reflects impairments 
in the dynamic formation of neural ensembles. Abnormalities of gamma 
synchronization have been noted in several experiments. The auditory oddball 
task allows probing of sensory processing, selective attention, and working 
memory, all of which have been implicated in schizophrenia. Abnormalities in 
P300 ERPs have been described in both schizophrenia and bipolar disorder.
Methods: Twenty seven control subjects, twenty two patients with first episode 
bipolar disorder, and eighteen first episode schizophrenia patients matched for 
age, sex, parental SES, and WAIS-R information score performed an auditory 
oddball task (1 kHz, 85%, 1.2 kHz 15%, 50 msec, 75 dB). Wavelet analysis of 
61 channel EEG allowed measurement of intertrial phase locking and evoked 
power in the gamma range (45-53Hz).
Results: Controls showed a greater PLV (phase locking value) in the 50-80 
msec gamma band response (GBR) to standard tones compared to both patient 
groups. By contrast both controls and bipolar psychotic individuals showed 
greater evoked power 275-325 msec following targets in the gamma range than 
individuals with schizophrenia.
Conclusions: Both Schizophrenia and psychotic bipolar subjects showed reduced 
early PLV deficits in the local GBR. Schizophrenic individuals showed a different 
pattern of gamma band response compared to both controls and individuals 
with affective psychosis, especially in the 300 msec interval, likely indexing the 
working memory and selective attention components giving rise to P300.
Supported by NIMH RO1-58704;NIMH RO1-40977
880. Quantitative Examination of a Novel Clustering 
Method using Magnetic Resonance Diffusion Tensor 
Tractography
Aristotle Voineskos1,2, Lauren O’Donnell3, Nancy Lobaugh4,
Doug Markant2, Marc Niethammer2, Benoit Mulsant1, Bruce 
Pollock1, Carl Frederik Westin3, Martha Shenton2
1Psychiatry; Geriatric Mental Health Program, University of Toronto, 
Toronto, ON, Canada,2Psychiatry Neuroimaging Lab; Brigham and 
Women’s Hospital, Harvard Medical School, Boston, MA,3Surgical 
Planning Lab; Brigham and Women’s Hospital, Harvard Medical 
School, Boston, MA,4Neurology; Sunnybrook Hospital, University of 
Toronto, Toronto, ON, Canada
Background: Magnetic resonance diffusion tensor imaging (DTI) is currently 
the only way to visualize the organization of white matter fiber tracts in vivo 
using DTI tractography. In this study, we examine scalar indices of the diffusion 
tensor with two different methods that use whole brain tractography: a novel 
clustering approach and a multiple region of interest (MROI) approach.
Methods: Twelve participants (schizophrenia: 58 ± 12 years, n=6; controls: 57 ± 21 
years, n=6) were studied. DTI images were acquired on a 1.5 Tesla GE system with 
diffusion gradients applied in 23 non-collinear directions with 2.6 mm isotropic 
voxels with the acquisition repeated three times. Tractography and fiber tract creation 
was performed using 3D Slicer software. The uncinate and inferior occipito-frontal 
fasciculi, genu of corpus callosum, and cingulum bundle were compared.
Results: Fractional anisotropy (FA) and trace values were highly correlated between 
the clustering and MROI methods (p<0.001 all tracts). Additionally, an analysis 
using paired t tests showed no difference in measurements of FA or trace for any tract 
between each method (no p <0.05). There was good spatial agreement between the 
two methods measured using the k criterion of Landis and Koch (1977).
Conclusions: Overall there is a high level of agreement between our clustering 
method and the MROI method both quantitatively and spatially. The 
clustering method is less susceptible to user bias and is an efficient method for 
studies examining multiple tracts. Therefore, the clustering method is a viable 
alternative to the MROI method with advantages in specific circumstances.
881. A fMRI Study on the Effects of the Nicotine 
Patch on Brain Activation during Finger Tapping
Narin Wongngamnit1, Laura F. Martin1,2, Jason R. 
Tregellas1,2, Jody L. Tanabe1,3
1Department of Psychiatry, University of Colorado Denver, Denver, 
CO,2Research Service, VA Eastern Healthcare System, Denver, 
CO,3Radiology, University of Colorado at Denver, Denver, CO
Background: Nicotine increases finger tapping (FT) rates in both healthy individuals 
and individuals with schizophrenia. The neurobiological effects of nicotine on cortical 
activity during FT have not been studied. We hypothesize that nicotine will not alter 
the sensorimotor cortex (SMC) activity patterns associated with finger tapping in 
healthy individuals when the behavioral rate of tapping is fixed.
Methods: This is a single-blind crossover trial of twelve non-smoking, right-
handed subjects performing a paced FT task one hour after placement of a 7mg 
nicotine or placebo patch. FT consisted of pressing a response box with the right 
index finger in response to auditory cues at rates of 1 hz, 2hz and 4 hz during 20 
second blocks. fMRI data were acquired using BOLD contrast technique in a 3T 
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MR scanner. Images were processed and analyzed using SPM2.
Results: The FT task elicited contralateral SMC and supplementary motor 
cortex activity. SMC activity increased with increasing FT rate. There were 
no effects of nicotine administration on SMC or SMA activation patterns. 
However, at a tapping rate of four Hz, nicotine was associated with greater 
temporal and reduced prefrontal cortical activity.
Conclusions: Our finding of increasing activity in SMC with increasing 
FT rate is consistent with prior work and is a potential confounding factor 
in pharmacological studies of FT. Nicotine did not affect SMC activity 
as we hypothesized; however, it did affect areas involved with the cognitive 
modulation of FT. Future studies will examine the effects of nicotine on FT in 
individuals with schizophrenia.
Supported by VA Research Service
882. Risperidone Long Acting Injection Treatment 
in Schizophrenia: 12-Month Results from the 
Electronic Schizophrenia Treatment Adherence 
Registry (E-STAR)
A. Alexandrov1, Jose Olivares2, Ivan Tuma3, Jos 
Peuskens4, Jan Pecenak5, Lars Eriksson6, B. Bork7,
Michael Povey8, Annette Lam9, Kostas Trakas10,
Zhongyun Zhao10
1De Zwolse Poort, Acute psychiatrie, Raalte, The Netherlands,2Hospital 
Meixoeiro Complejo, Hospitalario Universitario de Vigo, Vigo, 
Spain,3Medical School and Teaching Hospital Hradec Kralove, 
Charles University in Prague, Hradec Kralov, Czech Republic,4KU 
Leuven campus UC St. Jozef Kortenberg, Universitair Psychiatrisch 
Centrum, Kortenberg, Belgium,5Psychiatry, FNSP Bratislava, 
Bratislava, Slovakia,6Psychiatry, SU/Östra RPV, Hisings-Backa, 
Sweden,7Psychiatry, DP Tønder, Tønder, Denmark,8Statistics, SGS 
Life Science Services, Wavre, Belgium,9Health Economics, Johnson 
& Johnson Pharmaceutical Services, Toronto, ON, Canada,10Health 
Economics, Johnson & Johnson Pharmaceutical Services, Raritan, NJ
Background: To assess 12-month clinical and functioning outcomes of 
risperidone long-acting injection (RLAI) treatment in patients enrolled in 
the electronic-Schizophrenia Treatment Adherence Registry (e-STAR) from 
Belgium, Czech Republic, Denmark, Netherlands, Slovakia, Spain, Sweden.
Methods: e-STAR is an international, long-term, prospective, observational 
study of patients with schizophrenia who commence RLAI treatment. Data are 
collected retrospectively for 1 year and prospectively every 3 months for 2 years. 
Clinical outcomes measured by Clinical Global Impression-Severity (CGI-S) 
scale & patient functioning assessed by Global Assessment of Functioning 
(GAF) scale. Results are based on data from patients who have completed their 
12-month follow-up visit. 
Results: To date, 4,196 patients enrolled in e-STAR from the 7 European 
countries, 2,239 patients with at least 12-months of data available were included 
in this interim analysis. 61.8% were male with mean age of 38.7±12.0 years 
and mean time since diagnosis of 11.2±10.7 years. At 12 months, 89.7% of 
patients still continued on RLAI. Most frequent reasons for switching to RLAI 
were lack of compliance (36.4%) and lack of efficacy (28.9%) with previous 
therapy. Mean CGI-S score significantly decreased from 4.58±1.01 at baseline 
to 3.40±1.03 at 12 months (p<0.001). Percent patients with not ill/very mild/
mild illness increased from 12.2% to 52.7% and with marked/severe/extremely 
severe decreased from 51.7% to 12.4% (p<0.001). Mean GAF score improved 
significantly from 47.8±14.9 at baseline to 63.8±15.7 at 12 months (p<0.001).
Conclusions: This 12-month interim data from seven European countries 
show that schizophrenia patients initiated on RLAI experienced significant 
improvements in disease severity and functioning.
Supported by Johnson & Johnson
883. Pooled Analysis Comparing Non-High 
Density Lipoprotein in Patients with Schizophrenia 
Randomized to Aripiprazole or Olanzapine (Studies 
CN138-002, -003, -047ext)
Jonathan M. Meyer1, Trixia A. Camacho2, Ross A. 
Baker2, James Eudicone2, Andrei Pikalov3, Estelle 
Vester-Blokland2, Robert D. McQuade4, Gilbert J. 
L’Italien5,6, John W. Newcomer7
1University of California, Department of Psychiatry, San Diego, 
CA,2Bristol-Myers Squibb, 777 Scudders Mill Rd, Plainsboro, 
NJ,3Otsuka America Pharmaceutical, Inc., 2440 Research 
Boulevard, Rockville, MD,4Otsuka Pharmaceutical Development & 
Commercialization, Inc., 100 Overlook Drive, Princeton, NJ,5Bristol-
Myers Squibb, 5 Research Parkway, Wallingford, CT,6Yale University 
Medical School, 333 Cedar Street, New Haven, CT,7Washington 
University School of Medicine, 660 S. Euclid Avenue, St. Louis, MO
Background: CVD is the leading cause of death in patients with schizophrenia, 
partially related to underutilization of primary and secondary prevention.1
Given the absence of non-HDL-C data in antipsychotic studies and the 
growing interest in CVD risk prevention in patients with mental illness, we 
quantified the change in non-HDL-C, a significant predictor of CVD,2 in a 
pooled analysis of clinical trials assessing aripiprazole versus olanzapine.
Methods: Exploratory pooled post-hoc analysis of three trials compared 
olanzapine to aripiprazole in schizophrenia patients: one randomized, double-
blind, 26-week (CN138-002), one randomized, double-blind, 52-week 
(CN138-003), and one 52-week, open-label trial (CN138-047ext). Non-
HDL-C was calculated as Total Cholesterol minus HDL-C from data collected 
at weeks 6, 12, 26 and 52. Statistical comparisons were made using ANOVA 
with LOCF.
Results: Compared with baseline, there was a significant decrease in mean 
non-HDL-C at all time points (p<0.001) in aripiprazole patients, while 
olanzapine patients experienced a significant increase in mean non-HDL-C 
at all time points (p<0.001). The mean change in non-HDL-C in aripiprazole 
versus olanzapine patients was statistically significant as early as week 6 (-16.1 
mg/dL and +10.4 mg/dL, respectively) and was maintained at weeks 12, 26, 
and 52 (p<0.001, all time points).
Conclusions: The early and sustained improvement in non-HDL-C for 
aripiprazole patients versus the relative worsening observed for olanzapine 
patients suggest that antipsychotic treatment can influence an important risk 
predictor for CVD. These results further support the need to understand long-
term health implications when initiating or changing antipsychotic therapy.
1Newcomer. JAMA. 2007;298:1794-1796.
2Liu. AJC. 2006;98:1363-1368.
Supported by Bristol-Myers Squibb and Otsuka
884. A Comparison of Effects of Clozapine 
(CLZ) and Typical Neuroleptics (TYP) on 
Psychopathology, Tolerability and Functional 
Capacity in Neuroleptic-Responsive Schizophrenia 
(SCH) and Schizoaffective Disorder (SCHAD)
William V. Bobo, Herbert Y. Meltzer, Myung A. Lee, 
Philip Cola, Karuna Jayathilake
Department of Psychiatry, Vanderbilt University School of Medicine, 
Nashville, TN
Background: Due to risk of agranulocytosis, clozapine has been restricted 
to treatment-resistant cases of SCH. However, considering other therapeutic 
advantages of clozapine (decreased suicidality, improvement in cognitive 
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function) it is of interest to assess clozapine’s risks and benefits in neuroleptic-
responsive SCH.
Methods: This was a randomized, masked trial of two years duration involving 
85 early psychosis patients (CLZ n = 40; TYP n = 45) who met DSM-IV criteria 
for SCH or SCHAD and had a history of positive response to neuroleptic 
treatment. Assessments of psychopathology (using BPRS total and subscales, 
SAPS and SANS), quality of life (using the Quality of Life Scale [QOL]), and 
tolerability (BARS, AIMS) were obtained at baseline, 6 weeks, and 6, 12, and 
24 months. Groups were also compared on relapse/rehsopitalization, study 
drop-out, and cost of treatment.
Results: Both treatments produced non-significantly different improvement in 
psychopathology, as assessed with the Brief Psychiatric Rating Scale (BPRS) and 
its subscales. However, more relapse/rehospitalization and drop-outs occurred 
in the typical neuroleptic-treated compared to the clozapine-treated patients. 
In addition, two patients treated with typical neuroleptics, but none treated 
with clozapine, became non-responsive to their treatment. The only difference 
in tolerability of the two treatments was significantly greater weight gain in the 
clozapine-treated group compared to the typical neuroleptic group.
Conclusions: Clozapine may not provide comparatively greater improvements 
in psychopathology than typical antipsychotics among patients with early 
SCH and a history of positive response to neuroleptic treatment, but may be 
more effective in preventing relapse during long term treatment.
Supported by USPHS MH41684 and grants from the Elisabeth S. Prentiss 
FOundation, the John P Sawyer Foundation and the Stanley Foundation
885. Structural Neural Markers of Short-Term 
Clinical Outcome in First Episode Psychosis: 
A Voxel-Based Morphometry Study
Michael Bodnar, Philippe-Olivier Harvey, Ashok Malla, 
Ridha Joober, Martin Lepage
Clinical Division, Douglas Mental Health University Institute, Verdun, 
QC, Canada
Background: Outcome from psychotic disorders is heterogeneous with poorer 
outcomes frequently identified too late to be influenced. Reduced putamen 
and temporal lobe volumes along with increased ventricular volumes have been 
related to poor long-term clinical outcome; however, no neural correlates for 
short-term clinical outcome have been reported.
Methods: Using optimised voxel-based morphometry (VBM) methods, we 
set out to identify specific neural correlates of poor response in first episode 
of psychosis (FEP) patients at the start of a specialised treatment program. 
The present study included 51 FEP patients, divided into two groups (29 non-
responders, 22 responders) based on their therapeutic response (no or mild 
symptoms) six months after the initiation of treatment, along with 27 matched 
healthy controls.
Results: Non-responders had significantly smaller volumes in the bi-lateral 
superior frontal gyrii, bi-lateral inferior and middle temporal gyrii, and left 
occipital cortex compared to responders.
Conclusions: These findings suggest that specific neural correlates of not 
responding to treatment by six-months are present at the beginning of the 
treatment process in FEP patients. The affected areas may relate to visual and 
verbal processing deficits and to cognitive deficits of memory and executive 
functions that have been reported in psychotic disorders, which, in turn, 
negatively affect short-term outcome. The early identification of treatment 
non-response may encourage alternative treatments and/or the search for new 
medications in order to improve outcome.
Grey Matter Deficits in Non-Responders vs. Responders
Region BA Coordinates (x y z) t-value Cluster Size
Frontal
L Superior Gyrus 10 15 66 -8 3.95 518
R Superior Gyrus 10 -13 68 -8 3.85 218
L Insula 13 -41 -16 0 3.68 264
Temporal
R Inferior Gyrus 37 57 -56 -5 3.91
1919R Middle Gyrus 21 66 -45 -6 3.55
R Superior Gyrus 22 66 -42 6 3.62
L Inferior Gyrus 37 -59 -51 -9 3.85 1066L Middle Gyrus 21 -66 -44 -7 4.25
L Fusiform Gyrus 20 -49 -32 -24 3.67 109
Occipital
L Cuneus 17 -18 -91 3 4.62
13932L Middle Gyrus 18 -18 -95 17 4.50
18 -29 -88 2 4.50
Supported by Operating Grants: CIHR (#68961) and Sackler Foundation to 
Drs. Lepage & Malla
886. Remission in Schizophrenia and Patient-
Relevant Outcomes: Findings from Three Studies
Cynthia Bossie, CV Damaraju, Young Zhu, John 
Verbanac, Wayne Macfadden
???????????????????????????????????? ??????????????????????????????
Background: Remission criteria in schizophrenia include symptom severity 
(absent-mild ratings on core symptoms) and duration (≥6 consecutive months). 
We hypothesized that the duration component is required for improvement in 
patient-relevant outcomes.
Methods: Post-hoc analyses of three 1-year studies of schizophrenia patients 
assessed remission by the Positive and Negative Syndrome Scale. Mutually 
exclusive populations were defined: meeting symptom severity and duration 
criteria (≥6-month remitters); meeting symptom severity but not duration 
criteria (severity remitters); never meeting symptom severity criteria 
(nonremitters). Measures: Short-Form Health Survey (SF-36) functioning 
domains (study 1, N=633), Strauss Carpenter Levels of Functioning (LOF) 
and/or Personal and Social Performance (PSP) scale (study 2, N=316; study 3, 
N=235). ANCOVA assessed change scores.
Results: Study 1: ≥6-month remitters improved significantly more on SF-36 
domains of social functioning, role-emotional and role-physical than severity 
remitters (mean[SE] difference in change scores: 13.3[2.4];16.6[3.9]; 9.8[3.7], 
respectively) and nonremitters (17.9[2.4];16.9[3.9];14.2[3.7], respectively) (all 
P<0.01). Severity remitters showed no significant improvement vs nonremitters 
on these domains.
Study 2: ≥6-month remitters, but not severity remitters, improved significantly 
more than nonremitters on LOF domains of quality and quantity of useful 
work (mean[SE] difference in change scores:1.3[0.6]), frequency and quality of 
social contacts (1.2[0.4]) and fullness of life (0.4[0.1]) (all P<0.05).
Studies 2 and 3: ≥6-month remitters and severity remitters improved significantly 
more than nonremitters on PSP total score (P<0.05). However, ≥6-month 
remitters improved significantly more than severity remitters (P<0.05).
Conclusions: Remission for ≥6 months is important for improvement in 
patient-relevant outcomes.
Supported by Ortho-McNeil Janssen Scientific Affairs, L.L.C.
www.sobp.org/journal
282S BIOL PSYCHIATRY 2008;63:1S-301S Saturday Abstracts
887. A Double-Blind Placebo-Controlled Trial 
Comparing Paliperidone ER and Quetiapine in 
Patients with a Recent Acute Exacerbation of 
Schizophrenia 
Carla Canuso1, Jennifer Carothers1, Bryan Dirks2,
Young Zhu1, Colette Kosik-Gonzalez1
1???????????????????????????????? ???????????????????????????????2At 
the time of this analysis, was an employee of Ortho-McNeil Janssen 
?????????? ??????????????????????????????
Background: This analysis compared paliperidone extended-release (ER) 
and quetiapine monotherapy in schizophrenia patients with a recent acute 
exacerbation requiring hospitalization.
Methods: International, 6-week, double-blind study randomized recently and 
acutely exacerbated schizophrenia inpatients to paliperidone ER, quetiapine 
or placebo. A 2-week monotherapy was followed by a 4-week additive-therapy 
phase. Target doses: 9 or 12 mg/day paliperidone ER and 600 or 800 mg/
day quetiapine. Outcomes: Positive and Negative Syndrome Scale (PANSS) 
and adverse events (AEs). Primary endpoint: PANSS total change score from 
baseline to monotherapy endpoint for paliperidone ER vs quetiapine.
Results: Preliminary data on 399 patients are presented; 78% on paliperidone 
ER, 67% on quetiapine and 64% on placebo completed. Significant 
improvement was observed with paliperidone ER vs quetiapine in mean[SE] 
PANSS total change score from day 5 (-11.4[1.1] vs -8.2[1.1]; P=0.011) through 
2-week monotherapy endpoint (-23.4[1.8] vs -17.1[1.8]; P<0.001). Paliperidone 
ER, not quetiapine, showed significantly greater improvement vs placebo 
on PANSS total score. At 6-week study endpoint, paliperidone ER showed 
significant improvement vs quetiapine in mean[SE] PANSS total change score 
(-31.2[1.9] vs -26.6[1.9]; P=0.023). Most common AEs at monotherapy endpoint 
for paliperidone ER, quetiapine and placebo, respectively: tremor (14%, 5%, 
8%), somnolence (9%, 12%, 1%), insomnia (10%, 9%, 11%) and headache 
(12%, 8%, 14%). Discontinuations due to AEs at 6-week study endpoint for 
paliperidone ER, quetiapine and placebo, respectively: 4%, 10%, 6%.
Conclusions: Paliperidone ER exhibited greater short-term efficacy than 
quetiapine for treating a recent acute schizophrenia exacerbation requiring 
hospitalization.
Supported by Ortho-McNeil Janssen Scientific Affairs, L.L.C.
888. Early Onset of Antipsychotic Action in 
Schizophrenia: A Clinical Marker Discriminating 
Active Drug from Placebo
Bruce J. Kinon1, Lei Chen1, Jennifer Sniadecki1, Haya 
Ascher-Svanum1, Virginia Stauffer1, Sara Kollack-
Walker1, Shitij Kapur2
1Neuroscience, Eli Lilly and Company, Indianapolis, IN,2Institute of 
Psychiatry, King’s College of London, London, United Kingdom
Background: The objectives of this analysis were to determine if: a) early 
non-response is predictive of subsequent non-response in patients treated 
with placebo, b) early non-response discriminates placebo from active drug, 
and c) the difference observed early in treatment is sustainable at subsequent 
timepoints.
Methods: A post-hoc, pooled analysis of 2 randomized, clinical trials was 
performed comparing patients treated with placebo or low dose olanzapine 
(1 mg/day) (placebo/low dose, PBO group, n=170) to patients treated with 
haloperidol (10-20 mg/day) or olanzapine (7.5-17.5 mg/day) (active drug, AD 
group, n=252). Psychopathology was assessed with Brief Psychiatric Rating 
Scale (BPRS). Early improvement at 2 weeks was defined as at least 25% 
reduction in BPRS total score (minimal improvement). Subsequent response at 
6 weeks was defined as at least 40% improvement in BPRS total score.
Results: Based on 25% improvement in BPRS total score at 2 weeks, 71% 
of PBO patients were early non-responders while 48% of AD patients met 
criterion of early non-response. Early non-response was predictive of subsequent 
non-response in both the PBO (Negative Predictive Value, NPV=95%) and 
AD (NPV=84%) groups. At 2 weeks, the reduction in BPRS total score was 
significantly greater for AD group (LS mean=25.5%) compared to PBO group 
(LS mean=10.3%), and a significant between group difference was observed at 
every subsequent timepoint up to 6-weeks.
Conclusions: These findings suggest that early response/non-response may 
serve as a clinical marker of subsequent clinical improvement.
Supported by Eli Lilly and Company
889. Optimal Thresholds of Early Non-response 
to Atypical Antipsychotics: Application of Signal 
Detection Analysis
Lei Chen, Haya Ascher-Svanum, Virginia Stauffer, 
Bruce J. Kinon, Oladapo Tomori, Sara Kollack-Walker
Neuroscience, Eli Lilly and Company, Indianapolis, IN
Background: This study used signal detection methods to identify the optimal 
magnitude of early non-response to antipsychotic medication at various early 
time points that best predicts subsequent non-response at 8 weeks, using 
different criteria of subsequent non-response.
Methods: Data were pooled from 5 randomized, double-blind clinical trials of 
atypical antipsychotics in the treatment of patients with schizophrenia-related 
disorder, and included 1437 patients (n=1137 with at least moderate symptom 
severity; n=300 with lesser symptom severity). Signal detection methods were 
used to identify the optimal response threshold based on improvement from 
baseline on the Positive and Negative Syndrome Scale (PANSS) total score at 
different early time points (Week 1 to Week 4 of treatment) to predict subsequent 
non-response at 8 weeks, while controlling false positive rate at ≤30%.
Results: The optimal thresholds for patients with at least moderate symptom 
severity were 7-12% at Week 1, 14-23% at Week 2, 20-38% at Week 3, and 
26-45% at Week 4. For patients with lesser symptom severity, the optimal 
thresholds were 3-4% at Week 1, 7-12% at Week 2, 6-14% at Week 3, and 15-
20% at Week 4. Results were validated using data from another clinical trial.
Conclusions: For schizophrenia patients with at least moderate symptom 
severity, lack of at least 14-23% improvement on the PANSS total score at 2 
weeks is an optimal predictor of subsequent non-response following 8 weeks of 
treatment. This early response threshold appears to be an important clinical 
marker of subsequent non-response to antipsychotic therapy.
Supported by Eli Lilly and Company
890. The Metabolic Profile of Iloperidone: Summary 
of Phase III Schizophrenia Trials
Andrew J. Cutler1, John Feeney2
1Department of Psychiatry, University of Florida, Maitland, FL,2Clinical 
Affairs, Vanda Pharmaceuticals, Rockville, MD
Background: Many atypical antipsychotics are associated with adverse effects 
on metabolic parameters that may increase diabetes and cardiovascular risk. 
Iloperidone is a mixed D2/5-HT2 antagonist for the treatment of schizophrenia. 
Body weight, blood glucose, cholesterol, triglyceride, and prolactin level 
changes were assessed in a pooled analysis.
Methods: Four 4- to 6-week, phase III, double-blind, placebo-controlled trials 
of adults with schizophrenia were included in the analysis. Changes in weight 
and metabolic parameters were evaluated.
Results: A total of 2505 patients (iloperidone 4-24 mg/day, n=1344; haloperidol 
5-20 mg/day, n=118; risperidone 4-8 mg/day, n=306; ziprasidone 160 mg/day, 
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n=150; placebo, n=587) were included. In iloperidone, haloperidol, risperidone, 
ziprasidone, and placebo (I/H/R/Z/P) groups, mean changes from baseline to 
endpoint in body weight were +2.0,-0.1,+1.5, +1.1, and -0.1 kg, respectively, and 
the rates of meaningful weight gain (defined as ≥7% increase) from baseline to 
endpoint were 13.5%, 5.1%, 11.9%, 5.4%, and 4.3%. In I/H/R/Z/P groups, 
respective mean changes at endpoint in blood glucose levels were +9.0, +14.4, 
+1.8, +9.0, and 0.0 mg/dL. In I/H/R/Z/P groups, mean changes at endpoint in 
total cholesterol were 0.0, +3.9, -3.9, +3.9, and -7.7 mg/dL, and mean changes 
at endpoint in triglycerides were -17.7, -8.8, -26.5, +8.8, and -26.5 mg/dL. In 
I/H/R/Z/P groups, respective mean changes at endpoint in prolactin levels 
were -19.2, +133.0, +203.5, +2.0, and -40.9 μg/L.
Conclusions: Pooled analysis results indicate that iloperidone has a favorable 
short-term metabolic profile, with values similar to or better than the 
comparator antipsychotics used in these clinical trials.
Supported by Vanda Pharmaceuticals
891. Exploring SNPs of the Neuropeptide Y and 
Acetyl-Coenzyme A Carboxylase ? and ß Genes that 
may be Associated with the Direct Effects of some 
Antipsychotics on Lipid Levels
Jose de Leon1, Alexander Meary2, Maria J. Arranz2,
Francisco J. Diaz3
1Psychiatry, University of Kentucky, Lexington, KY,2Psychological 
Medicine, Institute of Psychiatry – King’s College, London, United 
Kingdom,3Department of Statistics, Universidad Nacional, Medellin, 
Colombia
Background: Antipsychotics may cause hyperlipidemia (hypertriglyceridemia 
or hypercholesterolemia) through two possible mechanisms: (1) an indirect 
mechanism, associated with weight gain, that leads to obesity; and (2) a direct 
mechanism by which some antipsychotics (particularly clozapine, olanzapine, 
and phenothiazines) can directly cause hyperlipidemia. Mirtazapine may also 
increase lipids.
Methods: In a sample of 357 patients taking antipsychotics, the acetyl-coenzyme 
A carboxylase ?, ACC? SNP (rs4072032) was significantly associated with 
a hypertriglyceridemia model. The neuropeptide Y, NPY (rs1468271) and 
ACCß, (rs2241220) were significant in the hypercholesterolemia model. The 
goal of this study was to further explore other SNPs in these genes that may 
be associated with direct effects of some antipsychotics on hyperlipidemia. 
From a published cross-sectional sample, 357 patients on antipsychotics were 
genotyped for the 8 additional ACC? SNPs (rs1266175; rs7208415; rs725038; 
rs9906543; rs4794750; rs12453407; rs4795194; and rs11650168), 7 additional 
ACCß SNPs (rs741402; rs2268391; rs2268387; rs2239608; rs3742026; 
rs7974040; and rs2268384); and 3 additional NPY SNPs (rs16145; rs16478; 
and rs16141). A total of 173 patients were taking olanzapine, quetiapine, 
chlorpromazine or mirtazapine which may directly cause hypertriglyceridemia 
or hypercholesterolemia. Another 184 patients taking other antipsychotics 
were controls.
Results: This extension of a prior analysis of these genes uses more systematic 
SNP assessments and haplotypes. These analyses reflect gene function better 
than prior analyses, which better establishes that these genetic variations may be 
associated with direct effects (not explained by obesity) of some antipsychotics 
on hyperlipidemia.
Conclusions: These SNPs and haplotypes need to be studied in other 
samples.
Supported by NARSAD, Roche Molecular Systems, Internal sources
892. Safety and Efficacy of Ziprasidone in Pediatric 
Bipolar Disorder
Melissa P. DelBello1, Robert L. Findling2, Paul P. 
Wang3, Balarama Gundapaneni3, Mark Versavel3
1Psychiatry, Cincinnati Children’s Hospital Medical Center, Cincinnati, 
OH,2Psychiatry, Case Western Reserve University, Cleveland, 
OH,3??????????????????????????????????????????????????????
Background: We conducted this study to evaluate the efficacy and safety of 
oral ziprasidone in children and adolescents with bipolar I disorder.
Methods: A 4-week, double-blind, placebo-controlled multicenter study of 
ziprasidone in subjects aged 10 -17 years with bipolar I disorder (manic or 
mixed). Subjects were randomized in a 2:1 ratio to flexible-dose ziprasidone 
(80-160 mg/d) or placebo, titrated over 1 to 2 weeks; treatment duration was 
4 weeks. The primary and key secondary outcome measures were the change 
from baseline to end point in YMRS total and CGI-S scores, respectively. 
Safety assessments included treatment-emergent AEs, vital signs, laboratory 
measures, ECGs, and movement disorder scales
Results: 150 subjects were randomized to ziprasidone and 88 to placebo. In the 
ITT population, the estimated least squares (LS) mean changes from baseline 
to end point in YMRS total score were -13.83 (ziprasidone) and -8.61 (placebo; 
p=0.0005); a significant difference was also confirmed in the per-protocol 
population (p=0.0004). The estimated LS mean changes from baseline to end 
point for CGI-S score in the ITT population were -1.43 (ziprasidone) and -0.74 
(placebo; p=0.0001). The most commonly reported AEs in the ziprasidone 
group were sedation (22%), somnolence (25%), nausea (13%), fatigue (13%), 
and dizziness (11%). No changes in mean BMI z scores, lipids, liver enzymes, 
or glucose levels were observed. QT prolongation ≥460 msec was reported in 1 
(0.7%) ziprasidone-treated subject.
Conclusions: These results suggest that ziprasidone is effective and generally 
well tolerated for the acute treatment of mania in children and adolescents with 
bipolar disorder.
Supported by Pfizer Inc.
893. Atypical Antipsychotic Drugs and Diabetes 
Mellitus in the US FDA Adverse Event Reporting 
System (AERS) Database in Pediatric and Adult 
Patients
P. Murali Doraiswamy1, Ramin A. Arani2, David Gan2,
Andrei Pikalov3, Quynh-Van Tran3, Raymond Mankoski4,
Ross A. Baker4
1Departments of Psychiatry and Medicine, Duke University Medical 
Center, Durham, NC,2Bristol-Myers Squibb, 311 Pennington-Rocky 
Hill Road, Hopewell, NJ,3Otsuka America Pharmaceutical, Inc., 2440 
Research Boulevard, Rockville, MD,4Bristol-Myers Squibb, 777 
Scudders Mill Rd, Plainsboro, NJ
Background: The risk of diabetes-related adverse events (DRAEs) is a substantial 
concern in younger patients receiving atypical antipsychotics, especially given 
recent and impending US FDA approvals for their use in the pediatric population.
Methods: Adjusted reporting ratios (Empiric Bayes Geometric Mean, EBGM) 
and 90% confidence intervals (EB05;EB95), were calculated to estimate 
the degree of association between 24 DRAEs and aripiprazole, clozapine, 
olanzapine, quetiapine, risperidone, ziprasidone, or haloperidol in patients 
stratified by age using a Multi-item Gamma Poisson Shrinker data-mining 
algorithm on the FDA AERS database (through December 2006). Drug-event 
combinations with EB05 ≥2 are considered potential drug-event associations.
Results: 258 cases of the 24 DRAEs were identified for patients <18 years of 
age; diabetes mellitus (DM, 58 cases) was among the most frequently reported. 
EBGM scores and EB05;EB95 CIs for DM were: aripiprazole 1.69 (0.83, 
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3.13), clozapine 4.10 (2.30, 7.50), olanzapine 3.83 (2.52, 5.67), quetiapine 2.42 
(1.31, 4.17), risperidone 2.45 (1.62, 3.58), ziprasidone 1.31 (0.48, 3.04), and 
haloperidol 1.31 (0.55, 2.75) For adults (18 to 64), all drug-event combinations 
for DM had EB05 ≥2 except haloperidol 2.29 (1.96, 2.68) and aripiprazole 
2.47 (1.97, 3.07).
Conclusions: The potential for an association between DM and haloperidol 
or aripiprazole was low in both pediatric and adult populations. In contrast, 
potential associations, as defined as EB05 ≥2, were observed between DM and 
olanzapine or clozapine in both populations. Potential associations were observed 
for risperidone, quetiapine, or ziprasidone only in adults. These results reinforce 
the importance of metabolic monitoring in both pediatric and adult patients.
Supported by Bristol-Myers Squibb and Otsuka
894. Differential Effects of Typical and Atypical 
Antipsychotic Drugs on Striatal Subregions in 
Patients with Schizophrenia: An FDG-PET and MRI 
Imaging Study
Nicola Dusi, Jonathan J. Entis, M. Mehmet Haznedar, 
Randall Newmark, Kingwai Chu, Erin A. Hazlett, Monte 
S. Buchsbaum
Psychiatry, Mount Sinai Hospital, New Yok, NY
Background: The dorsoventral gradient in D2 receptor density and 
anteroposterior organization for cognitive/motor function indicate the 
importance of examining the striatum in 3D.
Methods: We studied two samples: 1) 22 never-previously medicated psychotic 
adolescents (mean age 15.7, range 13-19) received an anatomical MRI and FDG-
PET scans at baseline and after 8-9 weeks of a randomized double-blind trial 
of either olanzapine or haloperidol and 2) 15 adult patients with schizophrenia 
(mean age 42.6, range 22-59) received an anatomical MRI and FDG-PET 
scan after 6 weeks of a randomized double-blind trial of either sertindole or 
haloperidol. Adult patients were then crossed to the other treatment and scanned 
again at week 12. The caudate and the putamen were traced on the anatomical 
MRI by a tracer blind to the diagnosis and applied to the FDG-PET
Results: Younger adolescents 13-15 treated with haloperidol had a significant 
increase in the relative metabolic rate of both the caudate and putamen at dorsal 
levels while treatment with olanzapine generally decreased metabolic rates. The 
difference between the two medications was most marked in the head of the putamen 
where only haloperidol showed a metabolic rate increase while any putamen increase 
with olanzapine was limited to small dorsolateral posterior regions. Similarly, in the 
adult sample we found that the metabolic rates of the caudate and the putamen were 
significantly higher with haloperidol than with sertindole.
Conclusions: These findings are consistent with the different D2 receptor 
occupancy of these drugs and consistent with striatal organization.
Supported by H. Lundbeck A/S and Eli Lilly and Company
895. Weight Gain and Hyperprolactinemia in 
Schizophrenic Patients Treated during Twelve 
Months with Long Acting Risperidone
Fabrice Duval, Frederico Duarte Garcia, Felix 
Gonzales Lopera, Marie-Claude Mokrani, Yann Hode, 
Said Fattah, Than Son Diep
Psychiatry, Centre Hospitalier, Rouffach, France
Background: Risperidone (RISP) may induce both elevated prolactin (PRL) 
levels and weight gain. The aim of this study was to evaluate body weight and 
mass index (BMI), and PRL modifications in schizophrenic patients treated for 
1 year with long-acting risperidone (LAR).
Methods: Body weight and BMI (calculated as weight in kilograms divided 
by height in meter squared) were determined at baseline and at endpoint in 19 
schizophrenic patients (9 men and 10 women; mean[SEM] age 33.4[2.9]years). 
PRL levels were determined at baseline, after oral risperidone treatment (mean 
length of treatment: 79[30] days; mean dose: 5.8[0.5] mg daily) and during a 
12 month treatment with LAR (mean dose : 50[10] mg every 2 weeks ; PRL 
levels were measured before each injection).
Results: At endpoint, a significant weight gain (?weight: 8,1[1,4] kg) and 
BMI (?BMI: 2,9[0,5] kg/m²) was observed (both p<0.0002). Compared with 
baseline, PRL levels were significantly increased (p<0.0007; mean ?PRL: 33[8]
ng/ml). There was an association between ?BMI>1,5 kg/m² and ?PRL>40 ng/
ml (p<0.04). Moreover ?BMI was linked to the length of treatment (rho=0.47; 
n=19; p<0.05).
Conclusions: Our results suggest a link between weight gain and long term 
hyperprolactinemia in patients treated with LAR. It has been hypothesized 
that PRL may have a role in the regulation of food intake by increasing leptin 
synthesis and secretion.
896. Withdrawn
897. FDG-PET and MRI Imaging of the Effects of 
Typical and Atypical Neuroleptics on the Medial 
Dorsal Nucleus of the Thalamus in Schizophrenia
Jonathan J. Entis, Nicola Dusi, William Byne, M. Mehmet 
Haznedar, Eileen Kemether, Randall Newmark, Kingwai 
Chu, Erin A. Hazlett, Ella B. Teague, Monte S. Buchsbaum
Psychiatry, Mount Sinai School of Medecine, New York, NY
Background: Schizophrenia is associated with sensory, cognitive, and motor 
impairments that have been linked to thalamic dysfunction. Typical and 
atypical neuroleptics have unique receptor binding and may differentially 
affect dopaminergic receptors in the thalamus.
Methods: Two samples were studied to assess thalamic activity after treatment 
with neuroleptics: 1) 22 never-medicated psychotic adolescents (mean age 16.2; 
range 13-20) received an MRI and FDG-PET scans at baseline and after 8-9 
weeks of a randomized double-blind trial of either olanzapine or haloperidol and 
2) 15 adult patients with schizophrenia (mean age 42.6, range 22-59) received 
an MRI and FDG-PET scan after 6 weeks of a randomized double-blind trial 
of sertindole or haloperidol. Patients were crossed to the other treatment and 
scanned again at week 12. In both samples, thalamic nuclei (MDN, PULV, and 
APN) were traced on the MRI and applied to the FDG-PET.
Results: In the adolescent sample, greater activity occurred after treatment 
with olanzapine in the mediodorsal nucleus (p=0.02) and anterior principle 
nucleus (p=0.04). Decreased activity in these nuclei occurred after treatment 
with haloperidol. In the adult sample, greater activity was found in the MDN 
(p=0.02) and the right APN (p=0.02) after treatment with sertindole than 
after treatment with haloperidol. Greater correlation between the metabolic 
rate change of the MDN and the prefrontal regions was found with olanzapine 
than with haloperidol. Sertindole/haloperidol patterns were similar.
Conclusions: These results suggest greater coordination between the MDN 
and prefrontal regions with atypical rather than typical neuroleptic treatment, 
possibly consistent with greater cognitive improvement.
Supported by H. Lundbeck A/S and Eli Lilly and Company
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898. Effect of Ziprasidone Dose on Rates of 
Medication Discontinuation in Acute Schizophrenia 
or Schizoaffective Disorder
Leslie Citrome1, Ruoyong Yang2, James Harnett2, Paul 
Glue2, Onur Karayal2
1Psychiatry, New York University School of Medicine, New York, 
NY,2????????????????????????????????????
Background: Prior research suggests that higher ziprasidone doses may be related 
to better outcomes in patients with schizophrenia or schizoaffective disorder.
Methods: Data were analyzed for the first 28 days from 4 pivotal, randomized, double-
blind, fixed-dose ziprasidone trials of patients with schizophrenia or schizoaffective 
disorder. Ziprasidone dose (40 mg/d, n = 186; 80 mg/d, n =154; 60mg/d, n = 125; 
160 mg/d n = 104) and its relationship to all-cause, efficacy and adverse event related 
discontinuations, within 28 days relative to placebo were examined using Cox 
proportional hazard models to adjust for confounding factors.
Results: All-cause discontinuation for ziprasidone ranged from 26.9% for 160 
mg/d to 40.9% for 40 mg/d compared with 49.5% for placebo. Doses of 120 
- 160 mg/d were the only ziprasidone regimens associated with significantly 
lower all-cause discontinuation rates versus placebo (p< 0.05). Ziprasidone 
160 mg/d was the only dose associated with a significantly lower all-cause 
discontinuation rate versus lower dose ziprasidone (40 mg/d and 80 mg/day, p< 
0.05). Lack of efficacy and AEs accounted for 51% and 8.6% of all medication 
discontinuations for ziprasidone, compared with 62% and 4.4% for placebo, 
respectively. Overall discontinuation due to lack of efficacy findings are 
consistent with all-cause discontinuation.
Conclusions: Higher doses of ziprasidone (120-160 mg/d) are associated with 
significantly lower all-cause medication discontinuation than placebo and 
160mg/d vs. lower dose ziprasidone (40-80 mg/d), primarily due to lower rates 
of discontinuation for lack of efficacy. These findings support other research 
associating higher doses of ziprasidone with improved treatment outcomes.
Supported by Pfizer Inc.
899. A 12 Weeks Open Label Trial of Quetiapine in 
Adolescents with Psychotic Disorders
Laurent Holzer1, Ulrich Preuss2, Stéphanie Clarke3,
Olivier Halfon4, Pierre Baumann5
1Child and Adolescent Psychiatry, Department of Psychiatry, 
LAusanne, Switzerland,2Child and Adolescent Psychiatry, 
Universitäre Psychiatrische Dienst, Bern, Switzerland,3Service 
de Neuropsychologie, CHUV, Lausanne, Switzerland,4Child and 
Adolescent Psychiatry, Department of Psychiatry, Lausanne, 
Switzerland,5UBPC, Department of Psychiatry, Lausanne, Switzerland
Background: Clinical effectiveness, tolerability and pharmacokinetics of 
quetiapine in adolescents with psychotic disorders have been established, but 
cognitive functions have not yet been examined specifically in this population.
Methods: 23 adolescents (13-18 years old) with psychotic disorders participated 
in a 12 weeks open label trial assessing clinical efficacy, tolerability and impact 
on cognitive functions of quetiapine (50 -750 mg daily).
Results: Adolescents were treated with lower doses compared to adults, a 
decrease in CGI and PANSS total score was observed while neuropsychological 
functioning remained stable after 12 weeks of quetiapine treatment.
Conclusions: Quetiapine is an effective and well tolerated treatment in 
adolescents with psychotic disorders, no improvement in cognitive functioning 
has been observed in this trial.
Supported by AstraZeneca
900. Safety and Tolerability of the Investigational 
Antipsychotic Paliperidone Palmitate Injected in the 
Deltoid or Gluteus Muscle in Patients with Schizophrenia 
Srihari Gopal1, Jean-Pierre Lindenmayer2, David 
Hough1, Rama Melkote1, Pilar Lim1, Mariëlle Eerdekens3
1CNS, J&J PRD, Titusville, NJ,2New York University, New York 
University, New York, NY,3Division of Janssen Pharmaceutica N.V, J&J 
PRD, Beerse, Belgium
Background: To assess safety and tolerability of initiating treatment with 
paliperidone palmitate via deltoid vs. gluteal injection given every 4 wks and of 
switching injection sites in adults with stable schizophrenia.
Methods: In this crossover trial, patients (N=252) were randomized 1:1:1 to 3 
treatment groups (Paliperidone palmitate 50, 75, or 100 mg eq.) and 2 injection 
sequences during the double-blind phase (blinded to dose): deltoid muscle (period 
1 [ 13 wks]) followed by gluteal muscle (period 2 [12 wks]) or the reverse.
Results: The ITT population had 249 patients: mean age= 43 (SD:12.8) yrs; 
men (57%); white (81%); baseline mean PANSS total score=56 (SD:11.5). The 
most common (≥5% overall) treatment-emergent adverse events (TEAEs) 
were: (period 1) insomnia, anxiety, headache, and agitation; and (period 2) 
insomnia, psychotic disorder, weight increase, and tachycardia. During 
treatment initiation (period 1), rates of systemic TEAEs were similar between 
the 2 injection sites across all dose levels (proportion of patients reporting 
TEAE for gluteus minus deltoid [90%CI]): -6.7% (-23.5, 10.7) for 50 mg eq.; 
-0.7% (-17.6, 16.5) for 75 mg eq.; and -3.4% (-20.4, 13.8) for 100 mg eq. The 
total difference between the rates (90% CI) across doses was -3.3% (-13.3, 
6.7). A comparison of systemic TEAE rates during the last 8 wks of the 2 study 
periods did not reveal significant differences upon switching of injection sites.
Conclusions: The incidence of systemic TEAEs was similar when initiating 
treatment with either deltoid or gluteal injections. Switching between injection 
sites was also safe and well tolerated.
Supported by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
901. Paliperidone Palmitate, an Injectable 
Antipsychotic, in Prevention of Symptom Recurrence 
in Patients with Schizophrenia: A Randomized, 
Double-Blind, Placebo-Controlled Study 
David Hough1, Srihari Gopal1, Ujjwala Vijapurkar1, Pilar 
Lim1, Margarita Morozova2, Mariëlle Eerdekens3
1CNS, Johnson & Johnson Pharmaceutical Research & Development, 
Titusville, NJ,2Mental Health Research Center, Mental Health 
Research Center, Moscow, Russian Federation,3Division of Janssen 
Pharmaceutica N.V, Johnson & Johnson Pharmaceutical Research & 
Development, Beerse, Belgium
Background: We assessed efficacy and tolerability of an investigational, 
injectable antipsychotic, paliperidone palmitate (PP), in preventing symptom 
recurrence in adults with schizophrenia.
Methods: Eligible patients (PANSS total scores <120) were transitioned 
to gluteal injections of PP during a 9-week (wk) open-label f lexible-dose 
phase. The first 2 injections of 50 mg eq. were given 1 wk apart. Subsequent 
injections, which could be adjusted (25, 50, or 100mg eq.), occurred every 
4 weeks. Patients with total PANSS <75 at wk 9 continued into the 24-wk 
maintenance phase. Patients clinically stable on a fixed dose for the last 12 
wks were randomized 1:1 to continue on their PP dose or start placebo in the 
double-blind phase of variable duration.
Results: The preplanned interim analysis at 68 recurrence events included 312 
patients: mean age=40 yrs, 55% men, 66% white, baseline PANSS (SD): placebo, 
69.5 (16.89); PP, 69.3 (17.39). Time-to-first-recurrence (primary measure) favored 
PP (p<0.0001, log-rank test): median time-to-first-recurrence was 163 days for 
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placebo and not estimable for PP. Based on the significant efficacy results, the 
study was stopped early. Treatment-emergent AE rates during double-blind 
phase (final analysis: N=408) were: 38% PP, 44% placebo. Weight increase 
and gastroenteritis (viral) occurred more frequently with PP (difference ≥2% 
vs. placebo). Local injection-site tolerability was good. For PP treated patients 
(n=205), the investigators reported injection-site pain as usually absent (81%) or 
mild (18%) at double-blind endpoint, similar to placebo-treatment.
Conclusions: Paliperidone palmitate treatment significantly delayed time-to-
first recurrence and was generally well-tolerated, locally and systemically, in 
patients with schizophrenia.
Supported by Johnson & Johnson Pharmaceutical Research & Development
902. The Safety and Effectiveness of High Dose 
D-Serine in the Treatment of Schizophrenia
Joshua T. Kantrowitz1, Rachel T. Ziwich1, Barbara A. 
Cornblatt2,3,4, Anil K. Malhotra2,3,4, Gail Silipo1, Scott W. 
Woods5, Daniel C. Javitt1,6
1Life Sciences, Nathan Kline Institute for Psychiatric Research, 
Orangeburg, NY,2Psychiatry, Zucker Hillside Hospital, Glen Oaks, 
NY,3Department of Psychiatry, Albert Einstein College of Medicine, 
Bronx, NY,4Early-Phase Schizophrenia Center, The Feinstein Institute 
for Medical Research, Manhasset, NY,5Department of Psychiatry, 
Yale University, New Haven, CT,6Department of Psychiatry, New York 
University School of Medicine, New York, NY
Background: D-serine is a potential novel medication for treatment of 
schizophrenia working via the allosteric modulatory site of the NMDA receptor 
complex. Randomized clinical trials of D-serine have been done with doses of 
30 mg/kg/day (approximately 2 g/day), but no formal dose escalation or PK/PD 
studies have been performed. This study describes effects of D-serine administered 
at a dose of 60 mg/kg/day (approximately 4 g/day) open label for 4 weeks.
Methods: 20 antipsychotic-stabilized patients with schizophrenia or 
schizoaffective disorder participated. Safety labs (SMA20, CBC, UA) were 
obtained weekly and clinical measures (PANSS, SANS) were obtained 
biweekly. Neuropsychological (MATRICS) and event-related potential 
measures (MMN, visual P1, auditory 40 Hz response) pre and post treatment.
Results: 19 patients completed. No clinically significant changes in any of 
the renal function, microscopic urinalysis, CBC, EKG, or liver function tests 
were noted. No statistical changes in extrapyramidal symptoms occurred. 
Mean peak concentration was 272.3±13.9 nmol/ml at two hours after dose 
administration, well below levels associated with preclinical nephrotoxicity.
Significant improvements were noted in the total PANSS (p=0.05;d=0.49), 
Hopkins Verbal Learning Test-Revised (p=0.009;d=0.67), Category Fluency 
(p=0.05;d=0.49), Continuous Performance Test (p=0.05;d=0.49) and 
nearly significant in negative symptoms (p=0.068;d=0.44). No significant 
improvements occurred in the SANS. Apparent improvements were noted in 
several ERP measures, including auditory MMN. In our earlier, 2 g/day trial, 
no significant neuropsychological improvements occurred.
Conclusions: This novel study of d-serine 60 mg/kg/day demonstrates safety 
and produces moderate effect size changes in multiple clinical and cognitive 
measures, calling for double-blind, placebo controlled investigations.
Supported by U01 MH074356
903. Effectiveness of Risperidone Long Acting 
Injection in the Treatment of Recently Versus Longer 
Diagnosed Patients with Schizophrenia
Tim Lambert1, Jose Olivares2, Ivan Tuma3, Jos 
Peuskens4, Jan Pecenak5, H. bij de Weg6, Lars 
Eriksson7, B. Bork8, Michael Povey9, Annette Lam10,
Kostas Trakas11, Zhongyun Zhao11
1Central Medical School, University of Sydney, Sydney, 
Australia,2Servicio de Psiquiatria, Hospitalario Universitario de Vigo, 
Vigo, Spain,3Medical School and Teaching Hospital Hradec Kralove, 
Charles University in Prague, Hradec Kralove, Czech Republic,4KU 
Leuven campus UC St. Jozef Kortenberg, Universitair Psychiatrisch 
Centrum, Leuven, Belgium,5Psychiatry, FNSP Bratislava, Bratislava, 
Slovakia,6Psychiatry, GGZ Friesland locatie Dammelaan, Leeuwarden, 
The Netherlands,7Psychiatry, SU/Östra RPV, Hisings-Backa, 
Sweden,8Psychiatry, DP Tønder, Tønder, Denmark,9Statistics, SGS 
Life Science Services, Wavre, Belgium,10Health Economics, Johnson 
& Johnson Pharmaceutical Services, Toronto, ON, Canada,11Health 
Economics, Johnson & Johnson Pharmaceutical Services, Raritan, NJ
Background: To evaluate treatment effectiveness of risperidone long-acting 
injection (RLAI) in recently diagnosed schizophrenia patients versus those 
diagnosed for a longer period.
Methods: The electronic-Schizophrenia Treatment Adherence Registry 
(e-STAR) is an international, long-term, prospective, observational study of 
patients with schizophrenia who start RLAI. Data are collected retrospectively 
for 1 year and prospectively every 3 months for 2 years. Effectiveness was 
measured by the Clinical Global Impression-Severity (CGI-S) and the 
Global Assessment of Functioning (GAF) scale. Recency of diagnosis was 
dichotomized into those diagnosed recently (<5 years) versus patients who have 
been diagnosed longer (≥5 years). This interim report is based on pooled data 
from Australia, Belgium, Czech Republic, Denmark, Netherlands, Slovakia, 
Spain, and Sweden.
Results: Among 4,252 patients enrolled in e-STAR, to date, 2,239 patients 
have been followed for at least 12-months with 44%classified as recently 
diagnosed. Compared to recently diagnosed patients, those diagnosed longer 
were older (42.5 vs. 31.4 years, p<0.001) and had longer disease duration 
(16.2 vs. 2.2 years, p<0.001). The proportion of patients still on RLAI at 12 
months was similar in both groups (diagnosed <5 years=85.2%, diagnosed ≥5 
years=85.6%). Both groups experienced significant improvements in CGI-S 
and GAF scores. However, the recently diagnosis group experienced greater 
improvements in CGI-S and GAF (CGI-S, -1.28 vs. -0.99, p<0.0001; GAF, 
+17.1 vs. +14.1, p=0.0002).
Conclusions: This 12-month interim data show that long-acting risperidone 
treatment significantly improves illness severity and patient functioning in 
patients with schizophrenia, those who were recently diagnosed experienced 
greater improvement compared to those diagnosed longer.
Supported by Johnson & Johnson
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904. The Monitor of Serum Prolactin Level and 
Related Clinical Observations among Individuals 
with Schizophrenia Spectrum Illnesses in a 12 
weeks Aripiprazole Treatment
Tsuo-Hung Lan1,2,3, Hsien-Jane Chiu1,2, Yu-Chuan Wu1,
Yun-Ru Liu3,4, Bo-Jian Wu1, Tsung-Ming Hu1, El-Wui 
Loh3, Keh-Ming Lin3
1Psychiatry, Yu-Li Hospital, DOH, Hualien, Taiwan,2Psychiatry, 
National Yang-Ming University, Taipei, Taiwan,3Division of Mental 
Health Research, National Health Research Institutes, Taipei, 
Taiwan,4Pathology, National Taiwan Univeristy, Taipei, Taiwan
Background: Aripiprazole as a partial dopaminergic agonist reduces prolactin 
level in most users. We present a clinical study to follow up serum prolactin 
level in patients treated with aripiprazole.
Methods: This is randomized open-label trial on serum prolactin monitoring 
in schizophrenic subjects. We enrolled 48 inpatients (29 Males, 19 Females) 
meeting DSM-IV criteria for schizophrenia from one Taiwan psychiatric 
hospital. After consent form fulfilled, participants were randomly assigned to 
three different treatment arms (dosage per day): (1) A - 10~15 mg aripiprazole 
; (2) B - 20~30mg aripiprazole; (3) C - 10 mg aripiprazole combined with 
1 mg risperidone. All subjects were evaluated by using PANSS scale and 
serum prolactin level at baseline, 4th week, 8th week, and 12th week. Other 
demographic data were also collected.
Results: The mean prolactin level reduced from 54.1± 40.9 (baseline) to 12.0± 
24.8 (12th week) with a p-value < 0.00001. The comparison of prolactin level 
between three arms of aripiprazole intervention shows no significant difference, 
although the reduction trend of Arm C was more than the other two Arms. 
The maximal prolactin level reduction was observed in the third week of 
aripiprazole, after adjusted for sex and previously prescribed antipsychotics.
Conclusions: It is suggested that prolactin level returns to normal after 3 weeks 
of aripiprazole treatment progressively and remains until the 12th week. The 
prolactin level is not observed elevated by 1mg risperidone in Arm C. This may 
be explained by the high affinity to dopaminergic receptors in aripiprazole.
Supported by YLH-IRB-9602
905. Positron Emission Tomography (PET) Study 
with RGH-188 in Healthy Volunteers
Istvan Laszlovszky1, Gyorgy Nemeth1, Gabriella 
Pasztor Meszaros2, Margit Kapas2, David J. Brooks3,
Nicola Pavese4, Zsolt Szombathelyi2
1Medical Division, Gedeon Richter Plc., Budapest, 
Hungary,2Pharmacological and Drug Safety Research, Gedeon Richter 
Plc., Budapest, Hungary,3Hammersmith Imanet Ltd., Hammersmith 
Hospital, London, United Kingdom,4Imperial College, MRC Clinical 
Sciences Centre, London, United Kingdom
Background: RGH-188 is a potent dopamine D3/D2 receptor antagonist/
partial agonist atypical antipsychotic. The aim of present PET study was to 
investigate the striatal dopamine D2/D3-receptor occupancy in healthy male 
subjects after single and multiple oral doses of RGH-188 and to investigate the 
associated plasma concentrations.
Methods: In an open-label study striatal D2/D3 receptor occupancy was 
measured by PET using 11C-raclopride. Two subjects received a single dose of 
0.5 mg RGH-188, while three subjects received 0.5 mg/day RGH-188 on Days 
1-2 and 1.0 mg/day on Days 3-14. PET scans were performed at baseline and 4 
h after the last dose. Pharmacokinetic plasma samples were analyzed for RGH-
188 and its two metabolites by HPLC-MS-MS.
Results: RGH-188 blocked specific binding in the investigated brain regions 
(caudate, putamen, ventral striatum). Across these regions, D2/D3 receptor 
occupancy was reduced by up to 12 % following single dose and 63 % to 79 % 
following multiple dosing. Low plasma RGH-188 concentrations after single 
dose administration were associated with low D2/D3 receptor occupancy, whilst 
higher plasma concentrations were associated with higher occupancy in the 
multiple dose group. Similar patterns were observed for the two metabolites.
Conclusions: Multiple administration of 1.0 mg RGH-188 resulted in over 
70% D2/D3 receptor occupancy in healthy male subjects and the displacement 
showed correlation with RGH-188 and metabolites levels.
Supported by Gedeon Richter Plc.
906. An Open-Label Study Changing Generic 
Clozapine Formulation to FazaClo® (clozapine, 
USP) Orally Disintegrating Tablets in Stable Patients 
with Schizophrenia or Schizoaffective Disorder
Jean-Pierre Lindenmayer1,2,3, Sashank Kaushik2,3,
Anzalee Khan2,3, Saurabh Kaushik2,3
1Psychiatry, New York University School of Medicine, New York, 
NY,2Psychopharmacology Research Program, Nathan S. Kline Institute 
for Psychiatric Research, Orangeburg, NY,3Psychopharmacology 
Research, Manhattan Psychiatric Center, Wards Island, NY
Background: FazaClo, an orally disintegrating clozapine formulation has been 
shown to be bioequivalent to Clozaril® tablets, but similar data on conversion 
of generic clozapine to Fazaclo is not available.
Methods: 16 treatment-refractory schizophrenia or schizoaffective inpatients 
enrolled in a 17 day open label study (mean total PANSS = 72.81 (5.49)). 
Patients were on stable b.i.d dosage of generic clozapine and on concomitant 
psychotropics for at least 28 days. Trough concentrations for clozapine and 
desmethyl-clozapine were obtained on Days 1, 3, 4, 10 and 17; patients were 
switched to Fazaclo on Day 4.
Results: 15 patients completed the study and 1 patient withdrew consent 
on Day 10. Clozapine and desmethyl-clozapine plasma levels at Days 1, 3 
and 4 did not show significant differences with Days 10 and 17. There was 
a significant difference in the clozapine/desmethyl-clozapine plasma ratio at 
Day 10 compared to Days 1-4. Patients with ≥ 71 PANSS total (n = 9) showed a 
significant increase in plasma level at Days 10 and 17 compared to patients with 
≤ 70 total PANSS. Results also indicated patients with higher psychopathology 
measured by the PANSS have a clozapine/desmethyl-clozapine ratio of 2.45 
while those with PANSS scores ≤ 70 had a ratio of 1.97. No study drug side 
effects were observed.
Conclusions: FazaClo is bioequivalent to generic clozapine, and both FazaClo 
and generic clozapine were tolerated similarly. FazaClo may be substituted for 
generic clozapine on a mg-for-mg basis. Further investigation is underway with 
a larger sample (current effect size = .348).
Supported by Azur Pharmaceuticals
907. Cardiovascular and Metabolic Status in 
Neuroleptic-Treated Schizophrenia Patients 
Screening for Clinical Trials: Comparison to 
NHANES Controls
Robert E. Litman1,2, Megan B. Shanahan1, Camelia M. 
Graham3
1Psychiatry, CBH Health, LLC, Rockville, MD,2Psychiatry, Georgetown 
University Medical Center, Washington, DC,3Bloomberg School of 
Public Health, Johns Hopkins University, Baltimore, MD
Background: People with schizophrenia are at risk for the development of co-
morbid metabolic and cardiovascular illness. Atypical antipsychotic therapy 
may be a contributing factor.
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Methods: Metabolic and cardiovascular data from 357 chronically ill (38.3 + 
10.05 years old, 251 Male, 70.4% African-American) schizophrenia patients 
who were screened for participation in clinical trials from 1998-2007 (80.2% 
on atypical antipsychotics, 12.3% on typical antipsychotics, 7.5% untreated) 
were compared to a sample of 2,531 non-schizophrenic age-matched controls 
from the 2003-2004 Center for Disease Control and Prevention’s National 
Health and Nutrition Examination Survey (NHANES) on measures 
including fasting blood sugars and lipids, BMI, and blood pressure.
Results: 29.1% of patients were overweight (BMI>25) and 37.8% were obese 
(BMI>30). Fasting lipids, cholesterol and triglycerides were elevated in 39.3% 
and 40.5% of patients respectively. Elevations in fasting blood sugar (FBS 
>110mg/dl) were found in 16.7% of patients with 7.6% having diabetes (FBS 
>126mg/dl). 15.5% were hypertensive (diastolic BP >85mmHg), and 54.5% 
had abnormal ECGs. 34% had metabolic syndrome (n=189). There were no 
differences across variables when compared to the age-matched NHANES 
controls. No association with either typical or atypical neuroleptic treatment 
was found based on ?2 tests of differences.
Conclusions: Lack of differences with recent NHANES control data and 
lack of association with neuroleptic therapy suggests that other factors 
besides neuroleptic treatment (eg. diet, lifestyle) play a role in metabolic and 
cardiovascular abnormalities found in schizophrenia patients.
908. Efficacy and Tolerability of Paliperidone 
Palmitate: 9-week, Placebo-Controlled Study in 
Schizophrenia Patients
Michelle Kramer1, Robert E. Litman2, Rosanne Lane1,
Pilar Lim1, David Hough1, Marielle Eerdekens3
1Johnson & Johnson Pharmaceutical Research & Development, 
Titusville, NJ,2CBH Health, LLC, Rockville, MD,3Johnson & Johnson 
Pharmaceutical Research & Development, Beerse, Belgium
Background: This study evaluated the efficacy and safety of paliperidone palmitate, 
a long-acting injectable agent, in the treatment of schizophrenia patients.
Methods: A 9-week, double-blind, placebo-controlled study randomized 
patients to placebo or paliperidone palmitate 50 or 100 mg eq. on Days 1, 8 and 
36 (without oral supplementation). Efficacy and tolerability were evaluated via 
changes in mean Positive and Negative Syndrome Scale (PANSS) total scores 
and adverse event (AE) reporting, respectively.
Results: The intention-to-treat population included 197 patients (male=62%, 
mean±standard deviation [SD] age=39.3±10.3y; placebo N=66; paliperidone 
palmitate 50 mg eq. N=63; paliperidone palmitate 100 mg eq. N=68). 
Mean±SD PANSS total scores significantly improved (p≤0.001) from baseline 
(87.0±12.5) to end point for paliperidone palmitate 50 mg eq. (−5.2±21.5) 
and 100 mg eq. (−7.8±19.4) versus placebo (+6.2±18.3), with significant 
improvements observed from Day 8. Responder rates (≥30% improvement in 
PANSS total score at end point) were significantly greater in both paliperidone 
palmitate groups versus placebo (p≤0.007). AEs occurring ≥3% more in either 
paliperidone palmitate group versus placebo (safety population, N=247) were 
insomnia, schizophrenia, restlessness, sedation, extrapyramidal disorder, 
hypertonia, attention disturbance, electrocardiogram abnormal, constipation, 
myalgia, asthenia and vertigo. Extrapyramidal symptoms−AE rates were 
comparable for paliperidone palmitate and placebo, with the exception of 
parkinsonism (7% and 1%, respectively). Serious AEs in ≥1 patient (any group) 
were schizophrenia and psychotic disorder. Injections were generally well 
tolerated. No deaths occurred.
Conclusions: Paliperidone palmitate (50 and 100 mg eq. doses) is effective and 
well tolerated in acute symptomatic schizophrenia.
Supported by Johnson & Johnson Pharmaceutical Services, LLC., and Johnson 
& Johnson Pharmaceutical Research & Development
909. Pharmacokinetics (PK) of Multiple Doses 
of Olanzapine Long Acting Injection (OLAI), an 
Intramuscular (IM) Depot Formulation of Olanzapine 
(OLZ), in Stabilized Patients with Schizophrenia
Darcie Kurtz, Richard Bergstrom, David P. McDonnell,
Malcolm Mitchell
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN
Background: Olanzapine pamoate is a long-acting depot formulation of OLZ 
that is an effective treatment for patients who benefit from the advantages of a 
depot. It has not yet been approved.
Methods: Schizophrenic patients stabilized on daily oral OLZ received multiple 
OLAI injections at doses of 100, 150, 160, 200, and 300 mg/2 weeks and 200, 
255, 300, and 405 mg/4 weeks for 24 weeks. After each injection, serial plasma 
OLZ concentration samples were collected. PK were characterized using non-
compartmental methods.
Results: The injections were well tolerated overall. Absorption-limited PK were 
observed. Plasma OLZ concentrations were sustained throughout both the 2- 
and 4-week injection intervals. On average, OLZ concentrations accumulate 
2- to 3-fold upon multiple dosing and reach steady-state conditions after 
about 3 months of dosing. Peak-to-trough fluctuation in OLZ concentrations 
averages 51% for the 2-week injection interval and 75% for the 4-week interval. 
Maximum concentration and area under the concentration versus time curve 
for OLZ were proportionate to OLAI dose. Relative to oral OLZ (tmax = 6 hr, 
t1/2 = 29 hr), the time of peak concentration following OLAI was 4 days and the 
half-life was approximately 26 days. The average steady-state concentrations 
sustained by OLAI correspond to those maintained by daily OLZ in the dosage 
range of 5-20 mg/day.
Conclusions: IM administration of OLAI is well tolerated and provides 
steady-state concentrations that are sustained over 4 weeks and are comparable 
to oral treatment.
Supported by Eli Lilly and Company
910. Relapse Prevention: Risperidone Long-Acting 
Injectable Vs Quetiapine or Aripiprazole
Rossella Medori
Medical Affairs, Janssen-Cilag, Beerse, Belgium
Background: To investigate if risperidone long-acting injectable (RLAI) 
provides better efficacy maintenance over 2 years, as measured by the time 
to relapse, in comparison to the oral atypical antipsychotic quetiapine or 
aripiprazole.
Methods: Open-label, active-controlled, multicenter, randomized, 2-year 
trial of RLAI versus oral quetiapine or aripiprazole in 731 patients with 
schizophrenia currently treated with oral risperidone, olanzapine or 
conventional neuroleptics. Symptomatically stable patients on a stable dose 
of an antipsychotic for ≥4 weeks were enrolled. Primary efficacy evaluation 
was time to relapse. Secondary efficacy evaluations included: Positive and 
Negative Syndrome Scale (PANSS), Clinical Global Impression-Severity 
(CGI-S), Montgomery-Asberg Depression Rating Scale (MADRS) and Social 
and Occupational Functioning Assessment Scale (SOFAS). Safety evaluations 
included adverse events monitoring, Extrapyramidal Symptom Rating Scale 
(ESRS), clinical laboratory tests and vital signs.
Results: 808 subjects were screened and 731 (58.3% male, mean age 41.5 
[SD:12.8] years) were randomised to treatment. Mean time since first onset 
was 13.9 (SD:11.2) years; mean time since first treatment was 12.5 (SD:10.7) 
years. At baseline 34.4% of subjects fulfilled the remission severity criteria. 
Reasons for switching (>1 allowed) included: insufficient efficacy; negative 
(29.8%), positive (14.1%), and general symptoms (21.1%) and adverse events 
(18.9%). Baseline scores were: PANSS: 73.0 (SD:21.8), CGI-S: 3.7 (SD:1.0), 
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MADRS: 13.1 (SD:7.6), SOFAS: 56.9 (SD:14.2) and ESRS: 4.3 (SD:7.0). 
Treatment outcome data will be presented.
Conclusions: This study shows that the subjects enrolled in this relapse 
prevention trial are representative of the present treatment habits, as well as 
identifies the unmet needs and dissatisfaction in current treatment options.
Supported by Jansen-Cilag EMEA
911. A 28-Week, Randomized, Double-Blind Study of 
Olanzapine versus Aripiprazole in the Treatment of 
Schizophrenia
John M. Kane1, Olawale Osuntokun2, Ludmila A. 
Kryzhanovskaya2, Wen Xu2, Virginia Stauffer2, Susan B. 
Watson2
1Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, 
NY,2Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN
Background: The current study evaluated the effectiveness of olanzapine 
(OLZ) versus aripiprazole (APZ) in patients with schizophrenia.
Methods: Patients 18 to 65 with schizophrenia were randomized to either 
OLZ (n=281) or APZ (n=285) for 28 weeks of double-blind treatment. The 
primary outcome was time to all-cause discontinuation. Symptom efficacy 
was measured by Positive and Negative Syndrome Scale (PANSS) total change 
from baseline (LOCF). Time-to-event data were analyzed via the Kaplan Meier 
method and log-rank test.
Results: Treatment groups did not differ significantly in time to all-cause 
discontinuation (p=.067) or discontinuation rates (OLZ 42.7%, APZ 50.2%, 
p=.053). OLZ patients had a significantly greater LS mean decrease in the 
PANSS (-30.2) than APZ patients (-25.9, p=.014). Mean weight change (kg) 
was +3.4 for OLZ and +0.3 for APZ (p<.001). Fasting mean glucose change 
(mg/dL) was +4.9 for OLZ and +0.9 for APZ (p=.045). Percent of patients with 
baseline glucose <100 and glucose ≥126 at any time was 1.7% for OLZ and 
0.6% for APZ (p=.623). Fasting mean total cholesterol change (mg/dL) was 
+4.1 for OLZ and -9.8 for APZ (p<.001). Percent of patients with baseline total 
cholesterol <200 and cholesterol ≥240 at any time was 9.2% for OLZ and 1.5% 
for APZ (p=.008).
Conclusions: OLZ and APZ groups did not differ significantly on the primary 
outcome. OLZ patients had significantly greater improvement in symptom 
efficacy. Significantly greater increases in weight, glucose, and total cholesterol 
were observed in OLZ-treated patients. Results are generally consistent with 
previous clinical trials comparing the 2 therapies.
Supported by Eli Lilly and Company
912. Long-Term Symptomatic Remission of 
Schizophrenia with Once-Daily Extended Release 
Quetiapine Fumarate
Joseph Peuskens1, Jitendra K. Trivedi2, Martin 
Brecher3, Ola Svensson4, Frank Miller4, Didier Meulien4
1Psychiatrisch Centrum, Universitair Psychiatrisch Centrum KU Leuven, 
Kortenberg, Belgium,2Psychiatry, King George Medical University, 
Lucknow, India,3Pharmaceuticals, AstraZeneca Pharmaceuticals LP, 
Wilmington, DE,4Pharmaceuticals, AstraZeneca R&D, Södertälje, Sweden
Background: Relapse prevention with once-daily extended release quetiapine 
fumarate (quetiapine XR) was evaluated in a randomized, double-blind, 
placebo-controlled study (D1444C00004) in schizophrenia.
Methods: Patients (n=327) were treated with open-label, f lexible-dose, once-
daily quetiapine XR (400, 600 or 800 mg/day) for a 16-week stabilization 
period. Following this, clinically stable patients were randomized to either 
continue (double-blinded) flexible-dose quetiapine XR or placebo. The primary 
endpoint was time from randomization to first schizophrenia relapse up to 1 
year. Interim analyses were planned after 45 and 60 relapse events. Remission 
rates (as defined by Andreasen et al, Am J Psychiatry 2005:162:441-9, ie PANSS 
≤3 for items P1, G9, P3, P2, G5, N1, N4 and N6 for ≥6 months) and time 
to non-remission were evaluated post hoc for patients who were in remission 
during the stabilization period. Time from randomization to relapse and non-
remission were analyzed using the Cox proportional hazards model.
Results: The study was terminated early after the first interim analysis, as 
quetiapine XR (mean dose 669 mg/day; mean randomized-treatment period 
4 months) was significantly superior to placebo for time to relapse: HR 0.16 
(95% CI 0.08, 0.34; p<0.001). Using the time to non-remission analysis, 
the estimated remission rates 6 months after randomization were 76% for 
quetiapine XR and 52% for placebo. Time to non-remission was significantly 
shorter with placebo compared with quetiapine XR: HR 0.39 (95% CI 0.19, 
0.81; p=0.009).
Conclusions: Once-daily quetiapine XR (400-800 mg/day) prevents relapse 
and is associated with sustained remission in patients with clinically stable 
schizophrenia.
Supported by AstraZeneca Pharmaceuticals LP
913. Asenapine in Schizophrenia: An Overview of 
Clinical Trials in the Olympia Program
Steven Potkin1, John M. Kane2, Robin A. Emsley3,
Dieter Naber4, John Panagides5
1Department of Psychiatry, University of California, Irvine, Orange, 
CA,2Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, 
NY,3Department of Psychiatry, University of Stellenbosch, Cape Town, 
South Africa,4Department of Psychiatry and Psychotherapy, University 
of Hamburg-Eppendorf, Hamburg, Germany,5Clinical Development, 
Organon, a part of Schering-Plough Corporation, Roseland, NJ
Background: Asenapine is a novel psychopharmacologic agent being developed 
for treatment of schizophrenia and mania associated with bipolar 1 disorder.
Methods: We reviewed completed schizophrenia studies in the 3000+ patient 
Olympia clinical trial program: 4 acute studies (Hera) and 1 long-term safety study 
(ACTAMESA). Results from long-term studies such as Aphrodite (481 patients), 
which focuses on prominent persistent negative symptoms, will be available soon.
Results: In 2 of the 4 randomized short-term Hera studies, a high placebo 
effect was observed: difference on the PANSS total score (asenapine-placebo) 
did not reach statistical significance. However, in 2 randomized controlled 
6-week trials (622 patients), asenapine produced 19- to 21-point reductions 
in PANSS total score (significantly superior to placebo using mixed-model 
for repeated measures analysis). Asenapine also showed benefit in reducing 
negative symptoms, a finding under further study in the aforementioned long-
term Aphrodite study. Asenapine was associated with mild effects on weight 
(0.5−0.7 kg vs −0.4 to 0.2 kg with placebo) and prolactin levels (−15 to −2 μg/L 
vs −19 to −4 μg/L with placebo). In the year-long randomized ACTAMESA 
study (1219 patients treated with flexibly dosed asenapine or olanzapine), 
overall adverse event (AE) rates were similar for asenapine and olanzapine 
(drug-related AEs, 60% and 61%, respectively; withdrawals due to AEs, 6.3% 
and 6.8%). Extrapyramidal symptoms were more common with asenapine 
(18% vs 8% with olanzapine), clinically significant weight gain was more 
common with olanzapine (36% vs 15% with asenapine).
Conclusions: Asenapine is effective and well tolerated in the treatment of 
schizophrenia.
Supported by Organon, a part of Schering-Plough
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914. Obsessive-Compulsive Symptoms or 
Obsessive-Compulsive Disorder in Patients 
with Schizophrenia Treated with Clozapine or 
Haloperidol
Antonio R. Sa, Ana G. Hounie, Aline S. Sampaio, 
Euripedes C. Miguel, Helio Elkis
Department & Institute of Psychiatry, Clinical Hospital, School of 
Medicine, University of São Paulo., São Paulo, Brazil
Background: We conducted a cross-sectional study to compare the prevalence 
and the severity of OCS and OCD in patients with schizophrenia treated with 
clozapine or haloperidol.
Methods: SCID-I/P was used for the diagnoses of schizophrenia and OCD. 
All subjects (n= 60) completed the Y-BOCS, PANSS and CGI. Best Estimate 
Diagnoses were assigned by the first author and two psychiatrists to assure 
reliability. Chi-square test with Yates correction, Mann-Whitney U test and 
Kruskal-Wallis test were used for the statistical analyses.
Results: Among the 60 schizophrenia patients evaluated, 10 (16.7 %) met 
DSM-IV criteria for both schizophrenia and OCD; 13 (21.7 %) had OCS but 
not OCD and 37 (61.6 %) had neither OCD nor OCS. The prevalence of 
OCD or OCS was similar in patients taking clozapine or haloperidol (40% 
vs 35% respectively). Patients using clozapine showed higher severity of OCS 
than patients using haloperidol (P= 0.027). Patients with schizophrenia and 
OCD also showed higher severity of schizophrenic symptoms when compared 
to patients with schizophrenia without OCS (P= 0.002).
Conclusions: Although the presence of OCS or OCD was similar in the 
groups taking clozapine or haloperidol, patients using clozapine showed higher 
scores on the YBOCS. These results may support an association between the 
exacerbation of obsessive-compulsive phenomena and the use of clozapine.
915. Correlating Functional Domains and Symptom 
Clusters in Schizophrenia 
Bruce Simonson, Wayne Macfadden, Tom Haskins, 
Cynthia Bossie, Young Zhu, Larry Alphs
??????????????????????????????? ??????????????????????????????
Background: Meaningful measures of functioning are important in 
determining treatment effectiveness for schizophrenia patients. The Personal 
and Social Performance (PSP) scale is a validated clinician-rated measure of 
patient functioning; how its domains correlate to other clinical measures has not 
been established. This analysis explored the relationship between PSP domains, 
measures of symptomatology and demographics in schizophrenia patients.
Methods: Post-hoc analysis evaluated baseline data from an open-label, rater-
blinded, multicenter study of patients randomized to risperidone long-acting 
injectable or aripiprazole for up to 2 years. Correlational and categorical 
analyses compared PSP total score and its four domain scores (socially useful 
activities, personal & social relationships, self-care, disturbing & aggressive 
behaviors) to the Positive and Negative Syndrome Scale (PANSS) factor scores, 
onset of illness and demographics.
Results: 355 evaluable subjects were included in this baseline analysis. Data 
did not suggest a significant relationship between PSP domain scores and 
age, gender or onset of illness. Each PSP domain score correlated with several 
PANSS factors, as follows: socially useful activities with positive (0.323; 
P<0.0001), negative (0.405; P<0.0001) and disorganized thoughts (0.489; 
P<0.0001); personal & social relations with negative (0.501; P<0.0001) and 
disorganized thoughts (0.454; P<0.0001); self-care with negative (0.344; 
P<0.0001) and disorganized thoughts (0.450; P<0.0001); and disturbing & 
aggressive behavior with positive (0.300; P<0.0001), disorganized thoughts 
(0.309; P<0.0001) and uncontrolled hostility/excitement (0.598; P<0.0001).
Conclusions: For the first time, functioning domains of the PSP have been 
shown to correlate with clinical measures of symptomatology used for treating 
schizophrenia.
Supported by Ortho-McNeil Janssen Scientific Affairs, L.L.C.
916. Naturalistic Treatment of Functional Deficits in 
the Schizophrenia Prodrome
Christopher W. Smith, Andrea Auther, Christoph 
Correll, Lauren Baskir, Danielle McLaughlin, Barbara 
Cornblatt
Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, NY
Background: Research on the schizophrenia prodrome has focused largely on 
determining rates and predictors of conversion to psychosis. However, social and 
role functioning are increasingly studied in the prodrome, both for prediction 
of conversion and as outcomes. The Recognition and Prevention Program 
previously found that functional deficits precede psychosis and are stable 
over time. However, examining group means can mask subgroup differences. 
This study will explore whether differences in naturalistic pharmacological 
treatment affect social and role functioning.
Methods: Study subjects (n=35) were considered prodromal based on attenuated 
positive symptoms assessed with SIPS/SOPS. Subjects were evaluated at baseline 
and ~12 months. Functioning was assessed using Global Functioning: Social 
and Role scales. Psychopharmacological treatment was prescribed by physician’s 
choice and included primary treatment with antipsychotics (AP; n=24) or 
antidepressants (ADP; n=11). Separate RMANOVAs were performed on social 
and role domains, with medication-group as the between-subjects factor.
Results: For social functioning, neither the main effect (p=.46), nor the 
interaction with medication-group (p=.86) were significant. For Role 
functioning, both the main effect of time (p=.01) and the interaction with 
medication-group (p<.0005) were significant, with ADP improving. No 
baseline symptom or functional differences between medication groups (p>.18) 
were observed.
Conclusions: Findings suggest that antipsychotics may not be useful for 
improving social or role functioning in the prodrome, but antidepressants 
may improve role functioning. Non-randomized medication assignment is a 
limitation. However, no obvious baseline differences exist between medication 
groups. Results indicate that social (moreso than role) deficits are core, 
treatment-resistant aspects of the vulnerability for schizophrenia.
Supported by RO1MH61523: Cornblatt, PI, Characterization of Prodromal 
Schizophrenia; P30MH74543: Kane, PI, Early Phase Schizophrenia: 
Optimizing Outcomes
917. Extrapyramidal Symptom and Akathisia Profile of 
Iloperidone in Phase III Schizophrenia Clinical Trials
Peter J. Weiden1, Rosarelis Torres2
1Center for Cognitive Medicine, Univeristy of Illinois at Chicago, 
Chicago, IL,2Clinical Affairs, Vanda Pharmaceuticals Inc., Rockville, MD
Background: Antipsychotic-induced extrapyramidal symptoms (EPS) and 
akathisia can influence functioning, quality of life, and treatment adherence. 
Iloperidone, a mixed D2/5-HT2 antagonist being developed for the treatment 
of schizophrenia, is under review by the FDA. Currently available atypical 
antipsychotics still show a range of liability to cause EPS or akathisia, so these 
adverse events are important aspects of any developing antipsychotic agent.
Methods: EPS and akathisia were assessed in a pooled analysis of iloperidone 
data from 4 short-term, Phase III, double-blind, placebo-controlled clinical 
trials of adult patients with acute schizophrenia. Outcomes include rates 
of treatment-emergent adverse events (TEAEs), changes from baseline in 
Extrapyramidal Symptoms Rating Scale (ESRS) and Barnes Akathisia Scale 
(BAS), and rates of concurrent anticholinergic use.
www.sobp.org/journal
Saturday Abstracts BIOL PSYCHIATRY 2008;63:1S-301S 291S
Results: A total of 2505 patients (iloperidone [ILO] 4-24 mg/day, n=1344; 
haloperidol [HAL] 5-20 mg/day, n=118; risperidone [RIS] 4-8 mg/day, n=306; 
ziprasidone [ZIP] 160 mg/day, n=150; placebo [PBO], n=587) were included. 
EPS was reported as a TEAE in 4.6% (ILO), 20.3% (HAL), 9.5% (RIS), 9.3% 
(ZIP), and 4.1% (PBO) of patients. Mean changes in overall ESRS from baseline 
to endpoint were -0.3 ILO, 1.8 HAL, -0.3 RIS, 0.2 ZIP, and -0.3 PBO. Akathisia 
was reported as a TEAE in 2.5% (ILO), 13.6% (HAL), 6.9% (RIS), 7.3% (ZIP), 
and 2.7% (PBO) of patients, and worsening of akathisia (BAS scores) was reported 
in 7.8% (ILO), 15.5% (RIS), 15.6% (ZIP), and 11.4% (PBO) of patients.
Conclusions: Iloperidone may have a lower propensity to cause EPS or 
akathisia than haloperidol, risperidone, or ziprasidone.
Supported by Vanda Pharmaceuticals funded this analysis
918. Suicide Attempts among Women during 
Hypoestrogenic Phases
Enrique Baca-Garcia1,2,3, Carmen Diaz-Sastre4, Antonio 
Ceverino5, M. Mercedes Perez-Rodriguez4, Jeronimo 
Saiz-Ruiz4,6, Jose de Leon7, Maria A. Oquendo1
1Department of Neurosciences, Columbia University Medical Center, 
New York, NY,2Psychiatry, Fundacion Jimenez Diaz Hospital, Madrid, 
Spain,3Psychiatry, Autonoma University, Madrid, Spain,4Department 
of Psychiatry, Ramon y Cajal Hospital, Madrid, Spain,5Department 
of Psychiatry, Fundacion Jimenez Diaz Hospital, Madrid, 
Spain,6Psychiatry, Alcala University, Madrid, Spain,7Mental Health 
Research Center (MHRC), Eastern State Hospital,, Lexington, KY
Background: To determine whether perimenstrual phases in fertile women are 
associated with acute risk for suicide attempt, to explore whether risk is elevated 
during all hypoestrogenic periods, and to examine the characteristics of suicide 
attempts during hypoestrogenic periods.
Methods: Women (N=431) recruited within 24 hours of a suicide attempt were 
assessed for psychopathology, suicidal behavior and LH, FSH, estradiol and 
progesterone blood levels.
Results: Women who attempted suicide during hypoestrogenic periods 
(menstrual phase, amenorrhea and menopause) reported more severe suicide 
intent than those whose attempts occurred during other phases.
Conclusions: Suicide attempts among women when estrogen levels are low are 
associated with greater severity. Low estrogen levels may constitute a key factor 
in the neurobiological basis of suicidal behavior among women, suggesting a 
novel, testable hypothesis regarding the underpinnings of suicidal acts.
Supported by Spanish government (Fondo de Investigación Sanitaria (FIS) 
PI050500 and PI060092
919. Differences in Suicidal Behavior may help to 
Differentiate between Narcissistic and Antisocial 
Personality Disorder
Hilario Blasco-Fontecilla1, Kanita Dervic2, José de 
León3, Maria Oquendo4, Enrique Baca-García5
1Department of Psychiatry, DR. R. Lafora Hospital, Madrid, 
Spain,2Department of Child and Adolescent Neuropsychiatry, University 
Hospital, Medical University of Vienna, Vienna, Austria,3Department 
of Psychiatry, University of Kentucky Mental Health Research Center 
at Eastern State Hospital, Lexington, KY,4Department of Psychiatry, 
Columbia University College of Physicians and Surgeons, New York, 
NY,5Department of Psychiatry, Fundación Jiménez Diaz, Madrid, Spain
Background: Narcissistic personality disorder (NPD) and antisocial PD (APD) are 
not always easily differentiated disorders. Though both PDs are grouped into DSM-
IV cluster B, subjects diagnosed with NPD might exert a better impulse control. 
Impulsivity and lethality seem to be inversely associated during suicide attempts. 
Our main objective was to test whether suicide attempts are different in terms of 
impulsivity/lethality in suicide attempters (SA) diagnosed with NPD and APD.
Methods: We assessed 446 SA admitted to the emergency room at two 
general Hospitals in Spain between 1999 to 2003. The diagnosis of PDs was 
made by using the DSM-IV version of the International Personality Disorder 
Questionnaire-Screening Questionnaire (IPDE-SQ). An adjusted cut-off 
point was used in order to increasing specificity. The following scales were used 
in order to measure impulsivity/lethality of suicide attempts: The Lethality 
Rating Scale (LRS), the Risk-Rescue Rating Scale, the Suicide Intent Scale 
(SIS), and the Barratt Impulsiveness Scale (BIS).
Results: subjects diagnosed with NPD had suicide attempts characterized by 
an increased expected lethality (SIS factor 1) (T= -4.244, gl= 439, p< 0.000), 
while in those diagnosed with APD were characterized by a higher impulsivity 
(BIS) (T= -3.961, gl= 442, p= 0.000).
Conclusions: Suicide attempts in subjects diagnosed with NPD are not 
characterized, in contrast to APD, by a higher impulsivity. The characteristics 
of a suicide attempts might help in differentiating between both PDs. Targeted 
therapies aimed to decreasing suicidal risk may be different depending on 
specified PD diagnosis.
Supported by NARSAD, FIS, CIBER
920. Lower CSF MHPG Predicts Short-Term Risk for 
Suicide Attempt
Hanga Galfalvy
Psychiatry, Columbia University, New York, NY
Background: Low cerebrospinal f luid (CSF) 5-hydroxyindoleacetic acid 
(5-HIAA) predicts suicide in mood disorders in prospective studies. Our goal 
was to study the association between other CSF monoamine metabolite levels 
and future suicide attempts.
Methods: 184 subjects presented for treatment within the context of a Major 
Depressive Episode. CSF levels of 5-HIAA, homovanillic acid (HVA) and 
3-methoxy-4-hydroxyphenylglycol (MHPG) were assayed. 159 subjects 
returned for follow-up interviews 3 months and/or 1 year later. Survival 
analysis was used to examine the association between monoamines and suicide 
attempts during follow-up.
Results: Low MHPG predicted future suicide attempt (HR=2.6, p=.023) and 
correlated with higher medical seriousness of attempts (r= -0.4, p = 0.038). HVA 
was inversely associated with the medical seriousness, but not the likelihood, 
of past or future suicide attempts. Low ratio of HVA to 5-HIAA levels was 
associated with the likelihood of past and future medically serious attempts 
(OR=1.9, p=.029; HR=2.5, p=.042). MHPG and HVA were significantly 
associated with history of drug or alcohol abuse/dependence and with current 
smoking, a predictor of future suicide attempts (HR=2.6, p=.015) but were not 
associated with severity of other psychopathology or childhood adversity.
Conclusions: We have identified a relationship between MHPG and both 
probability and lethality of future suicide attempts in major depression. In 
addition we confirmed previous studies showing that a low HVA/5-HIAA 
ratio is associated with a greater likelihood of and more serious future suicide 
attempts in depressed patients. Both HVA and MHPG are linked to tobacco 
use, another known predictor of future suicide attempts.
Supported by NIMH K25 MH074068, MH62185
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921. Risk Factors for Adolescent Suicidality in 
Offspring with and without Borderline Personality 
Disorder
Marianne Goodman1,2, Joseph Triebwasser1,2, Uday 
Patil1, Antonia New1,2, Elizabeth Diamond1, Larry 
Siever1,2
1Psychiatry, Mount Sinai School of Medicine, New York, NY,2Psychiatry, 
James J Peters VA Medical Center, Bronx, NY
Background: Suicide is the third leading cause of death in Americans aged 15-24; 
each year, 1,600 U.S. teenagers commit suicide (Gould et al., 2003). Borderline 
personality disorder (BPD) is an important cause of attempted and completed 
suicide in adults (Soloff et al., 2002). We present data about developmental 
antecedents of adolescent suicidality in a sample enriched for BPD.
Methods: We have gathered data on suicide attempts and suicidal ideation, 
via surveys of parents who have at least one adolescent and/or adult child with 
BPD. We have developed a questionnaire concerning both BPD and non-BPD 
offspring, with over 100 questions covering infancy through young adulthood, 
targeting the development of psychopathology and assessing suicide-related 
and deliberate self-harm variables in detail.
Results: To date over 800 surveys have been completed, with approximately 
500 having usable data. We report on 496 offspring, 170 with strictly defined 
BPD, 206 psychiatrically ill but without BPD, and 120 healthy controls. 
Significant predictors of adolescent suicidality, derived from binary logistic 
regression, included 1) childhood factors of few friends and picky eating 2) 
adolescent factors of delusions, homicidality, teenage romantic relationships, 
rape and pregnancy variables, property destruction, and impulsivity. Being a 
perpetrator of bullying was a protective factor.
Conclusions: Suicidality is frequent in adolescents with BPD and Axis 
I disorders. Adolescents at increased risk for suicidal behavior exhibit 
impulsivity, homicidality and delusions and experience interpersonal problems 
since childhood, and precocious sexual involvement in adolescence. Suicidal 
behavior appears to be distinct from outward expressions of aggression.
922. CSF 5-HIAA and DST Non-Suppression - 
Orthogonal Biologic Risk Factors for Suicide in 
Male Mood Disorder Inpatients
Jussi Jokinen, Anna-Lena Nordström, Peter 
Nordström
Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
Background: Two biomarkers of suicide risk; nonsuppression in the 
dexamethasone suppression test (DST) and low 5-hydroxyindoleacetic acid 
(5-HIAA) in the cerebrospinal f luid (CSF) have evidence for predictive power 
for suicide in mood disorders. The interrelation of the two systems seems to 
be different in suicide attempters compared to depressed inpatients without 
suicide attempt, indicating that two biomarkers may be seen as independent. 
This investigation determined the interrelation of low CSF 5-HIAA and the 
DST nonsuppression in suicide victims with mood disorder.
Methods: Fifty-eight mood disorder inpatients not receiving any treatment 
with antidepressants underwent lumbar puncture and the DST. Plasma cortisol 
levels at 8:00 a.m., 4:00 p.m. and 11:00 p.m. were analyzed in relation to CSF 
5-HIAA. All patients were followed up for causes of death and suicides were 
verified with death certificates.
Results: During follow-up (mean 21 years), 11 (19 %) patients had committed 
suicide. In male suicide victims (n=6), the serum cortisol level at 4:00 p.m. 
showed a significant positive correlation with CSF 5-HIAA. Low CSF 5-HIAA 
predicted all early suicides (within one year), whereas all males who committed 
suicide after one year were DST nonsuppressors. In female suicide victims 
(n=5), the postDST serum cortisol did not correlate with CSF 5-HIAA.
Conclusions: Low CSF 5-HIAA and DST nonsuppression are orthogonal 
biologic risk factors for suicide in male mood disorder inpatients. CSF 5-HIAA 
is associated with short-term suicide risk; HPA axis dysregulation seems to be 
a long-term suicide predictor.
923. Characterization of Decision-Making 
Impairment in Suicide Attempters and the Influence 
of Attention to Wins on Suicidal Intent and 
Repetition
Fabrice Jollant1, Sébastien Guillaume1, Isabelle Jaussent2,
Didier Castelnau3, Alain Malafosse4, Philippe Courtet1
1CHU Montpellier, Department of Psychological Medicine and 
Psychiatry, Université Montpellier 1 & Inserm U888, Montpellier, 
France,2Department of Biostatistics, Université Montpellier & Inserm 
U888, Montpellier, France,3Department of Psychological Medicine 
and Psychiatry, CHU Montpellier, Montpellier, France,4Département 
de médecine génétique et Laboratoires, Hôpitaux Universitaires de 
Genève, Geneva, Switzerland
Background: Impaired decision-making may represent a cognitive factor 
of vulnerability to suicidal behavior. Recent development in the analysis 
of decision-making performance measured by the Iowa Gambling Task 
(expectancy-valence model) enables to distinguish 3 modes of decision-making: 
decisions guided by attention to losses vs. to wins, decisions guided by past vs. 
recent outcomes and consistent vs. erractic choices.
Methods: We compared these 3 modes of decision-making in 143 healthy 
subjects, 125 patients with a past history of affective disorders but no history 
of suicidal acts (affective controls) and 179 patients with a past history of both 
affective disorders and suicidal acts (suicide attempters). All patients were 
normothymic at the time of assessment.
Results: In comparison to both control groups and after adjustment for age and 
gender, suicide attempters make decisions significantly more often on the basis 
of a higher attention to wins (p=0.03) and in an erractic way (p=0.03). Control 
groups were not different from each other. Moreover, a higher attention to 
gain was associated with higher suicidal intent of the most severe suicidal act 
(p=0.008) and with more than 3 past suicidal acts (p=0.02).
Conclusions: Different processes may underlie decision-making impairment in 
suicide attempters. Potential mechanisms and implications for understanding 
the cognitive aspects of vulnerability to suicidal behavior will be discussed.
Supported by CHU Montpellier (PHRC National 7653)
924. fMRI Markers of Early-Onset Suicide Attempt-
-Evidence of Decreased Activation in the Medial 
Prefrontal Cortex
Lisa Pan, Stefanie Hassel, Sharon Nau, David Brent, 
Mary Phillips
Western Psychiatric, University of Pittsburgh Med Ctr, Pittsburgh, PA
Background: Clinical and epidemiological studies consistently describe 
difficulties in emotion regulation and impulsivity in suicide attempters. 
However, these domains have rarely been assessed using standard performance 
tasks, which in turn are linked to neural function. The primary objective of this 
research project is to examine the neural circuitry underlying trait dependent 
abnormalities in adolescents with early onset suicidal behavior by focusing 
on emotional processing. We therefore aimed to employ fMRI to examine 
corresponding activity in neural regions implicated during performance of 
these tasks in suicide attempters versus control groups.
Methods: Three groups of adolescents, those with: (1) lifetime history of 
attempt and remitted MDD (attempters, SA); (2) history of remitted MDD, but 
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no attempt (affective controls, AC), and (3) healthy controls (HC) participated 
in the study. All participants performed standardized happy and fearful facial 
expression gender labeling tasks. Neural activity during performance of these 
tasks was compared in SA versus AC and HC.
Results: Preliminary data show reduced activity to angry faces in the medial 
pre-frontal cortex (PFC, BA 10/32) in SA (n=5), versus AC (n=3). Exposure 
to happy faces elicits no group differences in PFC activity. We are currently 
analyzing data in larger numbers of participants.
Conclusions: Brodmann Area 10/32, is involved in the exercise of restraint, 
and has been implicated in risky decision making in adults. Our findings in 
adolescent SA are consistent with previous studies that demonstrate a difficulty 
with regulation of negative emotion, beyond depression, related to the etiology 
of suicidal behavior.
Supported by Klingenstein Third Generation Foundation and American 
Foundation for Suicide Prevention
925. Hallucinations, Pseudohallucinations- Severity 
of Suicidal Ideations among Emergency Psychiatry 
Patients: A Pilot Study
Praveen Penagaluri1, Kristen L. Walker2, Rif S. El-
Mallakh1
1Psychiatry, University of Louisville School of Medicine, Louisville, 
KY,2Psychology, University of Louisville School of Medicine, Louisville, KY
Background: Prediction of suicide is a difficult but essential task in nearly 
all clinical psychiatric evaluations. A multitude of suicide risk factors have 
been identified that include symptoms such as psychosis and command 
hallucinations. Yet, despite knowledge of these factors, prediction of suicidal 
behavior remains suboptimal. Hallucinations, in particular command 
hallucinations, are significant risk factors. This study investigated relative 
relationships between auditory hallucinations and non psychotic hallucinations 
(pseudohallucinations) and suicidal risk.
Methods: A sample of 206 consecutive patients seen in an emergency 
psychiatric service were evaluated for the presence and intensity of hallucinatory 
experiences (assessed by the hallucination item of the Positive and Negative 
Symptoms Scale [PaNSS]), suicidal intensity (assessed by the suicide item of 
the Montgomery Asberg Depression Rating Scale [MADRS]), and cumulative 
suicide risk (determined by the total number of risk factors).
Results: Individuals with pseudohallucinations appeared to experience greater 
intensity of acute suicidal ideation compared with either subjects with no 
hallucinatory experiences (P = 0.006) or subjects with psychotic hallucinations 
(P = 0.003). There are no differences in the intensity of the hallucinatory 
experience, the number of risk factors for completed suicide in patients with 
pseudohallucinosis compared with patients with psychotic hallucinations or 
no hallucinatory.
Conclusions: Subjects with pseudohallucinosis experience more intense 
suicidality when they are ill than those with psychotic hallucinations 
or no hallucinatory experience. Suicidal evaluation can be improved if 
a determination is made as to the psychotic or nonpsychotic nature of 
hallucinatory experiences.
926. Suicidal Ideation, Violent Behavior, and Self-
Injury in Schizophrenia Patients Treated with Long 
Acting Risperidone: 12-Month Results from E-Star
Jos Peuskens1, Alex Rodriguez2, Ivan Tuma3, Jan 
Pecenak4, M. van Kooten5, Lars Eriksson6, B. Bork7,
Michael Povey8, Annette Lam9, Zhongyun Zhao10
1KU Leuven campus UC St. Jozef Kortenberg, Universitair 
Psychiatrisch Centrum, Leuven, Belgium,2Psychiatry, Centro Forum 
de Barcelona, Barcelona, Spain,3Medical School and Teaching 
Hospital Hradec Kralove, Charles University in Prague, Hradec 
Kralove, Czech Republic,4Psychiatry, FNSP Bratislava, Bratislava, 
Slovakia,5De Geestgronden-Buitenamstel, Ambulant ACT,, Binnenweg 
3 te Hoofddorp, The Netherlands,6Psychiatry, SU/Östra RPV, Hisings-
Backa, Sweden,7Psychiatry, DP Tønder, Tønder, Denmark,8Statistics, 
SGS Life Science Services, Wavre, Belgium,9Health Economics, 
Johnson & Johnson Pharmaceutical Services, Toronto, ON, 
Canada,10Health Economics, Johnson & Johnson Pharmaceutical 
Services, Raritan, NJ
Background: To examine the incidence of suicidal ideation, violent behavior, 
and deliberate self-harm in patients with schizophrenia treated with risperidone 
long-acting injection (RLAI) enrolled in the electronic-Schizophrenia 
Treatment Adherence Registry (e-STAR) from seven European countries 
(Belgium, Czech Republic, Denmark, Netherlands, Slovakia, Spain, Sweden).
Methods: e-STAR is an international, long-term, prospective, observational 
study of patients with schizophrenia who commence RLAI treatment. Data 
are collected both retrospectively for 1 year and prospectively every 3 months 
for 2 years. The treating physician evaluated whether there was a presence of 
suicidal ideation, violent behavior, and self-injury at baseline and prospectively 
at 3 monthly intervals. Pooled results presented are based on data from patients 
who have completed their 12-month follow-up visit.
Results: To date, among 4,196 patients enrolled in e-STAR from the seven 
European countries, 2,239 patients who have been followed for at least 12 months 
(89.7 % were still on RLAI) were included in this interim analysis. Most were 
male (61.8%) with mean age of 38.7±12.0 years and mean time since diagnosis 
of 11.2±10.7 years. Compared to baseline, significant reductions were observed 
in the occurrence of suicidal ideation (12.2% to 1.0%, p<0.001), violent behavior 
(11.9% to 0.5%, p<0.001), and self-injury (4.6% to 0.4%, p<0.001).
Conclusions: Results from this pooled interim analysis showed that the 
incidence of suicidal ideation, violent behavior, and self-injury decreased in 
patients with schizophrenia treated with RLAI for 12 months.
Supported by Johnson & Johnson
927. Gene Expression Alterations Implicated in 
Suicide in Mood Disorder Subjects
P. Adolfo Sequeira1, Marquis Vawter1, Ling Morgan1,
Jun Li2, Simon Evans3, Brandi Rollins1, Prabhakara 
Choudary4, David M. Walsh1, Richard M. Myers2,
Stanley J. Watson3, Huda Akil3, Edward G. Jones4,
William E. Bunney1
1Psychiatry and Human Behaviour, University of California, Irvine, 
Irvine, CA,2Stanford Human Genome Center, Stanford University, Palo 
Alto, CA,3Mental Health Research Institute, University of Michigan, 
Ann Arbor, MI,4Center for Neuroscience, University of California, Davis, 
Davis, CA
Background: Several lines of evidence point to an implication of mood 
disorders in suicide. Mood disorders patients often present suicidal behaviors 
and are at high risk to complete suicide. However, the majority of mood disorder 
patients never commit suicide. The purpose of this study was to investigate gene 
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expression changes in the dorsolateral prefrontal cortex (DLPFC) associated 
with suicide in mood disorder patients.
Methods: We used Affymetrix HG-U133 Plus 2.0 arrays to investigate gene 
expression changes and analysis of covariance to correct for age, pH, gender and 
RNA degradation. Confirmation was performed by RT-PCR with SYBRGreen 
and the DeltaDeltaCt method.
Results: A total of 121 genes were differentially expressed at the P<0.005 
level between suicides and non-suicides. Ingenuity pathway analysis and gene 
ontology analysis both converged to point out to signaling and serotonin 
receptor signaling as particularly altered in suicide victims. Confirmation of 
these results was performed for a group of differentially expressed genes in the 
DLPFC with satisfactory agreement. The most significant gene, the 5-HT2A 
serotonergic receptor, also showed expression levels that were dependent on 
the -1438A/G promoter polymorphism genotype, suggesting a genetic and a 
functional interaction of this gene with suicide.
Conclusions: In conclusion, molecular alterations specifically associated with 
suicide in major depression and bipolar disorder subjects were observed in the 
DLPFC pointing out to possible molecular markers or therapeutic targets for 
suicide in mood disorders.
Supported by Pritzker Neuropsychiatric Disorders Research Fund L.L.C.
928. Treatment-Resistant Depression Registry: 
Lifetime Profile of Pharmacotherapy at Baseline
Michael J. Burke1, Dana Soetaert1, Ingela Danielsson2
1Psychiatry, University of Kansas School of Medicine, Wichita, 
KS,2Clinical and Medical Affairs, Cyberonics, Inc., Houston, TX
Background: The Treatment-Resistant Depression (TRD) Registry was 
established in 2005 by the manufacturer of the vagus nerve stimulation system. 
This presentation introduces lifetime profiles of pharmacotherapy for Registry 
patients.
Methods: Enrollment required that patients be in a major depressive episode, 
chronic (≥2 years) or recurrent (≥3episodes), AND had not responded to 4 or 
more adequate antidepressant treatments. This report is from baseline screening 
forms of 202 patients enrolled at the June 30, 2007, data lock.
Results: Of 202 patients, 136 (67.3%) were female, age 49.8/51 years (mean/
median) at enrollment. Initial age at depression onset was 20.5/16 years with 
initial diagnosis at 29.7/30 years. Lifetime depressive episodes numbered 16.5/5 
(range, 1-200). Lifetime psychiatric hospitalizations numbered 3.1/1(range, 
0-62). During their lifetime, 60% had been hospitalized, 48% had attempted 
suicide. At baseline, pharmacotherapy courses averaged (mean, SD): 9.1 (3.3)
(n=202); 70% reported monotherapy trials: 4.0 (2.5); 87% reported combination 
therapies: 5.0 (3.4); 49% reported augmentation therapies: 4.0 (3.1). Regarding 
treatment response, 49.6% of medication courses elicited partial responses 
(n=158); 19.6% of treatment course were not tolerated (n=63). Medication 
courses included selective serotonin reuptake inhibitors (SSRI) 3/1-6 (median, 
range) (n=190); tricyclic antidepressants1/1-5 (n=103); other antidepressants 
3/1-6(n=193); lithium 1/1-2(n=92); anticonvulsants 1/1-5(n=152); atypical 
antipsychotic drugs 1/1-2(n=98); and stimulants 1/1-5(n=92).
Conclusions: Pharmacotherapy for these TRD patients was characterized by 
multiple SSRI, monotherapy, and combination therapy trials with relatively 
little use of monoamine oxidase inhibitors and lithium. Presentation will 
feature detailed analysis of pharmacologic treatments including additional 
enrolled patients from the December 2007 data lock.
Supported by Cyberonics, Inc.
929. Clinical Significance of Transcranial 
Magnetic Stimulation (TMS) in the Treatment of 
Pharmacoresistant Depression
Mark Andrew Demitrack1, Michael E. Thase2
1Medical, Neuronetics, Inc., Malvern, PA,2Psychiatry, University of 
Pennsylvania, Philadelphia, PA
Background: To explore the relationship between prior treatment resistance 
and clinical outcome in a recently completed multisite RCT of TMS for 
pharmacoresistant depression.
Methods: Clinical outcomes from a recently completed RCT of TMS in 
depression (O’Reardon, 2007) and an open-label extension study of treatment 
non-responders in that RCT (Avery, submitted) were stratified for the level 
of prior treatment resistance determined by the Antidepressant Treatment 
History Form (ATHF).
Results: Approximately half of the original study population (164/301; 54.5%) 
had failed to benefit from only one ATHF adequate antidepressant trial in 
current episode (median treatment exposures = 4, range 1 to 23). The primary 
outcome, MADRS total score change from baseline, was statistically significant 
in favor of active TMS (mean diff: -5.0, 95%CI [-7.8, -2.2], P, 0.0006) and was 
larger than the outcome observed in the remainder of the study population (ES = 
0.94 ATHF 1 vs -0.01 ATHF >2). Seventy-nine patients (48.2%) failed to benefit 
from the blinded, randomized treatment and were enrolled in the open-label 
extension study. In the open-label study, a similarly greater benefit was observed 
in the ATHF 1 population in sham non-responders from the RCT compared to 
the remainder of the study population (MADRS mean change from baseline: 
-20.8, 95%CI [-16.9, -24.7] ATHF 1 vs -13.3, 95%CI [-9.0, -17.5] ATHF >2).
Conclusions: Prior treatment resistance has a negative influence on subsequent 
treatment outcome. These data confirm the clinical significance of TMS in the 
treatment of patients with depression who have failed to benefit from prior 
pharmacotherapy.
Supported by Neuronetics, Inc.
930. Feasibility Study of an Implantable Cortical 
Stimulation System for Patients with Major 
Depressive Disorder
Darin D. Dougherty1, Michael E. Thase2, Robert 
H. Howland3, Karleyton C. Evans1, Harold Harsch4,
Douglas Kondziolka5, Emad Eskandar6, Alvaro Pascual-
Leone7
1Psychiatry, Massachusetts General Hospital, Charlestown, 
MA,2Psychiatry, University of Pennsylvania, Philadelphia, 
PA,3Psychiatry, University of Pittsburgh, Pittsburgh, PA,4Psychiatry, 
Medical College of Wisconsin, Milwaukee, WI,5Neurosurgery, University 
of Pittsburgh, Pittsburgh, PA,6Neurosurgery, Massachusetts General 
Hospital, Boston, MA,7Neurology, Beth Israel-Deaconess Medical 
Center, Boston, MA
Background: Repetitive transcranial magnetic stimulation has short-lived 
antidepressant effects when applied to the left DLPFC. These findings 
prompted study of an investigational implantable cortical stimulation (CS) 
system targeting the left DLPFC.
Methods: After an observation phase (≥8 weeks) with stable medication, 12 
refractory MDD patients were implanted with an epidural CS system (Renova™ 
DT, Northstar Neuroscience, Seattle, WA). Patients were randomized to 
single blind active or sham stimulation for 8 weeks (primary endpoint), then 
active stimulation. Medications were not changed unless indicated. Efficacy: 
Hamilton Depression Rating Scale (HDRS), Montgomery-Asberg Depression 
Rating Scale (MADRS), Global Assessment Function (GAF).
Results: Patients: 6 female, 6 male (48±6 years); MDD for 27±10 years; current 
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episode duration 6.9±8.1 years; failed 9.8±1.7 antidepressant treatments. Ten 
received ECT (16.2±23.2 treatments). At baseline: mean HDRS=35.3±5.8; 
MADRS=32.7±4.6; GAF=42.3±5.8. One patient was excluded from further 
analysis (protocol deviation). Week 8: HDRS decreased by 22±20% (active 
stimulation; n=6) vs 3±17% (sham; n=5); MADRS decreased 22±21% (active) vs 
8±15% (sham); GAF increased 23±32% (active) vs 12±9% (sham). Weeks 8 to 16 
(active stimulation; n=11): mean change scores improved: 21% to 26% (HDRS), 
22% to 32% (MADRS), 25% to 46% (GAF). No device-related serious adverse 
events. PET imaging results will be discussed relative to patient outcomes.
Conclusions: This study describes the first use of a CS system targeting 
the DLPFC. Preliminary results suggest that CS has a therapeutic effect 
that increases over time. A larger study is needed to confirm these findings. 
Funding: Northstar Neuroscience.
Supported by Northstar Neuroscience
931. The Antidepressant Effect of Transcranial 
Magnetic Stimulation is Strongly Correlated with 
the Distance of the Coil from the Midline
Gary Hasey1, Mark H. C. Shew1, Jackie Heaslip1,
Duncan MacCrimmon1, Gabby Abraham2, Roumen 
Milev2, Alvaro Pascual-Leone3, Russell Joffe4
1Psychiatry and Behavioural Neurosciences, McMaster University, 
Hamilton, ON, Canada,2Psychiatry, Queen’s University, Kingston, ON, 
Canada,3Neurology, Harvard Medical School, Boston, MA,4Psychiatry, 
New Jersey Medical School, Newark, NJ
Background: The inconsistent results of studies of the antidepressant effect of 
transcranial magnetic stimulation (TMS) may be related to differences in the 
site of stimulation. In this study we examine response in relation to the location 
of the treatment site (TS).
Methods: After a 10 day drug washout, 65 depressed subjects with Major 
Depressive Disorder or Bipolar Disorder were treated with SSRI antidepressants 
and either true or sham TMS at 90-110% motor threshold over 10 days to the left 
dorsolateral pre-frontal cortex (DLPFC) (10 Hz X 8 seconds/train X 20 trains /
day), the right DLPFC (1 Hz X 60 seconds/train X 2 trains /day) or both. The 
TS was marked on a spandex swim hat landmarked to the nasion, inion, vertex 
and auditory meati. TS was arbitrarily determined to be 5 cm forward, in a 
parasagittal plane, from the motor site. The distance of the TS from the anterior 
to posterior midline (DFM), variable across subjects, was measured. For subjects 
receiving bilateral TMS, DFM was defined as the mean of both sides.
Results: The % change of the Hamilton depression rating scale from baseline 
was positively correlated with DFM in subjects getting true TMS (N=43, 
R2= .184, p=0.004) but not in subjects getting sham TMS (N=22, R2= .016, 
p=0.571).
Conclusions: The magnitude of the antidepressant effect of TMS is strongly 
related to the positioning of the coil from the midline. More lateral coil 
placement is associated with superior efficacy. Further studies to determine 
optimal coil positioning are required.
Supported by Canadian Psychiatric Research Foundation, Ontario Mental 
Health Foundation, Stanley Research Foundation
932. TMS for Depression using an Optimized 
Prefrontal Coil Positioning
Kevin A. Johnson1, Qiwen Mu1, Ziad Nahas1, Multisite 
OPT-TMS Study Group2
1Psychiatry, Medical University of South Carolina, Charleston, 
SC,2Psychiatry, Columbia University, Emory University, Medical 
University of South Carolina, Washington University, Charleston, SC
Background: The antidepressant response to rTMS appears to be dose and 
target dependent. An ongoing NIMH funded study uses TMS parameters to 
maximize the stimulation duration and intensity. It also seeks to ensure that 
TMS is optimally positioned over the prefrontal (and not pre-motor) cortex 
following a visual inspection method (VIM).
Methods: All enrolled subjects receive an entry MRI scan, while wearing 
a swim cap with fiducials marking the motor thumb scalp position and the 
location of the presumed prefrontal target, 5 cm more anterior. A single 
researcher examines scans from all 4 sites and determines the clinical target 
site in reference to the anterior pole of temporal lobes. He then instructs 
investigators if they should move their coil placement by 1 cm to increase the 
probability of reaching the prefrontal cortex on either hemisphere.
Results: To date, VIM resulted in 50/123 recommendations to move the coil 1 
cm forward (left hemisphere) and 52/116 (right hemisphere) with 7 scans missing 
right fiducials. A repeated analysis identified 16/123 cases where fiducials sat at 
the border of pre-motor and prefrontal cortex. Percentages of nudging forward 
for the left hemisphere across 4 sites were 52%, 52%, 46% and 15%. Ongoing 
analysis using an automated system will provide complementary information 
on specific Brodmann areas and the validity of the VIM.
Conclusions: Using a conservative VIM algorithm, 40% of subjects have 
benefited from a stimulation site anterior to the standard 5 cm rule. Future 
analyses will link such targeting methods with treatment outcomes.
Supported by 5R01MH069887-04 and 5R01MH069896-04
933. Gamma Ventral Capsulotomy for Obsessive 
Compulsive-Disorder: Preliminary Results of a 
Randomized Controlled Trial
Antonio C. Lopes1, Anita Taub1, Carina C. D’Alcante1,
Maria E. de Mathis1, Marcelo Q. Hoexter2, Fernando 
S. Gouvêa1, Janaína P. Cecconi1, Marcelo Batistuzzo1,
Benjamin D. Greenberg3, Georg Norén4, Steven A. 
Rasmussen3, Miguel M. Canteras5, Fábio Duran1,
Daniel Fuentes1, Cláudio C. Castro6, Cláudia Leite7,
Geraldo Busatto Filho1, Eurípedes C. Miguel1
1Department of Psychiatry, Faculty of Medicine - University of São 
Paulo, São Paulo, Brazil,2Department of Psychiatry, Federal University 
of São Paulo, São Paulo, Brazil,3Department of Psychiatry and 
Human Behavior, Brown University, Providence, RI,4Department of 
Clinical Neurosciences - Neurosurgery, Brown University, Providence, 
RI,5Institute of Neurological Radiosurgery, Hospital Santa Paula, São 
Paulo, Brazil,6Heart Institute (INCOR), Faculty of Medicine - University 
of São Paulo, São Paulo, Brazil,7Department of Radiology, Faculty of 
Medicine - University of São Paulo, São Paulo, Brazil
Background: Up to 40 % of Obsessive Compulsive Disorder (OCD) patients do 
not respond to medications or psychotherapy. For this subgroup, an improved, 
stereotactic radiosurgery (Gamma ventral capsulotomy - GVC) is a treatment 
option which has been recently developed. We report the preliminary results 
from a pilot study with this new technique, as well as from a double-blind, 
randomized controlled trial (DB RCT).
Methods: Fifteen refractory DSM-IV OCD patients were selected. The first 
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935. Modeling Antidepressant Properties of Vagus 
Nerve Stimulation (VNS Therapy) in the Context of a 
12 Month Long Placebo Controlled Study
Ziad Nahas1, Annie S. Simpson2, Kit N. Simpson3
1Psychiatry and Neurosciences, Medical University of South Carolina, 
Charleston, SC,2Biometry and Epidemiology, Medical University of 
South Carolina, Charleston, SC,3Heath Administration and Policy, 
Medical University of South Carolina, Charleston, SC
Background: Conducting year long placebo controlled studies in treatment 
refractory depressed (TRD) subjects is critical to the field yet very problematic. 
Such studies are associated with ethical concerns of withholding effective 
treatments and prohibitive costs. VNS Therapy provides continued treatment 
delivery with good tolerability and clinical benefits in treatment-resistant 
depressed patients. Unfortunately, the open nature of these longterm follow-
ups greatly limits their interpretations.
Methods: We employed a Markov strategy to model antidepressant properties 
of VNS Therapy under 12-month double blind placebo controlled conditions 
where pharmacological treatment is held constant. We defined 5 possible 
Markov health states that were mutually exclusive and jointly exhaustive 
based on the Inventory of Depressive Symptoms Self Report (IDS-SR). We 
classified each patient observation at the beginning of each 3-month period. 
We constructed two “progression” transition matrices for both active and 
placebo conditions. To simulate blinded conditions, the ‘active’ matrix was 
weighed by the relative risks of failures (RRF) extracted from the open label 
and controlled VNS data in their first quarters. In the placebo-VNS model, we 
used the observed placebo transitions for the first quarter. For the following 
3 quarters we adjusted for the RRF derived from published pharmacological 
maintenance placebo controlled trials.
Results: At 12-month, 29.5% of VNS treated patients had no or mild depressive 
symptoms compared 5.0 % of placebo-VNS.
Conclusions: This model can compare expected longterm outcomes under 
strict conditions not otherwise feasible in clinical trials. It may prove useful in 
implantable brain stimulation devices and TRD clinical research.
Supported by Cyberonics Inc.
936. Patients with Psychosis Receiving Pharmaco- 
and Continuous ECT Treatment Show Different Slow 
Wave Activitis of Ictal EEG during Acute ECT
Masayuki Nakano, Koji Matuo, Noriko Abe, Fumihiko 
Higuchi, Kazuteru Egashira, Masatomo Suetsugi, 
Yoshifumi Watanabe
Division of Neuropsychiatry,Department of Neuroscience, Yamaguchi 
University Graduate School of Medicine, Ube, Japan
Background: Electroconvulsive therapy (ECT) is useful for treating patients 
with acute psychosis including severe major depressive disorder (MDD) 
and schizophrenia (Scz). However, there is little evidence suggesting which 
maintenance treatment should be preferred after acute ECT, pharmacotherapy 
or continuous ECT. Based on the evidence that high slow wave activity and 
postictral suppression of ictal electroencephalogram (EEG) during acute 
ECT are associated with therapeutic efficacy, we retrospectively studied the 
difference of ictal EEG findings during acute ECT between patients receiving 
continuous ECT and pharmacotherapy.
Methods: Twenty four MDD and Scz patients who recovered after acute ECT 
were studied. Twelve patients received continuous ECT (C-ECT) (6 MDD 
and 4 Scz, age 47.9±19.1y, female 80%) and the others took some psychiatric 
medications without continuous ECT (PHAR) (6 MDD and 4 Scz, age 
60.0±19.4y, female 60%). EEG was measured on the left frontal region during 
acute ECT. The Clinical Global Impression scale was used to assess clinical 
five patients were included in a pilot study. The other ten subjects were randomly 
assigned to receive active (5 patients) or “sham” radiosurgery (5 patients), 
as a DB RCT. Periodical pre and post-operative follow-up assessments were 
provided, including psychopathological, global status, neuropsychological and 
personality scales, and magnetic resonance imaging scans with voxel-based 
morphometry (VBM).
Results: Three patients from the pilot study and three patients from the RCT 
active group became responders. As a whole, six out of ten (60 %) patients who 
had received active radiosurgery responded, 12 months or more after surgery. 
For the sham group, none responded for 12 months of follow-up; one patient 
became responder only after an active procedure was conducted. Hypomanic/
manic episodes, delirium, episodic headaches, dizziness, nausea were few times 
observed. Improved simple visual attention (p=0.04), logical memory (p=0.04), 
and verbal/full IQs (p=0.04) were observed in the pilot patients.Pre and post-
operative VBM analysis is under way and will soon be available.
Conclusions: Preliminary findings indicate that GVC for OCD shows some 
efficacy, with relatively few adverse effects.
Supported by CAPES, Brazil (Dr Lopes). FAPESP (process n. 99/12205-7) and 
CNPQ (process n. 521369/96-7), Brazil (Dr Miguel)
934. Clinical Outcome of Ultrabrief ECT in Patients 
with Major Depression and Comorbid Personality 
Disorder
Angela Merkl, Jana Mertin, Arnim Quante, Eva-Lotta 
Brakemeier, Ion Anghelescu, Malek Bajbouj
Psychiatry, Charité, Berlin, Germany
Background: Previous research suggests that the comorbidity of major 
depression (MDE) with personality disorder is associated with poorer response 
to electroconvulsive therapy (ECT). We compared acute outcome of ECT in 
depressed patients with/without personality disorder (PD).
Methods: 55 patients with MDE who participated in a study on short-term 
and continuation right unilateral ECT were administered 28-item Hamilton 
depression rating scale (HAMDRS-28) at two time points: before starting ECT 
(T0) and after completing the acute course of ECT (T1), which was defined 
as the time after that response/remission of depressive symptoms had occurred 
or not. Patients were included with scores of at least 20 on HAMDRS-28. The 
SCID-II was conducted after completion of ECT. Due to small sample size PD 
group was not splitted into subgroups.
Results: Compared to patients without PD (N=33), patients with PD (N=22) 
showed no significant differences at T0 pre-treatment HAMDRS-28 scores 
(P=0.212). There were no differences in T1 post-ECT HAMDRS-28 scores 
(P=0.378). Patients with and without PD responded as well to ECT comparing 
response rate after completing the acute course (P= 0.659).
Conclusions: Comparing depressive patients with/without PD our results 
show no difference in response status to ECT. This is in line with one study on 
outcome of ECT in patients with comorbid PD. However, this might implicate 
that it is important to differentiate between different PD subgroups to explain 
poorer response in other PD groups, i.e. borderline personality disorder.
www.sobp.org/journal
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decision-making by psychiatric patients who viewed participation as a way of 
helping society and expressed increased hope associated with involvement.
Methods: We studied 313 psychiatric patients admitted to an inpatient 
research unit. At the time of discharge, each participant completed a structured 
questionnaire designed to assess the experience of research participation and 
willingness to participate in future studies. Six variables were hypothesized 
to be associated with willingness to participate, including overall satisfaction 
as well as satisfaction with the following: information received in research 
psychoeducation group, the degree to which they were educated or informed 
about participation; protocol specific information, including details of the 
protocol, potential risks/benefits, alternatives, confidentiality, and rights; the 
level of perceived safety; and symptom evaluation.
Results: In all cases where a significant relationship occurred, individuals 
who were more satisfied expressed willingness to participate in future research 
(p<.001). This relationship was obtained for their satisfaction with general and 
protocol-specific research education (p<.001), safety (p<.01), and symptom 
ratings procedures (p<.01).
Conclusions: Overall the data suggests that psychiatric patients are more 
willing to participate in research studies if they are provided education regarding 
overall principles of research, ongoing education pertaining to specific research 
protocols, and the degree of perceived safety during procedures.
939. Serotonin Transporter Promoter Polymorphism 
and Antidepressant Efficacy: Systematic Review 
and Meta-Analysis
Matthew J. Taylor1, Srijan Sen2, Zubin Bhagwagar2
1Department of Psychiatry, University of Oxford, Oxford, United 
Kingdom,2Department of Psychiatry, Yale University, New Haven, CT
Background: The 5HTTLPR is a polymorphism in the serotonin transporter 
promotor region. The short ‘S’ variant is associated with reduced transporter 
expression. Early reports suggested that this polymorphism was associated with 
poorer response to antidepressant treatment, however results from subsequent 
studies have been mixed.
Methods: A systematic review and meta-analysis was performed of trials in 
which response to antidepressant treatment of major depression was reported 
along with 5HTTLPR genotype. Conventional pooled estimates of differences 
in treatment outcome were calculated for models with either ‘S’ or ‘L’ alleles 
functionally dominant and expressed as relative risks (RR).
Results: Rates of response to antidepressant treatment did not significantly differ 
with genotype in either model (SS versus SL/LL, RR 0.97, 95% Confidence 
Interval (CI) 0.83 to 1.14; SS/SL versus LL, RR 0.83, 95% CI 0.67 to 1.03). 
This finding remained in sensitivity analyses removing the single largest trial 
(STAR*D) or restricting studies to those using selective serotonin reuptake 
inhibitors alone. However, rates of remission, reported in fewer studies, did 
appear to be affected by presence of the ‘L’ allele (SS versus SL/LL, RR 0.81, 95% 
CI 0.67 to 0.97; SS/SL versus LL, RR 0.9, 95% CI 0.79 to 1.03).
Conclusions: The 5HTTLPR polymorphism does not appear to be associated 
with overall differences in rates of response to antidepressant treatment. 
Presence of increased transporter function with the ‘L’ allele may increase rates 
of remission with treatment. This contrast warrants further investigation.
Supported by Wellcome Trust
improvement after acute ECT.
Results: Analysis of covariance with age and sex as covariates revealed that 
the PHAR patients showed higher slow wave amplitude (F=9.79, p<0.05) and 
more stable regularity (F=5.35, P<0.05) compared to the C-ECT patients. The 
C-ECT patients recovered more fully than the PHAR patients.
Conclusions: The results suggest that the slow wave findings of EEG during 
acute ECT may provide some help in choosing maintenance treatments after 
recovery following acute ECT.
937. Efficacy and Tolerability of Extended Release 
Quetiapine Fumarate (Quetiapine XR) Monotherapy 
in Major Depressive Disorder: A Randomized, 
Placebo-Controlled Clinical Trial (Study 003)
Nizar El-Khalili1, Michael Banov2, Brian Bortnick3,
David Adson4, Catherine Datto5, Shane Raines5, Willie 
Earley5, Martin Brecher5
1???????????? ????????????????????????????2Behavioral Medicine, 
Northwest Behavioral Reserach Center, Marietta, GA,3CNS: Atlanta, 
Comprehensive Neuroscience, Atlanta, GA,4Department of Psychiatry, 
University of Minnesota, Minneapolis, MN,5Neuroscience, AstraZeneca, 
Wilmington, DE
Background: To evaluate the efficacy and tolerability of once-daily extended release 
quetiapine fumarate (quetiapine XR) monotherapy for patients with MDD.
Methods: Multicenter, double-blind, randomized, parallel-group, placebo-
controlled study (D1448C00003) of quetiapine XR monotherapy. Eligible 
patients (HAM-D total score ≥22, item 1 score ≥2) received quetiapine XR 
150mg/day for 8 weeks; in patients with an inadequate response (failure to 
achieve ≥20% improvement in MADRS) at Week 2 the dose was adjusted to 
300mg/day for final 6 weeks.
Primary endpoint: change from randomization to Week 8 in MADRS total score. 
Secondary endpoints included: MADRS response (≥50% reduction in total score 
from randomization); changes from randomization to Week 8 in HAM-D and 
CGI-S. Adverse events (AEs) were recorded throughout the study.
Results: 310 patients were randomized to double-blind treatment: 154 
quetiapine XR, 156 placebo. At Week 8, quetiapine XR significantly reduced 
mean MADRS score versus placebo (-16.49 vs -13.10, respectively; p<0.01). At 
Week 1 (Day 8) mean MADRS score was significantly reduced by quetiapine 
XR versus placebo (p<0.05). MADRS response rates were significantly greater 
at Week 8 for quetiapine XR versus placebo (61.9% versus 48.0%, respectively; 
p<0.05). Change in HAM-D total score at Week 8 was -14.75 quetiapine XR 
versus -12.35 placebo (p<0.05). Change in CGI-S score at Week 8 was -1.64 
quetiapine XR versus -1.24 placebo (p<0.01). Most common AEs (>10% any 
group) were dry mouth, sedation, somnolence and headache.
Conclusions: In patients with MDD, quetiapine XR monotherapy is effective and 
generally well tolerated with symptom improvement seen as early as Week 1.
Supported by Research sponsored by AstraZeneca
938. Predictive Factors of Psychiatric Research 
Subjects’ Willingness to Participate in Studies
Aarti Sharma1, Cherise Rosen2
1College of Medicine, University of Illinois at Chicago, Chicago, 
IL,2Psychiatry, University of Illinois at Chicago, Chicago, IL
Background: Few studies exist that assess predictive factors of psychiatric 
patients’ willingness to participate in studies. When asked, psychiatric patients 
expressed clear views on biomedical research regarding attitudes affecting 
motivation to participate, autonomy, inclusion of vulnerable populations, and 
influences on participation decisions. These findings supported autonomous 
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are analyzing protein levels by western blot. Studies in monkey DLPFC with 
artificially created PMIs indicated that ?1 protein was well-preserved with 
PMIs up to 24hrs.
Results: GABA-A ?1 subunit mRNA expression was significantly reduced by 
17 % in layers 3-6 of the DLPFC in schizophrenia, whereas ?2 subunit mRNA 
showed a trend increase in layers 2-3. Blinded assessment of actin-corrected 
?1 protein levels in a subset of the subject pairs (all PMI < 20hrs) used for the 
mRNA analysis is in progress.
Conclusions: These findings indicate a decrease in the ratio of ?1 to ?2
subunits in GABA-A receptors in schizophrenia, which could impair the 
synchronized neuronal activity required for gamma oscillations.
Supported by NIH MH043784; MH045156
942. Expression Profiling of Post-Mortem Prefrontal 
Cortex from Persons with Major Depression versus 
Controls
Jomo Claiborne1, Richard C. Shelton1, Philip Ebert1,
Hal Manier1, David A. Lewis2, Karoly Mirnics1
1Psychiatry, Vanderbilt University, Nashville, TN,2Psychiatry, University 
of Pittsburgh, Pittsburgh, PA
Background: Major depression (MDD) is a condition that involves the 
dysregulation of the stress response axis (e.g., corticotrophin releasing hormone, 
adrenocorticotrophic hormone, and cortisol) and inflammatory factors. 
However, post-mortem tissue analysis has produced inconsistent results. The 
purpose of this study was to examine gene expression profiles of post-mortem 
brain (PMB) tissue samples from persons with MDD versus controls, using 
highly sensitive exon microarrays.
Methods: PMB samples from prefrontal cortex (Area 10) were obtained from 
the University of Pittsburgh CCNMD, and included persons with a lifetime 
history of MDD and matched controls (n=20 per group). Persons with MDD 
were not on psychotropics at the time of death. Premortem diagnosis was made 
via next-of-kin interview. mRNA expression was determined using Affymetrix 
133 plus 2 exon arrays.
Results: Samples from persons with MDD showed abnormal expression 
of a variety of mRNAs. Pathway analysis discovered altered regulation of a 
cytokine/inflammatory pathway that included: interleukin 1A (IL1A), IL2, 
IL3, IL4, IL5, IL6, IL8, IL9, IL10, IL12A, IL12B, IL15, IL16, IL18, interferon 
gamma (INF?), tumor necrosis factor ? (TNF?), and TNF?. The groupwise 
analysis showed marked between-groups separation.
Conclusions: These results suggest significantly altered regulation of the 
expression of a variety of mRNAs, but most particularly inflammatory factors 
include interleukins, tumor necrosis factors, and interferon.
Supported by R01MH73630
943. Altered Serotonin 2C Receptor RNA Splicing in 
Suicide: Association with Editing
Stella Dracheva1,2, Benjamin Chin1, Vahram 
Haroutunian1,2
1Psychiatry Research, Bronx VA Medical Center, Bronx, NY,2Psychiatry, 
Mount Sinai School of Medicine, New York, NY
Background: In our previous study we showed increases in the serotonin 
2C receptor (5-HT2CR) pre-mRNA editing in prefrontal cortex (PFC) that 
were specific to suicide victims irrespective of associated psychiatric diagnoses 
(bipolar disorder (BPD) or schizophrenia (SZ)). In this study we have tested 
the association between editing and splicing by investigating whether the 
differences in the 5-HT2CR editing in suicide subjects affect the splicing of 
their 5-HT2CR transcripts.
940. Differences in Peripheral Blood Gene-
Expression as Predictors of Response to Treatment 
with Lithium in Subjects with Bipolar Depression
Robert D. Beech1, Janine L. Leffert1, Mary M. Taylor1,
Sheila Westman2, Aiping Lin3, Ji Young Lee3, Anjana 
Muralidharan1, Boris Lorberg1, Hongyu Zhao4, Samuel 
S. Newton1, Shrikant Mane2, C. Neill Epperson1, Hilary 
Blumberg1, Zubin Bhagwagar1
1Psychiatry, Yale University, New Haven, CT,2W.M. Keck Biotechnology 
Resource, Yale University, New Haven, CT,3W.M. Keck Biostatistics 
Resource, Yale University, New Haven, CT,4Epidemiology and Public 
Health, Yale University, New Haven, CT
Background: Lithium is considered first line treatment for mania, acute bipolar 
depression, and maintenance treatment. However, the response to lithium is 
extremely heterogeneous, and there are currently no established predictors of 
response to treatment with lithium.
Methods: Microarrays were used to measure levels of gene-expression in whole 
blood of subjects with Bipolar Disorder (BPD, n=20) at baseline and every two 
weeks during 8-weeks of open label treatment with lithium. Gene-expression 
changes were also measured in 15 untreated healthy controls sampled on two 
occasions at least two weeks apart to determine the level of random variation.
Results: BPD subjects were divided into treatment-responders (n=10) and non-
responders (n=10) based on changes in mood-ratings. ANOVA analysis of the 
microarray data was used to identify a set of 127 genes with significant group 
x time interaction. Cluster analysis detected four distinct temporal patterns 
of change among these genes. Supervised learning algorithms (random forests 
and support vector machines) were used to identify 10 genes with the greatest 
predictive power in distinguishing lithium responders from non-responders 
among the BPD subjects. Baseline differences in the expression of a set of 8 of 
these genes were confirmed by RT-PCR.
Conclusions: Differences in clinical response to lithium were correlated with 
differences in gene-expression between lithium-responders and non-responders. 
These results support the hypothesis that differences in peripheral blood gene-
expression can be used to predict response to lithium prior to initiation of treatment.
Supported by Stanley Medical Research Institute (Grant # 05R-864), and the 
NIH/NIDA (K12 DA-00167)
941. Altered Expression of Cortical GABA-A 
Receptor ?1 Subunit in Schizophrenia
Monica Beneyto1, Takanori Hashimoto2, Holly Bazmi1,
Dominique Arion1, David A. Lewis3
1Department of Psychiatry, University of Pittsburgh, Pittsburgh, 
PA,2Department of Psychiatry, University of Kanazawa, Kanazawa, 
Japan,3Departments of Psychiatry and Neuroscience, University of 
Pittsburgh, Pittsburgh, PA
Background: Disturbances in the regulation of cognition in schizophrenia 
reflect functional abnormalities in the intrinsic circuitry of the dorsolateral 
prefrontal cortex (DLPFC). Working memory is associated with the gamma 
oscillations that are dependent upon fast inhibitory neurotransmission mediated 
by ?1-containing GABA-A receptors. Considering the electrophysiological 
differences that ?1 (fast kinetics) and ?2 (slower decay time) subunits confer to 
GABA-A receptors, reduced expression of ?1-containing GABA-A receptors, 
and/or an altered ratio of ?1/?2 subunits could contribute to the altered gamma 
oscillations in the DLPFC in schizophrenia.
Methods: We used in situ hybridization to compare the expression of ?1 and 
?2 subunit mRNAs in the DLPFC of 23 subjects with schizophrenia, each 
individually matched with a control subject for age, sex, and postmortem 
interval (PMI). To further evaluate the change in expression of ?1 mRNA, we 
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945. Serum Cytokine and Growth Factor Levels in 
Neuropsychiatric Disorders
Maureen V. Martin1, Brandi Rollins2, William E. 
Bunney2, Marquis P. Vawter2
1Department of Psychiatry and Human Behavior, University of 
California, Irvine, Irvine, CA,2Psychiatry and Human Behavior, 
University of California, Irvine, Irvine, CA
Background: The neurochemical responses to peripheral cytokines may 
contribute to the endocrine and behavioral responses in psychiatric disorders. 
Cytokine elevations have been observed in serum from subjects with psychiatric 
disorders.
Methods: We compared the levels of a panel of 20 cytokines in serum samples 
from subjects with schizophrenia, bipolar disorder and major depressive 
disorder that had received different medications to a control group. Serum 
samples were collected from adult subjects rapidly after death and a total of 
25 μl of serum was assayed per sample in duplicate. The Panomics’ Procarta 
Cytokine Assay system was used to simultaneously quantify protein levels of 20 
cytokines. Protein concentrations were measured using a Bradford assay, and 
data were analyzed by t-test after normalizing for total protein concentration.
Results: There was a significant increase (p < 0.05) in serum levels of IFN? in 
schizophrenia and bipolar disorder. There were trends towards increased IL-6 
and TNF-alpha in bipolar disorder and increased FGF2 in schizophrenia and 
major depressive disorder compared to controls. 
Conclusions: These results are consistent with previous literature reports of 
cytokine alterations in serum in psychiatric disorders and the results support 
the use of multiplex protein assays for identification of potential peripheral 
biomarkers for psychiatric disorders. The disease-specific profiles of cytokines 
suggest immune system activation may play a role in the pathogenesis of the 
disorders. More samples are being assayed in brain and blood and a replication 
in a larger, drug-naïve sample is needed as previous work suggests psychiatric 
drugs influence cytokine levels.
Supported by P50 MH60398; MH 024370; The Pritzker Family Philanthropic
946. Protein Kinase Protein and mRNA Expression in 
Post-Mortem Tissue from Prefrontal Cortex in MDD
Richard C. Shelton1, Philip J. Ebert1, Hal Manier1,
Karoly Mirnics1, David A. Lewis2
1Psychiatry, Vanderbilt University, Nashville, TN,2Psychiatry, University 
of Pittsburgh, Pittsburgh, PA
Background: Protein kinases play key roles in cell function, including the 
expression of genes such as brain derived neurotrophic factor (BDNF), tyrosine 
kinase receptor B (TrkB), CREB, and glucocorticoid receptors (GR). Reduced 
levels of protein kinases A (PKA) and C (PKC) have been demonstrated in 
peripheral tissues and post-mortem brain (PMB) samples from persons with 
major depression (MDD) versus controls. This study assessed all PKA and 
PKC isoform proteins and mRNA levels.
Methods: PMB samples of prefrontal cortex (Area 10) were obtained from 
persons with a lifetime history of MDD (psychotropic free) and matched 
controls (n=20 per group). Premortem diagnosis was made via interview with 
next-of-kin. Protein levels were determined via Western blot and mRNA 
expression levels via Affymetrix 133 plus 2 exon arrays.
Results: Significant reductions were found in the following proteins in MDD 
samples: PKA regulatory I? (PKARI?), PKC?2, and PKC?; and the following 
at a trend level: PKARI?, PKARII?, PKC?, and PKC?1 (p<0.10). mRNA 
expression was significantly reduced for: PKAC?, PKARII?, PKC? (p<05); 
and at a trend level for PKARI?, PKC?1 (p<0.10). Expression of a variety 
of regulatory factors, including phosphodiesterases and phosphatases were not 
different. BDNF, GR, and CREB1 expression levels were not altered, but the 
expression of TrkB was significantly reduced.
Methods: Using quantitative real time PCR, we have examined the expression 
of the 5-HT2CR splice variants in the same brain specimens that were employed 
in our previous editing study. The study cohort consisted of subjects with BPD 
or SZ, and normal controls (NC) (Ns=35); fifteen of BPD and 7 of SZ subjects 
committed suicide.
Results: The results demonstrated that the ratio between two major 5-HT2CR
splice variants was significantly increased in suicide, but did not differ among the 
diagnoses (BPD, SZ, NC). The association analysis between this ratio and mRNA 
editing parameters revealed: 1) positive association with editing efficiencies; 2) 
negative association with the non-edited mRNA variant (NONE); and 3) positive 
association with the most prevalent variant in PFC (ABCD).
Conclusions: This report provides further evidence that variation in 
posttranscriptional modification of 5-HT2CR mRNA by both editing and 
splicing may represent one of the risk factors for suicide that is distinct from 
those associated with the comorbid psychiatric disorders. The reported data 
also suggest that, consistent with previous in vitro findings, 5-HT2CR pre-
mRNA splicing is modulated by editing in human brain.
Supported by Merit Review (Department of VA) to SD
944. Chronic Life Stress Experience and 
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Background: Highly prevalent stress-related disorders like major depression 
(MD) are characterized by a dysregulation of the neuroendocrine system. 
Although heritability for these disorders is high, the role of genes in the 
underlying pathophysiology remains elusive.
Methods: Sixty-nine adolescents/young adults (20.1yrs M; ranging from 15-
32yrs, varying in degree of susceptibility to MD) who completed life event 
questionnaires, were exposed to acute psychological stress. Their MAOA-
VNTR and the intron 2-VNTR of their 5-HTT gene were assayed to test the 
hypothesis that exposure to severe life events as well as polymorphic variations 
of monoaminergic and serotonergic genes may convergently or additively affect 
endocrine stress response.
Results: We showed that polymorphic variations of the intron 2-VNTR of 
the serotonin transporter (5-HTT) and monoamine oxidase A (MAOA) 
influences hypothalamic-pituitary-adrenal (HPA)-axis response to acute 
psychological stress. Additionally, we found a significant effect of the degree of 
experienced life stress prior to the laboratory challenge, which did not interact 
with genotype, on individual’s glucocorticoid stress response.
Conclusions: Collectively, these results indicate a complex relationship 
between multiple monoaminergic genes and environmental factors regarding 
endocrine stress regulation. These findings point towards a complex underlying 
gene-environment interplay in the pathogenesis of stress-related disorders 
like MD. In this process, the functional influence of monoaminergic and 
serotonergic genes may become additive risk factors for such disorders in an 
adverse environment. If replicated, these findings may provide insights into 
strategies for clinically relevant gene targeting.
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Background: Attention deficit hyperactivity disorder (ADHD) in both children 
and adults is associated with impairments spanning multiple life domains 
including academic, employment, and interpersonal areas. Interestingly, a large 
number of ADHD individuals have been found to have motor abnormalities 
in both fine and gross motor tasks such as tapping and skills requiring manual 
dexterity. Previous functional imaging studies of motor control have shown 
abnormal activation in several brain regions in ADHD children, but no studies 
have yet examined adults. We sought to examine the neural underpinnings of 
motor abnormalities in ADHD adults by using a tapping task with functional 
magnetic resonance imaging (fMRI).
Methods: A sample of adults with ADHD (N = 21) and controls (N = 19) 
recruited from ongoing studies of adult ADHD, performed a finger tapping 
task paced to a tone every 500 ms during fMRI. The blood oxygenation level 
dependent (BOLD) fMRI response was used as a measure of neural activity.
Results: Behavioral data showed no differences between groups in mean tapping 
rate but a trend toward greater intrasubject variability for tap-to-tap intervals 
for ADHD adults relative to the controls. Preliminary analyses using Statistical 
Parametric Mapping demonstrated that, relative to controls, ADHD adults showed 
significantly decreased activity in frontal, parietal, insular and cerebellar regions.
Conclusions: These data demonstrate that functional abnormalities associated 
with motor control in ADHD persist into adulthood. Data will be discussed in 
the context of understanding motor abnormalities in ADHD.
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Background: Low levels of brain-derived neurotrophic factor (BDNF) peptide 
are linked to the pathophysiology of mood disorders. Several single nucleotide 
polymorphisms (SNPs) across the BDNF gene (BDNF) have been associated 
with bipolar illness. Since both elevated intracellular sodium and apoptosis 
are believed to contribute to cellular dysfunction in bipolar disorder, it is 
important to determine the effect of BDNF on apoptosis induced by the high 
levels of intracellular sodium seen in ill bipolar patients.
Methods: Human olfactory neuroepithelial progenitor cells were treated with 
monensin, a sodium ionophore that increases intracellular sodium and leads to 
apoptosis. Apoptosis was quantified with enzyme-linked immunosorbent assay 
(ELISA) for mono- and oligonucleosomes.
Results: Monensin induced apoptosis. BDNF 100 ng/mL pre-treatment or 
co-treatment attenuated the monensin-induced apoptosis. Pretreatment with 
Conclusions: These data confirm the reduction in specific PKA and PKC 
subunits. The patterns of protein and mRNA expression levels do not suggest 
that the reductions are related to altered expression of mRNAs or proteins or 
changes in regulatory factors.
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Background: Previous research using proton magnetic resonance spectroscopy 
(H-MRS) has documented alterations in amino acid neurotransmitter 
concentrations in patients with severe, melancholic major depressive disorder 
(MDD). We tested for similar alterations in a group of treatment-resistant 
depression (TRD) patients who failed to respond to at least 2 adequate 
antidepressant trials. TRD patients might possess a distinct neurobiology 
(e.g., impaired glial function leading to abnormal glutamate/glutamine/GABA 
cycling) which could contribute to persistent mood symptoms.
Methods: H-MRS scans were performed on 24 healthy volunteers (HVs), 20 
non-TRD MDD patients, and 13 TRD patients (all psychotropic-free) to assess 
regional concentrations of glutamate/glutamine (GLX) and GABA, expressed 
as ratios relative to the unsuppressed voxel tissue water signal (W), in 2 regions 
of interest: bilateral occipital lobe (OCC) and anterior cingulate cortex (ACC). 
A 3.0 T GE ‘EXCITE’ MR system was used to record from 3x3x2 cm3 voxels 
using the J-editing technique (TE/TR 68/1500 ms).
Results: OCC GABA/W concentrations were decreased in TRD patients in 
comparison to both HVs and MDDs (20.4% mean reduction; p<.001). All 
13 TRD patients exhibited OCC GABA/W concentrations below the group 
mean for non-TRD MDDs. No other group differences reached the threshold 
for significance (p’s > .05).
Conclusions: Our findings corroborate previous reports of decreased occipital 
GABA in severely depressed patients, and provide preliminary evidence for a 
distinct neuronal amino acid profile in TRD patients, in comparison to non-
TRD participants. These findings have possible implications for the treatment of 
TRD with agents that selectively target amino acid neurotransmitter function.
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BDNF reduced monensin-induced apoptosis by 93%. Co-treatment of BDNF 
and monensin reduced apoptosis by 66%.
Conclusions: Monensin models a process that is believed to occur during ill 
phases of bipolar illness. Treatment with BDNF greatly attenuates or prevents 
monensin-induced apoptosis. The functional consequences of BDNF SNPs 
known to be associated with bipolar illness, need to be examined.
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